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1. INTRODUCTION 
1.1.  Concepts in Medicinal Chemistry 
 
A major goal in medicinal chemistry is the development of drugs that act in the intended way at a 
selected target. This process includes the identification and validation of hit and lead structures, their 
pharmacological and toxicological characterization and the study of their structure-activity 
relationships to optimize potency and selectivity, as well as physicochemical and pharmacokinetic 
properties.  
Nowadays, there are many ways to identify hit and lead structures for further development. One 
of the most frequently used techniques, especially in an industrial environment, is high-throughput 
screening, which means automated testing of large compound libraries in a suitable test system. This 
procedure has the advantage of being fast and allows the testing of a large number of compounds. 
However, it also has some draw-backs. It is a very expensive undertaking, which needs an automated 
test system. Not all pharmacological assays are suitable for automatization, especially when it comes 
to cell-based assays that involve the exchange of media or filtering and washing steps. Another 
necessity is a large and diverse compound library. A relatively new method is computer-based virtual 
screening of huge compound libraries by using structural information of the target from crystal 
structure analysis or, if not available, from a homology model.  
Another possibility to identify new lead structures is by knowledge-based approaches. Already 
established ligands and information of the endogenous ligand can be used to identify a suitable lead 
structure. This is also termed “ligand-based approach”.  
Lead structures not seldom arise from natural products. In plants, bacteria, fungi, algae and animals 
a broad diversity of chemical structures exist, which can be tested for biological activity, and which 
have already been optimized by evolution for interacting with proteins. 
When identifying an active compound (‘hit compound’), it has to be evaluated for its suitability as 
a lead structure. Some small modifications can be undertaken to optimize the compound’s properties, 
a process, which is called “hit-to-lead” optimization. A good lead structure needs to fulfill some 
physiochemical requirements: an acceptable molecular weight and logP or logD value, solubility in 
aqueous solutions, positions on the scaffold that can be chemically modified, and a sufficient stability. 
It also should not have been reported to be toxic or contain functional groups that are known to have 
toxic effects. One has to investigate if the compound has been used for other purposes or whether it 
has already been described as a drug for some other target. Depending on the target of interest, a high 
degree of selectivity may be a requirement.  
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Figure 1: Development of potent and selective ligands in medicinal chemistry 
 
1.2. G protein-coupled receptors 
 
1.2.1. G protein-coupled receptors in medicinal chemistry 
 
The major common function of a G protein-coupled receptor (GPCR) can be described as 
transmission of an extracellular signal to the intracellular site, where it causes a response in the cell 
via a G protein and/or β-arrestin. GPCRs respond to a broad diversity of ligands, including peptides, 
lipids, nucleotides, biogenic amines, hydrogen ions and light. Over 800 GPCRs exist in the human 
genome.1 Some of these GPCRs have been targeted by drugs, before the structure and function of the 
receptor had been known. Many crucial (patho-)physiological events in the body are mediated via 
GPCRs.  
In 2006, the group of Brian Kobilka solved the crystal structure of the first human GPCR. They 
crystallized the β2-adrenergic receptor, a major drug target, and described its function on a molecular 
basis.2 This insight into their molecular structure fueled research on GPCRs. Brian Kobilka was awarded 
the Nobel Prize in 2012 together with Robert Lefkowitz, who discovered β-arrestin signaling of GPCRs.  
All GPCRs can be subdivided according to their phylogenetic relationship. The largest group consists 
of the so-called class A rhodopsin-like receptors. This family can be subdivided based on their 
phylogenetic relationships into four subfamilies (α-δ). The α-subfamily contains many well-known drug 
targets such as the adenosine, the serotonin, the cannabinoid, the melanocortin receptors and the 
opsins. The γ-subfamily comprises many peptide receptors, such as the opioid and chemokine 
receptors. The δ-branch receptors are the most diverse class, and include the P2Y receptors and the 
PAR receptors, but also contains many uncharacterized receptors with unknown function.1 
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Figure 2: Approved small molecule drugs by targets. Picture was taken from Santos et al.3 
 
GPCRs have been proven to be very druggable targets in the past and over 30% of all marked drugs 
target GPCRs (Figure 2).3 Through the human genome project, it became clear that there are many 
more receptors than had not been known before. The function of some of them has not yet been 
described, nor their role in (patho)physiological conditions. To target these yet poorly characterized 
receptors may provide many drugs for diseases that today can only insufficiently be treated.  
 
1.2.2. Structure and function of GPCRs 
 
The major common feature of GPCRs are the seven transmembrane spanning domains. The N-
terminus of the protein can be found extracellularly, the C-terminus intracellularly. GPCRs can be 
activated by a multitude of ligands including peptides, lipids, nucleotides, biogenic amines, protons 
and even light. The binding of an agonist results in a conformational change that leads to the activation 
of so-called G proteins. G proteins consist of three subunits (α,β,γ) and bind guanosine diphosphate 
(GDP) in their inactivate state. Upon activation by the GPCR, GDP is exchanged for guanosine 
triphosphate (GTP) and the α-subunit dissociates from the G protein complex. Depending on the type 
of Gα subunit different effects in the cell are mediated. A Gαs protein stimulates adenylate cyclase 
resulting in the formation of cyclic adenosine monophosphate (cAMP). The cAMP-dependent protein 
kinase A can then mediate further effects in the cell. A Gαi subunit inhibits adenylate cyclase and 
therefore inhibits the formation of cAMP. Gq/11 activates phospholipase C that forms inositol 
trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol-4,5-bisphosphate (PIP2). IP3 
triggers the release of calcium ions (Ca2+) in the cell. There are also further G proteins, as for example 
G12/13, which activates small GTPases like RhoA leading to the recruitment of transcription factors such 
as nuclear factor of activated T-cells (NFAT), nuclear factor 'kappa-light-chain-enhancer' of activated 
B-cells (NFκB) or serum-response element (SRE). The Gβγ subunit is able to induce a K+ ion influx into 
the cell by activating the so-called G protein-coupled inwardly-rectifying potassium channels (GIRKs) 
causing hyperpolarization. The G protein signal is abrogated by the Gα subunit-inherent GTPase 
activity. Thus, GTP is cleaved to GDP and the G protein returns into its inactive state.  
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The activated GPCR is phosphorylated to stop the activation signal. Phosphorylation triggers the 
recruitment of β-arrestin, a structural protein that mediates the internalization of the GPCR through 
clathrin-coated pits. Furthermore, β-arrestin can address signaling pathways on its own, as for example 
the mitogen-activated protein kinase (MAPkinase) pathway, which induces the phosphorylation of 
extracellular-signal regulated kinase (ERK). 
In Figure 3, the main structural features of a GPCR are depicted, exemplarily for the cannabinoid 
receptor 1 (CB1). 
 
Figure 3: The cannabinoid receptor 1 (5U09), TM = transmembrane domain, ECL = extracellular 
loops 
 
1.2.3. Measurement of GPCR activation 
 
In medicinal chemistry, the interactions of compounds with their targets are studied and the 
compounds are optimized to obtain the desired action at the target of interest. To study compound 
target interaction quantifiable assays are needed. As described above, GPCR activation induces 
different effects in the cell. Some of them can be quantified to study compound receptor interaction.  
Some types of read-out depend on the Gα subunit, to which the receptor is coupled, to analyze the 
change in the levels of a product of GPCR activation. Other read-outs are independent of the type of 
G protein involved.  
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Figure 4: Possibilities to measure GPCR activation, (CTX = cholera toxin; PTX = pertussis toxin; GRK 
= G protein-coupled receptor kinase) 
 
A rather universal read-out for the activation of a G protein is the [35S]GTPγS assay, for which a 
hydrolytically stable radioactively labeled GTP analog is applied. When the GPCR is activated, the G 
protein exchanges GDP for GTP, but it is not able to cleave the applied [35S]GTPγS, which can be 
quantified via liquid scintillation counting after separating bound from free radioligand, e.g. filtration.  
For measuring the activation of Gs- and Gi-coupled receptors the accumulation of cAMP can be 
quantified. Cells usually have relatively low amounts of cAMP, therefore, the inhibition of cAMP 
formation by Gi proteins can in most cases only be assessed in the presence of the direct adenylate 
cyclase activator forskolin. The Gi response can be blocked by “uncoupling” receptor and G protein 
with PTX (pertussis toxin), while the Gs response can be blocked with CTX (cholera toxin).4 
The Gq/11 or Gq response results in an increase in intracellular calcium ions. This can be measured in 
the presence of Ca2+-sensitive fluorophors. The formation of IP3 can be measured with an enzyme-
linked immunosorbent assay (ELISA). The same is true for the activation of RhoA.  
The G protein response in the cell is also influenced by the amount of the G protein of interest. If 
the G protein of interest is only available in low amounts the signal will be small or not quantifiable. 
Moreover, GPCRs can be promiscuous signaling through different G proteins. Another aspect when 
choosing an assay system are the costs. Antibodies, for example, are mostly very expensive and require 
many working steps, for example, washing steps. Therefore, they are mostly unsuitable for high-
throughput screening approaches.  
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β-arrestin recruitment can be measured as a read-out for GPCR activation. It is a G protein-
independent way to observe receptor activation. One possibility is the labeling of β-arrestin with a 
fluorescent marker and the visual observation of the recruitment process. When the receptor is also 
labeled with a fluorescent dye, the activation can be measured when the proteins come in close 
proximity by FRET (Förster Resonance Energy Transfer). Another possibility is the enzyme 
complementation assay. In this assay an enzyme that produces a readable output (for example, cleaves 
a substrate that leads to a chemoluminescence signal) is bound to β-arrestin, only lacking a small but 
essential part which is fused to the GPCR. When the receptor is activated and β-arrestin is recruited, 
the enzyme is complemented and ready to cleave its substrate. The advantage is the very specific read-
out for only one receptor with a high amplification rate of the signal. Draw-backs are the possibility of 
interaction of test compounds with the enzyme.5 β-Arrestin assays have been proven very valuable 
tools especially when investigating poorly characterized receptors.  
Independently from the measurable cellular response, the binding affinity of a radiolabeled ligand 
can be determined. Here, a highly potent ligand is necessary, which binds to the receptor. When 
radioactively labeled, the amount of bound ligand can be quantified. The independence from 
downstream signaling is one of the major advantages of the binding approach. Furthermore, the tissue 
distribution of a GPCR can be investigated by labeling it with a high affinity radioligand. However, the 
binding study itself gives no information on the functionality of the receptor. Especially, when it comes 
to poorly characterized receptors, this technique cannot always be used, due to the lack of highly 
potent compounds.6 
 
1.2.4. New trends in GPCR drug discovery 
 
For a long time, a ternary complex of ligand-GPCR-G-protein interaction has been used to describe 
GPCR-ligand interactions:  +  +  →  +  → . 
However, an activated GPCR can have different effects, depending on the ligand and the 
corresponding conformational state. For example, it can be able to address different downstream 
effects. Some GPCRs are able to signal through different G proteins (either depending on the ligand or 
the availability of the G protein in the cell). Another effect is the signaling through either β-arrestin or 
a G protein pathway. This phenomenon is known as biased signaling. Compounds that induce a 
conformation of the receptor that only leads to the activation or inhibition of a certain signaling 
pathway are called “biased” ligands.7 This concept can be of advantage when one signal pathway leads 
to undesired side effects while the other one generates the intended effect.  
Compounds inducing a partial activation or inhibition are so-called partial agonists or antagonists. 
They can be of interest when a full activation or inhibition causes side effects.  
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For many GPCRs a constitutive activity has been reported, which means a constant activation 
without the presence of an agonist. Inverse agonists are antagonists that are able to reduce the 
constant activity. Constitutive activity of GPCRs has been discussed to be a target of interest especially 
in cancer.8 
Another concept of great interest is the development of allosteric ligands. The binding site of the 
endogenous ligand defines the orthosteric binding site, whereas allosteric interactions occur in a 
different binding site. An allosteric ligand changes the conformation of a receptor protein in such a 
way that the affinity and/or efficacy of the endogenous ligand is altered. This can result in desirable 
therapeutic effects.9  
GPCRs have been reported to form homodimers and heterodimers. The special interaction of 
certain receptors and their mutual interaction may provide new targets for drug discovery. GPCR 
homodimer and heterodimer pharmacology needs to be further investigated to generate reliable 
concepts for medicinal chemistry.9  
For every therapeutic option, a certain kind of ligand may be desired that has advantages over 
another one.  
 
1.3. Cannabinoid receptors  
 
The cannabinoid receptors (CB receptors) are named after the most famous compound group that 
interact with them. The effects and structures of cannabinoids have been known long before it became 
clear on which targets they act. The psychoactive effects of Δ9-tetrahydrocannabinol (Δ9-THC) derived 
from the plant Cannabis sativa has been described as a major psychoactive constituent in the late 
1950s. Although a specific site of action for this compound and its derivatives had been postulated and 
characterized by radioligand binding,10 the cannabinoid receptor 1 (CB1) was not identified before 
1990, when it was cloned for the first time.11  
The endogenous ligand of the CB1 receptor was identified in the early 1990s, shortly after the 
identification of the CB receptors. Anandamide (arachidonoylethanolamide, AEA) was extracted from 
porcine brain tissue and later on characterized in various test systems to evoke the same 
pharmacological responses as previously known CB receptor agonists.1214; 13,13 It was therefore 
postulated to be the endogenous ligand of the CB receptor. In 1993, another CB receptor was 
discovered which was differently expressed, predominantly in the immune system.15 Later on, a 
second endogenous fatty acid derivative was reported as an endogenous agonist for both cannabinoid 
receptors, 2-arachidonoyl-sn-glyercerol (2-AG).16  
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Anandamide is primarily produced from N-acylphosphatidylethanolamide (NAPE) in the membrane 
by the enzyme N-acyl phosphatidylethanolamide phospholipase D (NAPE-PLD), whereas 2-AG can be 
formed by the cleavage of diacylglycerols by diacylglycerollipase (DAGL). Anandamide is degraded by 
fatty acid amide hydrolase (FAAH) to arachidonic acid and ethanolamine, whereas 2-AG is cleaved by 
monoacylgycerol lipases (MAGL) to arachidonic acid and glycerol. These enzymes control the 
formation and degradation of the endocannabinoids and represent possible targets in medicinal 
chemistry.  
In 2016, the crystal structure of the CB1 receptor was solved independently by two groups. The 
structures contain the antagonists taranabant and AM6538, respectively. Information from these 
structural insights will help to guide future ligand development for CB receptors.17,18 
 
Figure 5: Crystal structures of CB1; on the left side PSB:5UO9, on the right side PSB: 5TGZ 
 
1.3.1. Physiological role of the cannabinoid receptors 
 
The CB1 receptor was postulated to be the most highly expressed GPCR in the brain. Its expression 
was reported in hippocampus, cortex, basal ganglia and cerebellum, where the receptor can primarily 
be found presynaptically on both, excitatory glutamatergic and inhibitory GABAergic neurons.19 
Activated GABA-ergic neurons produce endocannabinoids at the postsynaptic end and activate the 
presynaptically distributed CB receptors. Upon activation, they suppress the neurotransmitter release 
and thus the postsynaptic neuron cannot fire action potentials as frequently as before. This retrograde 
modulation of transmission is called depolarization-induced suppression of inhibition and is one of the 
key features of cannabinoid functionality in the brain.20,21,22 However, postsynaptic expression of CB 
receptor has also been reported.19  
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The CB1 receptor displays in pleiotropic effects. It modulates the formation of anorexigenic leptin 
and orexigenic ghrelin in the brain, both major factors to control appetite and food intake.23 
Additionally, the CB1 receptor is involved in peripheral energy homeostasis by increasing the 
biosynthesis of fatty acids and triglycerides and by decreasing lipolysis.23 CB1 activation further leads 
to prolonged hypotension and bradycardia. For the CB2 receptor a protective role for the ischemic 
heart has been described. 24,25  
The CB2 receptor is mainly expressed in the immune system. It was found in almost all immune cells 
and seems to be involved in the migration of immune cells in maturation and. It promotes chemotaxis 
and chemokine formation. The immunosuppression by CB2 activation is a new possibility to target 
inflammatory diseases and pain. Especially, as the CB2 receptor was also found in microglia in the brain, 
the activation of CB2 receptors mediates immunosuppressive effects in neuroinflammation. 26,27 
The cannabinoid receptor 2 plays a key role in the formation of bones, where it can be found both 
in osteoclasts and osteoblasts. In CB2-/- knock out mice the bone mass is significantly reduced. 
Therefore, the activation by CB2 receptor agonists could serve as a future treatment for 
osteoporosis.28,29 
 
1.3.2. Medicinal chemistry of cannabinoid receptor ligands 
 
Compounds displaying affinity for CB receptors can be divided into four structurally different 
compound classes: the endogenous ligands for the two CB receptors, anandamide and 2-AG; Δ9-THC 
related phenolic compounds; N-alkyl-indoles originally designed by Huffman et al. and pyrazoles, as 
for example the CB1 receptor antagonist rimonabant, as well as other compounds, which do not belong 
to any of these groups.  
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Figure 6: CB receptor ligands 30 
 
The cannabinoid receptors both have been of great interest with regard to drug development. CB1 
agonists and their effects have been known for a long time. They are also the first group of CB receptor 
ligands that have been approved for medicinal use.  
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In Germany, the partial-synthetic dronabinol can be prescribed for the treatment of cancer- or 
AIDS-derived anorexia, kachexia and nausea. Nevertheless, it has to be prescribed and is treated as a 
controlled substance with all the accompanying formalities. It can be manufactured in the pharmacy 
shop from the crude drug, since no industrial product is distributed in Germany, but in the US it is sold 
under the tradename Marinol® as capsules. Repeatedly, Δ9-THC has been in discussion to be used for 
the treatment of multiple sclerosis, Morbus Crohn, Colitis ulcerosa and glaucoma. As a combination 
therapy together with cannabidiol (CBD), it was approved as a buccal spray (Sativex®) in several 
European countries. The fixed combination of Δ9-THC and CBD and can be prescribed as an add-on 
therapy for multiple sclerosis patients, who did not benefit from other therapies.31 It was further 
discussed to be beneficial in the treatment of chronic neuropathic pain.32 A synthetic derivative of 
Δ9-THC, nabilone, was developed by Eli Lilly and launched as a treatment against emesis and as a 
tranquilizer in the 1980s.33 
The draw-back of CB1 receptor agonists has always been their psychoactive side-effects, which 
makes them controlled drugs in most Western countries. To circumvent this problem some therapeutic 
options have been discussed. Local administration or development of peripherally acting cannabinoid 
receptor agonists could prevent the central side effects. Further, the anandamide-metabolizing 
enzymes fatty acid amide hydrolase could serve as a target, but unfortunately severe side-effect have 
been reported in phase I studies.34,35  
CB1 receptor antagonists have been developed for obesity.36 With rimonabant (Acomplia®, 
SR141716A) a drug was already marketed for this indication in Europe. The beneficial potential, 
especially when discussed in the context of the reported side-effects, led the FDA to refuse the 
approval of rimonabant. The reported side-effects, especially depression and suicidal behavior, led to 
the withdrawal of rimonabant.37 This experience emphasizes the complexity of the cannabinoids’ 
actions in the brain. Although several other CB1 receptor antagonists had been advanced, none of them 
entered into clinical development. New therapeutic options in the field of CB1 antagonists are allosteric 
modulators of CB1 receptors or peripherally acting CB1 antagonists.38 
As the potential of CB1 receptor antagonists will always be limited by undesirable central side-
effects, the interest in CB2 receptor ligands is emerging. The main distribution of CB2 in the immune 
system has made it an interesting target for neuropathic pain, immunologic diseases, cancer and 
osteoporosis.39 It is nowadays well accepted that CB2 is also expressed in the brain, especially in 
microglia, which is involved in inflammatory processes in the brain. The activation of CB2 has an 
immunosuppressive and anti-inflammatory effect. Especially, as there is no evidence of psychoactive 
side-effects, CB2 agonists are of great interest. Therefore, selective CB2 agonists are proposed as future 
drugs for diseases such as multiple sclerosis and Huntington’s disease.40 Furthermore, central CB2 
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agonists offer a possible treatment for neuroinflammatory diseases, as for example Alzheimer’s 
disease.41,42 
CB2 antagonists have not been of interest for drug discovery so far, but might become interesting 
in the context of immuno-oncology.  
Table 1: Possible application of ligands for CB receptors 
 (Possible) indication Drugs 
CB1 agonists Kachexia, nausea and emesis, 
multiple sclerosis, 
neuropathic pain 
Dronabinol (Marinol®), 
Sativex® (Δ9-THC, CBD), 
Nabilone 
CB1 antagonists Obesity, adipositas Rimonabant (Acomplia®) 
withdrawn because of side 
effects 
CB2 agonists Inflammation, 
neuroinflammatory diseases, 
e.g. multiple sclerosis, 
Huntington’s disease etc.  
osteoporosis 
- 
 
New CB receptor ligands may open up new therapeutic indications in the furture.  
 
1.3.3. Off-target effects of cannabinoid receptor ligands 
 
Cannabinoids can also act at other targets. For example, they influence the transient receptor 
potential cation vanilloid (TRPV) channels. These are thermosensitive cation channels involved in pain 
formation, which respond to the activation by lipid-like compounds, for example N-acyldopamine and 
similar lipids including anandamide. 43,44 
Lake et al. investigated the characteristic effect of direct cannabinoid-induced vasodilatation and 
observed that the anandamide-induced vasodilatory effects can neither be blocked with the CB1 
antagonist/inverse agonist rimonabant, nor mimicked by the CB1 receptor agonist Δ9-THC. The authors 
concluded that anandamide acts at an additional site and hypothesized that an endothelial 
anandamide receptor exist which is different from CB1 and CB2.45 Anandamide-induced vasorelaxtion 
of rat mesenteric arteries persists also in CB1-/--CB2-/- double knock-out mice. They further showed that 
abnormal-cannabidiol (abn-CBD), a regioisomer of CBD, both of which are inactive at the CB receptors, 
can also induce this effects. The mesenteric vasodilation is endothelium-dependent and can be blocked 
by CBD. They concluded from their experiments that an additional site of action for vasodilation exists 
in the endothelium for anadamide, and proposed a putative ‘abn-CBD-receptor’.46 This putative ‘abn-
CBD’ receptor has been further investigated, especially in rat mesenteric arteries. O-1918, an inactive 
cannabinoid-like compound, was shown to inhibit the vasodilatory signal and also to inhibit abn-CBD-
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induced phosphorylation of p42/44 MAP kinases and B/Akt kinases in HUVEC cells, an endothelial cell 
line, in a Gi/o-dependent manner.47 
 
1.4. Orphan G protein-coupled receptors 
 
Orphan GPCRs are GPCRs with yet unidentified endogenous ligands. Through the human genome 
project many more GPCRs were discovered than the known receptors. Over 800 GPCRs can be found 
in the human genome, about 400 when excluding the olfactory GPCRs. From them, still over 100 
remain orphan receptors.48  
In reverse pharmacology approaches screening for endogenous ligands is conducted, but the 
success rate of deorphanization has been decreasing.49,50 Different methods have been used to map 
known transmitters to newly identified receptors, first of all by reports of interactions and tissue 
distribution. Later on, orphan receptors were screened for new ligands, however with mixed success.  
Nevertheless, the (patho)physiological role of an orphan receptor can be investigated with 
surrogate ligands instead. Potent and selective ligands for orphan receptors can help to understand 
their role and validate them as targets for further therapeutic use.  
 
Figure 7: All non-sensory GPCRs, according to NC-IUPHAR classification (Source: 
http://www.guidetopharmacology.org/) 
 
In the class A rhodopsin-like GPCR subfamily almost one hundred orphan GPCRs can be found. Many 
of them belong to the δ-branch. Among others, two orphan GPCRs (GPR18 and GPR55) are located in 
this group of receptors, to which also the purinergic P2Y but also peptide-activated and lipid-activated 
receptors belong. These two orphan receptors have been reported to interact with cannabinoids.  
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1.4.1. GPR18 
 
GPR18 has been firstly described by Gantz et al. in 1997. They detected a so far unknown GPCR in 
canine parietal cells and a human colorectal adenocarcinoma cell line (Colo 320DM) by using relaxed 
low-stringency PCR, when they were trying to clone a possible bombesin receptor. Furthermore, they 
investigated expression levels of this new receptor and found GPR18 highly expressed in spleen and 
testis, and also in thymus, peripheral leukocytes and small intestine.51 Therefore, they proposed its 
involvement in immunological processes.  
Phylogenetically, GPR18 belongs to the δ-branch class A rhodopsin-like GPCRs.1 Many orphan 
receptors can be found in this branch. Interestingly, the CB receptors belong to the α-branch of class 
A GPCRs and are therefore genetically unrelated to the two orphan GPCRs. For GPR18, it is remarkable 
that there is no very closely related receptor. GPR34 can be considered as closest relative, and GPR183 
(EBI2) shares the highest sequence identity. Both of them are also orphan GPCRs, for GPR34 lyso-
phosphatidylserine,52 and for GPR183 oxysterols have been proposed as an endogenous ligand.53  
 
Figure 8: Phylogenetic relationship of GPR18 and GPR55 (phylogenetic tree designed with 
phylogeny.fr 55-57)55; 54; 56; 57) 
 
In chapter 1.3.3, we showed that a putative ‘abn-CBD receptor’ has been proposed that induces 
vasodilatation in the endothelium. The endothelial expression of GPR18 has been investigated in 
another study, which focused on the role of endogenous cannabinoids in epithelial cells. GPR18 and 
CB1 receptors were expressed along with TRPV1 channel, and these are involved in the regulation of 
inflammatory responses of the vascular bed.58 Endothelial cells also build the surface of the blood brain 
barrier, where GPR18 like CB1 and CB2 receptors were reported to be expressed. CB2 activation reduced 
the migration by tumor cells, but the role of GPR18 in this respect has not been clearly characterized 
by now.59 
1 Introduction 
15 
 
Endogenous ligands have been proposed for GPR18. In 2006, Kohno et al. introduced 
N-arachidonoylglycine (NAGly) as GPR18 agonist. Kohno et al. were investigating chemokine receptor 
4 (CXCR4)-like GPCRs in lymphoid cell lines and found GPR18 to be highly expressed, especially in 
HUT102 cells, a T-cell lymphoma cell line. To identify an endogenous ligand for GPR18, they screened 
a lipid library in Ca2+-mobilization assays on GPR18-transfected cells, and detected a signal induced by 
NAGly. They confirmed their finding by cAMP accumulation assays in CHO cells stably expressing the 
receptor and reported an IC50 value of 20 ± 8 nM. Their signal was abolished upon pretreatment with 
PTX, a Gi protein-decoupling agent.60 
NAGly (Figure 9) has been known before. It was found to be a substrate for FAAH,61 and suppressed 
pain in a formalin-induced tonic pain test.61 Although, it is structurally related to anandamide, the 
endogenous ligand of the cannabinoid receptors, it does not interact with them.62 However, it has 
been reported to inhibit the glycine transporter 2a (GIYT2a)63 and to increase calcium ion signals in 
primary β-cells.64 It was also proposed as an endogenous mediator with anti-inflammatory potential.65  
 
Figure 9: Chemical structure of N-arachidonoylglycine 66 
 
Conjugates of other fatty acids with the amino acid glycine are also possible. For the condensation 
product of palmitoic acid and glycine calcium influx in adult dorsal root ganglia was reported, and its 
involvement in anti-inflammatory and nociceptive processes was also suggested.67 
While characterizing a distinct site of action for endogenous cannabinoids in microglia McHugh et 
al.68 investigated also a possible involvement of the putative abn-CBD receptor. They found microglial 
migration strongly increased by NAGly and by abn-CBD in BV-2 cells, a mouse immortalized microglial 
cell line. p44/42 MAP kinase phosphorylation was enhanced, not only in BV-2 cells but also in HEK293 
cells overexpressing GPR18. The authors demonstrated the antagonism of the already mentioned O-
1918 and N-arachidonoylserine. They concluded from their experiments that GPR18 and the abnormal-
cannabinoid receptor are the same and NAGly is the endogenous agonist.69 With an siRNA knock-down 
experiment, they further supported their hypothesis that GPR18 mediates NAGly-induced migration 
in BV-2 cell lines.70 The microglial expression of GPR18 could also been observed by Malek et al. who 
found mRNA levels in primary rat microglia elevated after LPS treatment.71 
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McHugh et al. continued with research on the endometrial cell line HEC-1B, an epithelial uterus 
adenocarcinoma, which also showed increased migration in the presence of NAGly, but even more 
pronounced in the presence of AEA. They unsuccessfully tried to block the response with a selective 
CB1 antagonist (SR141716A). However, it was sensitive to SR144528, a selective CB2 antagonist. They 
demonstrated that AEA can be transformed into NAGly in HEC 1B, as already shown by Bradshaw et 
al. They concluded that NAGly-induced migration in this endometrial cell line is mediated by GPR18. 
Therefore, GPR18 has been proposed as target for endometriosis, a severe female disease of the 
uterus.72 
GPR18 was also discovered to be involved in the regulation of intraocular pressure. By being 
expressed in ciliary and corneal epithelium and also trabecular meshwork, it was proposed to play a 
role in the regulation of the intraocular pressure mediated by NAGly, which can be found in the tissue 
in amounts of 0.268 pmol/l. Along GPR18, they also showed cannabinoid receptor CB1 to be expressed 
and involved.73 In the studies of McIntyre et al. GPR18 has been found in the epithelial retinal 
microvasculature. NAGly and abn-CBD abolished endothelin-induced vasoconstriction.74  
The involvement of NAGly in inflammatory processes has been investigated by Burstein et al. 
Inflammation becomes chronic when the natural resolution factors fail to stop the inflammatory 
process. Burstein et al. observed that NAGly enhances resolution factors (PGJ and LXA4) in different 
myeloid and lymphoid cell lines (compare Table 2). They proposed a GPR18 mediated pathway due to 
a partial blocking of the resolution response by GPR18 antibodies.75 
In macrophages, Takenouchi et al. described GPR18 to be mainly expressed in the so-called M1 
macrophages, a classical proinflammatory stage. They investigated the cell viability in the presence of 
different concentrations of NAGly. When 30 µM NAGly was supplied, the cell viability was significantly 
reduced. By blocking specific pathways in the cells known to mediate cell death, they identified p38 
MAP kinases and MEK involved in the process. GPR18 therefore might be involved in NAGly-induced 
apoptosis signals in macrophages.76 The expression of GPR18 in the M1 macrophages was also 
reported by Jablonski et al. GPR18 and CD38, an ectonucleotidase, together with the formyl peptide 2 
receptor were proposed as M1 stage markers, because of their exclusive expression in this cell type.77 
The M1 stage of macrophages is known to be induced by bacterial infections. The resolution of the M1 
stage abrogates the inflammatory process. When the M1 stage is not resolved proinflammatory stages 
can occur resulting in chronic inflammation. The M1 stage has been linked to inflammatory diseases 
as arteriosclerosis and also multiple sclerosis.78  
Abn-CBD-stimulated responses, which might be mediated by GPR18, have also been reported in 
the rostral ventrolateral medulla, resulting in a lowered blood pressure. GPR18 was shown together 
with CB1 expression. In these specialized neurons, adiponectin and NO were enhanced as reactive 
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oxygen species were reduced.79 The authors concluded on a Gi/o protein-mediated effect via the 
PI3K/Akt pathway, which finally leads to an enhanced level of adiponectin and nNOS.80 
GPR18 has been detected to be highly expressed in metastatic melanoma by Qin et al. Melanoma 
is one of the most aggressive skin cancers for which not many therapeutics are available. Therefore, 
GPR18 could be a possible target for melanoma treatment.81 
In contrast to the previous studies, Yin et al. did not monitor any activation of GPR18 by NAGly 
when they were screening a lipid library in the PathHunter™ test system by DiscoveRx82, an enzyme 
complementation assay for β-arrestin recruitment. Furthermore, Lu et al. were also not able to report 
NAGly-induced GPR18 activation, although they investigated a range of possible cellular responses. In 
their experiments measuring Ca2+ currents, which can be mediated by Gi/o proteins, they observed no 
GPR18-mediated response, but NAGly was able to increase the Ca2+ currents independent of GPR18. 
The same was true for potassium channels. They were further not able to show any production or 
decrease of cAMP levels in GPR18-transfected cells. From their experiments they concluded GPR18-
independent pathways to be responsible for NAGly-related observations.83 
Finley et al. also investigated the response of cells to NAGly and could not observe any GPR18-
mediated signal, neither on calcium mobilization nor on changes in the cAMP level. However, GPR18 
showed a high degree of trafficking. In comparison to the cannabinoid receptor 1, it shows lower cell 
surface expression. When trying to find a suitable endogenous cell line to further test GPR18 activation, 
they investigated its expression in the already reported BV-2 and HEC-1a and HEC-1b cell lines but 
could not detect it.  
In another study on small intestininal CD8αα-positive T cells, NAGly did not show any migratory 
effect on GPR18-expressing cells. However, GPR18 was found to be important for the appropriate 
maturation and movement of intraepithelial lymphocytes.84 CB2 receptor-independent migration of 
primary murine macrophages has also been found to be mediated by GPR18 or GPR55, but both 
receptors do not response to the CB2 agonists applied (JWH-133 and HU-308). The response could be 
abolished by pretreatment with PTX.85 The authors concluded that there is an additional site of action 
for the mentioned CB2 agonists which is neither GPR18 nor GPR55.85 Becker et al. further investigated 
the function of GPR18 in intraepithelial lymphocytes both in wildtype mice and in GPR18-deficient 
mice. The number of the intraepithelial lymphocytes did not change between the knock-out and the 
wildtype mice, but when a bone marrow transplantation was carried out the wildtype mice 
reconstituted the intraepithelial lymphocyte function better than the knock-out mice.86  
In an attempt to explain discrepancies between reported results, Console-Bram et al. investigated 
both cannabinoid ligands (Δ9-THC, abn-CBD, O-1918 and O-1602) and NAGly in MAPK signaling, Ca2+ 
mobilization and β-arrestin signaling. They found both cannabinoid compounds and NAGly to stimulate 
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Ca2+ increase in the cell. This signal was sensitive not only to PTX but also to a Gq inhibitor. However, 
only Δ9-THC and partly also CBD, produced a signal in a β-arrestin assays. The authors concluded that 
biased signaling of the compounds towards β-arrestin or Gq or Gi took place.87 
Table 2: Reported expression levels of GPR18 
Reported expression of GPR18 Source 
Testis, Spleen, thymus, peripheral leukocytes, small 
intestine 
Gantz et al. 199751 
Lymphoid cell lines (HUT102, MOLT-4, MT-2, MT-4, 
Jurkat, HUT78) 
Peripheral lymphocytes: CD4+, CD4+CD45RA+, 
CD4+CD45RO+, CD8+ and CD19+-positive; but not in non-
lymphoid cell lines 
Kohno et al. 200660 
BV-2 cells (mouse), primary microglia McHugh et al. 201069 
Metastatic melanoma, primary melanoma cells Qin et al. 201081 
HEC-1B, endothelial adenocarcinoma of the uterus McHugh et al. 201272 
U937, HL60, MOLT4, RAJI Burstein et al. 201175 
RAW264.7 (a macrophage cell line) Takenouchi et al. 201276 
Ciliary and corneal epithelium, trabecular meshwork Cardwell et al. 201373 
Neurons of the rostral ventrolateral medulla (RVLM) in 
the brainstem (together with CB1) 
Penumati et al. 201479 
Endothelial cell lines (HUVEC, HCAEC, brain, liver, and 
lung derived endothelial cell lines), peripheral blood 
mononuclear cell (PBMC) 
Wilhelmsen et al. 201458 
Retinal cells  McIntyre et al. 201474 
Brain endothelial cells  Hasko et al. 201459 
CD8αα-intraepithelial lymphocytes Wang et al. 201484 
Primary murine macrophages Taylor et al. 201585 
Rat primary microglial cultures Malek et al. 201571 
Peripheral blood polymorph nuclear neutrophils, 
monocytes and macrophages, intraepithelial 
lymphocytes 
Chiang et al. 201588 
Intraepithelial lymphocytes Becker et al. 201586 
M1 stage macrophages Jablonski et al. 201677 
Glioblastoma cell lines Finlay et al. 201689 
Sperm Flegel et al. 201690 
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Figure 10: Chemical structure of cannabinoids proposed to act on GPR18 
 
The fatty acid derivative resolvin D2 was reported to solve inflammatory processes. Chiang et al. 
investigated the action of resolvin D2 on macrophages, where it stimulated the formation of cAMP. 
The effect was attenuated in GPR18-deficient mice. GPR18 deficient mice did not show any apparent 
pathological phenotype. In cells overexpressing GPR18 tritium-labeled resolvin D2 methyl ester 
showed a KD value of 9.6 nM in a radioligand binding assay and was displaced by resolvin D2. The 
authors proposed resolvin D2 as the endogenous ligand of GPR18. Furthermore, they investigated the 
effects of NAGly, which displaced the radiolabeled resolvin D2-methyl ester.88 It also reduced the 
bacterial titer of Staphylococcus aureus after infection significantly, which took not place in GPR18 
deficient mice.  
However, resolvin D2 (see Figure 11) is a chemical entity with poor stability. This has to be taken 
into account when working with this compound.91  
Resolvin D2 was known before to be a lipid mediator produced by leukocytes to abolish 
inflammatory processes.92 An involvement in wound healing, prevention of thrombosis, prevention of 
neuroinflammation e.g. Parkinson’s disease93 and revasculization processes after ischemic events were 
also proposed for the lipid.94 It showed inhibition of TRPV1 and TRPA1 channels (IC50 = 0.1 nM and 2 
nM, respectively), which could be blocked by PTX pretreatment. The authors therefore concluded the 
involvement of a GPCR.95 
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Figure 11: Chemical structure of resolvin D2  
 
Two antagonists for GPR18 have been described so far. One of them was identified in extracts of a 
marine sponge. The diketopipierazine amauromine is not only a potent CB1 receptor antagonist (with 
a Ki value of 0.178 µM), but also a GPR18 antagonist with potency in the low micromolar range.96 
Another antagonist, PSB-CB-5 (17), was obtained by optimization of a hit compound that was 
identified in a small screening campaign. Rempel et al. had screened compounds in β-arrestin assays 
(DiscoveRx) against 10 µM Δ9-THC. They investigated preliminary structure-activity relationships of this 
compound class and described PSB-CB-5 (17) as the first potent and select antagonist of GPR18. They 
also investigated the selectivity of the compound, which was found to be not active at the related 
GPR55. It showed no affinity to the CB1, but a weak affinity to CB2 with a Ki value of 4.03 µM, resulting 
a 14-fold selectivity for GPR18 versus CB2.66 
 
Figure 12: Chemical structures of GPR18 antagonists PSB-CB-5 and amauromine97 66 
 
Possible therapeutic options of GPR18 have yet to be confirmed. But, as has been discussed above, 
its predominant involvement in inflammatory processes suggests a role in resolution of inflammation. 
Thus, by activating GPR18 in the case of an inflammatory disease, the progression of the process might 
be attenuated. Several groups have reported a GPR18 expression in M1 macrophages, which is linked 
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to inflammatory diseases, including neuroinflammatory diseases. However, the involvement of GPR18 
in neuroinflammation and a possible advantage of GPR18 activation needs further confirmation.  
 
Figure 13: Possible physiological roles of GPR18 
 
GPR18 has also been discussed in relation to cancer and migratory processes. Here, antagonizing 
the GPR18 activity would lead to the desired therapeutic effects.  
Unfortunately, the uncertain situation on GPR18 agonists makes it very hard to rely on published 
results. Unselective compounds reduce the significance of a study. The inconsistent studies on the 
activation of GPR18 by NAGly complicate the evaluation of GPR18 effects. Whenever GPR18 
pharmacology is studied the effects of the applied agonists or antagonists have to be characterized in 
detail. Therefore, selective and potent compounds, both agonists and antagonists are required to fully 
understand the role of GPR18 in physiology and disease.  
 
1.4.2. GPR55 
 
GPR55 was firstly identified in 1999 along with another orphan GPCR, GPR52. It was found to be 
highly expressed in the putamen and in the caudate nucleus.98 From early on, it was suggested that 
GPR55 might be a receptor involved in the off-target effects of cannabinoids and discussed 
contradictorily.99,100 Phylogenetically, it is closely related to the orphan GPCR GPR35, a receptor that 
has been proposed to interact with kynurenic acid and lysophosphatidic acid.101 
In 2007, Oka et al. proposed an endogenous ligand for GPR55 distinct from the endogenous 
cannabinoids, also a fatty acid derivative.102 The so-called lysophosphatidylinositol (LPI) consists of a 
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fatty acid that is linked to glycerol, which is esterified with a phosphate group. To the phosphate group 
inositol is bound The chemical description “lyso” means that one of the glycerol hydroxyl groups is 
unsubstituted, not esterified with a fatty acid. In nature, many different fatty acids can be bound to 
glycerol, and the type of fatty acid can determine the bioactivity. In a study by Oka et al., LPI from 
soybeans was used and proved to elevate calcium transients in GPR55 transfected HEK cells but not in 
mock-transfected cells. Further, ERK phosphorylation was enhanced. Therefore, the authors concluded 
that LPI is a new ligand for GPR55.102 Furthermore, they studied the exact species of LPI, since LPI can 
be regarded as a molecular mixture because of the different fatty acids potentially present. For 
example, soybean LPI mostly contains palmitoic acid (2-lyso-LPI). Oka et al. found in total 37.5 nmol/g 
LPI in rat brain tissue mostly stearic acid derivatives (2-lyso-LPI, 50.5 %) and furthermore arachidonic 
acid derivatives (1-lyso-LPI, 22.1%). The latter was found to be the most potent species to activate 
GPR55, namely 2-arachionoyl-glycero-phosphatidyl-inositol (2-AG-PI) with EC50 value of 30 nM in 
calcium mobilization assays. Therefore, they concluded that this might be the true endogenous ligand. 
103,104 
However, also other endogenous substrates have been discussed to be the endogenous ligands for 
GPR55. Guy et al. reported lyso-phosphatidyl-β-D-glucoside to be released from glial cells to target 
GPR55, thereby directing the growth of nociceptive axons. This was found to be abolished in GPR55 
knock-out mice.105 
 
Figure 14: Chemical structure of lyso-phosphatidyl-β-D-glucoside 
 
GPR55 was reported to signal via the Gα13 pathway by different independent groups.106,107,108 The 
Gα13 pathway leads to oscillatory calcium transients and the activation of NFAT via RhoA (a small 
GTPase).107  
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Figure 15: Chemical structures of 2-arachidonoyl-lysophosphatidyl-inositol (2-AGPI) and 1-Stearyl-
2-lysophosphatidylinositol (LPI)  
 
GPR55 was shown to be sensitive to abn-CBD, but reports on the potency differ largely.109 
Moreover, effects of abn-CBD still persisted in GPR55-/ knock-out mice.110  
GPR55 and the CB1 have been reported to be co-expressed in some tissues. Kargl et al. investigated 
the possibility of the mutual effect of the receptors in HEK cells and found CB1 co-expression to inhibit 
GPR55-induced activation of transcription factors such as NFκB and SRE. CB1-induced effects were 
increased.111 Similarly, CB1 and GPR55 were shown to interact in the striatum, especially with regard 
to NFAT activation.112 CB2 receptors and GPR55 were also reported to form functional heteromers in 
cancer cells, for example, in a brain glioblastoma cell line. It was proposed that GPR55 activation 
silences CB2 activation.113 Functional cross-talk was also investigated in cells overexpressing both 
receptors, where GPR55 MAPK signaling was enhanced, and NFAT, NF-κB and cAMP response element 
activation was reduced in the presence of CB2 receptors.114 
Ryberg et al. reported very potent interactions of cannabinoids with GPR55 determined in 
[35S]GTPγS assays.106 However, many groups could not confirm similar potencies in their assay systems. 
In Table 3, some reported activities are shown exemplarily to demonstrate the diverse and 
controversial results of cannabinoid ligands at GPR55. Some groups tried to evaluate cannabinoid 
ligands in a special assay system to clarify the role of cannabinoids at GPR55. Anavi-Goffer et al. 
investigated cannabinoids in ERK-phosphorylation assays and postulated an allosteric mode of action 
for AM-251 and Δ9-THC.115 All groups observe an activation of GPR55 by LPI independent from the 
applied test system. However, the EC50 values vary between the different test systems and research 
groups. Henstridge et al. investigated the activation of GPR55 by LPI in various test system, e.g. 
reporter-gene assays, phosphorylation of kinases and the label-free dynamic mass redistribution, and 
reported EC50 values from about 10 nM to 1 µM.116 Nevertheless, an activation of GPR55 by LPI was 
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always observable. Cannabinoids have also been investigated by other research groups. However, the 
results on the cannabinoids are very diverse and contradictory, ranging between nanomolar potencies 
and inactivity. Therefore, the effect of cannabinoids on GPR55 should always be studied, before 
applying them to pharmacological purposes, as they are no reliable tools. Different small molecule 
agonist and antagonist have been developed which are selective against the CB receptors. They will be 
introduced in the following.  
Table 3: Reported effects of cannabinoids at GPR55  
  EC50 or IC50 
1 AEA 0.0183 µM (agonist, GTPγS-assaya)106 
>30 µM (no response, β-arrestin assayb)118, antagonist at 
10 µM (β-arrestin assayc)119 
2 2-AG 0.003 µM (agonist, GTPγS-assaya)106 
inactive at 5 µM (Ca2 increased)117 
>30 µM (no response, β-arrestin assayb)118 
3 CP55,940 0.005 µM (agonist, GTPγS-assaya)106 
inactive at 5 µM (Ca2 increased)117; no response (ERK-
phosphorylatione)115 
>30 µM (no response, β-arrestin assayb)118,  
4 Δ9-THC 0.008 µM (agonist, GTPγS-assaya)106 
>30 µM (no response, β-arrestin assayb)118 
6 WIN55212,2 >30 µM (no response, GTPγS-assaya)106 
inactive at 5 µM (Ca2 increased)117 
>30 µM (no response, β-arrestin assayb)118 
7 Rimonabant  3.9 µM (agonist, β-arrestin assayb)118, no response (ERK-
phosphorylatione)115 
12 CBD 0.445 µM (antagonist, GTPγS-assaya)106 
inactive at 3 µM (Ca2 increased)117 
>30 µM (no response, β-arrestin assayb)118 
21 LPI 1.2 µM (agonist, β-arrestin assayb)118 
0.045 µM (agonist, Ca2+ oscillationf)107; 1.10 µM (NFAT 
activationg), 0.074 µM (ERK-phosphorylationg), 0.093 µM 
CREB-phosphorylationg), 1.9 µM (NFκB activationg), 
0.009 µM (dynamic mass redistributiong)116 
amembrane preparations of HEK cells, stably transfected with human GPR55 
bU2OS cells, stably transfected with GPR55 and β-arrestin-2-GFP, redistribution of β-arrestin-2-GFP 
monitored imaged using a fluorescence microscope 
cU2OS cells, stably transfected with GPR55 and β-arrestin-2-GFP, redistribution of β-arrestin-2-GFP 
monitored imaged using a fluorescence microscope 
dCHO and HEK293 cells, stably transfected with GPR55 
eHEK293 cells, stably expressing 3xHA-GPR55 were used 
fHEK293 cells, stably expressing 3xHA-GPR55 were used 
gHEK293 cells, stably transfected with 3xHA-GPR55 were used 
 
The NIH Molecular Libraries Program initiated a screening campaign to identify small molecule 
ligands for GPR55. Agonists of three different scaffolds were found and investigated to study structure-
activity relationships and selectivity (compound 22-24, see Figure 16). They shared some features as 
the central amide bond.120,121 LPI and these agonists were further docked into a homology model of 
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GPR55 to predict possible binding modes and involved amino acids. The authors proposed an inverted 
L-or T-shape of the agonists binding to the receptor with their long lipophilic residue pointing deep 
into the binding pocket, interacting phenylalanine residues providing a hydrophobic environment. The 
polar head group can be found close to the extracellular loops, filling the upper top of the binding 
pocket and interacting with K2.60, a lysine that forms ionic interaction with the phosphate group of 
LPI. The agonists (compound 22-24) identified in the screening campaign mostly mimics this 
orientation.122 Binding of compound 24 was investigated in mutagenesis studies and crucial residues 
were identified which interact both with LPI and also with compound 24 (chemical structure in Figure 
16).123 Another homology modeling approach came to the same observation regarding the residue 
K2.60.124 
Partial agonists were described by Morales et al., who used a cell impedance assay to investigate a 
group of chromenopyrazoles (compound 26, Figure 16). They identified ligands with high potency, but 
moderate efficacy. The most potent ligand showed an EC50 value of 0.0004 µM and an efficacy of 51%. 
The selectivity profile was also investigated and the CB2 receptor showed some affinity to the 
ligands.125  
A screening approach of GlaxoSmithKline (GSK) identified compound 25 as agonist at GPR55 with 
an EC50 value of 0.631 µM. However, the compound was more potent at the glycine transporter 1 
(GlyT1).120 Yrjölä et al. developed biphenylic suolfonamides (compound 27 and 28), which showed a 
very high potency. Their physicochemical properties however were not favorable.126 
Although some agonists have been described for GPR55, no radioligand was developed until now. 
Some of the agonists were not potent enough and others were not selective. Further compound 
optimization is needed to obtain compounds with a high potency and suitable physicochemical 
properties.  
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Figure 16: Chemical structures of synthetic GPR55 agonists  
120; 127; 125; 126 
 
The NIH Molecular Libraries Program further identified and studied a group of antagonists 
(compound 29-31, Figure 17). They share some structural properties with the agonists described above 
especially in shape. The highest potency displayed compound 29 (ML-193) with an IC50 value of 0.221 
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µM. The other antagonist were less potent.127 Compound 30 was modified to study structure-activity 
relationships (Meza-Avina et al.) They tried different substitutions at the phenylcyclopropyl residue 
und observed slightly increased inhibitory activity when compared to the original para-methyl 
substitutions with para-chloro residues, up to an IC50 value of 0.64 µM (in β-arrestin assays). A pyridine 
ring instead of the phenyl ring at the oxadiazole core was also beneficial.128 
Rempel et al. identified and optimized coumarine-derived compounds as GPR55 antagonist. The 
most potent antagonist was PSB-SB-489 (32) with an IC50 of 0.113 µM, however, this compound was 
unselective against the CB receptors. The most selective antagonist of this series PSB-SB-487 (33) 
showed an IC50 value of 1.77 µM.129 GSK also identified an antagonist, which was investigated by Kargl 
et al. in various test system, where it showed potencies from 0.48 – 1.99 µM.130 
Comparably to the agonists, a possible binding pose of GPR55 antagonists was investigated by 
Kotsikorou et al. They proposed antagonists to bind closer to the surface of the receptor than the 
typical L-shaped agonists, where they possibly stabilize the M3.36-F6.48 ionic lock with aromatic or 
heteroaryl residues.131  
GPR55 antagonists described so far are not potent enough to be further developed as radioligand. 
Therefore, further compound optimization is needed to enhance potency and also optimize the 
physicochemical properties.  
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Figure 17: Chemical structures of synthetic GPR55 antagonists133; 127; 132 
 
1.4.2.1. Therapeutic potential of GPR55 
 
GPR55 mRNA levels were reported in small intestine, spleen, testis, thymus, brain and colon by Oka 
et al.108 Broad expression of GPR55 in the brain has been reported. When investigating GPR55-/- knock-
out mice for CNS performance, Wu et al. did not detect any prominent difference compared to 
wildtype littermates. When knock-out mice were challenged with complex motor coordinative tasks 
they performed worse, indicating a role of GPR55 in motor control.134 As already mentioned above, 
GPR55 was also found to be involved in the axon growth of nociceptive neurons. The receptor was 
further described to be involved in the axon growth of retinal ganglionic cells guiding the growth of 
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axons. When blocked growth was attenuated, and could be rescued with LPI. Knockout mice were 
found to have smaller growth cones of the axons than wildtype mice.135 Obara et al. found GPR55 but 
not CB receptors to be expressed in the PC-12 cell line, a model cell line for brain diseases. LPI induced 
retraction of neurites, but cannabinoids did not. GPR55-independent mechanisms of pain reduction 
have also been investigated and the direct activation of calcium2+-channels was proposed.136,137 In 
microglial cells the expression of GPR55 has been reported, where LPI treatment in the presence of 
interferon-γ induced ERK-phosphorylation.138 LPI further showed neuroprotective effects by inducing 
microglial migration.139  
These reports indicate a possible role of GPR55 in axon growth and sensation, especially in pain 
mediating neurons. GPR55 might therefore be an interesting target for neuropathic pain.140,141 Its 
possible role in microglial cells, which control inflammatory processes in the brain, indicate GPR55 to 
be a possible target for neuroinflammation.  
Andradas et al. found GPR55 expressed in several cancer cell lines, including breast cancer, 
pancreatic cancer, skin cancer and glioblastoma. The expression was correlated to cancer types with 
bad prognosis, late stage, and highly proliferative behavior mediated via ERK signaling.142 It was also 
reported in ovarian and prostate cancer cells, where it also promoted proliferation. The authors 
proposed an autocrine stimulation of GPR55 by released LPI.143 In glioblastoma, the high expression 
levels correlated well with bad prognosis.144 This was also found for triple negative breast cancer cells, 
which showed more tendency to metastasis when associated with high GPR55 expression.145 GPR55 
was also detected in MDA-MB-231 breast cancer cell line, and evoked LPI-induced migration.146 Kargl 
et al. investigated the inactivation of GPR55 by GPCR associated sorting protein 1 (GASP-1), which 
induces the internalization of GPR55 after prolonged agonist stimulation and could therefore be a 
target of interest for highly active GPR55.147 They further found GPR55 involved in the migration of 
colon carcinoma cells and their ability to attach to endothelial cells. By blocking GPR55 with the 
antagonist 35, the metastatic process could be attenuated.148 The antagonism of GPR55 was therefore 
proposed for antitumor therapy.  
GPR55 and the CB2 receptor have been reported to be co-expressed in neutrophils. The receptors 
pathways interference lead to a GPR55 modulated CB2 response in the migration behavior of 
neutrophils.149 Furthermore, GPR55 and CB1 are also co-expressed in the rat brain.112 This cross-talk 
might be used to circumvent CB receptor side-effects. We discussed above that new strategies are 
needed to address the CB receptors in therapy. GPR55 might be such a therapeutic options, when it 
fine-tunes CB receptor signaling, it might prevent undesired side-effects. However, the effects of 
GPR55 and CB1 or CB2 co-expression have to be described more in detail and the action of GPR55 
agonists and antagonists with its effects on CB1 and CB2 signaling has further to be investigated.  
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By blocking GPR55 with the antagonist 35 in mice, inflammatory responses in colitis could be 
reduced. Especially, the recruitment of macrophages and lymphocytes was attenuated and led to 
reduced levels of inflammation markers. The authors proposed GPR55 to play a role in chronic bowel 
diseases.150 This was corroborated by a study comparing different GPR55 expression levels in 
inflammatory bowel disease.151  
GPR55 has been found to be augmented in obese and type 2 diabetic compared to non-obese 
subjects.152 GPR55 agonists triggered insulin secretion.153 The influence of GPR55 on calcium levels was 
investigated in myocytes, where it fine-tunes calcium response depending on the receptor 
localization.154 In GPR55-/ knock-out mice compared to wildtype mice, an age-related effect of GPR55 
absence resulted in ventricular dysfunction.155 GPR55-/- knock-out mice were further reported to show 
increased fat and insulin resistance, mainly accompanied with reduced physical activity, but not with 
an altered feeding behavior.156 Another report of GPR55-/- knock-out mice showed an altered activity 
behavior during the night with an overall lower energy expenditure but no distinguishable other 
differences to wildtype mice.157 
The CB2 has already been mentioned in the context of osteoporosis. GPR55 was also found to be 
expressed in osteoclasts, a cell type that derives from macrophages. The proposed endogenous ligand 
LPI caused an inhibition of osteoclast formation, which did not occur in knock-out mice. Interestingly, 
the bone mass of male GPR55-/- mice was increased, whereas no difference could be observed in 
female knock-out mice.158 GPR55-mediated effects should be further investigated to elucidate its role 
in bone homeostasis.  
Since GPR55 triggers endothelial proliferation via N-arachidonoylserine, it was linked to wound 
healing.159 The antagonist 35 was reported to inhibit LPI-induced endothelial wound healing.130 
GPR55 has also been discussed as a candidate target to treat cannabinoid compound addiction.160 
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Figure 18: Proposed effects of GPR55 agonists and antagonists 
 
Altogether, GPR55 could be a target especially for cancer, where antagonists would be desirable. 
The reported effects of GPR55 in the central nervous system are of very great interest. However, the 
role of GPR55 in the brain needs further to be investigated, both the physiological as the immunological 
role. The results on bowel inflammation are very promising.  
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2. AIM OF THE STUDY 
 
The involvement of a specific receptor in a disease can be investigated by its activation and 
inhibition and observing the resulting effects. To this end, potent and selective agonists and 
antagonists with suitable physicochemical properties are required as pharmacological tools.  
GPCRs are the largest group of membrane proteins that represent important drug targets. 
However, there are still around 100 so-called orphan receptors for which the endogenous ligand is not 
known. The (patho)physiological characterization of these receptors and their validation as drug 
targets requires well-characterized tool compounds.  
The aim of this study has been the development of tool compounds for the orphan GPCRs GPR18 
and GPR55. In case of GPR18, the proposed endogenous agonist, N-arachidonoylgylcine (NAGly) has 
been controversially discussed and is questionable. Poorly characterized compounds limit the 
reliability of experiments. Therefore, we want to develop potent and selective tool compounds. 
Rempel et al. were already successful in developing the first potent and selective antagonist for GPR18, 
namely PSB-CB-5, an imidazothiazinone derivative. This compound class will be further studied and 
the structure-activity relationships will be extended. We further want to develop GPR18 agonists with 
suitable physicochemical properties. To achieve this, the compound library of the Pharma-Zentrum 
Bonn will be screened in β-arrestin recruitment assays. This compound library consists of different 
sublibraries, based on structural properties. This ensures a high hit rate upon screening a small number 
of appropriate compounds. The identification of hit compounds will be followed by a broad 
characterization. This includes determination of the dose-dependency of the observed effect, 
investigation of the compound’s selectivity and specificity of the observed effect.  
A further goal was to develop suitable GPR55 ligands. Therefore, we screened different libraries of 
the Pharma-Zentrum Bonn. The class of chromen-4-ones has already been described by our group as 
rather weak GPR55 antagonist. We now wanted to explore the structure-activity relationships of this 
compound class.  
Fuchs et al. described biphenylic magnolol derivatives as potent CB receptor ligands. They also 
investigated them at orphan GPR55 and GPR18. Here, we wanted to expand the structure-activity 
relationships of this compound class.  
In collaboration with the Institute of Forensic Medicine, we wanted to determine the CB receptor 
affinities of compounds described to be abused in incenses called ‘Spice’. We further want to 
investigate these compounds as possible ligands of GPR18 and GPR55.  
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3. MEDICINAL CHEMISTRY OF GPR18 AGONISTS AND ANTAGONISTS 
3.1. Cannabinoids and cannabinoid-like compounds 
3.1.1. Introduction 
 
Cannabinoid and cannabinoid-like compounds have been reported to interact with GPR18 and 
GPR55, although their effects have been controversially discussed (chapter 1.4.1 and 1.4.2). Here, we 
wanted to investigate the effects of selected cannabinoids in our established assay system.  
Dr. Viktor Rempel established the β-arrestin recruitment system PathHunter™ from DiscoverX, 
Fremont, CA, USA, in our laboratory for GPR18 and GPR55. This test system is based on a fusion-protein 
technology, where the receptor of interest is fused to a small sequence of amino acids, which is part 
of the enzyme β-galactosidase. The major part of β-galactosidase is fused to β-arrestin 2, the most 
important internalization mediator for many GPCRs. The measurement of β-arrestin recruitment has 
the advantage of being G protein-independent, which is in this case favorable, as we do not know the 
explicit G protein through which GPR18 is signalling. Gi protein recruitment has been reported in the 
literature, but needs to be confirmed. For GPR55, the signaling through G12/13 has been reported, which 
leads to activation of small GTPases as RhoA. This signal tranduction pathway can be measured by 
Western Blots or ELISA - methods that are not suitable to screen high numbers of compounds. 
Therefore, we will also use the β-arrestin technology, where we observed a stable response with an 
EC50 value of 1 µM for the reported endogenous agonist LPI.  
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Figure 19: Schematic description of the PathHunter™ β-arrestin recruitment assay (DiscoverX, 
Fremont, CA, USA 
 
Dr. Viktor Rempel investigated reported ligands for GPR18 and GPR55 in the β-arrestin test system 
and found NAGly to be inactive. However, he measured a signal for Δ9-THC, which was used as a 
standard agonist in this test system from then on. The activation of GPR18 by Δ9-THC can be seen in 
Figure 20, and could also be confirmed by Console-Bram et al.87 
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Figure 20: Activation of the human GPR18 in a β-arrestin recruitment assay by Δ9-THC. 
Luminescence signal in relative luminescence units (RLU), results by Dr. Viktor Rempel66 
 
 
Table 4: Potencies of Δ9-THC and NAGly in β-arrestin recruitment assay, results by Dr. Viktor Rempel 
  Human GPR18 Human GPR55 
 Compounda 
 
Agonistic activity Antagonistic actvity 
  EC50 ± SEM (µM) IC50 ± SEM (µM) 
4 Δ9-THC 4.61 ± 0.5066 14.2 ± 5.266 
10 NAGly >10 (15%)66 >10 (6%)66 
a chemical structures in chapter 1.3.2 and 1.4.1 
 
Here, additional cannabinoids that regularly have been reported in the context of either GPR18 or 
GPR55 will be investigated in β-arrestin recruitment assays, namely abn-CBD, CBD, O-1602 and O-1918. 
In addition, cAMP assays will be performed.  
 
3.1.2. Results for atypical cannabinoids  
 
The results for the atypical cannabinoids CBD, abn-CBD, O-1918 and O-1602 are shown in Table 5. 
 Table 5: Potencies of atypical cannabinoids in β-arrestin recruitment assays for GPR18 and GPR55 
  Human GPR18 Human GPR55 
 Compd.a 
 
Antagonistic 
activity 
Agonistic actvity 
Antagonistic 
activity 
Agonistic actvity 
  IC50 ± SEM (µM) EC50 (µM) IC50 ± SEM (µM) EC50 (µM) 
11 Abnormal 
cannabidiol 
(abn-CBD) 
>10 (42 ± 7%) > 10 (-50 ± 11%) >10 (33 ± 8%) >10 (-7%) 
12 Cannabidiol 
(CBD) 
> 10 (-41 ± 12%) 1.38 ± 0.20 10.7 ± 2.5 >10 (-4%) 
13 O-1602 >10 (29 ± 3%) >10 (7 ± 4%) >10 (24%) >10 (1%) 
14 O-1918 >10 (16 ± 6%) > 10 (12 ± 8%) 6.79 ± 0.98 >10 (-8%) 
 a chemical structure in Figure 10 
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CBD, which is structurally very similar to Δ9-THC, activated GPR18 with a comparable EC50 value of 
1.38 µM. The concentration-dependent activation is shown in Figure 21. It should be noted, that the 
last value of the curve was already lower than the previous value. This effect might be due to low 
solubility of this very lipophilic compound. Abn-CBD, which also had been reported to target GPR18, 
did not show any agonistic effect. The two atypical cannabinoids O-1918 and O-1602 were both 
inactive as agonists and as antagonists. 
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Figure 21: Activation of GPR18 by CBD; maximum effect corresponds to 10 µM Δ9-THC = 100% 
 
At GPR55 no agonistic activity could be observed for any of the compounds. However, two of them  
showed antagonistic activity. O-1918 displayed an IC50 value of 6.79 µM and CBD of 10.7 µM (see Figure 
22).  
 
Figure 22: Inhibition of LPI 1 µM-induced β-arrestin signaling by CBD and O-1918 
 
CBD has been proposed for the treatment of psychological disorders such as schizophrenia,161 
anxiety162 and hypoxic-ischemic encephalopathy.163 However, the site of action could not be identified. 
CBD has been reported to interact with a multitude of targets, as equilibrative nucleoside transporter 
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(ENT), GPR55, 5-HT1a receptor, α3 and α1 glycine receptor and TRPA1. In higher concentrations, it also 
should interact with PPAR-γ, TRPV1 and TRPV2 and inhibit FAAH. Further, it has been reported to act 
as an antioxidant.  
O-1602 has been described as an agonist for GPR55. Peripherally applied to rats it reduced 
mechanically evoked pain stimuli. Furthermore, O-1602 and CBD were used to target GPR55 in rat 
intestine, where they reduced LPS-induced effects.164 However, it was also reported that O-1602 
displays anti-inflammatory effects independent of GPR55 and the cannabinoid receptors in colitis in 
mice.165 It was further described to increase glucose tolerance via GPR55 in mice.166 O-1602 also 
triggers feeding behavior and increased food intake but independent of GPR55.167 
Here, we could show that the effects reported for the treatment with abn-CBD and O-1602 do not 
arise from GPR55-mediated β-arrestin signaling. We also did not observe a β-attestin-dependent effect 
of abn-CBD at GPR18, which was proposed to be the abnormal-cannabinol receptor. However, β-
arrestin signaling is not the only signaling pathway that GPCRs address. An effect of one of these 
compounds could also be mediated via a β-arrestin-independent signaling pathway.  
For O-1918 and CBD, we observed a weak inhibition of GPR55. However, these compounds have 
been reported to interact with many different targets. Although, they interact with LPI-induced β-
arrestin signaling, they are no selective tools for GPR55 blockade.  
CBD behaved as an agonist at GPR18. This is an interesting finding, as CBD has been reported as a 
weak/partial agonist at GPR18 before.168 Its structural similarity to Δ9-THC is high, therefore it might 
be assumed that these two compounds interact with the receptor in the same way. In the following 
experiments Δ9-THC was used as a standard agonist for GPR18.  
 
3.1.3. Results in cAMP accumulation assays for lipid cannabinoids and NAGly 
 
We followed up on the results by Dr. Viktor Rempel, who studied NAGly and Δ9-THC in β-arrestin 
recruitment at GPR18.66 He did not observe any activating effect of NAGly on GPR18. He prepared a 
GPR18 expressing Chinese hamster ovary (CHO) cell line (CHO flip-in) and selected two clones. Here, 
we investigated the effect of NAGly or Δ9-THC at 10 µM in cAMP accumulation assays. The results can 
be found in Figure 23. As a control, we also treated CHO K1 cells (lacking GPR18), and the previously 
used β-arrestin cell line.  
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Figure 23: Results of cAMP accumulation assays in presence or absence of 10 µM forskolin, 
normalized to the forskolin response; compounds were applied in concentration of 10 µM 
 
GPR18 has been reported to be Gi protein-coupled.60 This means, an activation of GPR18 would 
result in the inhibition of adenylate cyclase and in a decrease in cAMP levels in the cell. The basal level 
3 Medicinal Chemistry of GPR18 agonists and antagonists 
39 
 
of cAMP in the cell is rather low, so it cannot always be measured with high confident. Therefore, the 
activation of Gi proteins is investigated in the presence of 10 µM forskolin, a compound that activates 
adenylate cyclase directly.  
In Figure 23, the effect of the possible GPR18 ligands NAGly and Δ9-THC and additionally that of 
anandamide and 2-AG are depicted. In the upper panal, no forskolin was applied. All compounds were 
unable to elevate cAMP levels in the cells. The effects have been compared to the activation by 10 µM 
forskolin which was set at 100%. In the lower panel, the effect of the applied compounds was 
measured in the presence of 10 µM forskolin. First of all it can be noted that no compound was able 
to result in a cAMP decrease, meaning that none of the compounds acted in a Gi dependent manner. 
Anandamide was not able to produce an effect in any of the cell lines. The same was true for 2-AG. 
Here, the effect in the untransfected CHO-K1 cells was similar as in the transfected cells. This led us 
conclude that whatever causes the increase in cAMP in the cells is GPR18 independent. Δ9-THC caused 
an increase in cAMP predominantly in the CHO flip-in cells (clone V). Also, NAGly caused an increase in 
cAMP in both flip-in clones.  
From these results, it can be concluded that the investigated compounds, especially NAGly and Δ9-
THC, do not cause a Gi protein dependent decrease in cAMP levels.  
Whether the increase of cAMP is due to GPR18 further needs to be investigated.  
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3.2. Imidazothiazinones as GPR18 antagonists 
3.2.1. Introduction 
 
Rempel et al. discovered imidazothiazinones as antagonists of the orphan GPR18 by screening a 
compound library for antagonistic activity versus Δ9-THC in a β-arrestin recruitment assay. They 
investigated the structure-activity relationships of this compound class and were able to identify some 
basic features required for GPR18 inhibition. Subsequently, they developed PSB-CB-5 (17), the first 
potent and selective GPR18 antagonist, which was further characterized in this thesis.66 The results 
presented in this chapter complete previous studies of this first class of GPR18 antagonists.  
All investigated compounds were synthesized by the group of Professor Katarzyna Kiéc-Kononowicz 
in Cracow, Poland, and are part of the compound library of the PharmaZentrum Bonn (PZB).  
Previous results for this compound class, which are necessary to understand the structure-activity 
relationships are as follows: The compounds can roughly be divided into two groups: (i) derivatives 
with small substituents at the benzylidene residue and (ii) compounds with larger residues in meta-
position. As can be seen in Table 6, PSB-CB-5 (17) is the most potent GPR18 antagonist in this series 
with an IC50 value of 0.279 µM. It is a para-chlorobenzoyloxy-substituted derivative, one of the largest 
compounds in this set. The o,p-chloro-substituted compound 43 displayed a ten-fold weaker inhibition 
with an IC50 value of 2.55 µM. None of the compounds with smaller residues was able to inhibit GPR18 
activation. To test selectivity using the same β-arrestin test system at a related receptor, potency at 
the orphan GPCR GPR55 was always determined in parallel. Interestingly, some rather small 
substituents such as chlorine at the benzylidene residue resulted in compounds that were able to 
inhibit GPR55 activation. However, only the o-chloro and the o,m-di-chloro benzylidene derivatives 
were antagonists, but not the p-chlorobenzylidene-substituted one. For compounds with larger 
substituents, e.g. the p-chlorobenzoyloxy derivatives of PSB-CB-5 (17), no inhibition could be observed 
at GPR55. For some of the compounds, thiazepine analogues were obtained, the p-chlorobenzyloxy-
substituted derivative 45 completely failed to inhibit GPR18 activation, showing that the size was 
crucial at least in this case. However, compound 43 and 48, the latter being a thiazepine, showed 
almost no difference in potency. Interestingly, compound 45 turned out to be a GPR55 agonist of 
moderate potency with an EC50 value of 10.7 µM.66 
As can be concluded, the structure-activity relationships for this compound class is still incomplete 
and more modifications are needed to further explore the interaction of imidazothiazinones both with 
GPR18 and GPR55. The antagonist PSB-CB-5 (17) will be investigated to gain more insight in the 
functional profile of this compound.  
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Table 6: Potencies of chosen imidazothiazinones in β-arrestin assays for GPR18 and GPR55, data by Dr. 
Viktor Rempel66 
 
  Human GPR18 Human GPR55 
No Compd. Chemical structure Antagonistic 
activity 
Agonistic 
actvity 
Antagonistic 
activity 
Agonist 
activity 
  IC50 ± SEM 
(µM) 
EC50 (µM) 
IC50 ± SEM 
(µM) 
EC50 (µM) 
Imidazo[2,1-b][1,3]thiazin-3-ones (A) 
36 ChM-13 
 
 
>10 (5%) >10 (7%) >10 (25%) >10 (32%) 
37 B-54 
 
 
>10 (18%) >10 (13%) >10 (35%) >10 (-33%) 
38 ChM-6 
 
 
>10 (14%) >10 (-2%) >10 (42%) >10 (9%) 
39 ChM-1 
 
 
 
>10 (6%) >10 (20%) 5.09 ± 0.35 >10 (27%) 
40 ChM-40 
 
>10 (0%) >10 (17%) 6.91 ± 1.04 >10 (3%) 
41 ChM-3 
 
 
 
>10 (13%) >10 (-20%) >10 (16%) >10 (26%) 
42 CB-3 
 
 
 
7.22 ± 3.42 >10 (-4%) >10 (0%) >10 (37%) 
17 CB-5 
(PSB-CB-5) 
  
 
0.279 ± 0.11
1 
>10 (-27%) >10 (0%) >10 (21%) 
43 CB-4 
 
 
2.55 ± 0.71 >10 (-23%) >10 (0%) >10 (12%) 
44 CB-1 
 
>10 (14%) >10 (0%) >10 (16%) >10 (31%) 
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Imidazo[2,1-b][1,3]thiazepin-3-ones (B) 
45 ChM-72 
 
 
>10 (32%) >10 (-3%) - 10.7 ± 0.3 
46 CB-8 
 
>10 (15%) >10 (-6%) >10 (27%) ~10 (52%) 
47 CB-9 
 
 
6.48 ± 1.20 >10 (-19%) >10 (43%) >10 (7%) 
48 ChM-73 
 
4.61 ± 2.36 >10 (-32%) >10 (33%) >10 (16%) 
Imidazo[2,1-b][1,3]thiazin-2-ones (D) 
49 ChM-44 
 
>10 (2%) >10 (9%) >10 (0%) ~10 (59%) 
 
 
3.2.2. Pharmacological evaluation of PSB-CB-5 
 
The concentration-dependent inhibition of GPR18 by PSB-CB-5 (17) determined in a β-arrestin assay is 
shown in Figure 24. The inhibition of the Δ9-THC-induced signal reached only up to 60%. Therefore, 
PSB-CB-5 (17) can be regarded as a partial antagonist versus Δ9-THC. PSB-CB-5 (17) was also 
administered in a fixed concentration of 3 µM to different concentrations of Δ9-THC, showing a 
rightward shift of the activation curve (experiments by Viktor Rempel).66 This may indicate a 
competitive mechanism of inhibition at the binding site.  
 
Figure 24: Inhibition of β-arrestin recruitment of human GPR18 by PSB-CB-5 (17) (n = 3) 
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From the results in 3.1.2, we know that Δ9-THC does not generate the expected signal in cAMP 
assays in our test system. To get an idea if or how PSB-CB-5 (17) acts in cAMP assays it was 
administered with or without 10 µM of forskolin. The results are shown in Figure 25.  
 
Figure 25: Effects of PSB-CB-5 (17) on cAMP accumulation, in the presence or absence of forskolin 
in different cell lines stably expressing GPR18 
 
In the absence of forskolin, no cAMP was produced by 10 µM PSB-CB-5 (17). In the presence of 
forskolin, the cAMP level stayed the same compared to a forskolin control. Therefore, it can be 
concluded that as expected PSB-CB-5 (17) does not act as an agonist in a Gs or Gi protein-dependent 
manner at GPR18.  
So far, no GPR18 agonist has been identified that activates Gi or Gs. Therefore, PSB-CB-5 (17) cannot 
be evaluated as an antagonist in cAMP assays.  
 
3.2.3. Results for imidazothiazinones in β-arrestin assays 
 
Further compounds of this series were investigated in β-arrestin assays to establish comprehensive 
structure-activity relationships. All compounds were synthesized by the group of Prof. Kiéc-
Kononowicz. Both, the smaller ligands for GPR55 and the larger GPR18 ligands were further modified 
to systematically analyze the structure-activity relationships. In Table 7, Table 8 and Table 9, the 
potencies of these compounds are collected. Compounds in Table 7 belong to the class of 
imidazothiazin-3-ones (group A), which had been proven to be active (see 3.2.1).  
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Table 7: Potencies of imidazothiazinones at human GPR18 and GPR55 in β-arrestin assays 
 
  Human GPR18 Human GPR55 
No. Compd. Chemical structure Antagonistic 
activity 
Agonistic 
actvity 
Antagonistic 
activity 
Agonist 
activity 
  IC50 ± SEM 
(µM) 
EC50 (µM) 
IC50 ± SEM 
(µM) 
EC50 (µM) 
Imidazo[2,1-b][1,3]thiazin-3-ones (group A) 
 
 
    
 R1 R2 R3 R4 R5     
50 CB-11 F H H H H >10 (17%) >10 (6%) 5.56 ± 1.10 >10 (0%) 
51 CB-37 Br H H H H >10 (12%) >10 (-2%) 17.7 ± 6.1 >10 (-6%) 
52 CB-41 OH H H H H >10 (33%) >10 (-17%) >10 (30%) >10 (-24%) 
53 CB-36 CH3 H H H H >10 (8%) >10 (0%) >10 (39%) >10 (-5%) 
54 CB-39 H H F H H >10 (12%) >10 (12%) >10 (9%) >10 (-5%) 
55 CB-38 H H CH3 H H >10 (15%) >10 (13%) >10 (29%) >10 (-1%) 
56 CB-13 F F H H H >10 (3%) >10 (4%) 3.15 ± 0.20 >10 (0%) 
57 CB-46 CH3 CH3 H H H >10 (16%) >10 (-1%) 20.6 ± 5.8 >10 (-20%) 
58 CB-17 OCH3 OCH3 H H H >10 (10%) >10 (10%) 16.4 ± 5.8 >10 (0%) 
59 CB-14 F H F H H >10 (6%) >10 (11%) 3.46 ± 1.34 >10 (0%) 
60 CB-16 Cl H Cl H H >10 (14%) >10 (0%) 6.76 ± 1.37 >10 (0%) 
61 CB-42 Br H Br H H >10 (26%) >10 (16%) >10 (24%) >10 (-11%) 
62 CB-44 OH H OH H H >10 (2%) >10 (30%) 11.8 ± 1.8 >10 (-33%) 
63 CB-45 CH3 H CH3 H H >10 (15%) >10 (7%) 2.93 ± 0.30 >10 (-14%) 
64 CB-18 Cl H H H Cl >10 (0%) >10 (12%) >10 (0%) >10 (15%) 
65 CB-43 H Br Br H H >10 (17%) >10 (22%) >10 (4%) >10 (-15%) 
66 CB-34B H OH OH H H >10 (39%) >10 (-4%) 11.0 ± 0.5 >10 (-44%) 
67 CB-34A 
 
>10 (21%) >10 (3%) >10 (19%) >10 (-3%) 
68 CB-21 
 
>10 (3%) >10 (6%) 4.22 ± 1.66 >10 (-30%) 
69 CB-20 
 
1.73 ± 0.371 >10 -9%) 45.8 ± 21.0 >10 (-19%) 
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70 CB-22 
 
3.59 ± 2.25 >10 (2%) 9.45 ± 3.71 >10 (-31%) 
71 CB-15 
 
1.65 ± 0.45 >10 (8%) >10 (4%) >10 (10%) 
72 CB-19 
 
6.16 ± 2.86 >10 (0%) 11.8 ± 2.1 >10 (4%) 
73 CB-23 
 
>10 (16%) >10 (8%) 29.3 ± 13.9 >10 (-42%) 
74 CB-24 
 
1.49 ± 0.387 >10 (-30%) 6.04 ± 1.62 >10 (-49%) 
75 CB-30 
 
5.00 ± 0.392 >10 (-10%) 10.1 ± 2.4 >10 (-20%) 
76 CB-25 
 
3.25 ± 1.22 >10 (-16%) >10 (38%) >10 (-36%) 
77 CB-28 
 
2.38 ± 1.15 >10 (-16%) >10 (26%) >10 (11%) 
78 CB-26 
 
1.14 ± 0.44 >10 (-38%) 3.77 ± 0.23 >10 (-21%) 
79 CB-27 
 
0.650 ± 0.134 >10 (-37%) >10 (37%) >10 (-15%) 
80 CB-29 
 
1.15 ± 0.17 >10 (-25%) >10 (43%) >10 (-18%) 
81 CB-47A  
 
>10 (8%) >10 (4%) >10 (44%) >10 (-14%) 
82 CB-48 
 
>10 (42%) >10 (21%) 10.4 ± 2.4 >10 (-8%) 
83 CB-55 
 
8.63 ± 3.03 >10 (-27%) 3.70 ± 1.02 >10 (7%) 
84 CB-56 
 
>10 (33%) >10 (-9%) 12.8 ± 3.5 >10 (9%) 
a Percent inhibition of agonist-induced luminescence signal (GPR18: 10 µM THC; GPR55: 1 µM LPI) 
b Percent activation compared to agonist-induced luminescence signal (GPR18: 10 µM THC; GPR55: 1 µM LPI) 
 
 
The GPR55 inhibitors 39 (IC50 = 5.09 µM) and 40 (IC50 = 6.91 µM) were both chloro-substituted 
compounds, the first one in the ortho-position the latter one in the ortho- and meta-position of the 
benzylidene residue. This type of compound was further investigated. The corresponding ortho-fluoro-
substituted compound 50 showed a quite similar potency as compound 39 with an IC50 value of 5.56 µM. 
 3 Medicinal Chemistry of GPR18 agonists and antagonists   
46 
 
When this substituent was changed to bromo, the potency decreased ((compound 51: IC50 value of 
17.7 µM). The ortho-,meta-difluoro derivative 56 showed a slightly increased potency in comparison to 
the ortho-,meta-dichloro-analogue 40 with an IC50 value of 3.15 µM. When substituting with di-methyl or 
di-methoxy residues, the potency decreased. Additionally, the ortho-,para-difluoro compound 59 showed 
an IC50 value of 3.46 µM, which was in the same range as that of the ortho-,meta-di-substituted compound 
29. This can also be observed for the corresponding di-chloro-derivatives (compare compound 40 and 60). 
The ortho-,para-dibromo-substituted compound 61 was inactive 61, as also the hydroxyl-substituted 
derivative 62. Interestingly, the ortho-,para-dimethyl derivative 63 was slightly more active with an IC50 
value of 2.93 µM. This compound was the most potent compound at GPR55 of the whole series. None of 
the compounds showed any inhibitory or activating properties at GPR18 up to a concentration of 10 µM. 
It appears that GPR55 requires compounds with an ortho-substitution with a small lipophilic residue as 
such fluorine or chlorine. Compounds that are only substituted in the meta- or para-position were not 
inhibiting GPR55 (e.g. compound 38, 37 and 54). None of the compounds showed any activation of GPR55.  
Based on the structural properties of the potent and selective GPR18 antagonist PSB-CB-5 (17), further 
derivatives were synthesized and investigated. PSB-CB-5 (17) itself has a para-chlorobenzyloxy residue in 
the meta-position of the benzylidene residue. The corresponding fluorinated compound 68 showed no 
inhibitory potency at GPR18, but the brominated compound 69 displayed an IC50 value of 1.73 µM. The 
inhibition of Δ9-THC-induced β-arrestin recruitment by PSB-CB-5 (17) was incomplete and reached only 
60% (compare Figure 24 (A)). It can therefore be regarded as a partial antagonist versus Δ9-THC. However, 
compound 69 showed a complete inhibition of the signal and acted as a full antagonist. A comparable 
inhibitory potency was shown by compound 71, which has a chlorine atom in the ortho-position of the 
benzyloxy residue. The di-chlorinated compound 72 (in the para- and meta-position) and the methylated 
compound 70 both showed lower potency, with IC50 values of 6.16 µM and 3.59 µM, respectively. The 
phenylpropyloxy residue of compound 74 led to an IC50 value of 1.49 µM. However, the phenylethyloxy 
derivative 46 was without any activity up to a concentration of 10 µM. A series of phenyloxyalkyloxy-
substituted compounds was investigated. The length of the alkyl linker was varied from ethyl to hexyl and 
octyl. The results for these series of compounds are displayed in Figure 26.  
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Figure 26: Influence of the methylene chain length of the phenyloxyalkyloxy derivatives on GPR18 
inhibitory potency 
 
With six methylene groups in the phenyloxyalkyloxy residue and an IC50 value of 0.650 µM, compound 
79 was the most potent antagonist of this small series of compounds. It is not as potent as the already 
described compound PSB-CB-5 (17), but as can be seen in Figure 26 (B) the compound showed full 
inhibition of the Δ9-THC-induced effect and can be regarded as full antagonist at GPR18, while PSB-CB-5 
(17) displayed a maximal effect of only 60%. The compounds with eight or five methylene groups were 
slightly less potent with potencies of around 1 µM. When the alkyl chain length decreased also the activity 
decreased. Compound 75 (n = 2) showed weak inhibitory potency at GPR55 with an IC50 value of 10.1 µM. 
Compound 78 (n = 5), which was relatively potent at GPR18 (IC50 value of 1.14 µM) showed also moderate 
inhibitory potency at GPR55 (IC50 value of 3.77 µM). There appears to be no clear structural dependency 
for a compound’s activity at GPR55, yet. 
Some compounds with alkyl residues instead of the aromatic residue have been investigated. Only the 
octyloxy derivative 83 led to potency at GPR18 with an IC50 value of 8.63 µM. All other aliphatic 
substitutions were unbeneficial for GPR18 affinity. In contrast, most of them showed at least moderate 
potency at GPR55.  
Instead of varying the benzylidene residue, the imidazothiazinone can be exchanged for different 
heterocycles, thereby expanding or contradicting the sulfur-containing ring. Furthermore, the importance 
of the thiazine residue was to be monitored by deleting and exchanging it. The results of these 
modifications are shown in Table 8.  
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Table 8: Potencies for oxosulfanylimidazoles as GPR18 and GPR55 antagonists 
 
  Human GPR18 Human GPR55 
No. Compd. Chemical  
structure 
Antagonistic 
activity 
Agonistic 
actvity 
Antagonistic 
activity 
Agonist 
activity 
  IC50 ± SEM 
(µM)a 
EC50 
(µM)b 
IC50 ± SEM 
(µM)a 
EC50 
(µM)b 
Imidazo[2,1-b][1,3]thiazin-3-ones (A) 
85 CB-59 
 
 
33.0 ± 7.8 >10 (-14%) 32.4 ± 15.2 >10 (5%) 
86 CB-61 
 
 
>10 (22%) >10 (-38%) >10 (-18%) >10 (29%) 
87 CB-62 
 
 
>10 (4%) >10 (6%) >10 (-5%) >10 (22%) 
88 CB-63 
 
 
>10 (-10%) >10 (-1%) >10 (-1%) >10 (22%) 
89 CB-60 
 
 
13.8 ± 5.4 >10 (31%) >10 (47%) >10 (18%) 
90 CB-66 
 
 
>10 (23%) >10 (-2%) >10 (35%) >10 (-2%) 
91 CB-70 
 
 
>10 (3%) >10 (-17%) >10 (17%) >10 (21%) 
92 CB-74 
 
>10 (27%) >10 (23%) >10 (44%) >10 (-21%) 
93 CB-76 
 
 
>10 (35%) >10 (5%) >10 (41%) >10 (-10%) 
94 CB-71 
 
 
2.29 ± 0.72 
(max. 
inhibition: 
44%) 
>10 (-11%) >10 (36%) >10 (13%) 
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95 CB-75 
 
 
>10 (0%) >10 (4%) >10 (48%) >10 (-12%) 
96 CB-77 
 
 
>10 (17%) >10 (7%) >10 (33%) >10 (20%) 
97 CB-78 
 
 
4.78 ± 1.82 >10 (2%) >10 (27%) >10 (21%) 
98 CB-72-1,2 
 
 
>10 (25%) >10 (13%) >10 (19%) >10 (2%) 
99 CB-72-2,3 
 
>10 (40%) >10 (1%) >10 (42%) >10 (-3%) 
a % inhibition of standard agonist-induced luminescence signal (GPR18: 10 µM Δ9-THC; GPR55: 1 µM LPI) 
b % activation compared to standard agonist-induced luminescence signal (GPR18: 10 µM Δ9-THC; GPR55: 
1 µM LPI) 
 
 
Only two compounds of this set showed an IC50 value below 10 µM. These two compounds were 97 
(with an IC50 value of 4.78 µM and 94 (with an IC50 value of 2.29 µM, maximum inhibition: 44%). Both 
compounds shared a structural feature: an imidazole ring, substituted with a para-bromo-
benzylthioether (94) or a phenylpropylthioether (97). There were some compounds, which were also 
substituted with a benzylthioether, but they were not active at all (for example, compound 92, 95, 93). 
Compound 94 with its para-bromo-benzyl residue had one of the largest lipophilic residue and the 
lipophilic residue of compound 97 was even larger. It appears to be that the lipophilic bulky residue is 
necessary for GPR18 inhibition.  
The contraction of the heterocyclic system was not successful; none of the compounds with an 
imidazole was active. The only active compounds 94 and 97 have large lipophilic residues. None of the 
compounds showed activity at GPR55.  
PSB-CB-5 (17) contains a meta-benzyloxy-residue. A small set of para-substituted compounds were 
synthesized and evaluated, as can be seen in Table 9.  
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Table 9: Potencies of imidazothiazinones with para-orientated benzylidene-residue, results for GPR18 
and GPR55 
 
   human GPR18 human GPR55 
No. Compd. Chemical structure 
antagonistic 
activity 
agonistic 
actvity 
antagonistic 
activity 
agonist 
activity 
   
IC50 ± SEM 
(µM) 
EC50 (µM) 
IC50 ± SEM 
(µM) 
EC50 (µM) 
Imidazo[2,1-b][1,3]thiazin-3-ones (A) 
100 CB-10 
 
22.2 ± 8.6 >10 (-12%) 2.23 ± 0.30 >10 (-12%) 
101 CB-57 
 
>10 (17%) >10 (18%) 27.4 ± 11.0a >10 (11%) 
102 CB-12 
 
>10 (48%) >10 (-5%) >10 (28%) >10 (-11%) 
103 CB-58 
 
>10 (6%) >10 (-3%) >10 (12%) >10 (8%) 
104 CB-84 
 
>10 (34%) >10 (8%) >10 (39%) >10 (-12%) 
105 CB-83 
 
>10 (29%) >10 (18%) 12.2 ± 4.2 >10 (-40%) 
106 CB-64 
 
>10 (17%) >10 (-5%) >10 (25%) >10 (9%) 
107 CB-33 
 
>10 (-5%) >10 (15%) >10 (-3%) >10 (13%) 
108 CB-31 
 
>10 (17%) >10 (10%) >10 (-25%) >10 (9%) 
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109 CB-32 
 
>10 (7%) >10 (15%) >10 (-5%) >10 (12%) 
110 CB-65 
 
>10 (16%) >10 (31%) >10 (33%) >10 (-11%) 
111 CB-73 
 
>10 (31%) >10 (2%) >10 (49%) >10 (-12%) 
112 CB-69 
 
>10 (12%) >10 (16%) >10 (13%) >10 (-1%) 
113 CB-35 
 
>10 (13%) >10 (3%) >10 (18%) >10 (-3%) 
114 CB-68 
 
>10 (38%) >10 (22%) >10 (26%) >10 (2%) 
115 CB-40 
 
>10 (27%) >10 (9%) >10 (30%) >10 (-10%) 
Imidazo[2,1-b][1,3]thiazepin-3-ones (B) 
116 CB-67 
 
>10 (-14%) >10 (2%) >10 (-23%) >10 (30%) 
Imidazo[2,1-b][1,3]oxazin-3-ones (C) 
117 CB-80 
 
>10 (8%) >10 (2%) 9.09 ± 3.40c >10 (-10%) 
118 CB-86 
 
>10 (-10%) >10 (11%) >10 (38%) >10 (13%) 
Imidazo[2,1-b][1,3]thiazin-2-ones (D) 
119 CB-47B  >10 (4%) >10 (6%) >10 (46%) >10 (-7%) 
a % inhibition of standard agonist-induced luminescence signal (GPR18: 10 µM Δ9-THC; GPR55: 1 µM 
LPI) 
b % activation compared to standard agonist-induced luminescence signal (GPR18: 10 µM Δ9-THC; 
GPR55: 1 µM LPI) 
c extrapolated value 
 
The para-substituted analogue of PSB-CB-5 (17), compound 100, was the only compound of this 
series that showed inhibitory potency for the human GPR18, but with an IC50 value of 22.2 µM it is 80-
fold weaker as compred to PSB-CB-5 (17). Interestingly, it displayed a higher inhibition for GPR55, 
which is typically not inhibited by these larger residues. With an IC50 value of 2.23 µM, it was ten-fold 
more active at the human GPR55 than at GPR18. Further compounds of this group were tested and 
some also showed weak inhibitory potency for GPR55, but compound (100) was by far the most potent 
compound. None of the compounds were active at GPR18.  
Altogether, three very different substitution patterns have been evaluated at GPR18 and GPR55. 
The first hits were further investigated by introducing different substituents in different positions at 
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the benzylidene residue, and also by replacing the imidazothiazinones by different heterocycles. The 
results of this study are summarized in Figure 27.  
 
Figure 27: Structure-activity relationships of imidazothiazinones as GPR18 and GPR55 antagonists 
 
PSB-CB-5 (17) was the most potent compound of this series with an IC50 value of 0.279 µM, but it 
showed only a partial inhibition of the Δ9-THC-induced signal. Compound 79 was shown to inhibit the 
Δ9-THC-induced signal completely, but displayed a higher IC50 value of 0.650 µM. For GPR55 inhibtion, 
very small residues at the benzylidene residue were crucial, especially, an ortho-halogen or ortho-
methyl residue, which can be combined with a para-halogen or a methyl group. The most potent 
GPR55 antagonist so far was compound 63 with an IC50 value of 2.93 µM, but did not show any 
inhibition of GPR18 up to 10 µM.  
The structure-activity relationships of this compound class have been studied extensively at GPR18 
and GPR55. 68 new compounds have been investigated and described in this study. PSB-CB-5 (17) is 
still the most potent GPR18 antagonist.  
 
3.2.4. Selectivity of imidazothiazinones versus cannabinoid receptors 
 
The selectivity of GPR18 and GPR55 antagonists versus both cannabinoid receptors is of major 
importance. Cannabinoid receptors and orphan GPR18 share the ability to interact with similar ligands. 
For this study, a binding assay employing the tritiated radioligand CP55,940 was used. CP55,940 is an 
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agonist ligand of high affinity for both cannabinoid receptors, and therefore a suitable tool to test 
binding affinity for comparison.  
Table 10: Affinities of imidazothiazinones for CB1 and CB2 cannabinoid receptor determined in 
radioligand binding assays versus [3H]CP55,940 (for chemical structures view Table 7, Table 8, and 
Table 9) 
 Radioligandbinding 
  Human CB1 Human CB2 
No. Compd.b Ki (µM) vs. [3H]CP55,940 
(% inhibition of specific 
binding) 
Ki (µM) vs. [3H]CP55,940 
(% inhibition of specific 
binding) 
36 ChM-13a >10 (40%) >10 (18%) 
37 B-54a >10 (25%) >10 (23%) 
38 ChM-6a >10 (30%) >10 (2%) 
39 ChM-1a >10 (0%) >10 (21%) 
40 ChM-40a >10 (12%) >10 (40%) 
41 ChM-3a >10 (29%) >10 (8%) 
42 CB-3a >10 (25%) 1.11 ± 0.01 
17 PSB-CB-5a >10 (0%) 4.03 ± 0.51 
43 CB-4a 2.09 ± 0.08 0.950 ± 0.269 
44 CB-1a >10 (12%) >10 (0%) 
45 ChM-72a 0.251 ± 0.064 4.15 ± 0.39 
46 CB-8a 2.16 ± 0.07 >10 (37%) 
47 CB-9a 2.29 ± 0.46 0.98 ± 0.23 
48 ChM-73a 3.18 ± 0.49 1.65 ± 0.71 
49 ChM-44a >10 (26%) >10 (19%) 
50 CB-11 >10 (13%) >10 (0%) 
51 CB-37 >10 (-16%) >10 (10%) 
52 CB-41 >10 (2%) > 10 (17%) 
53 CB-36 >10 (2%) >10 (11%) 
54 CB-39 >10 (-25%) >10 (10%) 
55 CB-38 >10 (-6%) >10 (32%) 
56 CB-13 >10 (13%) >10 (0%) 
57 CB-46 >10 (-13%) >10 (25%) 
58 CB-17 >10 (18%) >10 (15%) 
59 CB-14 >10 (13%) >10 (0%) 
60 CB-16 >10 (8%) >10 (24%) 
61 CB-42 >10 (7%) >10 (18%) 
62 CB-44 >10 (5%) >10 (12%) 
63 CB-45 >10 (7%) >10 (-6%) 
64 CB-18 >10 (14%) >10 (4%) 
65 CB-43 >10 (35%) >10 (22%) 
66 CB-34B >10 (13%) >10 (20%) 
67 CB-34A >10 (11%) >10 (38%) 
68 CB-21 >10 (35%) >10 (46%) 
69 CB-20 >10 (4%) >10 (4%) 
70 CB-22 >10 (22%) >10 (25%) 
71 CB-15 >10 (0%) >10 (9%) 
72 CB-19 >10 (15%) >10 (0%) 
73 CB-23 >10 (24%) >10 (19%) 
74 CB-24 >10 (11%) >10 (23%) 
75 CB-30 >10 (21%) >10 (-9%) 
 3 Medicinal Chemistry of GPR18 agonists and antagonists   
54 
 
76 CB-25 >10 (18%) >10 (-2%) 
77 CB-28 >10 (-19%) >10 (3%) 
78 CB-26 >10 (8%) >10 (-11%) 
79 CB-27 >10 (-14%) >10 (12%) 
80 CB-29 >10 (-9%) >10 (-3%) 
81 CB-47A >10 (32%) >10 (34%) 
82 CB-48 >10 (33%) >10 (34%) 
83 CB-55 >10 (8%) >10 (19%) 
84 CB-56 2.48 ± 0.27 
max. inhibition of 
radioligand-binding: 75% 
1.91 ±0.55 
max. inhibition of 
radioligand-binding: 69% 
85 CB-59 >10 (30%) >10 (19%) 
86 CB-61 >10 (47%) >10 (26%) 
87 CB-62 >10 (43%) 22.8 ± 4.0 
88 CB-63 5.04 ± 1.09 
max. inhibition of 
radioligand-binding: 67% 
>10 (41%) 
89 CB-60 2.21 ± 0.57 0.591 ±0.031 
max. inhibition of 
radioligand-binding: 73% 
90 CB-66 >10 (19%) >10 (24%) 
91 CB-70 >10 (11%) >10 (46%) 
92 CB-74 >10 (42%) >10 (19%) 
93 CB-76 >10 (36%) >10 (30%) 
94 CB-71 >10 (31%) >10 (36%) 
95 CB-75 >10 (38%) >10 (22%) 
96 CB-77 >10 (15%) >10 (25%) 
97 CB-78 >10 (18%) >10 (33%) 
98 CB-72-1,2 1.67 ± 0.84 
max. inhibition of 
radioligand-binding: 60% 
>10 (41%) 
99 CB-72-2,3 >10 (18%) >10 (28%) 
100 CB-10 >10 (40%) >10 (12%) 
101 CB-57 >10 (21%) >10 (-11%) 
102 CB-12 >10 (-4%) >10 (-17%) 
103 CB-58 >10 (19%) >10 (20%) 
104 CB-84 >10 (33%) >10 (45%) 
105 CB-83 >10 (33%) 0.668 ± 0.253 
max. inhibition of 
radioligand-binding: (63%) 
106 CB-64 >10 (44%) 0.202 ± 0.086 
max. inhibition of 
radioligand-binding: 69% 
107 CB-33 >10 (35%) >10 (40%) 
108 CB-31 >10 (36%) > 10 (30%) 
109 CB-32 >10 (37%) > 10 (30%) 
110 CB-65 >10 (31%) 0.853 ± 0.358 
max. inhibition of 
radioligand-binding: (76%) 
111 CB-73 >10 (38%) >10 (46%) 
112 CB-69 >10 (49%) 0.942 ± 0.628 
113 CB-35 >10 (36%) >10 (18%) 
114 CB-68 >10 (23%) >10 (34%) 
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115 CB-40 >10 (3%) >10 (22%) 
116 CB-67 2.55 ± 0.22 
max. inhibition of 
radioligand-binding: 62% 
>10 (46%) 
117 CB-80 1.54 ± 0.51 
max. inhibition of 
radioligand-binding: 75% 
>10 (47%) 
118 CB-86 >10 (36%) >10 (45%) 
119 CB-47B >10 (34%) >10 (44%) 
a data determined by Dr. Viktor Rempel66 
b for chemical structures see Table 6, Table 7, Table 8 and Table 9 
 
PSB-CB-5 (17), the hit compound for GPR18 inhibition, showed a Ki value of 4.03 µM for the CB2 
receptor. This correlates to a 14-fold selectivity for GPR18 over CB2. Compound 43, which is also a quite 
potent GPR18 antagonist, showed a Ki value of 2.09 µM for CB1 and a Ki value of 0.95 µM for CB2. These 
two examples indicate that the selectivity of this compound class needs to be optimized.  
To understand the binding behavior of this class of compound completely, all compounds have 
been evaluated. Compound 106 showed the highest affinity for CB2 with a Ki value of 0.202 µM but 
only a partial inhibition of radioligand binding (69%). It is one of the compounds, which have a para-
substituted benzylidene residue, and were therefore not active at GPR18. Compound 45 showed the 
highest affinity for CB1 with a Ki value of 0.251 µM. It is the only GPR55 agonistic compound of this 
series with an EC50 value of 10.2 µM. Four other para-substituted compounds (110, 112, 116 and 117) 
showed Ki values in the low micromolar or submicromalor range for the CB2 receptor and two further 
at the CB1 receptor. In the group of compounds with different heterocycles linked to the benzylidene 
residue only compounds 89 and 88 showed some affinity to the CB receptors. They were not active at 
GPR18 or GPR55. The phenyloxyalkyloxy compound group that was discussed above does not show 
any affinity to one of the receptors.  
In summary, it can be concluded that most of the compounds are selective versus both CB 
receptors. Only very few compounds show an affinity to one or both CB receptors. The most potent 
GPR18 antagonist PSB-CB-5 (17) shows a 14-fold selectivity versus CB2 and no affinity up to 
concentrations of 10 µM for the CB1 receptor. Nevertheless, the selectivity should be optimized. 
Structural features, which led to for CB receptor binding, were especially the thiazepine ring together 
with the meta- or para- substituted benzylidene ring. Here bulky, lipophilic residues were preferred, 
as the p-chlorobenzyloxy substituent of compound 45 and PSB-CB-5 (17). However, the p-
bromobenzyloxy residue was not active. The structure-activity relationships were summarized in 
Figure 28. 
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Figure 28: Structure-activity relationships for imidazothiazinones at the CB receptors 
 
3.2.5. Selectivity versus GABAA receptors 
 
Some of the compounds, which were originally included in the screen, had been developed as 
GABAA receptor ligands, but had only shown low or moderate binding to the benzodiazepine binding 
site of the GABAA-receptor.169 To exclude the possibility that the newly developed GPR18 antagonists 
also interact with this target the lead compounds were evaluated for their ability to replace 
radiolabeled diazepame from its binding site at rat brain membrane preparations. For comparison, 
some of the previously developed compounds were also investiagted together with the most potent 
GPR18 antagonists (as can be seen in Figure 29).  
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Figure 29: Inhibition of specific binding of [3H]diazepam to rat brain membrane preparations by 
selected compounds 
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The two compounds 48 and 38 showed an inhibitory potential – which was expected based on the 
results reported by Kiéc-Kononowicz et al. (2004).169 For compound 48 the Ki value was determined 
and found to be slightly higher as the literature value (Ki = 2.2 µM)169, namely 18.9 µM in our current 
experiment. Heterologous competition was also performed with unlabeled diazepam to control 
whether the literature KD value (4 nM) can be used for further calculation. Diazepam showed a Ki value 
of 9.72 nM in the heterologous binding experiment, which was in the same range. 
 
Figure 30: Heterologous competition binding of diazepam (left side) and compound 48 (right 
side). Compound 48 showed a Ki value of 18.9 ± 5.4 after extrapolation 
 
Most importantly, PSB-CB-5 (17), our optimized GPR18 antagonist, does not show any affinity to 
the diazepam binding site of GABAA receptors up to concentrations of 10 µM. This was also true for 
structurally related compounds such as 43, 102 and 56. The optimized structures were no GABAA 
receptor ligand and it appears that by optimizing the compounds for GPR18 the GABAA affinity was 
lost.  
 
3.2.6. Summary: imidazothiazinones as GPR18 antagonists 
 
In this study, a series of 79 compounds was investigated for their ability to act as antagonists at 
GPR18 and GPR55. The most potent compound was PSB-CB-5 (17), which was first described by Viktor 
Rempel, with an IC50 value of 0.279 µM, but only partial inhibition of Δ9-THC-induced β-arrestin 
recruitment (60%). Three different types of substitutents were evaluated as shown in Figure 31. The 
results were used to analyze structure-activity relationships for this compound class.  
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Figure 31: Investigated structural variations of the hit compound PSB-CB-5 (17) 
 
Different heterocycles showed no improvement in potency at GPR18. The thiazepine ring of 
compound 45 led to a weak GPR55 activation (EC50 value of 10.1 µM), but to a loss in GPR18 potency. 
The substitution pattern of the benzylidene residue was of major importance to distinguish between 
GPR55 and GPR18 inhibition. Small lipophilic substitutions, such as o,p-difluoro and o,p- dimethyl led 
to an improved GPR55 inhibition without affecting GPR18 activation. ortho-Substitution was necessary 
to achieve GPR55 inhibition. For GPR18, long lipophilic residues in the meta-position were crucial for 
inhibitory potency. PSB-CB-5 (17), the para-chlorobenzyloxy compound, showed an IC50 value of 0.279 
µM with an efficacy of 60% against Δ9-THC induced β-arrestin recruitment. The para-position of the 
benzyloxy residue needed to be substituted with a lipophilic residue of a certain size; the 
corresponding bromo-derivative was moderately active, the para-fluoro derivative was not active at 
all. Long lipophilic residues such as a para-substituted phenyloxyalkyloxy residues showed also 
potencies in the submicromolar range. Compound 79 with a hexyl chain was the most potent derivative 
with an IC50 value of 0.650 µM and a maximal inhibition of 100%. This group of compounds showed 
potency, but their physicochemical properties are not favorable. The imdiazothiazinones are already 
very lipophilic compounds. By extending the lipophilic residues water-solubility and polarity are 
decreasing. Therefore, every further optimization should focus on decreasing the size and the 
lipophilicity of the compounds.  
 
Figure 32: Summary of the results of imidazothiazinones at GPR18 and GPR55 
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The selectivity of the compounds was also investigated not only against GPR55, but also against the 
cannabinoid receptors CB1 and CB2 and for few compounds also at the benzodiazepine binding site of 
GABAA receptors. Compounds with meta-substituted benzylidene residues were not active at GPR55, 
only compounds with small lipophilic residues especially in the ortho-position were GPR55 antagonists. 
A few compounds showed a moderate affinity to CB1 and CB2 receptors in radioligand binding assays. 
Some of the GPR18 antagonists bound weakly to CB2, as also the most potent compound PSB-CB-5 
(17). However, most of the compounds that bind to the CB receptors are not active at the orphan 
receptors. For selected compounds, GABAA receptor binding was investigated versus [3H]diezepam. 
The optimized GPR18 antagonists do not displace [3H]diazepam binding to rat brain cortex. In the 
future, the selectivity of the compounds against the CB receptors should be further enhanced.  
The antagonists for GPR18 were designed to act against the Δ9-THC-induced β-arrestin signal. As 
long as no endogenous ligand for GPR18 can be confirmed, it remains unclear whether these 
antagonists will inhibit the signal of an endogenous ligand. This information would be important to if 
the antagonists are to be used in native tissues or in animals.  
Nevertheless, the here investigated compound class can serve as useful tools to study GPR18 
pharmacology and (patho-)physiology.  
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3.3. GPR18 agonists 
3.3.1. Introduction 
 
As has been depicted in chapter 3.1, there is a growing number of compounds discussed to either 
activate or inhibit GPR18. Unfortunately, very controversial data exist in the literature for these 
compounds, which make it very difficult to rely on the effects of a compound in a biological system. 
Especially, as no clear confirmation for an endogenous ligand has been provided, the comparison of 
results from different test systems remains challenging. There is an urgent need to develop reliable 
tool compounds, both antagonists and agonists. Here, we want to show the results of an approach to 
study a new compound class of GPR18 agonists. These agonists are small molecules that do neither 
have a cannabinoid-like nor a lipid-like structure. For the first time, such synthetic small molecule 
agonists for the orphan GPR18 will be described. 
The here studied compound class was discovered through the screening of a sublibrary of the 
Pharma-Zentrum Bonn (https://www.pharma.uni-bonn.de/www/pharmchem1/ak-mueller/biblio-
thek). An initial hit from this screen was further investigated and could be confirmed. Subsequently, 
the structure-activity relationships of this compound class were established in cooperation with the 
group of Prof. Dr. Katarzyna Kiéc-Kononowicz from the Jagiellonian University of Cracow, who supplied 
the compounds. Selectivity versus cannabinoid receptors and also versus GPR55 was extensively 
studied. The pharmacological behavior against established antagonists was also studied and led to the 
assumption that GPR18 probably has more than one binding site. To further elucidate this, a modeling 
approach was conducted in collaboration with Jens Meiler from the Vanderbilt University including a 
research stay to learn the method and collect the data. The results of these studies will be presented 
in the following sub-chapters.  
 
3.3.2. Screening of Pharma-Zentrum Bonn libraries 
 
The Pharma-Zentrum Bonn maintains a professionally managed proprietary compound library. To 
also enable smaller screening campaigns with up to several hundred compounds, this compound 
library is subdivided into focused sublibraries. One of these sublibraries was used to screen for agonists 
and antagonists at the orphan GPR18 against 10 µM Δ9-THC as an agonist. Compounds were tested at 
a one-point screen in a concentration of 10 µM. Whenever compounds activated or inhibited GPR18 
by more than 50%, they were retested to confirm the result.  
One of the screened sublibraries, the xanthine library, consisted of 264 compounds. In the initial 
agonist screen, one prominent hit could be observed (see Figure 33, marked with an arrow). All 
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compounds were additionally tested for their potential antagonistic activity. The agonist hit could be 
confirmed.  
 
Figure 33: Initial screen of the xanthine sublibrary of the Pharma-Zentrum Bonn at the human 
GPR18 
 
For the hit compound 182, the concentration-dependent activation of GPR18 was further tested. 
As can be seen in Figure 34, the compound acted as full agonist in β-arrestin assays in comparison to 
the maximal effect of the agonist Δ9-THC with an EC50 value of 0.556 µM. The new agonist was a 
pyrimido-purindione derivative with an indolylethyl substitution. The indolylethyl-residue is a 
structural element that can be found quite often in natural products, - it is a component of tryptophan, 
one of the essential amino acids. Overall, it can be concluded that this compound does not display 
lipid-like structural properties. It rather displays a peptide-like structure. Further, it is a small molecule 
agonist with many positions that can further be investigated.  
 
 
Figure 34: Concentration dependent activation of human GPR18 in β-arrestin assays by 
compound 182 and chemical structure of compound 182.  
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3.3.3. Structure-activity relationship of indolylylethylaminoxanthines 
 
The newly identified compound class has been characterized by exploring the structure-activity 
relationships. The lead compound 182 consists of a xanthine moiety annelated with a 
tetrahydropyrimidine and an indolylethyl residue. There were several positions that were investigated 
for structure-activity relationships. As can be seen in Table 11, the tricyclic compound core has not 
been maintained in most compounds since it was discovered not to be required. A xanthine core was 
sufficient, where the N1- and the N7- positions were substituted with lipophilic residues of different 
sizes.  
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Table 11: Potencies of the indolylethylaminoxanthines at human GPR18 and human GPR55. 
  human GPR18 human GPR55 
No. Compd. Chemical structure Antagonistic 
activity 
Agonistic 
actvity 
Antagonistic 
activity 
Agonistic 
activity 
  
 
 
IC50 ± SEM (µM)a 
 
EC50 (µM)b 
% efficacyc 
IC50 ± SEM (µM)a 
 
EC50 (µM)b 
 
  R1 R2     
120 MZ1458 H H >10 (-30%) >10 (33%) >10 (27%) >10 (8%) 
121 KM-15-1 H CH3 >10 (2%) >10 (14%) >10 (3%) >10 (8%) 
122 MZ1459 H 
 
- 0.329 ± 0.064 
(104%) 
>10 (32%) >10 (2%) 
123 MZ1416 CH3 CH3 - 0.902 ± 0.148 
(132%) 
>10 (36%) >10 (-1%) 
124 KM-15-3 
 
CH3 >10 (-28%) >10 (30%) >10 (11%) >10 (3%) 
125 KM-15-4 
 
CH3 >10 (-7%) >10 (15%) >10 (22%) >10 (-11%) 
126 KM-15-5 
 
CH3 >10 (-11%) >10 (11%) >10 (-27%) >10 (25%) 
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127 KM-15-6 
 
CH3 >10 (10%) >10 (25%) >10 (-21%) >10 (22%) 
128 KM-15-7 
 
CH3 >10 (11%) >10 (22%) >10 (-23%) >10 (10%) 
129 KM-15-8 
 
CH3 >10 (-5%) >10 (11%) >10 (-22%) >10 (14%) 
130 KM-15-9 
 
CH3 >10 (-5%) >10 (18%) >10 (-20%) >10 (-2%) 
131 KM-15-10 
 
CH3 >10 (-25%) >10 (5%) >10 (35%) >10 (3%) 
132 KM-15-11 
 
CH3 >10 (3%) >10 (13%) >10 (9%) >10 (10%) 
133 KM-15-12 
 
CH3 >10 (-6%) >10 (3%) >10 (3%) >10 (-3%) 
134 KM-15-13 
 
CH3 >10 (-45%) >10 (37%) >10 (-55%) >10 (14%) 
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135 KM-15-17 
 
CH3 >10 (7%) >10 (26%) >10 (0%) >10 (10%) 
136 KM-15-14 
 
CH3 >10 (7%) >10 (27%) >10 (-29%) >10 (29%) 
137 KM-15-18 
 
CH3 >10 (15%) >10 (28%) >10 (-20%) >10 (9%) 
138 KM-15-15 
 
CH3 >10 (28%) >10 (14%) >10 (-19%) >10 (15%) 
139 KM-15-16 
 
CH3 >10 (-27%) >10 (15%) >10 (16%) >10 (17%) 
140 KM-15-19 
 
CH3 >10 (0%) >10 (30%) >10 (14%) >10 (5%) 
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141 KM-15-20 
 
CH3 >10 (13%) >10 (18%) >10 (1%) >10 (29%) 
142 KM-15-21 
 
CH3 >10 (-4%) >10 (23%) >10 (-13%) >10 (30%) 
143 KM-15-22 
 
CH3 >10 (-11%) 2.96 ± 0.97 
(47%) 
>10 (22%) >10 (16%) 
144 KM-15-23 
 
CH3 >10 (-27%) 1.67 ± 0.75 
(75%) 
>10 (13%) >10 (15%) 
145 KM-15-24 
 
CH3 >10 (-12%) 1.58 ± 0.55 
(70%) 
>10 (-6%) >10 (30%) 
146 KM-15-26 
 
CH3 >10 (-32%) >10 (28%) >10 (31%) >10 (-7%) 
147 KM-15-28 
 
CH3 >10 (-13%) >10 (44%) >10 (26%) >10 (-3%) 
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148 KM-15-29 
 
CH3 >10 (-28%) >10 (19%) >10 (14%) >10 (-15%) 
149 KM-15-30 
 
CH3 >10 (-25%) >10 (17%) >10 (7%) >10 (-13%) 
150 MZ1412 CH3 
 
- 0.190 ± 0.043 
(113%) 
>10 (-11%) >10 (21%) 
151 MZ1411 CH3 
 
- 0.196 ± 0.059 
(127%) 
>10 (-9%) >10 (48%) 
152 MZ1439 CH3 
 
- 0.0614 ± 0.0136 
(69%) 
>10 (3%) >10 (10%) 
153 MZ1441 CH3 
 
- 0.204 ± 0.042 
(122%) 
>10 (40%) >10 (12%) 
154 MZ1413 CH3 
 
- 0.151 ± 0.045 
(103%) 
>10 (18%) >10 (36%) 
155 MZ1437 CH3 
 
- 0.0602 ± 0.0108 
(111%) 
>10 (47%) >10 (30%) 
156 MZ1438 CH3 
 
- 0.127 ± 0.034 
(110%) 
>10 (29%) >10 (-15%) 
157 MZ1440 CH3 
 
- 0.0532 ± 0.040 
(45%) 
>10 (-3%) >10 (12%) 
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158 MZ1414 CH3 
 
- 0.149 ± 0.056 
(134%) 
>10 (41%) >10 (14%) 
159 MZ1451 CH3 
 
- 0.0246 ± 0.051 
(117%) 
>10 (35%) >10 (-16%) 
160 MZ1461 CH3 
 
- 0.138 ± 0.013 
(127%) 
>10 (3%) >10 (-22%) 
161 MZ1445 CH3 
 
- 0.0454 ± 0.081 
(84%) 
>10 (26%) >10 (-3%) 
162 MZ1415 CH3 
 
- 0.0191 ± 0.0034 
(141%) 
>10 (43%) >10 (8%) 
163 MZ1446 CH3 
 
- 0.0724 ± 0.547 
(65%) 
>10 (33%) >10 (13%) 
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164 MZ1463 CH3 
 
- 0.136 ± 0.017 
(111%) 
>10 (45%) >10 (-6%) 
165 MZ1457 CH3 
 
- 0.0426 ± 0.0155 
(98%) 
>10 (31%) >10 (-8%) 
166 MZ1462 CH3 
 
- 0.352 ± 0.096 
(111%) 
>10 (30%) >10 (-10%) 
167 MZ1448 CH3 
 
- 0.0711 ± 0.0174 
(85%) 
>10 (13%) >10 (33%) 
168 MZ1456 CH3 
 
- 0.101 ± 0.013 
(134%) 
>10 (34%) >10 (-27%) 
169 MZ1455 CH3 
 
- 0.137 ± 0.032 
(123%) 
>10 (13%) >10 (-8%) 
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170 MZ1460 CH3 
 
- 0.0604 ± 0.0122 
(129%) 
>10 (10%) >10 (-43%) 
171 MZ1454 CH3 
 
- 0.189 ± 0.027 
(148%) 
>10 (23%) >10 (-48%) 
172 MZ1452 CH3 
 
- 0.166 ± 0.024 
(122%) 
>10 (36%) >10 (-24%) 
173 MZ1442 CH3 
 
- 0.347 ± 0.0136 
(45%) 
>10 (24%) >10 (15%) 
174 MZ1444 CH3 
 
- 0.0642 ± 0.0308 
(72%) 
>10 (-4%) >10 (-5%) 
175 MZ1417 CH3 
 
- 0.442 ± 0.152 
(155%) 
>10 (45%) >10 (8%) 
176 MZ1453 CH3 
 
- 0.102 ± 0.024 
(103%) 
 
>10 (38%) >10 (-48%) 
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177 MZ1418 CH3 
 
- 0.120 ± 0.027 
(176%) 
>10 (45%) >10 (4%) 
178 MZ1429 CH3 
 
- 0.229 ± 0.048 
(64%) 
>10 (11%) >10 (-8%) 
179 MZ1430 CH3 
 
- 0.417 ± 0.173 
(64%) 
>10 (17%) >10 (13%) 
180 MZ1464 
 
 
- 0.340 ± 0.069 
(114%) 
>10 (30%) >10 (-10%) 
181 KD478 
 
- 5.68 ± 1.54 
(146%) 
>10 (20%) >10 (27%) 
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182 KD-107 
 
- 0.556 ± 0.126 
(106%) 
>10 (-5%) >10 (20%) 
183 KD477 
 
- 0.454 ± 0.156 
(171%) 
>10 (38%) >10 (21%) 
 
a % inhibition of standard agonist induced luminescence signal (GPR18: 10 µM Δ9-THC; GPR55: 1 µM LPI) 
b % activation compared to standard agonist induced luminescence signal (GPR18: 10 µM Δ9-THC; GPR55: 1 µM LPI) 
c in comparison to 30 µM Δ9-THC (maximal effect) 
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A series of 62 synthesized derivatives was investigated for their activity at the human GPR18 and 
GPR55 in both agonist and antagonist assays. The first compound set contained derivatives with 
different alkyl substitutions at the N1-position (R1). In the lead compound 182, this position is occupied 
by a methyl residue. Compound 121, the only unsubstituted derivative (R1 = H), showed no activity in 
the β-arrestin recruitment assay. Therefore, it can be concluded that a substituent is required. 
Compound 177 lacks the two methyl residues at the N1- and the N7-position. It also showed no activity 
at GPR18. This N1-substituent was consequently enlarged to ethyl (compound 124), propyl (compound 
125), and butyl (compound 130) but already the ethyl-substituted compound 124 showed no agonistic 
activity. More diverse substituents were introduced at this position, but only three compounds showed 
some activity at GPR18. Compounds 143, 144 and 145 displayed an EC50 value around 1-3 µM and an 
efficacy between 45-75%. Thus, they were weaker than the initial hit and did not exhibit full activation 
of GPR18 compared to Δ9-THC. The three compounds share a structural component. Of all the N1 
substitutions, these were the only phenylpropyl or phenoxyethyl residues. All other substituents were 
shorter in chain length and did not show any agonistic activity at 10 µM test concentration (compare 
the compounds 124 to 149). Therefore, the weak activation was linked to the chain length and 
aromaticity of the N1 residue. The compounds also have been tested as GPR18 antagonists, but also 
failed to inhibit by 10 µM THC activated GPR18 receptors.  
The initial hit compound 182 is a tricyclic xanthine derivative. As a first variation, the third ring was 
substituted by diazepane and an imidazolidine (compounds 183 and 181). The seven atomic diazepane 
ring showed a slightly increased EC50 value of 0.454 µM, compared to 182. In contrast, the five atomic 
imidazolidine ring showed ten-fold less activity with an EC50 value of 5.68 µM. Here, the two larger 
rings were clearly favored, indicating that a lipophilic interaction is important.  
The basic tricyclic structure does not provide many substitution opportunities. Therefore, the 
structure has been kept on the base of the xanthine and varied widely on the N7 position. The first 
compound without basic tricyclic structure was 139, with an indolylethylamino residue at C8 and a 
methyl substitution on the N7 nitrogen atom. With an EC50 value of 0.902 µM, the activity was 
decreased when comparing to compound 182. The N7 methyl residue was altered and the influence 
of different substitution investigated.  
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Figure 35: influence of the alkyl side chain substitution on GPR18 activation 
 
As can be observed in Figure 35, the activity of the compounds increased up to a pentyl chain 
(compound 155) with an EC50 value of 0.0602 µM. Compound 156 with a hexyl chain had a slightly 
reduced activity with an EC50 value of 0.127 µM. Branched alkyl chains were also evaluated. The 
isopropyl side chain (compound 152) was comparably more activate than the n-propyl compound 151 
with an EC50 value of 0.0623 µM. Further, there were two different isobutyl substituted compounds 
(153 and 157). The latter compound was with an EC50 value of 0.0532 µM more active than the 
unbranched alkyl-substituted compounds. However, compound 157 and also 152, the isopropoyl 
derivative, showed a reduced efficacy. In total, it can be concluded that from the small methyl-
substituent in compound 123 to the most potent compound 157 the activity increased from 0.902 µM 
to 0.0532 µM. This was a 17-fold change. Therefore, the lipophilic substitution can be regarded as a 
successful optimization concerning the potency.  
In the next step, aromatic substitutions were evaluated. Compound 158 has a benzyl-ring at the N7 
nitrogen and an activity of 0.149. It is more potent than a compound with only a methyl residue 
(compare to 123). In comparison to 154, an aliphatic compound with a longer chain as butyl (EC50 = 
0.151 µM) the activity is very similar. In Figure 36, different aromatic substitutions are plotted against 
the activity.  
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Figure 36: influence of the aromatic substitution at N7 on GPR18 activity, part I  
 
The para-methylation of the benzyl-residue increases the activity significantly, compound 159 
showed an EC50 value of 0.0246 µM, which was a 6-fold increase in potency. The para-methoxy 
compound 160 with an EC50 value of 0.138 µM was not as potent as 159. It showed a quite comparable 
activation to 158. With the para-fluoro-, chloro- and bromo- substitution the space was filled with a 
very lipophilic residue. All three compounds were more potent than the benzyl compound 158. The 
para-chloro substituted compound 162 was the most potent compound of the whole compound set 
with an EC50 value of 0.0191 µM. The para-bromo- and para-fluoro-compound 163 and 161 were both 
slightly less active with EC50 values of 0.0724 µM and 0.0454 µM, respectively. Compound 165 with a 
para-nitro function also showed an EC50 value of 0.0426 µM. These residues were comparably small 
and lipophil. Larger residues also have been investigated, e.g. compound 164, with a trifluoromethyl- 
and 166 with an isopropyl residue in para position of the benzyl-substituent. They both showed a 
reduced potency when compared to 162 with EC50 values of 0.136 µM and 0.352 µM. The space for 
this lipophilic interaction seemed to have an optimum with smaller lipophilic substitutions at the 
aromatic ring. Compound 175 with a phenylethyl-residue instead of the benzyl showed a further 
reduced activity with an EC50 value of 0.442 µM. The corresponding saturated residue (176) was more 
potent with an EC50 value of 0.102 µM. Compound 177, where the residue has been prolonged to 
phenylpropyl, was with an EC50 value of 0.120 µM also in the same range of potency. The 
phenyloxyethyl- and para-chlorophenyloxyethyl- compounds were even less potent. Altogether, this 
suggest that a lipophilic substitution at N7 is crucial for the high potency agonists. There seems to be 
an optimum for small but very lipophilic substitutions in para-position. If the residue gets too large, 
the activity decreases.  
 3 Medicinal Chemistry of GPR18 agonists and antagonists   
76 
 
So far, only para-substituted compounds have been described. In Figure 37, results for meta and 
ortho-substituted benzyl-residues are depicted.  
 
Figure 37: influence of the aromatic substitution at N7 on GPR18 activity, part II 
 
If we compare the meta-substituted compounds to their corresponding para-substituted 
compounds (162 and 167, 161 and 168, and 160 and 172), it can be observed that the meta-substituted 
compounds were all less active. The meta-chloro compound 167, for example, had an EC50 value of 
0.0711 µM in comparison of the 0.0191 µM of the para-choro-benzyl compound 162. For the halogen-
substituted compounds, there were further ortho-compounds (compare 161 and 169, 162 and 170, 
and 163 and 171) depicted in Figure 37. The ortho-substituted compounds were not as active as the 
para-substituted compounds. They showed very comparable activities in regard to the meta-
substituted compounds. Further, the 2,6-dichloro-benzyl compound 171 can be explored. It showed 
an even reduced activity when compared to the 2-chloro-benzyl- substitution (170). The 2,4-dichloro-
benzyl residue (174) showed an equal activation in regard to the ortho-chloro-compound 170. There 
was no further activity increase through the para-chloro substitution.  
Overall, in the N7 position an aromatic residue was preferred over the alkyl substitution. The most 
active compound was 162 with a para-chloro-benzyl residue with an EC50 value of 0.0191 µM. The 
structure-activity relationships described above show a clear favor for lipophilic substituents that do 
not exceed a certain size. The activity is reduced for larger lipophilic substitutions as para-isopropyl-
benzyl- or hexyl-side chains.  
The compound 122 resembles 162, the most active compound, with only one exception: In the R1 
position the methyl residue is exchanged by a hydrogen. In the first part of this structure activity 
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compound 122 showed an EC50 value of 0.329 µM. This is a 17-fold reduction in activity and can be 
viewed at in Figure 38. This underlines the importance of the methylation of the N1 moiety.  
 
Figure 38: Concentration-response curve for compound 162 and 122, which only differ in the R1 
substitution (162: R1 = -CH3; 122: R1 = -H) 
 
Another substitution has been investigated: 180 is the only compound, where the indole-residue 
has been altered. The indolylethylamino moiety might recall the look of a tryptophan, one of the 
essential amino acids. Tryptophan is also part of many important signaling molecules, such as 
tryptamine (2-(Indol-3-yl-)ethylamine) and its derivatives. One of this derivatives is serotonin, an 
crucial interaction partner in neurotransmission, which can chemically be described as 5-hydroxy-
tryptamine. In compound 180, the indolylethylamine has been varied to a 5-hydroxy-indolyl-
ethylamin. With an EC50 of 0.329 µM, it shows a reduced activity when compared to 162, with whom 
it shares both R1 as also R2.  
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Figure 39: Correlation between log D7.4 and pEC50value of the human GPR18 potency, log D values 
were calculated with Marvin 17.4.3, ChemAxon (http://www.chemaxon.com) 
 
The physicochemical parameter log D7.4 was correlated with the agonistic potency at the human 
GPR18 to investigate a possible connection with the lipophilicity. The calculated log D7.4 values ranged 
between 1.8 and 4.8 for the active compounds. Although the most active compounds showed log D7.4 
values of 4, there were also compounds with high potency which showed log D7.4 values of 2.6 
(compound 152). For drug design, a value between 0-5 is necessary and our compounds were in the 
range of 1.7 to 4.7. The properties are regarded advantageous when the log D value is lower 3.5, as 
high lipophilicity is often combined with bad solubility. Therefore, our most potent compounds could 
be optimized regarding their physicochemical properties. However, all reported GPR18 ligands have 
been very lipophilic compounds indicating that a distinct lipophilicity is needed to target GPR18. 
 
Figure 40: summary of the structure-activity relationships of 8-(indolyl-ethylamino)-xanthines 
 
A summary of the structure-activity relationships for this newly discovered class of GPR18 agonists 
can be found in Figure 40. As can be seen the two positions at N1 and N7 have already been 
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investigated with a set of diverse substitutions. Whereby substitution of the N7 position with lipophilic 
aromatic groups proved to increase the activity. On the N1 position only a methylation is tolerated. 
With the 5-hydroxy-indolyl-ethylamine compound a first attempt to study the structure-activity 
relationships at the indolyl-residue has been made.  
There are further positions, which also could be investigated, they are depicted in Figure 41.  
 
Figure 41: Further recommendations (in red) to study the structure-activity relationships 
 
Overall, the study of the structure-activity relationships has been proven to be very successful. 
From the initial hit compound 182 with an EC50 value of 0.556 µM, it was possible to improve the 
potency up to 0.0191 µM for compound 162. It is the most potent small molecule agonist for GPR18 
known to date.  
 
3.3.4. Selectivity versus the related orphan GPCR GPR55 
 
A first selectivity test was accomplished by testing the potency of the GPR18 agonists at the orphan 
GPR55. GPR55 was also expressed in the PathHunter™ test system (DiscoverX) and therefore the assay 
relies on the same principles as the GPR18 assay. This selectivity test serves as an important exclusion 
criteria. If a compound is nonselective acting at both cell lines in the same test system, it is either acting 
at both receptors or it interferes with the test system without even targeting a receptor. To exclude 
such possible false positive hits or artifacts, the compounds were tested simultaneously at GPR18 and 
GPR55 (for results, see Table 11). No activation or inhibition was observed for any compound at GPR55. 
Thus, the compounds showed complete selectivity for GPR18 versus GPR55 using the same test 
system.  
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3.3.5. Blockade of GPR18 agonists by antagonists 
 
The newly developed class of GPR18 agonists was further evaluated in experiments with the already 
established GPR18 antagonists. The most important question was, whether the antagonists were able 
to block the signal of the agonists and if so, whether the IC50 values were similar as versus Δ9-THC. 
Compound 162 and 182were selected as agonists, in addition to Δ9-THC. A series of antagonists (see 
section 3.2) was evaluated versus all three agonists, the lipid-like Δ9-THC and the small peptide-like 
newly discovered agonists 182 and 162. The results are summarized in Table 12. For comparability, the 
antagonists have all been evaluated against the EC80 of the respective agonist (for Δ9-THC: 10 µM; 182: 
1 µM; 162: 0.1 µM) and concentration-dependent inhibition of β-arrestin recruitment was determined.  
Table 12: IC50 values of selected GPR18 antagonists versus different agonists  
No. Compd. Chemical structure 
 
Δ9-THCa  
IC50  (µM) 
maximal 
inhibition (%) 
KD-107b  
IC50  (µM) 
maximal 
inhibition 
(%) 
MZ1415c  
IC50  (µM) 
maximal 
inhibition 
(%) 
17 PSB-CB-5 
 
0.279 ± 0.111 
(71%) 
11.3 ± 1.1 
(100%) 
29.2 ± 12.4d 
 
43 CB-4 
 
2.55 ± 0.71 
(100%) 
17.2 ± 8.7 
(100%) 
>10 (25%) 
69 CB-20 
 
1.73 ± 0.37 >10 (43%) >10 (8%) 
70 CB-22 
 
3.59 ± 2.25 12.6 ± 2.6 >10 (10%) 
71 CB-15 
 
1.65 ± 0.45 >10 (70%) >10 (-33%) 
74 CB-24 
 
1.49 ± 0.39 6.34 ± 0.71 >10 (23%) 
76 CB-25 
 
3.25 ± 1.22 8.70 ± 4.59 >10 (-6%) 
77 CB-28 
 
2.38 ± 1.15 6.28 ± 3.13 >10 (20%) 
78 CB-26 
 
1.14 ± 0.44 6.35 ± 2.61 >10 (14%) 
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79 CB-27 
 
0.650 ± 0.134 
(100%) 
2.21 ± 0.47 
(65%) 
22.4 ± 5.9 
(100%) 
80 CB-29 
 
1.15 ± 0.17 3.26 ± 1.43 >10 (-29%) 
a 10 µM; b 1 µM; c 0.1 µM (a,b,c concentration corresponding to EC80 of agonist) 
d extrapolated value 
 
It can be observed that the antagonists were able to inhibit the compound 182-induced signal, but 
most of them were not able to inhibit the 162-induced signal or they were far weaker versus that 
agonist.  
In Figure 42, the concentration-dependent inhibition of the three agonists Δ9-THC, 182 and 162 by 
PSB-CB-5 (17) is displayed. PSB-CB-5 (17) was a partial antagonist of Δ9-THC-induced GPR18 activation, 
with an IC50 value of 0.279 µM. Its inhibition curves were shifted to the right versus the new agonist, 
182 and 162. The IC50 value was 11.3 µM, 40-fold weaker versus  182, but it reached full inhibition. 
PSB-CB-5 (17) was even less potent against compound 162 (0.1 µM), and its IC50 value could only 
determined by extrapolation (29.2 µM).  
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Figure 42: Concentration-dependent inhibition of GPR18 activation by PSB-CB-5 (17). The agonists 
were employed at their EC80 concentrations (Δ9-THC: 10 µM; 182: 1 µM; 162: 0.1 µM) 
 
A competitive antagonist shifts the agonist curve to the right in a concentration-dependent manner, 
without lowering the maximal effect. Thereby, the EC50 value of the agonist increases. A non-
competitive antagonist decreases the maximal effect concentration-dependently, but does not change 
the EC50 value.  
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Figure 43: GPR18 activation with Δ9-THC in the absence and presence of 3 µM PSB-CB5, data by 
Viktor Rempel66 
 
 
Figure 44: Agonist stimulation in the absence and presence of different antagonists at different 
concentrations; (A) 182 versus PSB-CB-5 (17); (B) 182 versus 79 
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The behavior of the antagonists PSB-CB-5 (17) and 79 was investigated versus the newly identified 
compound 182 (see Figure 44). Viktor Rempel determined the rightward shift of the concentration-
effect curve of Δ9-THC in the presence of PSB-CB-5 (17); (see Figure 43).66 It was concluded that PSB-
CB-5 (17) is a competitive antagonist versus Δ9-THC. PSB-CB-5 (17) inhibited the activation of 
compound 182 by lowering the maximum effect, while the curve was not shifted to the right. The 
effect was more pronounced for higher concentrations of PSB-CB-5 (17) (10 µM and 15 µM), while a 
concentration of 3 µM showed no significant effect.  
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Figure 45: Concentration-dependent inhibition of 182-induced GPR18 activation by compound 79 
 
Moreover, it can be concluded that none of the already established antagonists inhibited the effect 
of compound 162 significantly. Some of the antagonists were able to inhibit the effect of 182, but the 
inhibition was weaker as compared to Δ9-THC. In addition, it could be shown that the antagonists 
behaved as allosteric rather than competitive antagonists versus 182, while they appeared to be 
competitive antagonist versus Δ9-THC. It appears likely that the agonists do not share the same binding 
site. Δ9-THC itself is a lipophilic compound similarly as the investigated GPR18 antagonists, while the 
newly discovered agonists display peptide-like properties.  
 
 
3.3.6. Selectivity of GPR18 agonists versus cannabinoid receptors 
 
The typical cannabinoid receptor ligand Δ9-THC interacts with a GPR18. Therefore, the receptor had  
been proposed as a new “cannabinoid-like” receptor.170 To investigate the selectivity of the newly 
discovered GPR18 agonist class, the compounds have been investigated at the classical cannabinoid 
receptors CB1 and CB2. For this purpose, a radioligand binding assay using membrane preparations 
overexpressing the receptor of interest was used and Ki values were determined (see Table 13).  
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Table 13: Affinities of identified GPR18 agonists at cannabinoid receptors determined in radioligand 
binding studiesa 
No. Compd. 
 
Human CB1 Human CB2 
  Ki (µM) vs. [3H]CP55,940 
(% inhibition of specific binding) 
Ki (µM) vs. [3H]CP55,940  
(% inhibition of specific binding) 
120 MZ1458 >10 (34%) >10 (18%) 
121 KM-15-1 >10 (-6%) >10 (13%) 
122 MZ1459 >10 (16%) 1.32 ± 0.17 
(100%) 
123 MZ1416 >10 (10%) >10 (15%) 
124 KM-15-3 >10 (29%) >10 (16%) 
125 KM-15-4 >10 (19%) >10 (21%) 
126 KM-15-5 >10 (20%) >10 (22%) 
127 KM-15-6 >10 (20%) >10 (29%) 
128 KM-15-7 >10 (9%) >10 (10%) 
129 KM-15-8 >10 (9%) >10 (15%) 
130 KM-15-9 >10 (-1%) >10 (17%) 
131 KM-15-10 >10 (6%) >10 (29%) 
132 KM-15-11 >10 (29%) 1.42 ± 0.42 
max. inhibition of radioligand-
binding: 66% 
133 KM-15-12 0.867 ± 0.329 
max. inhibition of radioligand-binding: 
56%  
0.950 ± 0.272 
max. inhibition of radioligand-
binding: 54% 
134 KM-15-13 >10 (24%) >10 (31%) 
135 KM-15-17 >10 (43%) >10 (39%) 
136 KM-15-14 >10 (48%) >10 (46%) 
137 KM-15-18 >10 (15%) >10 (18%) 
138 KM-15-15 >10 (42%) 2.00 ± 0.43 
max. inhibition of radioligand-
binding: 64% 
139 KM-15-16 1.61 ± 0.60 
max. inhibition of radioligand-binding: 
58% 
1.14 ± 0.38 
max. inhibition of radioligand-
binding: 59% 
140 KM-15-19 >10 (26%) >10 (42%) 
141 KM-15-20 >10 (49%) >10 (31%) 
142 KM-15-21 >10 (33%) >10 (32%) 
143 KM-15-22 1.80 ± 0.63 
max. inhibition of radioligand-binding: 
57% 
1.40 ± 0.54 
max. inhibition of radioligand-
binding: 71% 
144 KM-15-23 >10 (22 ± 10%) >10 (31 ± 6%) 
145 KM-15-24 >10 (42%) >10 (38%) 
146 KM-15-26 >10 (-11%) >10 (24%) 
147 KM-15-28 >10 (11%) >10 (5%) 
148 KM-15-29 >10 (12%) >10 (-1%) 
149 KM-15-30 >10 (-5%) >10 (7%) 
150 MZ1412 >10 (11%) >10 (39%) 
151 MZ1411 >10 (8%) >10 (42%) 
152 MZ1439 >10 (-8%) >10 (29%) 
153 MZ1441 >10 (42%) >10 (44%) 
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154 MZ1413 >10 (18%) 8.14 ± 2.58 
max. inhibition of radioligand-
binding: 84% 
155 MZ1437 >10 (47%) 1.72 ± 1.08 
max. inhibition of radioligand-
binding: 100% 
156 MZ1438 4.66 ± 1.09 
max. inhibition of radioligand-binding: 
82% 
0.571 ± 0.148 
max. inhibition of radioligand-
binding: 88% 
157 MZ1440 >10 (2%) 9.65 ± 4.37 
max. inhibition of radioligand-
binding: 100% 
158 MZ1414 >10 (14%) 3.06 ± 1.09 
max. inhibition of radioligand-
binding: 100% 
159 MZ1451 3.91 ± 1.08 
max. inhibition of radioligand-binding: 
58% 
0.827 ± 0.287 
max. inhibition of radioligand-
binding: 87% 
160 MZ1461 >10 (34%) 1.41 ± 0.38 
max. inhibition of radioligand-
binding: 100% 
161 MZ1445 >10 (40%) >10 (48%) 
162 MZ1415 1.18 ± 0.44 
max. inhibition of radioligand-binding: 
100% 
0.481 ± 0.104 
max. inhibition of radioligand-
binding: 100% 
163 MZ1446 1.08 ± 0.47 0.749 ± 0.344 
max. inhibition of radioligand-
binding: 77% 
164 MZ1463 >10 (35%) 1.15 ± 0.48 
max. inhibition of radioligand-
binding: 85% 
165 MZ1457 >10 (31%) 4.89 ± 0.91 
max. inhibition of radioligand-
binding: 81% 
166 MZ1462 6.28 ± 4.80 
max. inhibition of radioligand-binding: 
67% 
 
167 MZ1448 >10 (49%) 0.896 ± 0.157 
max. inhibition of radioligand-
binding: 100% 
168 MZ1456 3.48 ± 1.72 
max. inhibition of radioligand-binding: 
100% 
0.344 ± 0.104 
max. inhibition of radioligand-
binding: 67% 
169 MZ1455 >10 (40%) 2.28 ± 0.89 
max. inhibition of radioligand-
binding: 100% 
170 MZ1460 >10 (16%) >10 (47%) 
171 MZ1454 >10 (34%) 1.69 ± 0.91 
max. inhibition of radioligand-
binding: 76% 
172 MZ1452 >10 (36%) 1.62 ± 0.46 
max. inhibition of radioligand-
binding: 100% 
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173 MZ1442 >10 (45%) 1.09 ± 0.24 
max. inhibition of radioligand-
binding: 79% 
174 MZ1444 >10 (2%) >10 (43%) 
175 MZ1417 >10 (20%) 2.16 ± 0.72 
max. inhibition of radioligand-
binding: 100% 
176 MZ1453 >10 (47%) 0.786 ± 0.045 
max. inhibition of radioligand-
binding: 100% 
177 MZ1418 >10 (37%) 1.79 ± 0.55 
max. inhibition of radioligand-
binding: 100% 
178 MZ1429 >10 (7%) >10 (30%) 
179 MZ1430 >10 (9%) >10 (44%) 
180 MZ1464 10.2 ± 3.7 
max. inhibition of radioligand-binding: 
78% 
>10 (37%) 
181 KD478 >10 (30%) >10 (30%) 
182 KD107  >10 (11%) >10 (29%) 
183 KD477 >10 (24%) >10 (46%) 
a Chemical structures are shown in Table 11 
 
 
The most affine compound was 168 with a Ki value of 0.334 µM for the CB2 receptor. It was also a 
quite potent GPR18 agonist with an EC50 0.352 µM. The most potent GPR18 agonist 162 proved to be 
also active at both CB receptors. For the CB2 receptor, it showed a Ki value of 0.481 µM and a Ki value 
of 1.18 µM for the CB1 receptor. This corresponds to a 25-fold selectivity for GPR18 over CB2 and a 62-
fold selectivity over CB1.  
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Figure 46: Selectivity of the newly discovered GPR18 agonists versus the cannabinoid receptors, 
(A) selectivity versus CB1 receptor; (B) selectivity versus CB2 receptor 
 
In Figure 46, the affinity to the cannabinoid receptors was plotted against the activity at GPR18. 
From this graph, it is rather easy to identify the most selective compounds. The most selective 
compound was 161with no affinity to the CB receptors up to concentrations of 10 µM and an EC50 
value at GPR18 of 0.0454 µM. This result corresponds to a 220-fold selectivity for GPR18.  
 
Figure 47: the most selective compound 161 of the indolylethylaminoxanthines 
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Figure 48: Selectivity profile of the ten most potent GPR18 ligands and compound 180 
 
When analyzing the affinity of the compounds for the CB- receptors, it can be observed that the 
same group of compounds were both the most potent at the CB1 and to CB2 receptor. From this, it can 
be concluded that the compounds do not have a selectivity between CB1 and CB2, although most of 
them were slightly more affine to the CB2 receptors.  
 
Figure 49: Structure-activity relationships for the affinity at the cannabinoid receptors 
 
In Figure 49, the structure of some of the compounds are plotted with their R2 residue. The 
compounds with a high affinity to the CB receptors showed a quite large lipophilic substitution, the 
para-chloro and para-bromo-derivatives being very potent. Interestingly, the smaller fluoro-
substitution showed no affinity to the CB receptors up to 10 µM. For the para-nitro compound a low 
affinity to the CB2 receptor can be observed, but no affinity to CB1. With an EC50 value of 0.0462 µM 
for GPR18, it also belongs to the most potent compounds at this receptor.  
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One prominent result has to be mentioned: compound 180, which resembles 162, but differs only 
in the 5-hydroxy-group at the indole residue, showed no affinity to the CB2 receptor. With a Ki value of 
10.2 µM for CB1 it was a rather weak ligand. Compound 180 was not as potent as compound 162 for 
GPR18, but still had an EC50 value of 0.340 µM. 
Overall, it can be observed that some compounds of this new class of GPR18 agonists interact with 
CB receptors. The most potent compound 162 showed a 25-fold selectivity for GPR18 over CB2 and a 
62-fold selectivity over CB1. With compound 161, there was a compound that did not interact with the 
CB receptors up to a concentration of 10 µM. In general, compounds showed an affinity for the CB2 
receptor than for the CB1 subtype and it was a typically higher at CB2.  
However, structure-activity relationships are still limited, and more data are required to fully 
analyze specific structure-activity relationships for each of these receptors.  
 
Figure 50: Structure-activity relationships for the cannabinoid receptors. 
 
3.3.7. Selectivity of GPR18 agonists versus adenosine receptors 
 
The compound group of pyrimidopurinediones was originally synthesized to study their structure-
activity relationships at adenosine receptors. They have been investigated at A1, A2A, A2B and A3 
receptors 171-175 173; 172; 174; 171; 175  
In the series of studies on this compound class at the adenosine receptors, the authors could 
observe some important structural features for adenosine receptor binding. For the A2A receptor, 
phenylethyl-substituted compounds proved to be most potent.174 Compound 182 has originally been 
synthesized in this set of compounds (compare Drabczyńska et al. 2007). In the whole series, only two 
compounds exist with an indole residue. Compound 182 is one of them. The other one, compound 184, 
has also been tested at GPR18, but showed no activity up to a concentration of 10 µM. As can be seen 
in Figure 51, it has a propyl residue in position R1. In 3.3.3, we observed the importance of the methyl 
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substitution for R1. Compound 184with its propyl residue was not expected to be active and it fitted to 
the expectation.  
 
Figure 51: Chemical structures of compound 182 and  184 
In Table 14, the affinities of compound 182 and 184 are collected. Both compounds showed an 
affinity to the A2A receptor. Compound 182 was more potent with a Ki value of 0.330 µM at the rat A2A 
receptor.  
Table 14: affinities of compound 182 and 184 at adenosine receptors, data were taken from 
Drabczyńska et al. 2007.174 
Compd. 
 
Radioligand binding 
  Ki (µM) (% inhibition of specific binding) 
  rat A1 rat A2A human A2B human A3 
182 KD-107 >25 (41%)a 0.33 ± 0.07 ~10 (56%) >10 (21%) 
184 KD-168 1.79 ± 0.48 0.90 ± 0.11 Ndb >1 (9%)c 
a tested at 25 µM 
b nd, not determined 
c tested at 1 µM 
 
All compounds that were synthesized in this series were collected in a sublibrary. Many of these 
compounds show different substitutions instead of the indole residue. They were screened at the 
human GPR18 in β-arrestin assays (for results see Figure 53). The screen was performed for agonistic 
and antagonistic effects, and was repeated in case the initial screen was positive. In the first screen 
same few positive results could be detected. However, when they were retested three times none of 
the compounds showed any effects.  
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Figure 52: Lead structure of the compounds that had been synthesized for adenosine receptor 
ligand optimization. 
 
Figure 53: Screening result at GPR18. Initial screen with black labels, positive findings from the 
first screen were retested three times (red label). On the left side (A): screening of antagonists 
against 10 µM Δ9-THC, on the right side (B): agonist screening, effects were compared to the 
activation of 10 µM Δ9-THC. 
 
From these results, it can be learned that the indole residue is very important for GPR18 activity. 
This sublibrary consists of many compounds with different substitution patterns at the 8-amino 
residue. Only compound 182 was a GPR18 agonist.  
It should be further kept in mind that the initial hit compound 182 displays an affinity especially to 
the A2A adenosine receptor. The newly synthesized compounds should also be tested for selectivity at 
the A2A receptor.  
 
3.3.8. Results and discussion 
 
A new class of GPR18 agonists has been discovered and investigated in this study. The initial hit was 
found to be a moderately potent and selective agonist with an EC50 value of 0.556 µM. Its main 
structural feature was a pyrimido-purinedione ring system, substituted with an indolylethyl group. 
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Structure-activity relationship were subsequently investigated, which resulted in the optimized 
compound 162 with an EC50 value of 0.0191 µM. The indole residue proved to be crucial for GPR18 
activation, as also the methylation of the N1-atom. Every attempt to change the N1-substitution 
resulted in a decrease in potency. At the N7-position, a lipophilic substitution was advantageous, with 
para-chloro-benzyl resulting in the most potent compound.  
The selectivity of the compounds was assessed versus GPR55, a closely related orphan receptor in 
the same assay system, at which it showed no activity at all. Furthermore, the compounds were 
evaluated at the cannabinoid receptors, whereby compound 162 showed a 25-fold selectivity for 
GPR18 over CB2 and a 62-fold selectivity over CB1. Future studies should focus on modifications of the 
N3 and substitution of the indole ring.  
Experiments with GPR18 antagonists led to the conclusion that Δ9-THC and the new agonist class 
do not share the same binding site in the receptor. As a next step, we want to identify the binding site 
of compound 162 to understand the binding behavior and the generated data. This will be 
accomplished by site-directed mutagenesis studies. In this set-up, selected amino acids will be 
exchanged for other amino acids. If the selected amino acids are crucial for ligand binding, the EC50 
value of the agonist will change. In order to know which amino acids may be important for ligand 
binding a homology model will be established. Based on docking studies, amino acids can be proposed 
that are predicted to interact with the ligand, and proposals for mutagenesis studies can be generated. 
The homology models were generated in cooperation during a three-month research stay in the 
laboratories of Prof. Jens Meiler, Vanderbilt University, Nashville, TN, USA, and continued in Bonn. 
Compound 182 and 162 and all here investigated compounds share the indolyl residue, which is a 
preferred structure in nature. Especially, the amino acid tryptophan and its natural derivatives, for 
example, the tryptamines, contain such an indolyl residue. From a structural perspective compound 
162 resembles more a peptide than a lipid. Aromatic substitution at N7 was beneficial for GPR18 
activity. A possible overlay of the structures of a hypothetical dipeptide and compound 162 can be 
found in Figure 54. Other peptide-activated receptors can be found in relatively close phylogenetic 
relationship to GPR18, for example, the PAR1 receptor. There are also many related receptors, for 
which an endogenous ligand is not known. As long as the endogenous ligand has not been 
unambigously confirmed other hypotheses should also be considered and investigated.  
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Figure 54: Structural similarity of compound 162 to peptides 
  
 3 Medicinal Chemistry of GPR18 agonists and antagonists   
94 
 
 
3.4.  GPR18 agonists: Evaluation at the mouse GPR18 receptor 
3.4.1. Introduction 
 
The newly described GPR18 agonists were evaluated at the mouse GPR18. GPCRs can share a high 
degree of conservation between related species, but there are also many examples, where the 
interspecies sequences are very different. There is no guarantee that a ligand developed and optimized 
for a human GPCR will also act in the same way or with the same potency at its mouse orthologue. 
Major species differences have been described for GPR35, which is closely related to GPR18. Kynurenic 
acid, which was identified in rat and proposed as an endogenous GPR35 agonist, acts only very weakly 
on human GPR35.176,177 Therefore, it is now doubted that kynurenic acid could be the endogenous 
ligand.178 Similarly, the human GPR35 radioligand [3H]PSB-13-253 binds with high affinities to the 
human GPR35 with an EC50 of 12.1 nM in β-arrestin assays179 and a KD of 5.27 nM180 in radioligand 
binding experiments, but displays only a micromolar EC50 value at the mouse orthologue (Meyer and 
Thimm, unpublished results).  
An important reason for investigating the activity of the ligands at mouse receptor is the fact that 
many experiments are conducted in mice. Especially, for target validation mice are of major 
importance. Knock-out mice, one of the most important pharmacological tools, exist for many genes 
(although none has been described for GPR18 so far). When working with a mouse model, it has to be 
ensured that the applied ligands are well characterized at the mouse receptor. Mouse studies are 
typically undertaken before a drug is delivered to humans for the first time. Therefore, a well-
characterized pharmacological tool compound is needed for the mouse receptor.  
 
3.4.2. Expression and establishment of a prolink1-mouse GPR18 cell line 
 
The human and the mouse orthologues of GPR18 share a sequence identity of 86% (NCBI Blast). 
This reflects a high degree of homology. An alignment of the two sequences can be found in Figure 55.  
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Figure 55: Alignment of the mouse (Mus musculus) and human (Homo sapiens) GPR18 sequences. 
 
For pharmacological evaluation, the mouse receptor was expressed in a prolink1 vector from 
DiscoverX. The prolink1 vector contains the β-arrestin-galactosidase fusion protein. When ligated 
correctly into the plasmid, the receptor is expressed along with the enzyme complementation peptide, 
which is necessary for galactosidase activity. The purified plasmid will then be expressed via lipofection 
in CHO cells (DiscoverX®, suitable for β-arrestin assays), a cell line that already carries the gene for the 
β-arrestin-galactosidase fusion protein and a hygromycin resistance. The prolink1 vector contains a 
G418 resistance, which is used to select transfected cells. Non-transfected CHO-β-arrestin cells 
(DiscoverX) will be used as a control. After selection with G418, a first assay was conducted. If the first 
results were promising, a monoclonal selection would be undertaken, which ensures a high signal-to-
noise ratio and a stable luminescence range.  
 
Figure 56: Signal-to-noise ratio for different mouse GPR18 clones. 
mus M A T L S N H N Q L D L S N G S H P E E Y K I A A L V F Y S C I F L I G L F V N V T A L W V F S C T T K K R T T V T I Y
homo M I T L N N Q D Q P V P F N S S H P D E Y K I A A L V F Y S C I F I I G L F V N I T A L W V F S C T T K K R T T V T I Y
mus M M N V A L L D L V F I L S L P F R M F Y Y A K G E W P F G E Y F C H I L G A L V V F Y P S L A L W L L A F I S A D R Y
homo M M N V A L V D L I F I M T L P F R M F Y Y A K D E W P F G E Y F C Q I L G A L T V F Y P S I A L W L L A F I S A D R Y
mus M A I V Q P K Y A K E L K N T G K A V L A C G G V W V M T L T T T V P L L L L Y E D P D K A S S P A T C L K I S D I T H
homo M A I V Q P K Y A K E L K N T C K A V L A C V G V W I M T L T T T T P L L L L Y K D P D K D S T P A T C L K I S D I I Y
mus L K A V N V L N F T R L I F F F L I P L F I M I G C Y V V I I H S L L R G Q T S K L K P K V K E K S I R I I M T L L L Q
homo L K A V N V L N L T R L T F F F L I P L F I M I G C Y L V I I H N L L H G R T S K L K P K V K E K S I R I I I T L L V Q
mus V L V C F V P F H I C F A V L M L Q G Q E N S Y S P W G A F T T F L M N L S T C L D V V L Y Y I V S K Q F Q A R V I S V
homo V L V C F M P F H I C F A F L M L G T G E N S Y N P W G A F T T F L M N L S T C L D V I L Y Y I V S K Q F Q A R V I S V
mus M L Y R N Y L R S V R R K S V R S G S L R S L S N M N S E M L predicted helix
homo M L Y R N Y L R S M R R K S F R S G S L R S L S N I N S E M L typical conserved regions
disulfide
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In Figure 56, the signal-to-noise ratio for different mouse GPR18 cell line monoclones are depicted. 
The ratio can be found in the table in Figure 56 (D). Clone 7 and 8 performed equally well and showed 
the best signal-to-noise ratio higher than that of the polyclonal cell line. These were subsequently 
applied for further testing.  
 
3.4.3. Standard ligands at the mouse GPR18 
 
Some standard ligands have been investigated at the mouse GPR18 to characterize its 
pharmacology. First of all, the two agonists 162 and 182 were investigated. As can be seen in Table 15, 
the potencies of the standard agonists differ for both orthologue receptors.The compounds were more 
potent at the human as compared to the mouse GPR18. Compound 162 and 182, the indole derivatives 
were 3-fold more potent at the human receptor.  
Table 15: Potencies of standard agonists at the mouse and human GPR18 
 EC50 (µM) mouse GPR18  EC50 (µM) human GPR18 
KD-107 1.78 ± 0.62 0.556 ± 0.126 
MZ1415 0.0541 ± 0.0241 0.0191 ± 0.0034 
 
 
Figure 57: Concentration-dependent activation of the mouse GPR18 by selected agonists, (A) 
compound 162, (B) compound 182 
 
In Figure 57, the concentration-dependent activation of GPR18 by the selected agonists can be 
observed. The maximum signal was obtained by applying 3 µM of compound 162 as a control. 
Compound 182 was also a full agonist compared to 162.  
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Figure 58: Potencies of Δ9-THC, compound 182 and 162 at the human and the mouse GPR18 (ns= 
not significant; p > 0.05, pEC50 values with SD) 
 
In Table 15, we could already see that compound 182 and 162 do not share the same EC50 value at 
both orthologous receptors. In Figure 58, the pEC50 values are compared for both species and a 
significance level was calculated. The pEC50 values of compound 162 and 182 were not significantly 
different (two-tailed t-test, p > 0.05). The compound class of indolylethylaminoxanthines was further 
investigated at the mouse GPR18 to get more information on the differences and similarities of the 
compound response. We also studied the effects of some cannabinoid compounds at the mouse 
GPR18.  
 
3.4.4. Potencies of GPR18 agonists at the mouse GPR18 
 
Here, all indolylethylaminoxanthines were tested to completely characterize their pharmacology at 
the mouse GPR18.  
Table 16: Potencies of indolylethylaminoxanthines at the mouse GPR18 
 mouse GPR18 
No. Compd.a 
 
antagonistic activity agonistic activity 
  IC50 ± SEM (µM)b 
 
EC50 ± SEM (µM)c 
% efficacyd 
    
120 MZ1458 >10 (-9%) >10 (19%) 
121 KM-15-1 >10 (-3%) >10 (12%) 
122 MZ1459 - 0.527 ± 0.020 (79%) 
123 MZ1416 - 2.97 ± 1.02 (132%) 
124 KM-15-3 >10 (-8%) >10 (35%) 
125 KM-15-4 >10 (3%) >10 (23%) 
126 KM-15-5 >10 (-8%) >10 (11%) 
127 KM-15-6 >10 (-3%) >10 (17%) 
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128 KM-15-7 >10 (19%) >10 (12%) 
129 KM-15-8 >10 (11%) >10 (12%) 
130 KM-15-9 >10 (-3%) >10 (19%) 
131 KM-15-10 >10 (-6%) >10 (16%) 
132 KM-15-11 >10 (-6%) >10 (24%) 
133 KM-15-12 >10 (3%) >10 (24%) 
134 KM-15-13 >10 (-3%) >10 (24%) 
135 KM-15-17 >10 (-13%) >10 (41%) 
136 KM-15-14 >10 (6%) ~10 (52%) 
137 KM-15-18 >10 (-13%) >10 (36%) 
138 KM-15-15 >10 (7%) >10 (39%) 
139 KM-15-16 >10 (8%) >10 (13%) 
140 KM-15-19 >10 (11%) >10 (19%) 
141 KM-15-20 >10 (9%) >10 (39%) 
142 KM-15-21 >10 (-6%) >10 (21%) 
143 KM-15-22 - 1.69 ± 0.23 (106%) 
144 KM-15-23 - 1.67 ± 0.47 (115%) 
145 KM-15-24 - 3.15 ± 1.91 (75%) 
146 KM-15-26 >10 (4%) >10 (16%) 
147 KM-15-28 >10 (-12%) >10 (47%) 
148 KM-15-29 >10 (-10%) >10 (10%) 
149 KM-15-30 >10 (-9%) >10 (4%) 
150 MZ1412 - 0.379 ± 0.055 (85%) 
151 MZ1411 - 0.299 ± 0.109 (81%) 
152 MZ1439 - 0.129 ± 0.040 (85%) 
153 MZ1441 - 0.288 ± 0.055 (103%) 
154 MZ1413 - 0.207 ± 0.038 (111%) 
155 MZ1437 - 0.114 ± 0.024 (135%) 
156 MZ1438 - 0.156 ± 0.056 (120%) 
157 MZ1440 - 0.160 ± 0.066 (127%) 
158 MZ1414 - 0.194 ± 0.053 (116%) 
159 MZ1451 - 0.0463 ± 0.0058 (95%) 
160 MZ1461 - 0.171 ± 0.013 (96%) 
161 MZ1445 - 0.124 ± 0.056 (79%) 
162 MZ1415 - 0.0541 ± 0.0241 (100%) 
163 MZ1446 - 0.058 ± 0.008 (105%) 
164 MZ1463 - 0.216 ± 0.066 (112%) 
165 MZ1457 - 0.280 ± 0.194 (155%) 
166 MZ1462 - 0.150 ± 0.019 (87%) 
167 MZ1448 - 0.220 ± 0.062 (134%) 
168 MZ1456 - 0.180 ± 0.033 (101%) 
169 MZ1455 - 0.128 ± 0.018 (106%) 
170 MZ1460 - 0.157 ± 0.007 (96%) 
171 MZ1454 - 0.156 ± 0.013 (92%) 
172 MZ1452 - 0.245 ± 0.030 (108%) 
173 MZ1442 - 0.559 ± 0.050 (101%) 
174 MZ1444 - 0.244 ± 0.026 (104%) 
175 MZ1417 - 0.288 ± 0.071 (108%) 
176 MZ1453 - 0.127 ± 0.013 (100%) 
177 MZ1418 - 0.223 ± 0.043 (104%) 
178 MZ1429 - 0.334 ± 0.080 (88%) 
179 MZ1430 - 0.444 ± 0.084 (84%) 
180 MZ1464 - 0.638 ± 0.159 (114%) 
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181 KD478  >10 (37 ± 12%) 
182 KD-107  1.78 ± 0.62 (104%) 
183 KD477  0.583 ± 0.214 (111%) 
a for chemical structures see Figure 27 
b % inhibition of standard agonist induced luminescence signal, 0.3 µM compound  162 
c % activation compared to standard agonist induced luminescence signal, 0.3 µM compound 162 
d in comparison to 3 µM MZ1415 
 
 
In Table 16, the potencies of all indolylethylaminoxanthines are collected. The two most potent 
compounds were 162 and 159, the latter with an EC50 of 0.0463 µM. This resembles the results for the 
human receptor. Both compounds were slightly less active at the mouse receptor, but as we discussed 
above, this difference was not significant 
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Figure 59: Structure-activity relationships for the mouse GPR18, (A) aliphatic substitutions at R2; 
(B) p-substituted aromatic substitions at R2; (C) other aromatic substitutions in R2 
 
Overall, the structure-activity relationships were equal to those of the human GPR18. A slight 
decrease in activity was observed at the mouse as compared to the human GPR18. This decrease was 
for some compounds larger, for example, for compound 165 or for 181, which was not active up to 10 
µM. But some compounds also displayed the same activity at both receptors. There was no clear 
pattern observable. When Figure 59 was compared to the results in 3.3.3, it can be concluded that the 
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structural elements defining GPR18 activation were preserved also for the mouse receptor. A 
correlation of the pEC50 values of the human and the mouse GPR18 is shown receptor in Figure 60.  
 
Figure 60: Potencies of indolylethylaminoxanthines at the human and mouse GPR18, r2 = 0.8754 
 
As can be seen above, the potencies laid on a straight line, indicating that the potency for both 
orthologues was linear. The slope of the straight line was 1.1, there was a slight preference for the 
human GPR18. Compound 165, for example, was the compound with the strongest human GPR18 
preference (compare human GPR18 EC50: 0.0426 µM and mouse GPR18 EC50: 0.280 µM) and 
compound 166 displayed the largest mouse GPR18 preference (compare human GPR18 EC50: 0.352 
µM and mouse GPR18 EC50: 0.150 µM). The structure-activity relationships study and the selectivity 
plot both indicate that the GPR18 agonists were almost equipotent at both orthologues. This will be 
useful with regard to further studies in mice.  
 
3.4.5. Evaluation of lipids and cannabinoids at the mouse GPR18 
 
GPR18 has been described in the literature to be activated by several lipids, as for example AEA and 
NAGly (compare chapter 1.4.1). Rempel et al. could not observe any activation of the human GPR18 in 
β-arrestin assays by both lipids66, although they have been reported to interact with GPR18 by Kohno 
et al.60 and McHugh et al. 69,181 The latter group used a rat-derived cell line for their experiments, 
immortalized BV-2 microglia cells, which are employed as a model for microglial cells.182 The most 
important lipids of this studies have also been investigated at the newly generated mouse GPR18 cell 
line. For this purpose, NAGly, AEA and AA-5-OH-HT have been chosen.  
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Table 17: Potencies of lipid compounds at the mouse GPR18 
No. 
 
compound antagonistic activity agonistic activity 
  IC50 ± SEM (µM)a EC50 ± SEM (µM) 
1 AEA >10 (8%) >10 (4%) 
10 NAGly >10 (0%) >10 (5%) 
185  AA-5-HT 14.6 ± 3.2b >10 (-2%) 
a 0.3 µM compound 162 was applied as agonist 
b extrapolated  
 
None of the lipids showed any activation of the mouse GPR18. AA-5-HT (arachidonoyl-serotonine) 
displayed weak inhibitory effects.  
Cannabinoids also have been described to interact with GPR18, this has been investigated for the 
human receptor already in 3.1. Here, the potencies of the compounds have been evaluated for the 
mouse receptor.  
Table 18: Potencies of phenolic cannabinoids at the mouse GPR18 
compound 
 
antagonistic activity agonistic activity 
  IC50 ± SEM (µM)a EC50 ± SEM (µM) 
11 abn-CBD 13.1 ± 1.7 >10 (8%) 
12 CBD 8.59 ± 1.77 >10 (14%) 
13 O-1602 >10 (40%) >10 (0%) 
14 O-1918 17.3 ± 4.2b >10 (16%) 
a 0.3 µM compound 162 were applied as agonist 
b extrapolated  
 
CBD, which was found to be an agonist at the human receptor of comparable potency to Δ9-THC, 
acted as weak antagonist against compound 162 at the mouse receptor with an IC50 value of 8.59 µM. 
Abn-CBD and O-1918 also displayed weak inhibitory potency.  
 
3.4.6. Discussion 
 
The indolylethylaminoxanthines have been proven to be potent GPR18 agonists at the human 
orthologue of the receptor. In this chapter, they were also investigated at the mouse GPR18. This is 
important for their applicability in early target validation studies, which are typically conducted in 
mouse models. It could be shown that the agonists display a comparable activation at the mouse 
receptor. Only few compounds such as compound 182, were slightly less active at the mouse receptor, 
but most other compounds showed no significant difference or were slightly more potent.  
The GPR18 ligands described in literature such as anandamide (AEA) and arachidonoylglycine 
(NAGly) did not interact with the mouse GPR18 to recruit β-arrestin. Controversies regarding the 
reported activation data cannot be explained by interspecies differences. Nevertheless, further 
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investigation is necessary to understand the complex ligand behaviour of the endogenous lipids. For 
investigating GPR18 signalling, the newly developed compounds provide a reliable basis to study 
GPR18 pharmacology also in mice.   
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3.5. Molecular modeling of the human GPR18 
 
3.5.1. Introduction 
 
In section 3.3.5, it could be observed that the two agonists Δ9-THC and the newly identified class of 
indolylethylxanthines probably interact with different sites of the receptor since antagonists behave 
differently when tested against each of the two agonist classes. While Δ9-THC is a lipid-like compound 
the xanthines represent peptide-like structures. GPCR signaling can be modified by ligands in many 
ways. It has been known for a long time that so-called orthosteric and allosteric ligands can be 
differentiated. “Orthosteric” meaning the same binding site as the endogenous ligand and “allosteric” 
meaning a different binding site. As the GPCR receptor family consists of many diverse receptors, they 
also show very different binding sites for their endogenous ligands, thus reflecting the broad spectrum 
of very diverse endogenous ligands. The binding position of a large peptide consisting of hundreds of 
atoms and a small agonist with only dozens of atoms, will be completely different. Nevertheless, GPCRs 
all function in the same way and obey to the same rules.183 
Especially in the δ-branch of class A GPCRs, this phenomenon has been observed before. When 
Zang et al. crystallized the P2Y1 receptor, a nucleotide receptor and not too far relative of GPR18, in 
complex with a non-nucleotide antagonist, BPTU. This antagonist was found to probably approach its 
binding site at the very periphery of the helical bundle from the membrane side.184 However, BPTU 
was an antagonist inhibiting the receptor. Kruse et al. crystallized the muscarinic M2 receptor not only 
in its inactive state, but also in its active state, using the superagonist iperoxo, which is more potent 
than the endogenous agonist acetylcholine, and additionally with a positive allosteric modulator. This 
positive allosteric modulator was shown to bind way up in the extracellular site of the receptor.185 
Recently, a binding site deep in the membrane and from the outside bending over helix VI has been 
reported for the glucagon receptor, a class B GPCR. Here, the antagonist captures the quite flexible 
helix VI, which is the major key player in receptor signal transduction towards the G protein.186 But 
also, this compound was an antagonist. As it is much harder to get crystal structures of agonist-bound 
receptor states not so many crystal structures in the active state have been solved yet.  
Which techniques are available to predict and understand ligand binding behavior? We used 
functional assays to characterize our newly designed agonists. A much more precise experiment, is to 
investigate the ligand binding in a radioligand binding experiment, in which the ability of a ligand to 
replace a labelled ligand is monitored. However, the design and establishment of a radioligand requires 
compound optimization, synthesis optimization and assay development. To fulfil the expectations on 
a radioligand, the corresponding compound has to have a high affinity (in the low nanomolar range) 
and suitable physiochemical properties, to reduce non-specific binding. Furthermore, there has to be 
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a suitable chemical structure that allows the labelling with a radioactive isotope in the last synthesis 
step. If a radioligand is replaced, the competing ligand and the radioligand likely share the same binding 
site. Allosteric modulation of radioligand binding can also be observed, but is much more challenging 
to interpret.183  
Nevertheless, to know the exact binding partners of a ligand in a binding pocket, mutagenesis 
studies are necessary. An amino acid is exchanged for another one, which displays different functions. 
Most commonly, an amino acid is exchanged for a small amino acid such as alanine. Large changes can 
influence the protein topography, which can lead to non-functional receptors that may not be 
expressed on the cell surface. A receptor like a GPCR consists of many amino acids, and a binding 
pocket is formed by amino acids that can be positioned almost everywhere in the amino acid sequence. 
They do not even need to be neighboured since the folding of the protein generates an overall 
conformation, which is on the one hand defined by the arrangement of the amino acids direct next to 
each other, but also by amino acids from completely different parts of the sequence. Therefore, it is 
challenging to predict the amino acids that form a binding site if no crystal structure is available.  
This kind of prediction is achieved with bioinformatic tools. To construct a model of a receptor a 
method called homology or comparative modeling is used, which is a so-called structure-based 
approach. This means, the gathered information is derived from a protein structure and corresponding 
models. First of all, it has to be checked, if a crystal structure of the target receptor exists. For the 
GPCRs it is rather hard to obtain crystal structures, because they are membrane bound proteins, that 
do not crystallize easily outside of lipophilic surroundings. When the first human GPCR was crystallized 
in 2007 by Brian Kobilka,2 this was a breakthrough in the field. Nowadays, the number of crystallized 
GPCRs has been increasing, but still some GPCR families are unrepresented. In the δ-branch of class A 
GPCRs, only three receptors have been crystalized so far. For GPR18, there is no available crystal 
structure, so we used a homology modeling approach to construct a model of the receptor. The crystal 
structures of related receptors were used as templates. The sequences was compared and then a 
model was built based on the homology of the receptors. The less similarity between the receptors 
exists the more challenging is this approach. Several other conditions can also limit the success of the 
modeling performance: the number and states of the available templates, the resolution, the unique 
structural differences of the receptor of interest with the templates and the fitness of the method 
applied.187 The basic principle of this method is depicted in Figure 61.  
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Figure 61: Structure-based molecular modeling approach 
 
There exist different computational solutions to solve this task. In our study, we used the software 
Rosetta during a research stay in the laboratory of Prof. Jens Meiler the Vanderbilt University, 
Nashville, TN, USA. The Rosetta software suite, a command line driven application for Linux operating 
systems, has been developed and distributed by the labratory of Prof. David Baker from the University 
of Washington, Seattle, WA, USA. It works based on two major approaches: Rosetta takes on the one 
hand fragments out of the pdb library to obtain optimal conformations of the local peptide orientation 
and, on the other hand it optimizes the overall structure.188 It uses Metropolis Monte-Carlo simulation 
algorithms. Rosetta was originally designed as a de-novo folding prediction tool for proteins that have 
no templates available. This means a construction from the primary structure directly to the correct 
conformation of a functional protein. However, this is a challenging task that has many limitations. De-
novo folding reaches its limits at amino acid sequence lengths of 150. For larger proteins, the template-
based approach is a much more productive way to circumvent the drawbacks of the de-novo 
predictions. In the Critical Assessment of Techniques for Protein Structure Prediction (CASP), Rosetta 
was able to solve one of the problems in de-novo folding almost perfectly.189 Nevertheless, every 
modeling approach has its own challenges and difficulties.  
The modeling undergoes a certain operational procedure, which is depicted below (Figure 62). 
 
Figure 62: Workflow of by comparative modeling 
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All parts that involve modeling were done by this procedure, and each step was individually adapted 
to solve the arising problems. As a second step, the small molecule ligand was docked to the built 
model. Both procedures require selection processes. No prediction can produce a correct solution 
instantly. Every time, a large number of models were built, and out of this pool of models the most 
probable ones have been selected. The selection was based on a score that describes the energetic 
state of the model. The lower the value of the energy descriptor, the better the model is scored, the 
higher is the confidence in it. As the natural state is regarded as the energetically most favorable one, 
this is a rather straightforward kind of selection. But sometimes the best scoring model is not the 
natural state. Therefore, a second method is applied, which is called clustering. It ensures that not only 
the best scoring models will be taken forward, but also the models that are created most frequently. 
This is important to ensure a high degree of diversity, so that the final ensemble will most probably 
enclose models which resemble the natural state of the protein.190 
One of the biggest challenges of this approach was to capture the loop conformations accurately. 
The transmembrane helical part of the GPCRs is quite well described and quite homologous in all 
known GPCR structures, and therefore, the confidence in the prediction of that part was higher. The 
major difference is found in the loop regions. GPCRs have three extracellular and three intracellular 
loops, which fulfill different functions. The outer loops can be involved in the ligand binding and 
activation processes, as for example in the PAR1 receptor (protease-activated receptor 1), where part 
of the N-terminal residues are cleaved by a protease and then activate the receptor.191 On the 
intracellular site, the loops are involved in the G protein binding and activation. These loops will not 
be optimized in this project, because they presumably do not play an important role for ligand binding.  
For GPCR comparative modelling, around 40 crystal structures are available. In some GPCR 
subfamilies, there are more solved structures than in others. GPCRs can be divided into different 
classes (in our case: class A rhodopsin-like GPCRs, the by far largest class), and further subdivided into 
subfamilies (in our case: δ-branch receptors). This already narrows down the available models. 
Normally, they are chosen by sequence identity. A sequence identity of less than 30% makes 
comparative modeling approaches more challenging. For GPR18 modeling, only class A GPCRS were 
taken as templates, class B receptors were already too different in sequence and structure. The largest 
number of known crystal structures exists for α-branch and γ-branch GPCRs. The γ-branch consists 
mainly of peptide receptors, and they all show some specific features, as for example, the occurrence 
of β-strands in their second extracellular loop (ECL2). The crystallization process in most cases requires 
a bound ligand (this minimizes the energy), but most of the receptors have been crystalized with an 
antagonist. Only very few models exist with an agonist bound. The first agonist state receptor that was 
crystallized by the Kobilka lab was the β2-adrenergic receptor.192 
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The chosen models were taken forward to the next step of the modeling process, and either further 
modeling procedures or ligand docking were applied. Docking was executed by an application of 
Rosetta: RosettaLigand. Rosetta itself is designed as a software that can be easily adapted to specific 
scientific questions, by constructing applications in Rosetta via so-called xml-files. In these files, the 
special calculations and processes one wants the program to undertake, can be specified and adopted 
to one’s needs. This gives the researcher a big freedom in the experimental set-up. RosettaLigand was 
designed as an xml-application, where key parameters can be adapted as required.193,194 
To further evaluate the ligand position and to generate the right conformers the BCL 
(BiochemicalLibrary) was used, a software suite that is distributed by the laboratory of Jens Meiler. 
The BCL can construct quantitative structure-activity relationship models and be applied to ligand-
based compound development.195 In our case, it will be used to evaluate the docking procedure.  
 
3.5.2. Alignment and template search 
 
The sequence of the human GPR18 was downloaded in FASTA format from Pubmed protein 
sequence database (accession number: AAH66927, compare Figure 63). At first, suitable templates 
were identified and downloaded from the RCSB protein data bank. The NCBI Blast tool was used to 
search for appropriate structures. We specified to only search for amino acid sequences that have 
been crystallized (the so-called “pdb-search”).196 Structures were chosen according to their sequence 
homology in percent, the e-value (it describes the possibility to find random matches in large 
databases, the lower the value, the better, and the more significant is the match), the resolution of 
the crystal structure (the resolution in Ångstrom is a measure of the variability of the atom in space, it 
should be lower than 3 Å), and the conformational state of the model. All agonist state models were 
included, as we are going to dock an agonist to our models.  
 
>hGPR18 
MITLNNQDQPVPFNSSHPDEYKIAALVFYSCIFIIGLFVNITALWVFSCTTKKRTTVTIYMMNVALVDLIFIMTL
PFRMFYYAKDEWPFGEYFCQILGALTVFYPSIALWLLAFISADRYMAIVQPKYAKELKNTCKAVLACVGVWIMTL
TTTTPLLLLYKDPDKDSTPATCLKISDIIYLKAVNVLNLTRLTFFFLIPLFIMIGCYLVIIHNLLHGRTSKLKPK
VKEKSIRIIITLLVQVLVCFMPFHICFAFLMLGTGENSYNPWGAFTTFLMNLSTCLDVILYYIVSKQFQARVISV
MLYRNYLRSMRRKSFRSGSLRSLSNINSEML 
Figure 63: sequence used for modeling, (accession number: AAH66927). 
 
 
In total, a number of 18 crystal structures were chosen. They are briefly described in Table 19.  
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Table 19: Selected pdb templates.  
Pdb-code Receptor and description 
3VWL 
PAR1 receptor bound to the antagonist voraxapar, 2.2 Å, Zhang et al.191, 
δ-branch receptor, 30% sequence identity 
4XNV 
P2Y1 receptor bound to the allosteric ligand BPTU, 2.2 Å, Zhang et al.,184 
δ-branch receptor, nucleotide receptor, 23% sequence identity 
4NTJ 
P2Y12 receptor bound to AZD1283, a non-nucleotide-antagonist, 2.62 Å, 
Zhang et al.197, δ-branch receptor, nucleotide receptor, not listed by pdb-
blast, but selected because of close phylogenetical relation 
5DHG 
Nociceptin/orphanin FQ receptor (NOP) in complex with C-35 (small 
molecule ligand), γ-branch receptor, peptide receptor, 3.0 Å, Miller et 
al.,198 25% sequence identity 
4DJH 
κ-Opioid receptor, in complex with JDTic (small molecule antagonist), 2.9 
Å, Wu et al.,199 γ-branch receptor, peptide receptor, 27% sequence 
identity  
5C1M 
µ-Opioid receptor with small molecule agonist BU72, 2.1 Å, Huang, et 
al.200 γ-branch receptor, peptide receptor, 27% sequence identity 
4N6H 
δ-Opioid receptor in complex with naltrindole (small molecule 
antagonist), 1.8 Å, Fenalti et al.,201 γ-branch receptor, peptide receptor, 
26% sequence identity 
4ZUD 
Angiotensin receptor, in complex with the small molecule antagonist 
ZD7155, 2.8 Å, Zhang et al.,202 γ-branch receptor, peptide receptor, 29% 
sequence identity 
4MBS 
CCR5 chemokine receptor bound to the small molecule antagonist 
maraviroc, 2.71 Å, Tan et al.,203 γ-branch receptor, peptide receptor, 26% 
sequence identity 
2LNL 
CXCR1 chemokine receptor in phospholipid bilayers, NMR structure, Park 
et al.,204 γ-branch receptor, peptide receptor, 26% sequence identity 
3ODU 
CXCR4 chemokine receptor in complex with the small molecule antagonist 
IT1t, 2.5 Å, Wu et al.,205 γ-branch receptor, peptide receptor, 28% 
sequence identity 
4XES 
Neurotensin receptor in an active-like state bound to neurotensin, 2.6 Å, 
Krumm et al.,206 β-branch receptor, peptide receptor, not listed by pdb-
blast, but taken because of active state 
2YDO 
A2A-receptor bound to adenosine, active state, 3.0 Å, Lebon et al.,207 α-
branch receptor, nucleotide receptor, 24% sequence identity 
3PBL 
Dopamine D3 receptor bound to eticlopride (small molecule antagonist), 
2.89 Å, Chien et al.,208 α-branch receptor, biogenic amine receptor, not 
listed by pdb-blast, but taken to includediversity 
4QKX 
β2-adrenergic receptor, agonist state bound to 35V, 3.3 Å, Weichert et 
al.,209 α-branch receptor, biogenic amine receptor, 21% sequence identity 
4IAR 
5-HT1B serotonin receptor bound to ergotamine (small molecule 
antagonist), 2.7 Å, Wang et al.,210 α-branch receptor, biogenic amine 
receptor, 20% sequence identity 
3RZE 
H1 histamine receptor in complex with the small molecule ligand doxepin, 
3.1 Å, Shimamura et al.,211 α-branch receptor, biogenic amine receptor, 
not listed by pdb-blast, but taken because of diversity 
3UON 
M2 muscarinergic receptor bound to 3-quinuclidinyl-benzilat (small 
molecule antagonist), 3.0 Å, Haga et al.,212 α-branch receptor, biogenic 
amine receptor, 23% sequence identity 
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In a first step, only the transmembrane domains were of major importance. The GPR18 protein 
sequence was aligned with ClustalOmega and transferred as textfile to Excel, where the alignment was 
adapted manually. The helix domains of each receptor were marked as determined visually in PyMOL. 
For GPR18, the transmembrane spanning domains were predicted with Octopus 
(http://octopus.cbr.su.se).213 These domains were expected to be in the same range as the helix 
domains of the others. In this first step, the loop regions were not exactly aligned, they would be 
evaluated and eventually also modeled, when their performance was not good enough.  
GPCRs are a big family of receptors that mediate quite comparable reactions – the transduction of 
a signal across the membrane to activate G proteins and recruit β-arrestins. Therefore, they also share 
some common structural sequences. Most of the receptors show two conserved motifs, the E/DRF 
motif at the end of the third helix, which maintains a hydrogen bond network that stabilizes the 
receptor. GPR18 shows this structural motif. Another common motif is the NPxxY motif at the end of 
the seventh helix, also establishing hydrogen bonds that are disrupted upon activation. Here, GPR18 
is missing the conserved sequence, as can be observed in Figure 64. 
 
Figure 64: Detail from the alignment: helix seven, hypothetical NPxxY motif, proline is numbered 
according to Ballesteros-Weinstein nomenclature.214 Yellow: possible membrane spanning domains, 
beige: observed helix in crystal structure or model, magenta: conserved proline; h = human. 
 
As can be seen in the detail of the alignment, GPR18 lacks the conserved proline and shows a valine 
instead. Proline is the only amino acid with a secondary amine – which means that the amine is not 
able to establish as many hydrogen bonds as a primary amine in the other amino acids. In the tertiary 
structure of proteins, it displays helix breaking properties. In many cases, the proline interrupts a 
straight helix and the amino acid chain bends at this point. Therefore, the exchange of conserved 
proline to a valine, as in this case, can be estimated to play a role in the formation of the tertiary 
structure. But not all GPCRs have this conserved proline, only around 90%.215 Especially δ-branch 
GPCRs can show other motifs. All six depicted receptors (Figure 64) show an aspartate instead of an 
asparagine vicinal to the P7.50, but the common opinion on that is, that both can maintain the same 
function in the hydrogen bond network. The two crystallized receptors, P2Y1 and P2Y12, both share the 
expected proline, but GPR55 and GPR35 have a valine or the related alanine, respectively. If and how 
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these lipophilic amino acids can contribute to the tertiary structure in comparison to proline still has 
to be evaluated, especially, as none of the already crystallized structures shows replacement of the 
proline P7.50. This structural abnormality has to be taken into account, when judging the models.  
Furthermore, it can be observed that GPR18 has one of the two “conserved disulfide bonds”, 
between helix III and the extracellular loop 2, but not the other one that is present, for example, in 
P2Y1 between the N-terminus and helix VII.184 
Overall, GPR18 shows some of the common features of a GPCR, but also some specialties of the 
δ-branch receptors. In all further experiments, these will have to be evaluated in the context of the 
GPCR structures we already know.  
The alignment for every step of homology modeling is always in construction and can be changed 
from one modeling round to the other quite fluently. Therefore, the presented alignments always refer 
to a certain problem and may not be true for every step.  
 
3.5.3. Building the transmembrane domain 
 
In the first approach of homology modeling, the transmembrane domains was built. Nevertheless, 
the whole receptor was constructed, but the orientation of the extracellular loops was of minor 
priority, as they were cleaved off and built individually when not performed correctly. For building the 
transmembrane domain, the RosettaCM application was used as described by the example material of 
the RosettaWorkshops, distributed by the laboratory of Prof. Dr. Jens Meiler (version: Rosetta 3.6 - 
2016; and Rosetta 3.5 - 2015, http://www.meilerlab.org/index.php/rosetta-tutorials) and the 
protocols that were published by Bender et al.216 with some adaptions to the system and problems of 
the present study.  
In this first step, the transmembrane domains were aligned most tightly to avoid any holes in the 
transmembrane domains. This alignment was then used to generate so-called threaded templates – 
i.e. the alignment information was transferred into pdb coordinate information. With this and the 
applied information of transmembrane domains from Octopus-prediction, disulfide connection 
information and fragments RosettaCM constructed a large number of models. The models were 
refined by relax, and than evaluated by scoring and clustering. Out of 8800 models, 20 were chosen to 
be further proceeded. In Figure 65, the results of this first step can be observed, namely an ensemble 
of models, which were clearly different from each other. Subsequently, a single model is depicted.  
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Figure 65: (A) Top scoring model ensemble, (B) a single model. 
 
In this first step, the helices are judged based on visual examination. Important key issues are the 
kinking of helices, when a proline is present in the sequence. Also, the part of the model is examined, 
where the NPxxY motif is located. This can be observed in Figure 66. 
 
Figure 66: Detail from the ensemble: the arrow points to the position where GPR18 has a valine 
instead of the “conserved” proline.  
 
Special attention was paid to capturing a broad diversity of models in this region. As no structure 
with such a motif exists every assumption could be misleading, and therefore models with the greatest 
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RMSD difference over this certain helix region were also included, when their overall performance was 
acceptable.  
Interestingly, helix VIII was almost always completely built. There seemed to be a high degree of 
confidence in this secondary structural element, which does not exist in all GPCRs. For example, the 
P2Y12 receptor also shows it, but not the P2Y1 or the PAR1 receptor.184,191,197 On the other hand, 
crystallization is always a non-natural state, because of the extreme conditions used in this procedure; 
more flexible regions will be impaired by crystallization more likely than rigid ones.  
 
Figure 67: Top scores in RosettaEnergyUnits (REU) and RMSD (root mean square deviation) of the 
α-carbon atoms in comparison to the best scoring model 
 
Only very few models have been completely disrupted or destroyed. In the Figure 68, the RMSD 
versus the top scoring energy units is pictured. The applied method should generate an ensemble of 
conformational diverse models, which can be measured by the RMSD (a measurement of the spatial 
similarity between proteins). Here, it can be seen that the best scoring model and all other models 
differ in the top scoring range between 2 to 4 Å RMSD, which can be regarded as an appropriate 
diversity.  
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Figure 68: (A) One model out of the ensemble, the arrow points to an area that seems to be 
undefined in its secondary structure; (B) top view of the ensemble. 
 
In Figure 68, the arrow points to a region, where the helix was not formed accurately. This must not 
be a sign of bad performance, especially in the case shown here. Whenever proline or glycine occurs 
in a helix, it will disrupt its straight orientation. By visual inspection, the best scoring models were 
selected when their helical orientation was accurate.  
Nevertheless, the loop performance was not acceptable. The N-terminus was still too long and 
interacted with the protein structure to an extent that was not realistic (which is based on the 
assumption of the program to minimize surfaces). Therefore, it was chopped off. In the next chapter, 
we will discuss the orientation of the amino acids in the loops one by one, and there we will also see 
that the preliminary models did not capture the known side-chain orientations in an acceptable 
manner. This is the major reason for cutting the loops off and remodel them in a step-by-step 
procedure. 
 
3.5.4. Loop building 
 
There are three extracellular loops in a GPCR. ECL1 is a rather short and well-conserved loop, which 
was the reason to establish it first. ECL2 is long and curvy and can contain certain secondary structural 
elements, for example, β-strands, as in most of the γ-branch GPCRs (which are all peptide receptors). 
Therefore, it was built last. ECL3 is a little bit longer (5-9 amino acids), not so conserved but very well 
defined. A schematic overview is given in Figure 69. In contrast to the first modeling steps, the 
structure to be build comes with a template itself and additional sequence information. Moreover, 
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only the interesting parts of the template structures will be used to obtain models. We did not design 
the intracellular loops, as they do not play a significant role in ligand binding.  
Subsequently, we tried to build the loops in the presence of the ligand. This should prevent the 
collapsing of the ligand binding pocket. This requires some adaptions to the protocol used for the 
hybridization step. To maintain an open conformation in the ligand binding pocket, the ligand MZ1415 
will be docked in between.  
 
Figure 69: Procedure for loop modeling. 
For the design of the loops, the alignments were adapted as necessary. For example, the A2A 
receptor showed a completely different conformation in the ECL2, therefore, it will not be used as a 
template. By template selection and the alignment with the exactly matching amino acids, the loops 
were refined.  
In total, the loop modeling will be pursued in the following sequence (compare Figure 70). 
 
 
Figure 70: Workflow for loop modeling. 
 
3.5.4.1. Extracellular loop 1 
 
The extracellular loop 1 shows a highly conserved conformation in most of the GPCR subfamilies. 
With very few exceptions, it is characterized by a conserved tryptophan residue, which shows a very 
specific sidechain conformation (compare Figure 72 (A)); this has to be captured in a modeling 
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approach. As very good templates for modeling the peptide receptors of the γ-branch could be 
identified. They also contain the WPFG sequence that GPR18 shows. Therefore, we compared the 
sidechain orientation in these peptide receptors to evaluate our loop modeling results. The only 
receptor, that has no conserved tryptophan in that position, is the adenosine A2A receptor. It shows a 
phenylalanine, which is also an aromatic amino acid (see alignment in Figure 71). The loop is located 
in light blue region. The conserved tryptophan is marked.  
 
Figure 71: Alignment for modeling of ECL1. ECL1 in light blue, conserved tryptophan in blue and 
conserved cysteines, forming a disulfide bond, in turquoise. 
 
The procedure for loop modeling resembles the procedure for the overall receptor modeling, with 
the difference, that the program is provided with template files, that only consist of the part of the 
receptor, which is shown in the alignment. In the beginning, it was almost impossible to capture 
conformations with tryptophan in a plausible orientation (compare Figure 72, (B)). The tryptophan 
tended to flip around. By exactly determining the pose of the tryptophan in the templates, certain 
defined key features could be noted, as, for example, the angles of the bonds between the C-α and C-
β atom of the tryptophan. They were then constrained. A constraint in Rosetta means a defined 
specification that is provided to the program and has to be fulfilled. For this tryptophan, we 
constrained angles and distances to the neighboring atoms of different residues. With this addition to 
the protocol, the tryptophan could finally be located as it was supposed to, compare Figure 72, (C).  
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Figure 72: Conformation of the conserved tryptophan in ECL1 (pink residue): (A) templates (grey) 
3VW7, 4N6H, 4XNV; (B) first modelling attempt (C) after constraining the conserved tryptophan; 
overlay of models (light blue) and the template structure 4MBS (grey). 
 
3.5.4.2. Extracellular loop 3 
 
The extracellular loop 3 contains five amino acids in GPR18. When aligning the templates to GPR18 
based on the starting point of the helices, it became obvious, that ECL3 can have different lengths in 
different templates. In Figure 73, the amino acids that were aligned to the two last helix residues are 
highlighted.  
 
Figure 73: ECL3 – in pink the residues that resemble TYR in GPR18 and in green those that resemble 
LEU in GPR18 are shown. 
 
In the alignment in Figure 74, it can be observed that the length of the ECL3 appears to be typical 
for each branch. The short ECL3 is shared by the α-branch receptors (many biogenic amine receptors). 
The peptide receptors of the γ-branch have the longest ECL3, or longer helices. The last amino acid of 
the helices were determined in the GPR18 models and in the aligned templates by visual inspection 
(pink and green residues in Figure 73). An additional grey helix turn can be observed for some 
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structures above the pink colored residue. This refers to the templates with more amino acids. To 
prevent Rosetta from applying helix turns in the models, the alignment shows a gap at this point.  
The alignment of the structures and sequences further shows that the GPR18 ECL3 resembles more 
the α-branch receptors.  
 
Figure 74: Alignment of ECL3 with the corresponding templates, green and pink border refer to 
the designated residues in Figure 73 
 
In this step, we generated 4400 models. They were evaluated by visual inspection, and by scoring 
and clustering. When first inspecting the models, it became obvious that the arrangement of the side 
chains of the former models were altered again. This could be prevented by applying the former 
constraints also in this step, compare Figure 75.  
 
Figure 75: In each part of the picture are 35 random models; blue = the ligand, pink = tyrosine, 
green = leucine. (A) After the relax step (without constraints) the TRP that was carefully assigned in 
3.5.4.1 is turned around again. (B) After the hybridize step, it can be seen that the TRP is already 
moved around. (C) putting the ECL1 constraint in the relay step prevents it from turning around. 
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When selecting appropriate models, one key issue was the tyrosine (pink in Figure 75), which should 
be pointing into the receptor inner space. Loops, where it bent far to the outside, did not resemble the 
template conformations so well.  
ECL3 was the only loop, where it was possible to construct the loop in the presence of the ligand. 
This is the reason, why the ligand (blue) is visible in the pictures in Figure 75.  
Overall, it can be concluded that the straightforward loop modeling of the ECL3 came rapidly to a 
plausible result. The first obstacle, the ECL1-TRP conformation, could be overcome easily by applying 
a logical constraint.  
 
3.5.4.3. Extracellular loop 2 
 
The extracellular loop 2 is by far the longest missing structural element. When comparing the ECL2’s 
of different templates some structural differences can be observed. There are receptors, as the γ-
branch receptors, but also the δ-branch receptors, that have beta-strands in the ECL2. Another 
important feature, that has to be noticed, is the conserved disulfide bond, that forms between helix III 
and the ECL2. The most important goal of this approach is the reformation of this disulfide bond.  
 
Figure 76: Comparison of ECL2 of (A) 4N6H/δ-opioid, 4ZUD/angiotensin, 5C1M/µ-opioid, 4DJH/κ-
opioid and (B) δ-branch receptors (3VW7/PAR1, 4XNV/P2Y1). 
 
In Figure 76, these two subfamilies can be compared. It can be observed, that all of the receptors 
show a disulfide bond. Nevertheless, there are differences. For example, the β-strand of the γ-branch 
receptor form directly the next helix, while the δ-branch receptors on the righthand side show an 
additional coil before forming the helix. Furthermore, the β-strand seems to be one residue longer in 
the γ-branch receptors, having the disulfide bond situated a little bit higher. In the alignment, this was 
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taken into account. Still, it has to be mentioned, that visualization is not without mistake and some 
differences might also be due to the visualization software.  
Another aspect has to be pointed out: the GPR18 sequence in this region is quite unique. In contrast 
to the sequence observed in the template structures, it shows a proline in the region, where a β-strand 
could be expected (compare Figure 77). Proline cannot participate in as many hydrogen bonds as other 
amino acids. In β-strands, every amino group is part of the necessary hydrogen bonding - therefore, in 
this case, proline can be assumed to not favor β-strand formation. The two neighbor amino acids have 
to form the hydrogen bonds. GPR18 can form the conserved disulfide bond, as the templates also do.  
 
Figure 77: Sequence alignment of the human GPR18 and chosen templates for ECL2.  
 
When predicting the secondary structure for the ECL2 loop region with jufo_2 and psipred (depicted 
in Figure 78), the results were not completely clear, but showed a strong preference. Wherever an E 
can be observed in the third row, the program proposes a β-strand. As this is an anti-parallel β-strand, 
there have to be two parts of β-strand prediction, which was the case with psipred. Further, psipred 
predicted both strands with six amino acids, which can be critically assessed. In the models, a lysine 
forms the last helix amino acids, it is lysine with the pose number 142, which therefore will not be part 
of a possible β-strand. This prediction was more accurate with jufo_2. On the other hand, for jufo_2, 
there was only one region of Es to be observed, which is undecided on the possible formation of anti-
parallel β-strands. As both at least indicate the later part of the β-strand, the full formation was with a 
high probability the right structural element to choose.  
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Figure 78: Secondary structure predicition using the tools jufo_2217 and psipred218, in the first row 
the Rosetta pose number can be found, then the amino acid one letter code, the predicted 
secondary structure (H = helix, C = coil, E = β-strand) and the probabilities for each of these 
secondary structures. 
 
When pursuing the ECL2 loop modeling, initial results were quite disappointing. There was a bad 
recovery of the disulfide bond and the loop was not built in the right place. Some adaptions to the 
original protocol were executed and led to an optimized performance, view Figure 79 (major 
optimization included: the template to model ratio in xml files, the alignment of 3D coordinates of 
templates and models for threading process, and the inclusion of far more template material in the 
threading process and deletion of the ligand).  
 
Figure 79: (A) First attempts to model ECL2, (B) the optimized protocol shows appropriate results. 
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After optimization, a satisfactory result was obtained. The disulfide was built in almost all models 
and the other loops stayed in a correct place. After the hybridize step, 62 out of 4335 models showed 
β-strands (1.43%) in PyMol. They could however not be preserved through the normal relax step.  
For the docking of the ligand itself, the formation of β-strands was regarded as not so important, 
as long as the amino acids are located rationally. In order to save time for further protocol adaption 
and test runs, 85 models were selected based on scoring and clustering.  
The formation of the β-strands in GPR18 will be further pursued in a project, optimizing the relax 
process to rescue the β-strand conformation from the hybridize step.  
 
3.5.4.4. Evaluation of modeling in the presence of the ligand 
 
For all loop building steps, we tried to perform them in the presence of the docked ligand to 
maintain a conformation suitable for ligand docking. The program generally tries to minimize surfaces 
towards the outside and therefore tries to close open space. Furthermore, the prospect of modeling 
the loop conformations in the presence of the ligand has the elegant aspect of complementarily 
optimizing receptor and ligand position.  
We tried to perform the loop modeling in all three cases in the presence of the ligand. But in two 
out of three steps problems due to the ligand’s presence arose. As the space of the loops is normally 
covered with atoms that are interacting with others, this possible space can be occupied by the ligand 
and block the space for the loop’s sidechains.  
Table 20: Evaluation of loop modeling in the presence of the ligand. 
 POSSIBLE TO OBTAIN EXCEPTABLE 
RESULTS? 
COMMENTS? 
ECL1 No – ligand was discarded Ligand was interfering with the space 
where the loop should be built  
ECL2 No – ligand was discarded Ligand was interfering with the space 
where the loop should be built 
ECL3 Yes, modeling succeeded in the 
presence of the ligand 
Probably possible because the ligand 
did not interact much with the 
necessary space 
 
 
In total, it was only possible to model a loop in the presence of the ligand for ECL3. This could be 
possible because the ligand is not interfering with the space of ECL3 in most of the docking results. 
Also, when we take a look at the results in 3.5.5, we will see, that the ligand is interacting with amino 
acids both in ECL2 and ECL1. The missing interaction can also be a problem for the docking step. The 
results are summarized in Table 20.  
3 Medicinal Chemistry of GPR18 agonists and antagonists 
123 
 
In total, the objective of this approach can be regarded as promising and helpful to get an overall 
plausible receptor conformation, but the technical difficulties in interpreting the ligand in the 
comparative modeling step and the rather poor performance were certainly a drawback. There is 
definitively need for protocol optimization. This first approach shows that it is possible (ECL3) but 
afflicted with problems (ECL2 and ECL1) that need to be solved.  
 
3.5.5. Docking 
3.5.5.1. Docking procedure  
 
We performed the docking of the agonist 162 with the RosettaLigand application.193 The ligand was 
placed into the possible binding pocket and then its position was further optimized by so-called 
focused docking. The major read-out was the interface_delta, the energy gain of the system, through 
binding the ligand in that exact position. As this is an energy term, the lower the energy of the system, 
the better is the stability, and therefore, the probability increases. But, it has to be noted that this 
energy term is a rosetta-specific one which cannot be compared to other energy terms, for example, 
experimentally obtained binding energies. In the focused docking process, the angle and the space in 
which the ligand can move were narrowed down, until the docking score did not get any lower.  
In this approach, the agonist 162 has been selected for docking, because it is the most potent ligand 
of the GPR18 receptor so far. Furthermore, structure-activity relationships for this compound class are 
already established and can be taken into account when examining the proposed poses. With the 
results from the docking procedure, hypotheses will be generated, to test the proposed binding sites 
by mutagenesis experiments. Naturally, docking results can be improved based on experimental data 
from mutagenesis studies. Therefore, the whole docking process can be regarded as a hypothesis that 
has to be experimentally proven. On the other hand, every experimental result can improve the model. 
Modeling is always a mutual process depending on experiments. 
To start the docking procedure, a conformer library of the ligand is needed, which was acquired by 
using the bcl::ConformerGenerator.219 The program calculates every possible conformation of a ligand, 
as depicted in Figure 80. The number of possible conformers depends on the flexibility of the ligand, 
especially its rotatable bonds. During the docking process, RosettaLigand will pick different 
conformers. In the sorting and scoring process, the best models will be selected, and certain 
conformers will be scoring higher than others.  
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Figure 80: Conformer library of compound 162. 
 
One of the conformers was manually positioned in the starting models in PyMol. The first round of 
docking was carried out and from that, a large number of models was chosen (~500). This ensures a 
broad range of positions of the ligand in the possible binding pocket.  
All models with a negative interface_delta (that means all models where the binding of the ligand 
showed an energy gain) were transferred to the second round of docking. There, the ligand was still 
allowed to rotate and move with in a quite large space (rotation = 360°, space to move = 4 Å). These 
docking rounds were evaluated by their docking score, and also by clustering and therefore sampling 
the most frequently observed conformations. Of course, this clustering was only be allowed up to a 
certain interface_delta value, that ensures reasonable conformations. By plotting the interface_delta 
as energy read-out against the ligand-RMSD an idea about the energy probability against the frequency 
of a certain position can be visualized. In the end, all of the interesting poses were visually evaluated. 
The docking was further focused by adapting the spacial movement and the rotation of the ligand. The 
docking was not further progressed when the interface_delta remained static and no improvement 
could further be achieved. In Figure 81 and Table 21, the progression of the docking procedure can be 
observed.  
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Figure 81: Focused docking: (A) first round, (B) second round, (C) third round, (D) fourth round, (E) 
fifth round; in each figure the interface_delta (REU) is plotted against the ligand-RMSD (Ångstrom) of 
the best scoring ligand.  
 
Only models with a better interface_delta than -10 REU were plotted. The process was running 
from (A) to (E), and by comparing the lowest energy values, it can be tracked how the score improved 
in each round, beginning with (A) (interface_delta > -19 REU) to (D) and (E), where the best model 
scores with < -24 REU) were found. It can also be observed, that the number of negative models 
increases with every further round, compare Table 21. 
From Figure 81, it can be further observed that certain positions of the ligand stand out of the point 
cloud. The Ligand-RMSD, which was taken as a measure for the diversity of the ligand poses, indicates 
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the difference compared to the best-scoring model, nevertheless it wa a good surrogate parameter to 
estimate the similarity of the poses.  
 
Table 21: Focused docking: change of interface_delta over the different docking rounds 
Round of 
Docking 
Rotation 
Spacial 
movement 
Best interface 
delta (REU) 
Number of 
negative scoring 
models 
round_02 360° 4 Å -19.355 5309 
round_03 270° 3 Å -21.141 7614 
round_04 180° 2 Å -23.368 8344 
round_05 90° 1 Å  -24.288 8472 
round_06 45° 0.5 Å -24.187 8586 
 
With the sixth round of docking, the interface_delta did not improve further. This set of models was 
further analyzed regarding the ligand position. From this ensemble, we will deduce proposals for 
mutagenesis studies.  
 
3.5.5.2. Evaluation and proposals for GPR18 mutagenesis experiments 
 
In this section, we analyzed the models that have been generated by the docking procedure, and 
deduced proposals for further experimental studies. When taking a closer look at the ligand-RMSD vs. 
interface_delta plot, certain groups of models could already be identified that clustered together. In 
the case of this modeling approach, the best model (-24.187 REU) did not belong to the biggest cluster 
(the most often sampled conformation). In Figure 82, the ligand-RMSD is plotted against the best 
model of the biggest cluster (differently to the plots before, where it was just plotted against the best 
scoring model). It can now be observed that all other poses are 6 Å far away from this biggest cluster.  
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Figure 82: Interface_delta (>-20 REU), sixth docking round, plotted against the best model of the 
biggest cluster (which is not the best model overall). 
 
With the help of the BCL, the models were clustered (only <-20 REU) and as can already be visually 
observed from the plot, the largest cluster was Cluster_1082. At a distance of 6 Ångstrom, the best 
scoring cluster can be found, which was rather small.  
 
 
Figure 83: The best ten models of the best clusters.  
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In Figure 83, the best ten models out of the best clusters are shown. Cluster_1065 and Cluster_1095 
obviously share the same difference in ligand-RMSD but not the same best-scoring interface_delta. 
The same ligand-RMSD does not necessarily has to mean the exact same position, it just indicates the 
difference compared to the selected model: here, the difference was 6 Å. By visually checking the pose 
of the ligand, the complex can be further investigated. Furthermore, it can be noted that two clusters 
scored better by 2 REU, namely Cluster_1082 and Cluster_1095. 
For the mutagenesis proposals, Cluster_1065 was not used as it scored comparably less good than 
Cluster_1095 while having the same ligand-RMSD.  
A summary of the results of the docking analysis is provided in Table 22 and Table 23. Some key 
issues were evaluated there, which provide an idea, whether the pose can be used for the prediction. 
One very important point was the ability of the models to capture the structure-activity relationships 
that were already established. In particular, a decrease in potency when prolonging the N1-alkyl chain 
was used for critical assessment.  
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Table 22: Characterization of the obtained clusters, part I.  
Hypothesis I Hypothesis II Hypothesis IIb 
Cluster name 1082 1095 1065 
Linkage (RMSD) 0.453864 1.60199 0.299187 
Cluster size 377 57 39 
Interface_delta (REU) -24.058 -24.187 -22.873 
Energy_breakdown: 
Top 10 aminoacids 
 
Pose-
Nr. 
Aa % 
235 PHE 22.19 
156 LEU 16.88 
164 LEU 11.70 
64 TYR 11.41 
167 VAL 5.52 
238 LEU 5.37 
157 LYS 5.12 
247 TYR 4.76 
65 TYR 4.32 
145 ASP 3.31 
Pose-
Nr. 
Aa % 
250 TRP 22.88 
254 THR 11.39 
235 PHE 9.04 
143 TYR 6.69 
238 LEU 6.46 
156 LEU 6.31 
64 TYR 5.61 
85 VAL 5.23 
155 CYS 4.21 
234 CYS 3.57 
 
Pose-
Nr. 
Aa % 
235 PHE 22.77 
156 LEU 20.89 
164 LEU 12.01 
64 TYR 8.21 
143 TYR 5.54 
70 TRP 4.33 
80 LEU 3.76 
167 VAL 3.17 
155 CYS 2.49 
231 PHE 2.32 
 
Pose 
 
 
 
In accordance with 
SAR? 
Yes  
N1-methyl blocked 
Yes 
N1-methyl blocked 
Yes 
N1-methyl blocked 
Hydrogen-bonds TYR 64 – phenolic hydroxylgroup interacts 
with indole nitrogen 
THR 254 – with secondary amine (acceptor) 
of the linker to the indole (as hydrogen 
bond donator) 
ASN 171 (with C6-xanthine-oxygen 
(ketone)) 
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Table 23: Characterization of the obtained clusters, part II.  
Hypothesis III Hypothesis IV Hypothesis V 
Cluster name 1093 1088 1097 
Linkage (RMSD) 1.47901 0.619756 1.87483 
Cluster size 27 18 14 
Interface_delta (REU) -22.352 -22.745 -22.389 
Energy_breakdown: 
Top 10 aminoacids 
Pose-
Nr. 
Aa % 
156 LEU 20.87 
235 PHE 19.01 
54 PHE 17.32 
61 ARG 8.14 
64 TYR 7.29 
231 PHE 6.23 
84 THR 5.76 
83 LEU 3.79 
80 LEU 3.74 
251 GLY 3.46 
 
Pose-
Nr. 
Aa % 
247 TYR 21.99 
70 TRP 13.76 
157 LYS 13.59 
64 TYR 7.69 
235 PHE 6.30 
238 LEU 6.10 
251 GLY 4.46 
80 LEU 3.59 
250 TRP 3.42 
158 ILE 3.38 
 
Pose-
Nr. 
Aa % 
64 TYR 19.98 
84 THR 12.16 
54 PHE 10.48 
70 TRP 10.42 
247 TYR 9.46 
156 LEU 8.87 
80 LEU 6.29 
61 ARG 5.18 
231 PHE 5.08 
252 ALA 4.19 
 
Pose 
 
  
In accordance with 
SAR? 
No - N1-methyl has a lot of space… Yes, N1-methyl blocked Yes, N1-methyl blocked 
Hydrogen-bonds weak – THR 84, to N9 of the xanthine LYS 157, to N9 of the xanthine THR 255 – with C6-keto group 
ARG 61 – to N9 of the xanthine 
THR 254 – C6-keto group 
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The information provided in the tables can be summarized as follows: cluster_1082 was the by far 
biggest cluster with over 300 models included. Cluster_1095 was nevertheless the best-scoring cluster, 
but comparably infrequently sampled. There were three further clusters, which all scored 2 REU less 
well. They were also quite small with around 20 models each. Cluster_1082 was by all means the 
largest and also quite well-scoring. When checking the already established structure-activity 
relationships, the N1-substituent of the xanthine was located in an area, where an enlargement of the 
alkyl sidechain would not be further tolerated, which is in agreement with experimental data.  
 
Figure 84: Pose of compound 162 in the model of Cluster 1093. 
 
For cluster_1093, it can be observed (Figure 84) that the methyl residue in position N1 was quite 
free in the space of the binding site. A methyl has been shown in our structure-activity relationships 
as the only residue to be tolerated, whereas larger substituents or the lacking of the substituent was 
detrimental. Therefore, the Cluster 1093 was not included in further analysis due to its lack to resemble 
experimental data.  
 
Figure 85: Overlay of the best-scoring model of the Clusters 1082, 1095, 1088 and 1097. 
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In Figure 85, out of the four reasonable clusters the best-scoring model can be observed. First of 
all, it can be noted that each model derived from a different original model, which shows that all 
attempts to ensure diversity were successful. The ligand was in all models quite similarly oriented, the 
indole residue pointed towards the ECL1. The conformation of the ECL2 also played a role. In some 
models the loop curved deeper down into the space of the binding pocket. If this was the case, the 
space could not be filled by the ligand. If the loop was a little bit more up towards the extracellular 
space either the xanthine or the para-chlorobenzyl residue could fit into this space. Only the cluster 
1097 showed a somewhat different orientation of the ligand pose. Here, the xanthine reisdue pointed 
straight down into the receptor core. There can be different poses observed for ligands in GPCR binding 
sites, therefore, it is not easy to predict the correct orientation. The deeper pose was not as easily 
accessible as the other poses, and this might be a reason why it was not sampled that often. On the 
other hand, the large difference in the interface_delta together with the far less probable sampling led 
to the assumption, that it might not be preferable. These four poses also covered the obtained 
structure-activity relationships. Their possible interactions with amino acids in the binding pocket were 
evaluated and also their ability to form hydrogen bonds was studied. For all four poses, possible 
hydrogen bonds could be observed, but very different ones. For cluster 1082, a possible hydrogen 
bond of the indole nitrogen with a tyrosine of helix II was found, but for the clusters 1088 and 1096 
the N9 of the xanthines interacted with possible hydrogen bond donors.  
Cluster_1082 served as a primary hypothesis as it was the best-scoring and most often sampled 
pose. As can be observed in Figure 86, the ligand was positioned quite high in helix V below the bow 
of the ECL2. In the other poses, this position could be blocked by the ECL2 bending further down, and 
therefore the xanthine moiety did not have the space to fill this position. The para-chlorobenzyl-
residue pointed into a hydrophobic pocket, where valine and isoleucine created a suitable surrounding. 
The indole was stabilized through a hydrogen bond from a tyrosine of helix II. The position of the ligand 
was in total rather high up in the pocket, towards the extracellular space. Further experiments will 
have to prove this hypothesis. 
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Figure 86: Pose of the ligand in cluster_1082, (A) from the top, (B) from the side.  
 
As asummary of this evaluation, the four clusters 1082, 1095, 1088 and 1097 were further 
investigated and their interaction with the amino acid residues of the receptor wiere examined. Due 
to the probability and strength of this interaction the best ten interactions were selected and then a 
proposal was provided for subsequent mutagenesis studies. In this approach, the cluster 1082 served 
as the primary hypothesis. If this hypothesis would fail, the others can also be considered. In total, ten 
point mutations will be made, seven were predicted from cluster 1082, and in addition from each other 
cluster a crucial interaction was picked as well.  
In chapter 3.4, we already investigated the ability of the identified potent agonist of the human 
GPR18 to activate the mouse GPR18. In the next section, these results were compared to the predicted 
interactions to corroborate our hypothesis of the proposed binding site.  
 
3.5.6. Proposals for mutagenesis 
 
Proposals for mutagenesis were generated by analyzing the possible interaction partners of the 
ligand in the hypothetical binding pocket. This was done on one hand with Rosetta and on the other 
hand by visually determining the nature of the interaction. The Rosetta tool used to calculate the 
energy gain of ligand binding, is called energy_breakdown. It breaks up the total sum of interactions 
of all residues in the model with each other into the interaction between each of the residues– but 
here, we only took the interactions with the ligand into account. This was not only done for one model, 
but for the best ten models of each cluster. The total energy scores were summed up and the ratio of 
each residue was determined in percentage. Whenever the possibility was detected that a hydrogen 
bond could be formed this was also be inspected (and can also be viewed in Table 22 and Table 23).  
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At first, we analyzed the ten highest impact interactions of every cluster and collected the results 
in Table 24. In Table 25, the collected interactions were transferred into rational proposals for the 
mutagenesis studies.  
Table 24: Overview of all involved amino acids, their type of interaction and proposals for 
mutagenesis experiments; bold text for amino acids involved in hydrogen bonding (note: pose 
numbers refer to Rosetta pose numbering and not to the total sequence).  
 
Total involved 
amino acids 
Cluster 
 
Type of interaction Mutagenesis proposals 
1 235 PHE 1082, 1088 1082:π-π-interaction with benzyl residue 
1088: interaction less pronounced 
ALA (LEU is observed in 
nature) 
2 65 LEU 1082 nonpolar interaction, with indole core GLY or PHE 
3 164 LEU 1082 nonpolar interaction, with methyl group GLY, or change to 
polar, like SER 
4 64 TYR 1082, 
1095,1088, 
1097 
is a conserved YY-feature in δ, but in other 
GPCRs D,V,N etc. 
PHE, ALA 
5 167 VAL 1082 nonpolar interaction with methyl, forms 
outer border for methyl residue, in fish 
GPR18=ASP 
GLY, ASP 
6 238 LEU 1082 part of a lipophilic pocket, probably no big 
impact 
ILE? 
7 157 LYS 1082, 1088 in this model backbone interaction, in other 
models it is a hydrogen bond donor 
(alternative hypothesis); loop region 
ALA 
8 247 TYR 1082, 1088 here more of a backbone interaction, but in 
other models also involved in binding , 
anchor point for ECL3 
ALA 
9 65 TYR 1082 π-π-interaction, but part of conserved YY-
motif, ILE in other GPCRs observed 
ALA 
10 145 ASP 1082 loop region, in no other hpyothesis ALA 
11 250 TRP 1095, 1088 interacting with xanthine ALA 
12 254 THR 1095 hydrogen bond aceptor! VAL/ALA 
13 143 TYR 1095 lipophilic pocket/π-π-interaction ALA 
14 238 LEU 1095, 1088 interacting with methylgroup ALA 
15 156 LEU 1095, 1097 no clear result ALA 
16 85 VAL 1095 
   
17 155 CYS 1095 close to indole, lipophilic part, disulfide 
bridge 
no exchange 
18 234 CYS 1095 next to methyl group ALA 
19 54 PHE 1097 
      
20 61 ARG 1097 frames xanthine ALA 
21 80 LEU 1088 
      
22 247 TYR 1097 π-π-interaction ALA 
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23 70 TRP 1088, 1097 π-π-interaction, highly conserved TRP -? no 
24 251 GLY 1088 backbone interaction ALA/VAL 
25 158 ILE 1088 frames the p-chlorobenzyl residue ALA 
26 231 PHE 1097 frames the xanthine residue with both 
methyl residues 
ALA 
27 84 THR 1097 interaction not completely clear GLY/ALA 
28 252 ALA 1097 
 
backbone interaction 
 
no 
29 255 THR 1088 possible hydrogen bond in Cluster 1097 ALA/VAL 
 
Eleven proposals were made for further experimental conformation in mutagenesis studies. We 
will ude the results of the mutagenesis studies subsequently to optimize the modeling performance 
by feeding the data back into the process. Such proposals will be regarded as rational that have a high 
probability of making a difference to the ligand binding. Therefore, it does not make sense to change 
a leucine to an alanine, because there is not enough difference in the amino acids. However, 
exchanging a tyrosine for a phenylalanine, when a hydrogen bond has been proposed, should make a 
large impact on ligand binding (for example, Tyr 64). From the ten proposals, seven were from 
cluster_1082 and also include amino acids that have been found in other clusters to interact with the 
ligand. Three additional proposals were selected from the other poses8 (seeTable 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 Medicinal Chemistry of GPR18 agonists and antagonists   
136 
 
Table 25: Proposals for mutagenesis (note: pose numbers refer to Rosetta pose numbering and 
not to the total sequence). 
Entry Amino acids Cluster Mutagenesis 
proposals 
1 235 PHE 1082, 1088 ALA (LEU is observed in 
nature) 
2 64 TYR 1082, 
1095,1088, 
1097 
PHE 
3 64 TYR 1082, 
1095,1088, 
1097 
ALA 
4 157 LYS 1082, 1088 ALA 
5 247 TYR 1082, 1088 ALA 
6 65 TYR 1082 ALA 
7 145 ASP 1082 ALA 
8 143 TYR 1095 ALA 
9 250 TRP 1095, 1088 ALA 
10 254 THR 1095 ALA 
11 255 THR 1088 ALA 
 
In total eleven proposals will be evaluated in mutagenesis studies.  
 
3.5.6.1. Comparison of the human and mouse receptor for docking evaluation 
 
In the previous chapter, it was already mentioned that the mouse GPR18 data will be compared to 
the human receptor data, to further evaluate the possible predictions for the mutagenesis. The 
sequence of the human and mouse receptor share a high degree of identity; nevertheless, there are 
also differences. Further, the sequences of GPR18 for different species will be compared to know if the 
residues proposed for mutagenesis are conserved and if not, to which amino acids they were 
converted during evolution.  
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When the activation data were compared, compound 162 showed an EC50 for the human receptor 
of 19.1 nM and of 54.1 nM for the mouse receptor. To get an idea, whether this meant a significant 
difference a two-tailed t-test was performed, as can be seen in Figure 87 and Figure 88.  
 
Figure 87: Activation curve of compound 162 in β-arrestin recruitment assays, 100% = maximum 
effect. 
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Figure 88: human vs. mouse GPR18: two-tailed t-test, p>0.05, ns = not significant. 
 
The EC50 value of the mouse receptor was not significantly different from that at the human GPR18, 
(two-tailed t-test, p > 0.05). The difference can therefore not be regarded as more than a trend. This 
means that the amino acids involved in ligand binding probably do not differ significantly between the 
two species. The predicted amino acids will be compared (see Figure 89).  
Sequences of all species were aligned for which a confirmed GPR18 sequence was available in 
pubmed (https://www.ncbi.nlm.nih.gov/pubmed). It turned out to be the mammalian species mouse 
(Mus musculus, NP_877958.1), rat (Rattus norvegicus, NP_001073178.1), chimpanzee (Pan 
troglodytes, NP_001233295.1), cattle (Bos taurus, NP_001029861.1), horse (Equus caballus, 
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NP_001296104.1), and the two fish species catfish (Ictalrus punctatus, NP_001187728.1) and atlantic 
salmon (Salmo salar, ACN10695.1).  
First of all, none of the predicted amino acids (black frame), was different between human and 
mouse – which was in accordance with the experimental data. When comparing the known sequences 
of all eight species, some interesting effects could be observed. Residue 143, which was a tyrosine in 
the human and mouse receptor, was an aspartate in rat and salmon, and a glutamate in catfish. 
Nevertheless, these are all amino acids that can form hydrogen bonds. The other predicted amino 
acids, where a difference can be observed, was residue 235 which was a phenylalanine in all species 
except for salmon, which showed a leucine, also a lipophilic but not an aromatic residue.  
In conclusion, GPR18 is a very well conserved receptor in the analyzed species. The largest 
differences exist between the two fish species and the mammalian receptor, as can be expected. The 
two fish receptors, for example, show a shorter N-terminus. All of the sequences show a modified 
“NPxxY” motif, as discussed for the human receptor in 3.5.2. It is not always exactly the same: the 
human sequence is DVILY, whereas the two fish species are DIILY and the two murine receptors contain 
DVVLY (see Figure 89). 
Overall, the most frequent changes existed in the small lipophilic residues. The sequences most 
commonly varied between valine, isoleucine, methionine and leucine, which should not generate a big 
difference in ligand binding.  
It can be noted that there were no differences between the mouse and the human receptor, which 
could effect ligand binding and subsequent receptor activation. This was in accordance with the 
experimental obtained data. From this analysis, there was no reason to discard any of the poses that 
were modeled.  
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Figure 89: Multi-species alignment. ECL= extracellular loop, ICL = intracellular loop, species only from complete mRNA from pubmed..
helix
typical conserved regions
disulfide from here model was constructed
amino acids proposed for mutagenesis helix I ICL1 helix II
model-Pos.-Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
mus M A T L S N H N Q L D L S N G S H P E E Y K I A A L V F Y S C I F L I G L F V N V T A L W V F S C T T K K R T T V T I Y
rattus M A I P S N R D Q L A L S N G S H P E E Y K I A A L V F Y S C I F L I G L L V N V T A L W V F S C T T K K R T T V T I Y
homo M I T L N N Q D Q P V P F N S S H P D E Y K I A A L V F Y S C I F I I G L F V N I T A L W V F S C T T K K R T T V T I Y
pan M I T L N N Q D Q P V P F N S S H P D E Y K I A A L V F Y S C I F I I G L F V N I T A L W V F S C T T K K R T T V T I Y
bos M T T P H S Q A Q P G L P I D P H P D E Y K V A A L V F Y S C I F I I G L F V N V T A L W V F S C T T K K R T T V T V Y
equus M T T P H N Q V Q L G P S N D S H P D E Y K I A A L V F Y S C I F I I G L F V N V T A L W V F S C T T K K R T T V T I Y
ictalurus - - M E Q N T S L T I N P E G Y L P P A F K I V S L V F Y S I I F S V G L V V N L T A L W V F A L T T K R R S S V T I Y
salmo - - M E Y S - - - S A R S V E Q V P T E Y R I A G L V F Y C V I F T I G I V V N V T A L W V F A L T T K R R N S V S V Y
ECL1 helix III
model-Pos.-Nr. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103
mus M M N V A L L D L V F I L S L P F R M F Y Y A K G E W P F G E Y F C H I L G A L V V F Y P S L A L W L L A F I S A D R Y
rattus M M N V A L L D L V F I L S L P F R M F Y Y A K G E W P F G D Y F C H I L G A L V V F Y P S L A L W L L A L I S A D R Y
homo M M N V A L V D L I F I M T L P F R M F Y Y A K D E W P F G E Y F C Q I L G A L T V F Y P S I A L W L L A F I S A D R Y
pan M M N V A L V D L I F I M T L P F R M F Y Y A K D E W P F G E Y F C Q I L G A L T V F Y P S I A L W L L A F I S A D R Y
bos M M N V A L L D L V F I M S L P F R M L Y Y A K G E W P F G E Y F C R I L G A L T V F Y P S I A L W L L A F I S A D R Y
equus M M N V A L L D L I F I M S L P F R M F Y Y A K G E W P F G E Y F C Q I L G A L T V F Y P S I A L W L I A F I S A D R Y
ictalurus M I N V A V V D L I F I L L L P F R M A Y Y S G D Y W P F G D M F C R I N A A L T V L Y P C L A L W L F A L I S A D R Y
salmo M I N V A I V D L V F I I L L P F R M V Y Y G Q D Y W P F G D I F C R V S A A L T V F Y P C M A L W L F A L I S T D R Y
ICL2 helix IV ECL2
model-Pos.-Nr. 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162
mus M A I V Q P K Y A K E L K N T G K A V L A C G G V W V M T L T T T V P L L L L Y E D P D K A - S S P A T C L K I S D I T
rattus M A I V Q P K Y A K E L K N T G K A V L A C V G V W I M T L T T T V P L L L L D E D P D K A - S S P A T C L K I S D I I
homo M A I V Q P K Y A K E L K N T C K A V L A C V G V W I M T L T T T T P L L L L Y K D P D K D - S T P A T C L K I S D I I
pan M A I V Q P K Y A K E L K N T C K A V L A C V G V W I M T L T T T T P L L L L Y K D P D K D - S T P A T C L K I S D I I
bos M A I V Q P K Y A K E L K N T C K A V M A C V G V W I M T L T T T I P L L L L Y E D P D T A S S T P P T C L K I S D I I
equus M A I V Q P K Y A K E L K N T C K A V L A C V G V W I M T L T T T I P L L L L Y E D P D K G - S T P A T C L K I S D I I
ictalurus V A I V Q P R H S K E L K N V H K A L L S C V G I W V M T L G G A A S L L F L E E D P D L F - S N H T T C L K M H D I V
salmo V A I I Q P K H S K E L K N I P K A L V A C I G V W I M T L G S T V P L L F P D H D P D R S - S N F T T C I K M R D I I
helix V ICL3 helix VI
model-Pos.-Nr. 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222
mus H L K A V N V L N F T R L I F F F L I P L F I M I G C Y V V I I H S L L R G Q T S K L K P K V K E K S I R I I M T L L L
rattus H L K A V N V L N F T R L I F F F L I P L F I M I G C Y V V I I H S L L R G Q T S K L K P K V K E K S I R I I V T L L L
homo Y L K A V N V L N L T R L T F F F L I P L F I M I G C Y L V I I H N L L H G R T S K L K P K V K E K S I R I I I T L L V
pan Y L K A V N V L N L T R L T F F F L I P L F I M I G C Y L V I I H N L L H G R T S K L K P K V K E K S I R I I I T L L V
bos Y L K A I N A L N F T R L I F F F L I P L F I M I G C Y L V I I H S L L H G K T S K L K P K V K E K S I R I I I T L M V
equus H L K A I N M L N F T R L I F F F L I P L F I M I G C Y L V I I H S L L H G R T S K L K P K V K E K S I R I I I T L M V
ictalurus Y L R R D N S V H F A R L A F F F L V P M L I M V G C Y I S I V D N L I H G R T S K L K P N V K Q K S I R I I I T L I M
salmo H L R T D N P V H F T R L A F F F L V P I S I M I G C Y V V I V D N L V H G R T S K L K P K V K Q K S I R I I I T L I V
ECL3 helix VII mysterious NPxxY motif helix VIII
model-Pos.-Nr. 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281
mus Q V L V C F V P F H I C F A V L M L Q - G Q E N S Y S P W G A F T T F L M N L S T C L D V V L Y Y I V S K Q F Q A R V I
rattus Q V L A C F V P F H I C F A L L M L Q - G E E N S Y S P W G A F T T F L M N L S T C L D V V L Y Y I V S K Q F Q A R V I
homo Q V L V C F M P F H I C F A F L M L G - T G E N S Y N P W G A F T T F L M N L S T C L D V I L Y Y I V S K Q F Q A R V I
pan Q V L V C F M P F H I C F A F L M L G - T G E N S Y N P W G A F T T F L M N L S T C L D V I L Y Y I V S K Q F Q A R V I
bos Q V L V C F M P F H I C F A F L M L G - G D E N S Y N P W G A F T T F L M N L S T C L D V I L Y Y I V S K Q F Q A R V I
equus Q V L V C F M P F H I C F A F L M L G - G D D N S Y N P W G A F T T F L M N L S T C L D V I L Y Y I V S K Q F Q A R V I
ictalurus Q V L V C F V P F H V C F V L L L F E - N I G Q D Y S T W G A F T T F L M N M S T V L D I I L Y Y I V S K Q F Q D R V I
salmo Q V L V C F V P F H V C L V V L L L E G G D G S A Y S T W G A F T T F L M N L S T V L D I I L Y Y I V S K Q F Q D R V I
model - end
model-Pos.-Nr. 282 283 284 285 286
mus S V M L Y R N Y L R S V R R K S V - - R S G S L R S L S N M N S E M L
rattus S V M L Y R N Y L R S V R R K S V - - R S G S L R S L S N M N S E M L
homo S V M L Y R N Y L R S M R R K S F - - R S G S L R S L S N I N S E M L
pan S V M L Y R N Y L R S M R R K S F - - R S G S L R S L S N I N S E M L
bos S V M L Y R N Y L R S V R R K S F - - R S G S L R S L S N I N S E M L
equus S V M L Y R N Y L R S V R R K S F - - R S G S L R S L S N I N S E M L
ictalurus S V I L Y R N Y L R S V R R K S R - - H T G S V R S L S N L T S A M I
salmo S V I L Y R N Y L R S V R R K S R R T H T G S V R S L S N L T S A M I
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3.5.7. Discussion and outlook  
 
In the modeling approach, compound 162, the most potent compound we developed so far, was 
docked to a modeled receptor. The modeling of the receptor required information about templates, 
the unique sequence of GPR18 and the applied techniques to generate models with the Rosetta 
protein design software. The models were established using Rosetta Comparative Modeling based on 
information from multiple sequence alignments of GPCR templates with GPR18. It could be learned 
that GPR18 has some unique features that only exist in the δ-branch of the class A GPCRs, for example, 
it lacks the NPxxY motif conserved in the majority of GPCRs. Which impact this has on receptor 
activation and signaling has yet to be elucidated. Furthermore, the extracellular loops of GPR18 were 
closely examined and modelled step by step to ensure an optimal performance. In this process, the 
conformation of the ECL2 was predicted as β-strand, which, however, could not be rescued into the 
final models. For the docking itself, this does not make a big difference, but there is further need to 
evaluate and adapt these results.  
Compound 162, the most potent ligand of GPR18 known to date, was docked to the receptor model 
and the docking pose was optimized by a procedure called focused docking. Compound 162 was 
chosen due to its high potency. Other potent compounds were structurally very similar to 162, so that 
there would probably not be a great difference in the positioning of the ligand. Another ligand, Δ9-THC, 
not potent enough to give a confident feedback on the docking pose. It is likely that compound 162 
and Δ9-THC bind to different sites since their structure are very different, compound 162 being more 
peptide-like, and Δ9-THC being lipid-like.  
For compound 162, different docking poses could be observed and which were analyzed. The most 
often sampled and best-scoring positions were selected. To verify the proposed docking pose, the 
interaction of the residues of the receptor and the ligand were predicted and suitable proposals for 
mutagenesis studies were developed. The alternative docking poses were kept as back-up possibilities, 
if the predicted interactions should not be confirmed experimentally. The modeling approach can 
subsequently be adapted to be in accordance with the mutagenesis results, and the ligand position 
can then be optimized.   
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4. NATURAL PRODUCTS AS LIGANDS FOR CANNABINOID AND CANNABINOID 
LIKE RECEPTORS 
4.1. Introduction 
 
Naturally occurring chemical substances are a major source of biologically active drugs. More than 
75% of all marketed drugs are directly or indirectly derived from natural products.220 For drug 
development, the use of plant-derived scaffolds is a promising way to enlarge the chemical space and 
develop new tool compounds. Some of the most famous drugs from nature are morphine, derived 
from the seeds of Papaver somniferum, atropine from the fruits of Atropa belladonna or taxol from 
Taxus brevifolia.221; 222 In 2015 the Nobel prize was awarded to William C. Campbell and Satoshi Omura 
for their discovery of avermectin from Streptomyces avermitilis, which is used against parasites such 
as round worm infections, and to Youyou Tu for the identification of the antimalarial drug artemisinin 
from Artemisia annua, a traditional chinese herbal medicine.223 The first compound known to target 
the cannabinoid receptors and later on GPR18 has been Δ9-THC, also a plant derived drug. This shows 
the significance of natural products for medicinal chemistry and also for our project. 
Although the techniques for drug development have undergone major changes towards more 
rational and computer-based approaches, drugs derived from natural products still give a high impact 
in research.224 Therefore, natural products have also be part of our approach to identify and investigate 
new ligands for cannabinoid and cannabinoid-like receptors.  
In the first part of this chapter, we present the continuation of a project, in which the natural 
product tetrahydromagnolol (186) is used as a lead structure for the development of CB1- and CB2 
receptor agonists and potential ligands for the orphan GPR55. In the second part, the test results for a 
group of compounds is presented, which are similar in structure to the recently published CB1 receptor 
antagonist amauromine225, that was also shown to inhibit the orphan GPR18. Moreover, screening 
results of a natural product library will be presented.  
 
4.2. Magnolol and honokiol derivatives as cannabinoid receptor ligands 
 
4.2.1. Introduction to magnolol and honokiol derivatives as cannabinoid receptor 
ligands 
 
The two lignans magnolol (187)and honokiol are constitutional isomers; both can naturally be found 
in the leaves and bark cones of the herbal drugs Magnolia officinalis and Magnolia grandifolia of the 
Magnoliaceae plant family. They are established in the traditional herbal medicine of Japan and China, 
especially in the so-called Kampo medicine. Honokiol (188) has been known for its pleiotropic effects, 
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for example, it has been described to display antimicrobial activity, especially against methicillin-
resistant Staphylococcus aureus.226 Also anti-cancer applications due to antiangiogenetic effects have 
been described.227 Magnolol shares some of the pharmacological properties of honokiol. Both have 
been reported to produce central depressant effects as sedation, ataxia, muscle relaxation and a loss 
of the righting reflex in mice.228 Furthermore, they were anxiolytic229 and displayed neuroprotective 
and antidepressant effects.230,231 Magnolol further showed antiepileptic and protective effects against 
Alzheimer’s disease.232 
 
Figure 90: Chemical structure of tetrahydromagnolol (186) and magnolol (187) and honokiol (188)  
 
However, a specified target mediating these effects is still in discussions one of their main 
mechanism of action, antioxidative properties have been proposed and investigated.233 For example, 
Chuang et al. showed that both compounds inhibited NMDA receptor induced superoxide production 
in microglial cells.234 Both, honokiol and magnolol have been reported to act on the metabolic regulator 
PPARγ with EC50 values in the low micromolar range in reporter-gene assays.235 
Later, it could be shown that the binding behavior of ligands of the GABAA receptor channel was 
increased in the presence of honokiol (188) or reduced in the presence of magnolol (187).236 An 
allosteric mode of action was hypothesized. The antiepileptic effects of magnolol (187) were 
attenuated by the GABAA channel antagonist flumazenil.237 In the presence of the GABAA receptor 
activator pentobarbital magnolol (187) enhanced the sleeping behavior in mice.238 In the brain many 
different GABAA receptor isoforms are present, distinguishable in their subunit composition (α1-5, β1-3, 
γ1-3, δ, π, ε, θ, ρ1-3).which defines function and selectivity. Five of these subunits are located around an 
inwardly rectifying Cl—channel, which upon activation leads to a hypopolarization of the synapse. It 
has been reported that magnolol (187) or honokiol (188) either interact with receptors containing the 
α2239 or with the δ subunit.240 Baur et al. further investigated this, and expressed different GABAA 
receptor isoforms in Xenopus oozytes to compare the effect of an equimolar concentration in patch-
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clamp experiments, with the conclusion, that different α and β subunits show effects, but no other 
subunit. They further showed that 4-O-methylhonokiol (189) potentiated currents more strongly in 
their system than honokiol (188). With different pharmacological tools they tried to block the 
potentiation of 4-O-methylhonokiol (189), but could not identify a binding site for this compound.241 
4-O-methylhonokiol (189) is a natural product, it can be extracted from the seed oil of Magnolia 
grandiflora.242  
Lee et al. investigated the protective effects of Magnolia officinalis extracts against Alzheimer’s 
disease and showed that lipopolysaccharide-induced memory deficiencies can be attenuated by 
feeding Magnolia extract.232 Their main conclusion was that the extract prevents a neuroinflammatory 
process in the brain. Later on, 4-O-methylhonokiol (189) was shown to act as a selective CB2 receptor 
inverse agonist in osteoclasts.243 The authors argue that CB2 receptor-mediated effects may also be 
responsible for the observed neuroprotection.244 CB2 is the more broadly distributed receptor in the 
immune system, CB1 is a major regulator of GABAergic and glutamatergic signaling. Both can be 
involved in neuroinflammatory processes.  
Previously, Rempel et al. from our group investigated the other constituents of Magnolia officinalis 
- mainly magnolol (187) and honokiol (188) - at both cannabinoid receptors. In this study, magnolol 
(187) showed a higher affinity to the CB2 receptor than honokiol (188), which was unselective. Both 
showed Ki values in the low micromolar range. Magnolol (187) acted as partial agonist in functional 
cAMP studies. Honokiol (188) as well as magnolia officinalis extract proved to act as inverse agonists 
at the CB2 receptor, while they act as agonists at the CB1 receptor. Furthermore, one of the main 
metabolites of magnolol (187) was investigated: tetrahydromagnolol (186), which showed to have an 
even higher affinity for the CB2 receptor than magnolol (187) with a Ki value of 0.416 µM. It could be 
characterized as an agonist at the CB1 receptor and as a partial agonist at CB2. From these findings it 
was hypothesized that magnolol (187) undergoes bioactivation. Tetrahydromagnolol (186) also 
showed antagonistic effects in β-arrestin assays at the orphan GPR55 with an IC50 value of 
13.3 µM.245,133 Tetrahydromagnolol (186) can be regarded as a promising lead compound for 
cannabinoid receptor ligand development. CB2 receptor agonists are of interest as drugs for treating 
neuropathic and chronic pain, as well as inflammatory diseases such as arthritis and multiple sclerosis.  
 
4.2.2. Structure-activity relationships of tetrahydromagnolol derivatives at 
cannabinoid receptors and GPR55 
 
The tetrahydromagnolol (186) structure bears some resemblance to other plant-derived 
cannabinoid ligands, especially to Δ9-THC, which also features a phenolic structure, with a lipophilic 
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substituent and a second ring system. Fuchs et al. subsequently investigated the structure-activity 
relationships of tetraydromagnolol derivatives by changing the para- positioned lipophilic side chain 
and by methylation of the phenyl residues.133 
It could be observed that symmetrical substitution with alkyl chains para-positioned to the phenolic 
hydroxyl group led to CB2 receptor-preferring compounds, with an affinity optimum for the propyl-
substitution. Whenever one of the phenolic groups was methylated - leading to an unsymmetrical 
compound - CB2 receptor preference was lost resulting in potent unselective agonists for both CB 
receptor subtypes. By removing one lipophilic side chain and by varying the other one, an optimal 
length could be determined. By keeping this length fixed the other lipophilic side chain was 
investigated. This proved to be crucial for CB2 receptor affinity. Thus, the affinity could be increased 
from methyl to propyl, but was reduced upon further enlargement of the alkyl chain. Now this optimal 
side chain was fixed and the other one was investigated. The highest affinities for both receptors were 
observed for a hexyl substitution. Subsequently, one phenolic group was methylated, but as this 
compound is unsymmetrical two possibilities arise. When the para-positioned phenolic group to the 
large hexyl residue was methylated the CB2 affinity significantly decreased. When the para-positioned 
phenolic group to the propyl residue was methylated the CB1 affinity strongly increased (compound 
191; Ki CB1: 0.00957 µM and Ki CB2: 0.0238 µM).133  
 
190 AF026 
Figure 91: Improvement of compound affinities through subsequent investigation of the alkyl 
moieties: compound 186, 190 and  191 
 
Further, Fuchs et al. also investigated 4’-O-methylhonokiol (189), for which they could show similar 
affinities in radioligand binding as described before, but not an inverse agonistic effect in functional 
assays. They reported an agonistic effect – in contrast to the data of Schuehly et al.243 Additionally, 
Fuchs et al. tested the activity of their tetrahydromagnolol derivatives also at GPR55, a cannabinoid-
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like orphan GPCR, which has been described to interact with different CB receptor ligands, for example 
the phenolic compound CP55,940. Typically, GPR55 is inhibited by CB receptor agonists, while it is 
activated by CB antagonists (inverse effects).106,132 For the tetrahydromagnolol derivatives, which are 
all agonists at the CB receptors, only antagonistic effects at the orphan GPR55 could be found. The 
antagonistic potency could be markedly increased, when the phenolic hydroxyl group para to the hexyl 
moiety was methylated. The most potent compound of this series showed an IC50 value of 3.25 µM.133 
 
Figure 92: Chemical structure of the most potent GPR55 antagonist of the tetrahydromagnolol 
series compound  192 
 
The structure activity-relationshipsknown sofar can be summarized up as follows:  
 
Figure 93: Summary of established structure-activity relationships for tetrahydromagnolol 
derivatives133 
 
In this study, we further investigated the structure-activity relationships substituents in different 
positions. The length of the ether sidechain was varied and an optimal length was determined. In 
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another approach, the biphenylic core structure was replaced by a phenylaminophenol. All compounds 
were synthesized by Dr. Alexander Fuchs and pharmacologically evaluated in the present study.  
 
4.2.3. Results for tetrahydromagnolol derivatives for the cannabinoid receptor 
 
The already established structure-activity relationships were completed by two additional 
compound sets. In the first group, we varied the alkyl substitution of the ether in chain length (from 
ethyl to propyl and isopropyl to compare these modifications to the methylated compounds). This has 
been done for both possible phenolic substitutions. We determined the affinity of the compounds in 
the same radioligand binding experiment versus 0.1 nM [3H]CP55,940. The results are listed in Table 
26.  
Table 26: Affinities of magnolol derivatives with varying lipophilic substitutions on the ether residue at 
the cannabinoid receptors 
No. Compd. Chemical structure Radioligand binding  
  
 
Human CB1 Human CB2 
  
R1 R2 
Ki (µM) vs. 
[3H]CP55,940 
Ki (µM) vs. 
[3H]CP55,940  
193 AF097 H ethyl 0.882 ± 0.369 1.36 ± 0.77 
194 AF098 H propyl >10 (40%) 1.184± 0.64 
195 AF099 H isopropyl >10 (26%)  0.599 ± 0.115 
196 AF100 ethyl H 0.291 ± 0.100 0.412 ± 0.172 
197 AF101 propyl H 0.175 ± 0.052 0.132 ± 0.058 
198 AF102 isopropyl H 0.189 ± 0.079 0.178 ± 0.101 
199 AF105 
 
0.163 ± 0.039 0.0673 ± 0.0082 
 
The first group (compound 193, 194 and 195) is characterized by an alkylated phenolic hydroxyl 
group in the para-position to the hexyl residue. Their potencies can be compared to compound 192, 
which has a methoxy residue. 
O
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Figure 94: Cannabinoid receptor affinities. A: 5’-hexyl-2’-alkyloxy derivatives, B: 5’-propyl-2’-
alkyloxy derivatives 
As can be seen in Figure 94, the lead compounds for either variation, compound 192 and 191, 
displayed in both cases higher affinities, thus the enlargement of the alkyl function was not favorable. 
For both cases, the methoxy compound was the most potent one. Notably, the CB1 affinity was lost for 
the 5’-hexyl-2’-alkyl-oxy derivatives when a chain length of propoxy or isopropxy was reached, 
although the CB2 affinity was preserved. For the 5’-propyl-2’-alkyloxy derivatives the decrease in 
affinity was rather large, only showing Ki values around 1 µM – in contrast to the highly potent methoxy 
compound 191. Larger moieties were not tolerated here.  
Furthermore, a compound was synthesized that lacks the second phenolic group: 199. It showed a 
slightly higher Ki value for CB2, than compound 190, which has a phenolic group. The CB1 receptor Ki 
value was slightly lower.  
In a second compound set, the biphenylic core of the compounds was exchanged for a 
phenylaminophenol (see Table 27).  
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Table 27: Affinities of diphenylamine derivatives at cannabinoid receptors 
 
For these compounds, it was found that the CB1 affinity always ranged in the low micromolar range. 
Three compounds showed a nanomolar Ki value for CB2. None of them was as potent as 191, the most 
potent compound of the series. In general, the compounds showed a slightly higher affinity for CB2 
than for CB1. Some of the already for the biphenylic compounds oberserved structure-activity 
relationships could also be found in this compound set. The three best CB2 ligands had a pentyl or hexyl 
residue in the para-position to the phenolic hydroxyl group. The shorter this chain the higher the Ki 
value. The exchange of the 5’-alkyl chain from methyl to propyl was not beneficial for affinity. The most 
potent compounds were the 5’-methyl-5-pentyl 202 and 5’-methyl-5-hexyl derivatives 203. Overall, 
the biphenylic core was superior to the diphenylamine.  
 
4.2.4. Cannabinoid receptor affinities of honokiol-like compounds 
 
As already mentioned above, 4’-O-methylhonokiol (189) has been reported to act as a positive 
allosteric modulator of the GABAA receptor.241 The group of Dr. Erwin Sigel investigated a group of 
honokiol and magnolol derivatives in patch-clamp experiments, which were synthesized by Dr. 
Alexander Fuchs. In the present study, these compounds have further been investigated at the CB 
receptors to determine their selectivity. 4’- O-methylhonokiol (189) itself showed a Ki values of 8.43 
µM for CB1 and 0.0432 µM for CB2 receptors. In the study of Fuchs et al. honokiol-like compounds 
turned out to be very potent in current potentiation at the GABAA  receptor, especially compound 209, 
210 and 212 showed an >1000 % allosteric potentiation at 3 µM test concentration in the presence of 
0.5 µM GABA. The compounds were found to probably interact with the β-subunit. The benzodiazepine 
No. Compd. Chemical structure Radioligand binding  
  
 
Human CB1 Human CB2 
  
R1 R2 
Ki (µM) vs. 
[3H]CP55,940 
Ki (µM) vs. 
[3H]CP55,940  
200 AF128 methyl propyl 14.1 ± 4.2 5.01 ± 2.56 
201 AF127 methyl butyl 2.55 ± 0.20 1.55 ± 0.23 
202 AF126 methyl pentyl 1.48 ± 0.28 0.258 ± 0.032 
203 AF125 methyl hexyl 1.42 ± 0.13 0.295 ± 0.018 
204 AF132 propyl propyl 10.8 ± 2.3 1.65 ± 0.793 
205 AF135 propyl pentyl 2.34 ± 0.16 0.509 ± 0.143 
206 AF137 pentyl propyl 4.01 ± 0.61 2.11 ± 1.33 
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binding site could be excluded.246 Recently, an additional binding site has been described for the 
endogenous cannabinoid 2-arachidonoylglycerol (2-AG) on the β2 subunit of the GABAA-receptor.247 
The honokiol derivatives might also bind to this newly characterized site.246 Data of CB receptors 
affinities are shown in Table 28.  
Table 28: Cannabinoid receptor affinities of honokiol-like compounds with variations in length of the 
lipophilic chain.  
No. Compd. Chemical structure Radioligand binding  
  
 
Human CB1 Human CB2 
  
R1 R2 
Ki (µM) vs. 
[3H]CP55,940 
Ki (µM) vs. 
[3H]CP55,940  
207 AF114 methyl methyl 2.97 ± 0.52 0.834 ± 0.074 
208 AF085 ethyl methyl >10 (22%) 2.40 ± 0.952 
209 AF083 propyl methyl >10 (49%) 0.472 ± 0.178 
210 AF115 butyl methyl 8.07 ± 1.84 0.549 ± 0.116 
211 AF116 pentyl methyl 2.73 ± 0.80 0.134 ± 0.029 
212 AF084 hexyl methyl 0.339 ± 0.135 0.642 ± 0.383 
213 AF112 heptyl methyl 3.69 ± 1.48 0.591 ± 0.255 
214 AF113 octyl methyl 1.95 ± 0.80 1.66 ± 0.49 
215 AF117 hexyl ethyl 0.125 ± 0.015 0.595 ± 0.127 
216 AF118 hexyl propyl 0.205 ± 0.177 0.453 ± 0.177 
217 AF119 hexyl isopropyl 2.57 ± 0.73 0.243 ± 0.082 
 
Compared to the lead structure 4’-O-methylhonokiol (189), the affinity to the CB2 receptor was 
reduced, while the affinity to the CB1 receptor was constant or even increased. The most potent 
compounds 209, 210 and 212 differ in the length of the R1 moiety increasing from propyl and butyl to 
hexyl. The compounds with the two smaller chains had no affinity to the CB1 receptor up to 10 µM or 
were rather weak with 8.07 µM. For compound 208 the CB1 affinity was with 2.73 µM in the low 
micromolar range and therefore also moderate. The hexyl-substituted derivative 212 on the other 
hand showed an increased affinity for CB1 with a Ki value of 0.339 µM. The longer lipophilic residue 
seemed to be beneficial for CB1 affinity – the compounds 215 and 217, which both share the hexyl 
residue, showed comparable Ki values. For the CB2 receptor, the affinity could be overall reduced in 
comparison to 4’-O-methylhonokiol (189). The three most potent compounds showed affinity between 
0.472 µM to 0.642 µM – thus a ten-fold decrease in affinity. Nevertheless, the CB2 affinity was still 
high. The most potent CB2 ligand of this series was the pentyl-substituted compound 211. This 
resembles the already described correlation for the magnolol derivatives, where a chain length of 
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pentyl and hexyl was also favoured. The affinity decreases when the chain was too long, see compound 
214, or when the chain was too short, see compound 208.  
Overall, it can be concluded that the 4’-O-methylhonokiol derivatives are a promising lead 
structures for the further development of positive allosteric potentiators for the GABAA receptor. They 
still show affinities for the CB receptors, more pronounced for the CB2 receptor.  
 
4.2.5. Activity of magnolol and honokiol derivatives at the cannabinoid-like receptors 
GPR18 and GPR55 
 
It was already mentioned, that tetrahydromagnolol derivatives have been shown to act as 
antagonist at the orphan GPR55. The most potent compound with an IC50 value of 3.25 µM was 192.133 
Here, we investigated all newly synthesized compounds at the two orphan GPCRs GPR18 and GPR55 
to analyze these structure-activity relationships.  
The already described magnolol derivatives, which varied in their ether substitution, are listed 
below in Table 29.  
Table 29: Potencies of magnolol derivatives with varying lipophilic substitutions at the ether residue, 
at human GPR18 and GPR55 
  human GPR18 human GPR55 
No. Compd.a Antagonistic 
activity Agonistic actvity 
Antagonistic 
activity Agonist activity 
  
IC50 ± SEM (µM) EC50 (µM) IC50 ± SEM (µM) EC50 (µM) 
 
193 AF097 >10 (29%) >10 (-5%) 6.03 ± 1.38 >10 (-36%) 
194 AF098 >10 (8%) >10 (9%) 8.55± 1.13 >10 (20%) 
195 AF099 >10 (21%) >10 (9%) 9.13± 2.26 >10 (17%) 
196 AF100 >10 (16%) >10 (17%) 7.24± 1.44 >10 (23%) 
197 AF101 >10 (3%) >10 (9%) >10 (37%) >10 (12%) 
198 AF102 >10 (15%) >10 (9%) 6.08 ± 0.98 >10 (35%) 
199 AF105 >10 (15%) >10 (19%) 9.01 ± 1.29 >10 (40%) 
a for chemical structures see Table 26 
As can be seen almost all of the compounds, except 197, showed a moderate inhibition in the 
micromolar range, but none of them was more active then 192. They also did not differ much in their 
inhibitory strength, so explicit structure-activity relationships could not be deduced. In the first group 
(the 5’-hexyl-2’-alkyloxy derivatives), there seemed to be a tendency, that the smaller ether 
substitutions were favored. In the second group a clear dependency could not be determined.  
Further the phenylanilin derivatives were investigated, the results can be found in Table 30.  
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Table 30: Potencies of diphenylamine derivatives for human GPR18 and GPR55 
  human GPR18 human GPR55 
No. Compd. a Antagonistic 
activity Agonistic actvity 
Antagonistic 
activity Agonist activity 
  IC50 ± SEM (µM) EC50 (µM) IC50 ± SEM (µM) EC50 (µM) 
200 AF128 >10 (10%) >10 (19%) >10 (36%) >10 (19%) 
201 AF127 >10 (25%) >10 (26%) >10 (25%) >10 (30%) 
202 AF126 >10 (17%) >10 (42%) >10 (31%) >10 (34%) 
203 AF125 >10 (23%) >10 (25%) >10 (45%) >10 (18%) 
204 AF132 >10 (25%) >10 (-3%) >10 (41%) >10 (1%) 
205 AF135 >10 (24%) >10 (13%) >10 (43%) >10 (20%) 
206 AF137 >10 (18%) >10 (-7%) ~10 (53%) >10 (18%) 
a for chemical structures see Table 27 
All of the diphenylamine derivatives turned out be inactive at both receptors, indicating that an 
intact biphenyl core structure is necessary to achieve inhibitory effects of GPR55. Furthermore, the 4’-
O-methylhonokiol compounds have been investigated – the results can be found in Table 31.  
Table 31: Potencies of honokiol-like compounds for human GPR18 and GPR55 
  human GPR18 human GPR55 
No. Compd.a Antagonistic 
activity 
Agonistic 
actvity 
Antagonistic 
activity 
Agonist 
activity 
  
IC50 ± SEM (µM) EC50 (µM) IC50 ± SEM (µM) EC50 (µM) 
 
207 AF114 >10 (15%) >10 (8%) >10 (-32%) >10 (3%) 
208 AF085 ~10 (52%) >10 (23%) >10 (33%) >10 (-20%) 
209 AF083 >10 (22%) >10 (25%) >10 (36%) >10 (-15%) 
210 AF115 >10 (18%) >10 (2%) >10 (29%) >10 (-8%) 
211 AF116 >10 (35%) >10 (-4%) >10 (22%) >10 (12%) 
212 AF084 ~10 (60%) >10 (4%) >10 (-9%) >10 (-15%) 
213 AF112 >10 (36%) >10 (-16%) >10 (-18%) >10 (21%) 
214 AF113 >10 (24%) >10 (12%) >10 (0%) >10 (7%) 
215 AF117 >10 (29%) >10 (-11%) >10 (20%) >10 (9%) 
216 AF118 >10 (22%) >10 (-19%) >10 (34%) >10 (13%) 
217 AF119 >10 (25%) >10 (-12%) >10 (34%) >10 (6%) 
a for chemical structures see Table 28 
The 4’-O-methylhonokiol derivatives also were all inactive at both investigated receptors. These 
results clearly show, that only tetrahydromagnolol derivatives were able to inhibit GPR55 activation. 
It can be concluded that tetrahydromagnolol derivatives should be further investigated, while honokiol 
derivatives are inactive  
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4.2.6. Summary of the structure-activity relationships for magnolol and honokiol 
derivatives as cannabinoid receptor ligands 
 
The obtained results complete our efforts to study the structure-activity relationships of the 
tetrahydromagnolol and honokiol derivatives. As has been discussed above, we investigated the 
substitution of both phenolic hydroxyl groups by different lipophilic residues, also diephenylamine 
derivatives in contrast to the already established biphenylic compounds and different derivatives of 
4’-O-methylhonokiol were examined. All of them have been studied at the cannabinoid receptors CB1 
and CB2 and at orphan GPCRs GPR18 and GPR55.  
The structure-activity relationships for the cannabinoid receptors can be summarized as follows: 
 
Figure 95: Updated structure-activity relationships for tetrahydromagolol derivatives at the 
cannabinoid receptors, new results in red 
 
For the orphan GPR55 it can be summarized, that the realized variations were not superior to the 
already established compound 192. The tetrahydromagnolol derivatives showed some inhibitory 
effects, while the 4’-O-methylhonokiol derivatives and the diphenylamine were inactive. 
Tetrahydromagnolol (186) could be confirmed as a lead structure, whereas the other two compound 
classes were less suitable.  
Thus, the investigations that were carried out further helped to analyze the structure-activity-
relationships of this compound class.  
 
4.3.  Stemphol derivates 
 
We further investigated a class of different natural products that was isolated by the research group 
of Prof. Dr. Gabriele König, especially by Dr. Jan Schroer and Dr. Mahmoud Elsebai (see Table 32). A 
4 Natural products as ligands for cannabinoid and cannabinoid like receptors 
153 
 
phenolic compound named stemphol (218) was obtained from the fungus Stemphylium globuliferum, 
which belongs to the sooty molds. Normally, this fungus causes crop damage, because it lives on fruits 
and vegetables. However, the group of Prof. König was able to isolate this fungus from algae. Stemphol 
(218) already has been described to display some mycotoxic effects in its vegetable hosts.248 We 
wanted to investigate stemphol due to its lipophilic properties and because of its phenolic structure 
on cannabinoid and cannabinoid-like receptors. Other compounds were 4-butyl-3,5-dihydroxy benzoic 
acid (219), coriolide (220) – a macrolide, that was discussed to play a role in the chemoattraction of 
Costa Rica longwing butterflies249, and infectopyrone (221), which has been described to occur in 
Stemphylium genera which grow on rotten tomatoes.250 The group of Prof. König found all these 
compounds in marine fungi, which had not been known before. Another group of phenolic compounds 
was investigated, they belong to the paniceines, and were isolated by Dr. Mahmoud Elsebai. These 
group of compounds were already identified in the marine sponge Reniera fulva before.251  
 
 
Table 32: Affinities of stemphol (218) and other lipophilic natural products at the cannabinoid 
receptors  
   Radioligand binding 
No. Compd. Chemical structure Human 
CB1 
Human 
CB2 
   Ki (µM) vs. 
[3H]CP55,940 
Ki (µM) vs. 
[3H]CP55,940  
218 Stemphol 
 
6.65 ± 1.61 2.92 ± 0.27 
219 4-Butyl-3,5-
dihydroxy-
benzoic acid 
 
>10 (18%) > 10 (3%) 
220 Coriolide  
 
>10 (11%) >10 (9%) 
221 Infectopyrone 
 
>10 (7%) >10 (8%) 
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222 Panicein C 
(RmF-36) 
 
>10 (46%) >10 (38%) 
223 Panicein B3 
(RmF-37) 
 
>10 (33%) >10 (27%) 
224 Panicein B2 
(RmF-82) 
 
 
>10 (38%) >10 (25%) 
225 Panicein 
hydrochinon 
(RmF-83) 
 
 
>10 (38%) >10 (23%) 
226 Panicein A 
(RmF-84) 
 
>10 (21%) >10 (11%) 
 
 
As can be seen in Table 32, the compound stemphol (218) showed weak affinity in the low 
micromolar range to the CB receptors. This might not be surprising, because the compound contains 
a phenolic group and a lipophilic pentyl side chain, as already observed in the magnolol derivatives. 
The lack of the second aromatic moiety might also explain why it only displayed weak affinity. The 
other compounds, including the paniceins, had no affinity towards the CB receptors. Further, the 
compounds were also tested at the orphan GPR55 and GPR18 (see Table 33).  
 
Table 33: Potency of stemphol (218) and other lipophilic natural products at GPR18 and GPR55 
  Human GPR18 Human GPR55 
No. Compd.a Antagonistic 
activity 
Agonist 
activity 
Antagonistic 
activity 
Agonistic 
activity 
  IC50 ± SEM (µM) EC50 (µM) IC50 ± SEM (µM) EC50 (µM) 
218 Stemphol n.d. n.d. >10 (37%)b >10 (32%)c 
219 4-Butyl-3,5-
dihydroxy-benzoic 
acid 
n.d. n.d. >10 (-26%)b >10 (43%)c 
220 Coriolide  n.d. n.d. >10 (-18%)b >10 (41%)c 
221 Infectopyrone n.d. n.d. >10 (-21%)b >10 (37%)c 
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222 Panicein C 
(RmF-36) 
11.1 ± 0.4 >10 (23%)c 1.68 ± 0.35 >10 (-9%)c 
223 Panicein B3 
(RmF-37) 
>10 (41%)b >10 (-34%)c 2.13 ± 0.91 >10 (-12%)c 
224 Panicein B2 
(RmF-82) 
>10 (16%)b >10 (9%)c 5.39 ± 1.33 >10 (1%)c 
225 Panicein 
hydrochinon 
(RmF-83) 
>10 (44%)b >10 (-37%)c 8.52 ± 1.41 >10 (-14%)c 
226 Panicein A 
(RmF-84) 
>10 (18%)b >10 (-4%)c >10 (36%)b >10 (-8%)c 
a for chemical structures see Table 32.  
b % inhibition of standard agonist induced luminescence signal (GPR18: 10 µM Δ9-THC; GPR55: 1 
µM LPI) 
c % activation compared to standard agonist induced luminescence signal (GPR18: 10 µM Δ9-THC; 
GPR55: 1 µM LPI) 
 
The paniceins showed some inhibitory activity for the orphan GPR55 in the low micromolar range. 
Compound 222 was the most potent one with an IC50 value of 1.68 µM. This compound is also the most 
polar one, all its phenolic groups are not methylated compared to in the other paniceins. The second 
most active compound 223 lacks the 3-phenolic hydroxyl group but showed almost the same IC50 value 
of 2.13 µM. The potency decreases the more phenolic groups are substituted – compare compound 
224 and 225. The last compound 226, which has no free hydroxyl group, was not active.  
It has to be mentioned, that the paniceins contain aromatic aldehyde functions. Aldehydes are 
reactive and might form covalent bonds. Some of the compounds contain hydroquinone or quinone 
structures, which are also known to be reactive due to their oxidizing properties. Even if these 
compounds would reach their desired site of action in the body metabolic enzymes could rapidly 
inactivate them. Therefore, they can probably not be considered as good lead structures for further 
development.  
 
4.4.  Amauromine derivatives 
 
Amauromine (18) is an alkaloid derived from the fungus Auxarthron reticulatum that lives together 
with the marine sponge Ircinia variabilis and was isolated by Dr. Mahmoud Elsebai. It is a symmetric 
diketopiperazine. The chemical structure arises from two tryptophan units, which are both 
prenylated.225 Amauromine (18) was originally isolated from Amauroascus sp., which lives in the 
Japanese woods and has been reported to act as vasodilatator when superperfusing rat aortic strips.252 
It was further shown by Elsebai et al. to act as a CB1 receptor antagonist with a high binding affinity 
showing a Ki value of 0.178 µM. In cAMP accumulation assays the compound could further be 
described as a neutral antagonist.225 No affinity to the CB2 receptor could be observed, thus, 
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amauromine is a selective CB1 receptor antagonist. In further experiments it could be shown, that 
amauromine (18) is also a moderate inhibitior of Δ9-THC induced β-arrestin recruitment at human 
GPR18 with an IC50 value of 3.74 µM.225  
 
Figure 96: Chemical structure of the natural product amauromine (18) 
 
We wanted to get more insight in this structurally new class of CB receptor antagonists and 
investigated twelve diketopiperazine synthezised by the research group of Prof. Dr. Stefan Bräse. 
Originally, these compounds were synthesized because they belong to a group of biological active 
mycotoxines.253 
To further investigate this compounds class the following compounds were screened at both CB 
receptors and the two orphan receptors GPR18 and GPR55. 
Table 34: Affinities of diketopiperazines at human cannabinoid receptors  
   Radioligand binding 
No. Compd. Chemical structure Human 
CB1 
Human 
CB2 
   Ki (µM) vs. 
[3H]CP55,940 
Ki (µM) vs. 
[3H]CP55,940  
227 SZ 47  
 
>10 (8%) >10 (19%) 
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228 SZ 85 
 
 
>10 (6%) >10 (24%) 
229 SZ 65  
 
>10 (-1%) >10 (19%) 
230 SZ 85 F3 
 
 
>10 (4%) >10 (17%) 
231 SZ 66 
 
 
>10 (18%) >10 (23%) 
232 SZ 87 
 
 
>10 (3%) >10 (17%) 
233 SZ 67 
(racemat) 
 
 
>10 (36%) >10 (25%) 
234 SZ 88 
 
 
>10 (11%) >10 (-1%) 
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235 SZ 69 
 
 
>10 (3%)  >10 (2%) 
236 MSS 22 
(scalemic) 
 
 
>10 (9%) >10 (2%) 
237 SZ 83  
 
>10 (13%) >10 (6%) 
238 MSS 20 
 
 
>10 (5%) >10 (2%) 
 
None of the investigated compounds showed any effect in radioligand binding at both CB receptor 
subtypes. Thus, the structural similarity to amauromine has to be greater to get more ideas, which 
residues are important to achieve CB1 receptor antagonism. 
Table 35: Potencies of diketopiperazines at human GPR18 and GPR55 in β-arrestin recruitmenta 
  human GPR18 human GPR55 
 compound Antagonistic 
activity 
Agonist 
activity 
Antagonistic 
activity 
Agonistic 
activity 
  IC50 ± SEM (µM) EC50 (µM) IC50 ± SEM (µM) EC50 (µM) 
227 SZ 47 >10 (10%)0 >10 (16%) >10 (8%) >10 (4%) 
228 SZ 85 >10 (8%) >10 (-5%) >10 (4%) >10 (-1%) 
229 SZ 65 >10 (17%) >10 (14%) >10 (8%) >10 (-1%) 
230 SZ 85 F3 >10 (3%) >10 (13%) >10 (1%) >10 (2%) 
231 SZ 66 >10 (-6%) >10 (21%) >10 (-32%) ≈10 (56%) 
232 SZ 87 >10 (43%) >10 (33%) >10 (19%) >10 (8%) 
233 SZ 67  >10 (51%) >10 (6%) 9.77 ± 2.41 >10 (9%) 
234 SZ 88 (64%)b >10 (-100%) (64)%b >10 (-23%) 
235 SZ 69 >10 (2%) >10 (9%) >10 (3%) >10 (10%) 
236 MSS 22  >10 (-20%) >10 (21%) >10 (7%) >10 (7%) 
237 SZ 83 >10 (16%) >10 (50 %) >10 (3%) >10 (13%) 
238 MSS 20 >10 (-8 %) >10 (34%) >10 (-8 %) >10 (13%) 
a for chemical structures see Table 34; b no concentration-dependent inhibition could be observed 
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The most closely related compound to amauromine 227 showed no inhibitory or activatory effects. 
Compared to amauromine (18) and also the agonists described in section 3.3 the indole nitrogen was 
substituted to a carbamin. This further strengthens the hypothesis of the necessity of an indole 
residue. But also, this compound lacks the prenylated side chains, which also can be of certain 
importance as lipophilic substituents. All other compounds lack the indole. Compound 234 showed 
promising results in the screens, but no curve was obtained at neither receptor. As these compounds 
have been synthesized because they are mykotoxins, a toxic effect on the cells may be possible. Even 
the small compounds 238 and 236, which contains the diketopiperazine structure, displayed no effects. 
Thus suggesting that a certain size is necessary and that this core structural motif is not sufficient for 
inhibition of Δ9-THC induced β-arrestin signaling.  
For further investigations, it would be interesting to test derivatives that are more related to 
amauromine. As a necessary structural component the indole residue should be present.  
 
4.5.  Summary on natural products as ligands for cannabinoid and cannabinoid-
like receptors 
 
In this section, we showed our results on the study of natural products as cannabinoid receptor 
ligands, and also the approach to further investigate these compounds at the two cannabinoid-like 
orphan receptors GPR55 and GPR18.  
Magnolol and honokiol-derived compounds as CB receptor ligands were introduced by Fuchs et 
al.133 Here, we expanded the structure-activity relationships for this compound class (see Figure 97).  
 
Figure 97: Structure-activity relationships of the magnolol and honokiol-derived CB ligands 
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The magnolol-derived compounds were the more potent than the diphenylamines and 4’-O-
methylhonokiol-derived compounds. However, we were not able to develop a more potent ligand than 
compound 192, which was the most potent compound of this compound class before. The magnolol-
derivatives proved to be GPR55 antagonists with IC50 values in the low micromolar range. Most of the 
diphenylamines showed a preference for the CB2 receptor, especially compounds 202 and 203 were 
potent CB2 ligands with Ki values of 0.258 and 0.295 µM, respectively, and a 6-and 5-fold preference 
of the CB2 receptor, respectively. The 4’-O-methylhonokiol derivatives were potent CB2 ligands, 
especially compound 211 with a Ki value of 0.134 µM and a 20-fold preference for CB2.  
Different phenolic natural products were investigated at the CB receptors and the orphan GPR18 
and GPR55. Some so-called paniceins showed a moderate inhibition of GPR55 in the low micromolar 
range. The most potent was compound 222 with an IC50 value of 1.36 µM. However, these compounds 
were chemically not preferable as they contain reactive aldehydes.  
We further investigated compounds with a similar scaffold as amauromine (18), a CB1 and GPR18 
antagonist. However, the here investigated compounds were inactive at both receptor.  
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5. CHROMEN-4-ONES AS AGONISTS AT GPR55 
5.1. Chromen-4-ones as lead structure for GPCR ligands 
 
Chromen-4-ones have been shown to be a privileged structure for the development of drugs. Many 
compounds can be found in natural products that contain a chromenone core structure, for example, 
the large group of flavonoids.  
Chromenones have already been described as useful lead structures for the development of ligands 
for GPCRs. Pranlukast (239) is a marketed drug for asthma; it blocks the cysteinyl-leukotriene receptor 
1 (CysLT1 receptor),254 which is a δ-branch class A rhodopsin-like GPCR. Pranlukast has been shown to 
also act as a weak antagonist at GPR17.255 This confirms the utility of chromenone derivatives as GPCR 
ligands being suitable lead structures for drug development.  
Furthermore, chromen-4-ones were extensively investigated by Funke et al. and optimized as 
GPR35 agonists.179 The authors were able to design a radioligand for GPR35, a useful tool to study the 
(patho)physiology of this orphan receptor.179 In their study, chromen-4-ones were also tested at the 
orphan GPR55 to prove the selectivity of their compounds. This is of primary interest, because GPR35 
is closely related to GPR55. From this study, it was already known that some of the compounds were 
able to inhibit LPI-induced β-arrestin signaling in GPR55-expressing CHO-β-arrestin cells with moderate 
potencies in the low micromolar range. 179; 180 Chromen-4-ones have also been designed and optimized 
to act at the orphan receptors GPR17 and GPR84.256  
 
Figure 98: Pranlukast and PSB-13253 (240), chromenone ligands that are used in pharmacological 
research255,257; 258 
 
In the present study, a large in-house library of chromen-4-ones was investigated for interaction 
with GPR55. We analyzed structure-activity relationships including previous as well as new data. This 
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will provide a better understanding of the potencies of the compounds at GPR55 and a clear selectivity 
profile for the GPR35 agonists of this series.  
5.2. Chromen-4-ones as GPR55 agonists 
5.2.1. Previous results of chromen-4-ons at GPR55 
 
All compounds were synthesized by Anne Meyer (ANM-compounds), Mario Funke (MF-
compounds) and Thomas Blaschke (THB-compounds). The investigated compounds differ in many 
positions and cover a broad range of structural diversity. Funke et al. discovered that chromen-4-ones 
can be moderate antagonists of GPR55, while being very potent GPR35 agonists. An acidic functionality 
proved to be mandatory for GPR35 activation, because GPR35 contains positively charged amino acids, 
mainly arginines, in the binding pocket, which form ionic interactions with the negatively charged 
acidic function.259 Another crucial structural feature for GPR35 activation is the bromo-substitution in 
position 6 of the chromenone core, together with relatively small substitutions at the 8-benzamido-
residue in the para-position.257 MF203 241 
The most potent GPR55 antagonists of this series so far have been compound 241 and 242with IC50 
values of 2.65 µM and 4.34 µM, respectively (see Figure 99). All compounds that have been shown to 
act at GPR55 display some common features. Most of them have rather small or no substitutions at 
position 6. In contrast to GPR35 agonists, there have to be bulky lipophilic residues in the para-position 
of the benzamido moiety to achieve high GPR55 potency. Compound 242, for example, contains a 
para-fluorobenzyloxy residue, and compound 241 an even longer para-phenylbutoxy residue. This 
pattern confirms previously obtained results for GPR55 antagonists (data not shown).256 
 
Figure 99: The most potent chromen-4-one antagonists at GPR55, a data by Stephanie Weyer and 
Dr. Aliaa Abdelrahman, b data by Dr. Dominik Thimm, c data by Katharina Sylvester and Dr. Meryem 
Köse 256; 261; 260  
 
The GPR35 agonists were subsequently further optimized and in this context investigated at the 
GPR35 orthologues. To further enhance the selectivity profile of these compounds, we also monitored 
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them at GPR55 and analyzed the structure-activity relationship. The results of this study can be found 
in the following parts of this chapter.  
5.2.2. Activities of chromen-4-ones at GPR55 
 
The investigated compound set can roughly be subdivided in three different classes. The first group 
of compounds is primarily substituted in the para- or ortho-position at the benzamido residue and can 
also be substituted in an additional position at the benzamido-residue. The second group consists of 
compounds that are modified in the meta-position. In the fourth group, compounds are described 
which do not fit into anyone of the three groups described before.  
The para-substituted compounds have previously been shown to act as weak GPR55 antagonists 
by Funke et al.179 In Table 36, more compounds with comparable substitutions are investigated as 
GPR55 antagonists and agonists. 
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Table 36: Potencies of para- and ortho- substituted chromen-4-one derivatives at the human GPR55 
 
 
 
 
   Human GPR55 
No. Compd. Chemical structure 
antagonistic 
activity 
agonistic 
activity 
  R1 R2 R3 R4 R5 IC50 ± SEM (µM) EC50 (µM) 
243 ANM158 H 
 
H H H 8.34 ± 1.16 >10 (7%) 
244 ANM177 F 
 
H H H 3.26 ± 0.14 >10 (0%) 
245 ANM170 Cl 
 
H H H 23.6 ± 10.6 >10 (-2%) 
246 ANM6 Br OCH3 F H H >10 (45%) >10 (9%) 
247 ANM7 Br OCH3 F F H >10 (44%) >10 (-4%) 
248 ANM47 Br OCH3 OCH3 H H >10 (8%) >10 (-9%) 
249 THB10 Br SCH3 H H H 12.9 ± 1.7 
(56%)a 
>10 (-18%) 
250 ANM190 Br -CH2-CH3 H H H 17.4 ± 6.4 
(53%)a 
>10 (-10%) 
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251 THB47 Br 
 
H H H 11.7 ± 0.8 
(54%)a 
>10 (-1%) 
252 ANM34 CH3 OCH3 H H H >10 (18%) >10 (7%) 
253 ANM27 CH3 OCH3 H H F >10 (27%) >10 (-15%) 
254 ANM59 CH3 
 
H H H >10 (6%) >10 (11%) 
255 ANM173 CH3 
 
H H H 4.54 ± 1.63 >10 (2%) 
256 ANM172 -CH2-CH3 OCH3 H H H >10 (8%) >10 (-8%) 
257 ANM97 -CH2-CH3 
 
H H H >10 (29%) >10 (0%) 
258 ANM217 -CH2-CH3 
 
H H H >10 (23%) >10 (-10%) 
259 ANM40 OCH3 OCH3 H H H >10 (4%) >10 (12%) 
260 ANM58 OCH3 
 
H H H >10 (5%) >10 (-3%) 
261 ANM123 OCH3 
 
H H H >10 (31%) >10 (-5%) 
262 ANM68 OCF3 OCH3 H H H >10 (17%) >10 (-14%) 
263 ANM77 
 
OCH3 H H H >10 (-16%) >10 (7%) 
264 THB28 
 
OCH3 F F H >10 (28%) >10 (0%) 
265 ANM98 
  
H H H >10 (1%) >10 (-1%) 
266 THB27 
  
H H F 16.2 ± 6.0 
(46%)a 
>10 (-13%) 
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267 ANM139 
  
H H Cl >10 (21%) >10 (10%) 
268 ANM130 
  
H H H >10 (0%) >10 (8%) 
269 ANM141 
  
H H H >10 (35%) >10 (-2%) 
270 ANM151 
  
H H H >10 (13%) >10 (-15%) 
271 ANM152 
  
H H Cl >10 (5%) >10 (7%) 
272 ANM196 
 
OCH3 H H H >10 (46%) >10 (-5%) 
273 ANM138 
  
H H H >10 (-4%) >10 (3%) 
274 ANM143 
  
H H H >10 (13%) >10 (16%) 
275 ANM203 
  
H H H >10 (31%) >10 (4%) 
276 ANM142 
  
H H H >10 (1%) >10 (4%) 
277 ANM78 See above H H H >10 (-6%) >10 (1%) 
278 ANM182 See above H H H 12.8 ± 1.3 
(47%)a 
>10 (0%) 
279 THB22 See above H H H >10 (11%) >10 (10%) 
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280 ANM26 Br H 
 
 
H H 8.54 ± 0.55 >10 (6 ± 7%) 
a percent inhibition at 10 µM test compound concentration 
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From the results in Table 36, it can be learned that small substituents in position R1 are favorable 
for GPR55 inhibition. R1 has been varied from very small substituents such as hydrogen to halogens 
including fluorine, chlorine and bromine and to alkyl groups such as methyl, ethyl, as well as aromatic 
residues. The active compounds contained hydrogen, small halogens or a methyl group. Ethyl or 
phenyl-substituted compounds were all inactive. Next, R2 has been varied from very small methoxy 
goups to large lipophilic substituents such as cyclohexylalkyloxy groups with different chain lengths 
and corresponding aromatic derivatives. The most potent antagonists in this series were compound 
255 and 244 with IC50 values between 3-4 µM. Both of them feature a cyclohexylbutoxy residue for R2, 
but differ in R1. Compound 244 has a fluorine in position R1, while compound 255 contains a methyl 
residue, thus both have rather small residues in the R1 position. The corresponding chlorine-
substituted compound 245 and the methoxy-substituted 261 were inactive at a concentration of 
10 µM.  
Only one ortho-substituted compound 280 displayed weak antagonistic activity versus GPR55, as 
has been observed for similar residues in position R2 with para-substituted compounds. 
The most favorable R2 residue for GPR35 activation (a methoxy residue) resulted in a completely 
inactive GPR55 ligand. This crucial structural feature of GPR35 activation therefore proves to be not 
tolerated at GPR55. The active GPR55 antagonists all show a large lipophilic side chain.  
A second group of chromen-4-ones has been investigated at GPR55 (see Table 37). 
 
Table 37: Potencies of compounds with meta-substituted benzamido-residues at the human GPR55. 
 
 
   Human GPR55 
No. Compd. Chemical structure antagonistic 
activity agonist activity 
  R1 R2 
IC50 ± SEM (µM) 
EC50 (µM) 
(% efficacy) 
281 ANM234 H 
 
>10 (45%) >10 (20%) 
282 ANM236 H 
 
6.30 ± 2.05 >10 (-3%) 
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283 THB49 H 
 
4.41 ± 0.28 >10 (2%) 
284 ANM263 H 
 
1.48 ± 0.38 >10 (16%) 
285 ANM267 H 
 
>10 (38 %) >10 (25%) 
286 THB75 H 
 
>10 (46%) 
0.111 ± 0.042 
(29%) 
287 ANM178 H 
 
>10 (-51%) 
0.474 ± 0.099 
(73%) 
288 ANM250 H 
 
>10 (-21%) 
0.202 ± 0.048 
(52%) 
289 ANM264 H 
 
6.88 ± 1.70 >10 (10%) 
290 ANM270 H 
 
3.96 ± 0.82 >10 (14%) 
291 ANM265 H 
 
>10 (38%) >10 (18%) 
292 ANM280 H 
 
>10 (21) >10 (45%) 
293 THB73 F 
 
>10 (8%) 
0.117 ± 0.034 
(29%) 
294 THB71 F 
 
>10 (-93%) 
0.373 ± 0.038 
(71%) 
295 ANM346 structure see above >10 (-70%) >10 (-9%) 
296 ANM252 F 
 
>10 (36%) 
0.263 ± 0.074 
(58%) 
297 THB74 Cl 
 
>10 (-23%) 
0.323 ± 0.121 
(40%)d 
298 THB72 Cl 
 
>10 (-115%) 
0.342 ± 0.039 
(57%) 
299 ANM251 Cl 
 
>10 (-39%) 
0.196 ± 0.041 
(86%) 
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300 ANM334 Cl 
 
>10 (36%) >10 (39%) 
301 ANM337 Cl 
 
>10 (9%) 
0.0400 ± 0.006 
(39%) 
302 ANM335 Cl 
 
>10 (-11%) 
0.113 ± 0.064 
(65%) 
303 ANM20 Br 
 
10.6 ± 1.2 
(87%)a 
>10 (-2%) 
304 ANM22 Br 
 
>10 (36%) 
0.507 ± 0.033 
(39%) 
305 ANM21 Br 
 
>10 (-87%) 
0.597 ± 0.137 
(53%) 
306 ANM235 Br 
 
>10 (-15%) 
0.481 ± 0.84 
(31%) 
307 ANMDOT6 Br 
 
18.1 ± 7.1 
(59%)a 
>10 (16%) 
308 ANM26 Br 
 
>10 (18%) >10 (6%) 
309 ANM277 structure see above >10 (31%) >10 (27%) 
 
When testing this compound series, some compounds such as 287 were found to act as agonists at 
GPR55.  
 
Figure 100: Concentration-dependent activation of compound 287 at the human GPR55, an EC50 
value of 0.474 µM and an efficacy of 73% were determined 
 
Although all chromen-4-ones investigated before had acted as antagonists, compound 287 
displayed agonistic activity at GPR55 with high potency and an efficacy of 73% (compared to the full 
activation by 10 µM LPI, Figure 100). To further study this effect, a series of compounds were 
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synthesized that share different meta-substitutions. The results can be found in Table 37. The 
cyclohexylbutoxy residue of compound 287 was exchanged for smaller residues and for aromatic 
substituents or the alkyl chain length was reduced. In position 6, R2 was exchanged for comparably 
small halogen atoms. This was done according to the former results described above, where small 
halogens proved to be preferred.  
 
Figure 101: Potencies of 8-(3-cyclohexylbutoxy)benzamidochromen-4-one-2-carboxylic acids with 
different substitutions at position 6 
 
In Figure 101, the effects of differently substituted derivatives of compound 287 are shown. 
Compound 294 and 298 have a fluorine or a chlorine at position 6. The activity increased slightly, which 
can be observed in Figure 101 (A), while the efficacy stayed unaltered (in Figure 101 (B) the maximum 
of the GPR55 activation did not change). Altogether, there was an insignificant advantage of a chlorine 
residue in position 6.  
The R2 residue was also intensively studied. First of all, the chain length of the cyclohexylalkyloxy 
group was varied. This was done for different R1 substituted compounds. 
 
Figure 102: Influence of different alkyl chain length of the cyclohexylalkyloxy residue on GPR55 
activation 
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In Figure 102, the cyclohexylalkyloxy residue for R2 was investigated. The alkyl chain length of the 
first hit compound 287 was a butyloxy moiety. With compound 286 and 288, propoxy and pentoxy 
moieties were also investigated. Compound 286 showed an EC50 value of 0.111 µM, but an efficacy of 
only 29%. Compound 288 was equally potent as 287, with a slightly reduced efficacy. These three R2 
side chains have also been combined with derivatives with a fluorine or chlorine atom in R1 position. 
For fluorine-substituted compounds, the same dependency could be observed as for the unsubstituted 
compounds. Compound 293 was the most potent compound of the fluorinated series with an EC50 
value of 0.117 µM and an efficacy of 29%. Compound 294, the cyclohexylbutoxy compound, was less 
potent but comparable to 287, also regarding the efficacy. Compound 296, the cyclohexylpentoxy 
derivative, was similar to 288. Furthermore, a set of chlorinated compounds was investigated. In this 
series, the cyclohexylpentoxy derivative 299 was the most potent compound with an EC50 value of 
0.196 µM and a high efficacy of 89%. Compound 297, the cyclohexylpropoxy derivative, was the 
weakest compound of the three, both in potency as and efficacy. Out of these nine compounds, 299 
was the most efficacious with the highest GPR55 activation.  
The R2 residue was varied to cyclohexylethoxy and cyclohexylmethoxy in compound 285 and 284. 
Both compounds were not active at a concentration of 10 µM.  
 
Figure 103: Functional difference between aliphatically and aromatically substituted compounds 
 
Aromatic substitutions have also been tested in the meta-position of the benzamido residue. 
Compound 283 is corresponding to 287. Surprisingly, compound 283 showed no activating potency, 
but acted as antagonist versus LPI with an IC50 value of 4.41 µM. Further, the compounds 289 and 290 
- both of them share aromatic substituents attached by different lengths of alkyl linkers - acted as weak 
antagonists at GPR55. Thus, aromatic residues prevent GPR55 activation. Aliphatic substitutions are 
necessary to activate the receptor, while aromatic substitutions lead to receptor blockade.  
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It has been shown before that para-substituted bulky lipophilic residues can lead to a moderate 
GPR55 inhibition, for both aliphatic and aromatic residues. In the meta-position, there is a switch 
between agonistic and antagonistic functionality for aliphatic and aromatic substitutions, especially 
when R1 is a hydrogen or fluorine atom. However, there is a restriction: For compounds with a bromine 
atom in position 6, some benzyloxy residues (the para-chloro-, bromo- and methylbenzyloxy 
substituted compounds 304, 305 and 306) showed a quite potent activation with EC50 values of around 
500 nM. However, they all displayed a very low efficacy (between 31-53% of the maximum effect of 
LPI). The only aliphatic brominated compound 280 showed no activation of GPR55. For fluorinated and 
unsubstituted compounds with aromatic residues in the meta-position no agonistic potency could be 
detected. They were inactive or had a moderate antagonistic effect.  
A compound lacking the acidic function of the chomen-4-ones, such as compound 309, did not 
activate or inhibit GPR55 signaling at all. The acidic function seemed to be necessary for GPR55 
inhibition and activation.  
The 8-benzamido-chromen-4-ones had been unfavorable for the mouse orthologue of GPR35. 
When the benzamido moiety was exchanged for an oxalic acid monoamide, which also introduced a 
second acidic function, the potency at the mouse receptor increased significantly. These compounds 
have now also been investigated at GPR55.  
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Table 38: Potencies of compounds with an additional acidic function at GPR55. 
 
   Human GPR55 
 compound Chemical structure antagonistic activity agonist activity 
  R1 IC50 ± SEM (µM) EC50 (µM) 
310 THB12 H >10 (-8%) >10 (-14%) 
311 ANM295 F >10 (9%) >10 (34%) 
312 ANM296 Cl >10 (6%) >10 (27%) 
313 ANM183 Br >10 (1%) >10 (3%) 
314 ANM298 -CH3 >10 (11%) >10 (29%) 
315 ANM297 -OCH3 >10 (-1%) >10 (27%) 
316 ANM299 -CH2-CH3 >10 (27%) >10 (19%) 
317 ANM383 -CH2-CH2-CH2-CH3 >10 (2%) >10 (48%) 
318 ANM287 
 
>10 (17%) >10 (46%) 
319 ANM300 structure see above >10 (34%) >10 (15%) 
320 ANM379 -CH3 >10 (14%) >10 (4%) 
321 ANM367 Br >10 (11%) >10 (-4%)- 
322 ANM365 structure see above >10 (22%) >10 (16%) 
 
It could be seen that none of these compounds was active at GPR55 at a concentration of 10 µM. 
This confirms their selectivity for GPR35.  
Overall, the structure-activity relationships for the chromen-4-ones at GPR55 can be described as 
being very complex. While aliphatic meta-substitutions at the benzamido residue led to GPR55-
agonistic activity, aromatic residues at the same position resulted in compounds with antagonistic 
effects. Aromatic and large aliphatic substitutions in para-position at the benzamido residue resulted 
in weak antagonistic activity. In position 6 of the chromen-4-one, agonists require small lipophilic 
substituents such as fluorine or chlorine. Larger residues were not tolerated. The acidic function of the 
chromen-4-ones appears to be required for interaction with GPR55. 
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Figure 104: Structure-activity relationships of chromen-4-ones at the human GPR55 
 
Several agonists for GPR55 have been described in the literature, as discussed in 1.4.2. We 
compared the newly investigated GPR55 chromen-4-one agonists to those previously identified 
structures. Chemical structures and potencies can be viewed in Figure 16.  
Heynen-Genel et al. described three structural related GPR55 agonists by using a β-arestin assay 
with a fluorescence read-out (Transfluor® from Molecular Devices) and detected a 100% efficacy 
compared to the activation by LPI.121 When comparing the new chromen-4-one agonists with these 
agonists some structural similarities but also differences are evident. All structures, including the 
chromen-4-ones, show an amide bond in the center of the molecule. This functional group might form 
hydrogen bonds. ML-186 (23) and ML-184 (24) both contain sulfonamide groups, whereas our 
chromen-4-ones contain a carboxylic acid residue. Both structures are bioisoteres and might bind to 
the same binding site. The GPR55 agonists GSK522373A (25) described by Brown et al. is structurally 
very similar to the agonists described by Heynen-Genel et al.120 It also features an amide bond and a 
sulfonamide. The agonists 27 and 28 described by Yrjölü et al. have a comparable thiourea moiety in 
the center of the molecule.126 
None of the reported GPR55 agonists has an acidic function, although this might be an important 
interaction partner in the biding site. For the compounds described by Heynen-Genel et al. and also 
for compound 299 and derivatives, a certain spacial arrangement between the “head group” with the 
polar functions and the lipophilic residue can be observed. Kotsikorou et al. proposed an L-shaped 
topology for GPR55 agonists. They investigated possible binding modes in homology modeling 
approaches, by which they created the hypothesis, that the long aliphatic tail of the 2-AG-PI or LPI 
binds deep down into the cavity of the transmembrane domain helix bundle, whereas the polar head 
groups point to the surface and show interactions with the extracellular loops.262 For the compounds 
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investigated by Heynen-Genel et al. they proposed similar poses of the ligands. The chromen-4-one 
derivatives are also able to form analogous conformations (see Figure 106).  
The physicochemical properties of the known GPR55 agonists described are quite comparable to 
the new GPR55 agonists identified in the present study. All compounds name a molecular weight of 
around 500 g/mol, which is at the limit defined by the Lipinski Rule of Five for peroral bioavailability.263 
However, the natural ligand LPI also shows a high molecular weight of 572.63 g/mol. Due to its charged 
phosphate group and the polar sugar moiety, LPI has a very low log D value both at pH 2.0 and also at 
pH 7.4. The described ligands however show comparably high log D values. Especially, the thiourea 
derivatives described by Yrjölä et al. are highly lipophilic. The advantage of our newly identified GPR55 
agonists, is the reduced log D7.4. The acidic function is deprotonated at a pH value of 7.4 and reduces 
the lipophilicity compared to an acidic environment. The only compound with less lipophilicity is the 
agonist 26 described by Morales et al. However, it only shows an activation of 51% and has no acidic 
character.  
Table 39: Physicochemical properties of different GPR55 agonists (logD values were calculated with 
Marvin 17.4.3, ChemAxxon). 
 Compounda molecular weight 
(g/mol) 
Log D2.0 Log D7.4 
19 LPI 572.63 1.68 -0.30 
22 ML-185 461.56 3.24 3.24 
23 ML-186 436.54 1.58 3.60 
24 ML-184 470.63 4.37 4.34 
25 GSK522373A 516.56 4.37 4.38 
26 22 Morales 440.24 -1.44 2.02 
27  17b Yrjölä 519.61 5.95 5.95 
28  17l Yrjölä 491.58 4.87 4.87 
299 ANM251 512.00 6.32 3.13 
a for structure see Figure 16 
 
Especially, when comparing the chromen-4-ones to the possible endogenous ligand LPI, many of 
the discussed features become meaningful.  
A possible endogenous agonist for GPR55 might be 2AG-PI, which is the 1-lyso-
arachidonoylphosphatidylinositol, described by Oka et al.264 The molecule contains the fatty acid 
arachidonic acid, a very lipophilic group, which is linked via glycerol to a negatively charged phosphate 
group, bound to the inositol. The latter two groups represent polar structures (see Figure 105).  
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Figure 105: Chemical structure of 2AG-PI, a possible endogenous ligand for GPR55 
 
When we compare this structure to our newly identified GPR55 agonists, especially to 
compound 299, some common features can be determined ( see Figure 106). The carboxylic acid of 
compound 299 will be negatively charged at physiological pH values, similarly to the phosphate group 
of 2AG-PI and LPI. The 4-carbonyl function of compound 299 and derivatives is located in a similar 
position as the hydroxyl function of 2AG-PI. The ester function and the amide of compound 299 are 
superimposable. The arachidonic acid is a polyunsaturated fatty acid and contains four double bonds, 
which are cis-configurated. It matches well with the long lipophilic side chain of compound 299.  
The two molecules are congruent in their topology regarding the lipophilic part, the linker and the 
negative charge, but 2AG-PI contains further a polar head group, inositol, which is lacking in compound 
299. This might be one reason for the partial agonism of the chromen-4-one derivatives compared to 
LPI. Exploration of the inositol binding pocket should be further explored.  
 
Figure 106: Superimposition of compound 299 and 2AG-PI 
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The results for GPR55 have been generated in β-arrestin assays only. To confirm the obtained 
results, the compounds should be tested in an additional assay system. GPR55 has been described to 
activate G12/13 signaling, which results in the activation of small GTPases such as RhoA, and the 
phosphorylation of ROCK kinases.  
Furthermore, the selectivity of the compounds has to be studied. The structure-activity 
relationships that have been established by Funke et al. suggest already a high degree of selectivity for 
GPR55, because GPR35 activation required a bromine at position 6.257 The selectivity of the compounds 
versus GPR35, GPR18 and the cannabinoid receptors will be discussed in subsequent chapters.  
 
5.3. Selectivity of GPR55 ligands versus GPR35, GPR18 and cannabinoid 
receptors 
5.3.1. Selectivity of GPR55 ligands versus GPR35 
 
The selectivity of the chromen-4-ones was investigated by testing them against the most closely 
related receptor, GPR35.  
Assays have been performed  by Dr. Dominik Thimm in the same test system as used for GPR55.261 
Table 40: Potencies of chromen-4-ones at the human GPR35 in β-arrestin recruitment assays 
  Human GPR35 
No. Compd. agonist activity 
  EC50 ± SEM (µM)a 
243 ANM158 >10 (12%)  
244 ANM177 >10 (-2%) 
245 ANM170 >10 (3%) 
246 ANM6 0.00446 ± 0.00030 
247 ANM7 0.00554 ± 0.00029 
248 ANM47 0.0162 ± 0.0009 
249 THB10 0.0150 ± 0.0009 
250 ANM190 0.0570 ± 0.0055 
251 THB47 >10 (22%) 
252 ANM34 0.0377 ± 0.0036 
253 ANM27 0.00437 ± 0.00048 
254 ANM59 >10 (22%) 
255 ANM173 >10 (31%) 
256 ANM172 0.0306 ± 0.0074 
257 ANM97 7.47 ± 1.38 
258 ANM217 0.791 ± 0.228 
259 ANM40 0.0255 ± 0.0027 
260 ANM58 >10 (33%) 
261 ANM123 >10 (35%) 
262 ANM68 0.0104 ± 0.0017 
263 ANM77 0.00548 ± 0.00089 
264 THB28 0.00108 ± 0.00011 
265 ANM98 >10 (40%) 
266 THB27 0.381 ± 0.021 
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267 ANM139 >10 (48%) 
268 ANM130 >10 (8%) 
269 ANM141 >10 (13%) 
270 ANM151 >10 (1%) 
271 ANM152 >10 (2%) 
272 ANM196 0.00821 ± 0.00189 
273 ANM138 >10 (4%) 
274 ANM143 >10 (5%) 
275 ANM203 0.583 ± 0.002 
276 ANM142 >10 (20%) 
277 ANM78 >10 (28%) 
278 ANM182 1.87 ± 0.08 
279 THB22 1.87 ± 0.08 
280 ANM26 >10 (-2%) 
281 ANM234 >10 (40%) 
282 ANM236 >10 (27%) 
283 THB49 >10 (22%) 
284 ANM263 >10 (23%) 
285 ANM267 >10 (8%) 
286 THB75 >10 (-7%) 
287 ANM178 >10 (-3%) 
288 ANM250 >10 (-2%) 
289 ANM264 4.20 ± 0.57 
290 ANM270 >10 (40%) 
291 ANM265 >10 (14%) 
292 ANM280 >10 (11%) 
293 THB73 >10 (-4%) 
294 THB71 >10 (-6%) 
295 ANM346 >10 (2%) 
296 ANM252 >10 (-9%) 
297 THB74 >10 (-5%) 
298 THB72 >10 (-6%) 
299 ANM251 >10 (-8%) 
300 ANM334 >10 (5%) 
301 ANM337 >10 (-1%) 
302 ANM335 >10 (-1%) 
303 ANM20 >10 (7%) 
304 ANM22 >10 (16%) 
305 ANM21 >10 (6%) 
306 ANM235 >10 (35%) 
307 ANMDOT6 >10 (4%) 
280 ANM26 >10 (20%) 
309 ANM277 n.d. 
310 THB12 0.264 ± 0.017  
311 ANM295 0.106 ± 0.011 
312 ANM296 0.0293 ± 0.0015 
313 ANM183 0.0118 ± 0.0015 
314 ANM298 0.104 ± 0.003 
315 ANM297 0.0938 ± 0.0087 
316 ANM299 0.0275 ± 0.0025 
317 ANM383 0.0318 ± 0.0025 
318 ANM287 0.00968 ± 0.00048 
319 ANM300 0.00547 ± 0.00072 
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320 ANM379 0.0295 ± 0.0046 
321 ANM367 0.037 ± 0.0021 
322 ANM365 0.0214 ± 0.0021 
a for structures see Table 36, Table 37 and Table 38 
b Effects were normalized to the signal induced by 30 µM zaprinast 
 
Figure 107: Correlation of EC50 values of chromen-4-ones for human GPR35 and human GPR55 
 
In Table 40 and in Figure 107, the potencies of the compounds at the human GPR35 are shown. The 
chromen-4-one series contains many very potent GPR35 agonists, but the structure-activity 
relationships are very different from those at GPR55. GPR35 requires a bromine atom at position 6 and 
small lipophilic substitutions at the benzamido ring, preferably fluorine in the ortho-position and a 
methoxy group in the para-position for high potency. In contrast, GPR55 does not tolerate bromine 
substitutions in position 6 of agonists. On the other hand, GPR35 cannot be activated by chromen-4-
ones with long aliphatic residues in the meta-position of the benzamido ring. In Figure 107, it can be 
observed that selectivity is obtained. Compounds, that activate GPR55, do not activate GPR35.  
 
5.3.2. Selectivity of versus GPR18 
 
GPR18 is another receptor that is closely related to GPR55. In contrast to GPR35 it can interact with 
cannabinoids like GPR55 (compare chapter 1.4.1). Therefore, we studied the selectivity of the 
identified GPR55 ligands at GPR18 (see in Table 41).  
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Table 41: Potencies of the chromen-4-one derivatives at the human GPR18 
  Human GPR18 
No. Compd.a antagonistic activity agonist activity 
  IC50 ± SEM (µM) EC50 (µM) 
243 ANM158 >10 (36%) >10 (5%) 
244 ANM177 >10 (29%) >10 (-15%) 
245 ANM170 >10 (6%) >10 (-24%) 
246 ANM6 >10 (-28%) >10 (12%) 
247 ANM7 >10 (11%) >10 (10%) 
248 ANM47 >10 (7%) >10 (18%) 
249 THB10 >10 (18%) >10 (-10%) 
250 ANM190 >10 (22%) >10 (-9%) 
251 THB47 >10 (30%) >10 (-7%) 
252 ANM34 >10 (-10%) >10 (34%) 
253 ANM27 >10 (20%) >10 (-3%) 
254 ANM59 >10 (10%) >10 (-24%) 
255 ANM173 >10 (22%) >10 (-33%) 
256 ANM172 >10 (2%) >10 (-23%) 
257 ANM97 >10 (16%) >10 (-13%) 
258 ANM217 >10 (23%) >10 (-10%) 
259 ANM40 >10 (-20%) >10 (15%) 
260 ANM58 >10 (-12%) >10 (11%) 
261 ANM123 28.1 ± 16.4 >10 (-57%) 
262 ANM68 >10 (-1%) >10 (18%) 
263 ANM77 >10 (24%) >10 (-8%) 
264 THB28 >10 (15%) >10 (4%) 
265 ANM98 >10 (8%) >10 (-47%) 
266 THB27 >10 (17%) >10 (-9%) 
267 ANM139 >10 (19%) >10 (26%) 
268 ANM130 >10 (26%) >10 (-33%) 
269 ANM141 >10 (26%) >10 (-50%) 
270 ANM151 >10 (30%) >10 (-1%) 
271 ANM152 >10 (28%) >10 (41%) 
272 ANM196 >10 (-1%) >10 (17%) 
273 ANM138 >10 (38%) >10 (-9%) 
274 ANM143 >10 (10%) >10 (25%) 
275 ANM203 >10 (22%) >10 (16%) 
276 ANM142 >10 (10%) >10 (-16%) 
277 ANM78 >10 (-17%) >10 (29%) 
278 ANM182 >10 (31%) >10 (16%) 
279 ANM26 >10 (4%) >10 (1%) 
280 THB22 >10 (16%) >10 (-4%) 
281 ANM234 >10 (-2%) >10 (2%) 
282 ANM236 >10 (23%) >10 (25%) 
283 THB49 >10 (18%) >10 (-1%) 
284 ANM263 >10 (-2%) >10 (9%) 
285 ANM267 >10 (28%) >10 (5%) 
286 THB75 >10 (14%) >10 (13%) 
287 ANM178 >10 (3%) >10 (14%) 
288 ANM250 >10 (34%) >10 (-16%) 
289 ANM264 >10 (-17%) >10 (1%) 
290 ANM270 >10 (-7%) >10 (-4%) 
291 ANM265 >10 (1%) >10 (-5%) 
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292 ANM280 >10 (23%) >10 (0%) 
293 THB73 >10 (3%) >10 (17%) 
294 THB71 >10 (22%) >10 (13%) 
295 ANM346 13.1 ± 3.0 >10 (-51%) 
296 ANM252 >10 (8%) >10 (6%) 
297 THB74 >10 (11%) >10 (12%) 
298 THB72 >10 (16%) >10 (14%) 
299 ANM251 >10 (25%) >10 (-4%) 
300 ANM334 >10 (3%) >10 (10%) 
301 ANM337 9.24 ± 2.39 >10 (12%) 
302 ANM335 >10 (32%) >10 (19%) 
303 ANM20 >10 (15%) >10 (6%) 
304 ANM22 >10 (26%) >10 (11%) 
305 ANM21 >10 (27%) >10 (18%) 
306 ANM235 >10 (-13%) >10 (26%) 
307 ANMDOT6 >10 (4%) >10 (4%) 
280 ANM277 >10 (2%) >10 (15%) 
309 ANM23 >10 (26%) >10 (4%) 
310 THB12 >10 (1%) >10 (-4%) 
311 ANM295 >10 (11%) >10 (23%) 
312 ANM296 >10 (32%) >10 (25%) 
313 ANM183 >10 (-22%) >10 (14%) 
314 ANM298 >10 (8%) >10 (15%9 
315 ANM297 >10 (9%) >10 (16%) 
316 ANM299 >10 (16%) >10 (17%) 
317 ANM383 >10 (-3%) >10 (11%) 
318 ANM287 >10 (17%) >10 (36%) 
319 ANM300 >10 (8%) >10 (12%) 
320 ANM379 >10 (0%) >10 (0%) 
321 ANM367 >10 (-1%) >10 (-4%) 
322 ANM365 >10 (-12%) >10 (14%) 
a for structures see Table 36, Table 37 and Table 38 
 
The chromen-4-one derivatives showed no potency at the human GPR18, with only four exceptions. 
Three compounds displayed a weak inhibition of Δ9-THC-induced β-arrestin recruitment mediated by 
GPR18. Compound 261 showed with an IC50 value of 28.1 µM very weak potency and did also not 
activate the human GPR18. This was also true for compound 295, which displayed an IC50 value of 13.1 
µM, at GPR18. Compound 301 had an IC50 value of 9.24 µM, a compound that contains a heptoxy side 
chain in the meta-position at the benzamido moiety. It is one of the low efficacy GPR55 agonists (EC50 
= 0.040 µM, efficacy = 39%). Thus, a high degree of selectivity of the GPR55 compounds against GPR18 
was confirmed.  
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5.3.3. Selectivity of GPR55 ligands versus the cannabinoid receptors 
 
GPR55 can interact with by cannabinoids, for example the potent cannabinoid receptor agonist 
CP55,940 is a moderately potent antagonist at GPR55.265 We determined the affinity of selected potent 
GPR55 agonists in radioligand binding against tritiated CP55,940 (seen Table 42).  
Table 42: Affinities of selected GPR55 agonists at cannabinoid receptors 
  Radioligand binding 
No. Compd.a Human CB1 Human CB2 
 
 
Ki (µM) vs. [3H]CP55,940 
(% inhibition of specific 
binding) 
Ki (µM) vs. [3H]CP55,940 
(% inhibition of specific 
binding) 
286 THB75 6.46 ± 2.06 >10 (23 ± 11%) 
287 ANM178 13.0 ± 7.1 36.7 ± 16.6 
293 THB73 7.21 ± 1.15 20.2 ± 6.1 
294 THB71 8.92 ± 2.05 21.4 ± 5.1 
299 ANM251 14.6 ± 2.2 16.0 ± 7.0 
a for structures see Table 37 
 
The compounds showed weak displacement of the radioligand binding. All Ki values ranged from 
around 5 to 40 µM. Therefore, they can be regarded as weak cannabinoid receptor ligands. The affinity 
of compound 299 with Ki values of 14.6 µM and 16.0 µM correlates to a 75-fold selectivity for GPR55 
versus the CB1 and 82-fold selectivity versus CB2 receptors.  
In further compound optimization studies the selectivity versus CB receptors has to be monitored. 
So far it appears to be no problem to achieve selectivity for GPR55 agonists.  
Some of the chromen-4-one derivatives have also been investigated as ligands for the orphan 
receptors GPR17 and GPR84. The results of these studies for selected compounds are collected in Table 
43. The potencies are in the low micromolar range. Compound 299, which was inactive at hGPR84, was 
active at hGPR17 with an IC50 of 1.58 µM. It still displayed an 8-fold selectivity for the human GPR55.  
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Table 43: Potencies of selected GPR55 agonist at the two orphan GPCRs GPR17 and GPR84a 
  Antagonistic activity 
 Compound Human GPR84 Human GPR17 
 
 
IC50 (µM)b 
cAMP accumulation 
assay 
IC50 (µM)c 
Ca2+ mobilization 
assay 
286 THB75 >3 (29%) 4.28 ± 0.49 
287 ANM178 6.36 ± 1.94 1.71 ± 0.04 
293 THB73 1.68 ± 0.57 4.63 ± 0.60 
294 THB71 1.03 ± 0.04 2.67 ± 0.49 
299 ANM251 >3 (33%) 1.58 ± 0.49 
293 THB73 1.68 ± 0.57 4.63 ± 0.60 
adata kindly provided by Katharina Sylvester and Dr. Meryem Köse (hGPR84) and Stepfanie Weyer and 
Dr. Aliaa Abdelrahman (hGPR17) bcAMP accumulation assay in CHO β-arrestin hGPR84 cells, in the 
presence of 100 µM Forskolin, activation with decanoic acid. cCa2+-mobilization assay in 1321N1 
astrocytoma cells stably expressing GPR17, activation with MDL29,951. 
 
5.4. Discussion and Outlook  
 
A series of chromen-4-one derivatives has been investigated and optimized for the human GPR55. 
Those derivatives that have been developed as GPR35 ligands bromine in position 6 and a para-
substituted benzamido residue in position 8, showed only weak inhibitory potency against GPR55 or 
were inactive. In this study, it was discovered that long aliphatic residues in meta-position of the 
benzamido moiety led to GPR55 activation. Different substitutents were investigated: 
cyclohexylalkyloxy residues displayed the highest potencies at the human GPR55, and the resulting 
compounds were partial agonists. The compound with the highest potency and efficacy was 
compound 299 (6-chloro-8-(3-((5-cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylic 
acid) with an EC50 value of 0.196 µM and an efficacy of 86%. When the alkyl chain length was reduced 
the efficacy decreased. Chloro-substitution in position 6 of the chromen-4-one proved to be superior 
to other halogen atoms or a hydrogen atom.  
Comparing compound 299 to other published GPR55 agonists, it displays similar potency, bit lower 
efficacy according to published data. All known GPR55 agonists show some molecular features, e.g. 
shape and functional groups.  
Whenever the aliphatic moiety was exchanged for an aromatic substituent, the agonist properties 
were lost and weak antagonists potency was observed instead (agonist-antagonist-switch).  
For further investigation, compounds with a polar group linked to the carboxylic function should be 
explored. Of major importance would be the confirmation of the agonism of the chromen-4-one 
derivatives in a second assay system, as well as investigation of potential species differences in rodents 
as compared to humans.   
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6. PHARMACOLOGICAL EVALUATION OF SYNTHETIC CANNABINOIDS 
IDENTIFIED AS CONSTIUENTS OF SPICE 
6.1. Introduction 
 
Many cannabinoids have been consumed because of their psychoactive effects. First of all, the 
herbal derived Δ9-THC, which is found in marihuana (the flower and flower near leafs of the Cannabis 
sativa plant) or as hashish, then meaning the highly Δ9-THC-rich resin of the female hemp, has been 
used to generate favorable psychic effects. These effects of hashish and marihuana have been known 
for many centuries. The main active chemical compound could be identified, isolated and synthesized 
in the 1960ies by Raphael Mechoulam from the Hebrew University.266,267 They further investigated the 
biosynthesis of Δ9-THC and some other cannabinoid compounds in the hemp plant, and established 
the structure-relationships of this compound group, at a time when the pharmacological target of the 
cannabinoids was not known.268,269 In 1988, a cannabinoid receptor binding site in rat brain membrane 
preparations was identified by binding experiments with the tritiated ligand CP55,940, a compound 
that was developed by Pfizer as an antinociceptive drug.12 Devane et al. proposed the CB receptor to 
be a G protein-coupled receptor,10 Matsuda et al. could verify this in 1990 by cloning the cannabinoid 
receptor 1 for the first time.11 
Δ9-THC containing plant material, hashish and marihuana, have been known for a long time. First 
mentioning of the use of hemp for medicinal and recreational purpose dates back to the early Chinese 
and Assyrian civilizations270 Although used for many purposes, cannabis effects have been discussed 
controversially. Following the legal drugs tobacco and alcohol, it is probably the most abundantly 
abused substance in the world. Nevertheless, till now the use of marihuana and hashish is regarded as 
rather safe, as no direct lethal effects of overdoses have been reported. An LD50 was determined for 
rat and mice (29 mg/kg and 43 mg/kg, respectively, when administered intravenous, 666 mg/kg and 
482 mg/kg when given perorally).271,272 The chronic administration, which can cause psychotic effects, 
is therefore more dangerous, as it comes along with tolerance and withdrawal symptoms.273 But even 
here it should be noted that measurable neurotoxic effects occur in rodents after chronic 
administration of cannabis smoke for three month with some changes in the hippocampal pyramidal 
neurons. In rhesus monkeys these effects could not be observed after chronic treatment for a full 
year.274 Therefore, the chronical toxic effects are still not clearly characterized.  
Today, the use of cannabis is controlled in most of the countries in the world. In Germany, cannabis 
plant material and also Δ9-THC as a purified substance are part of the controlled substances act, 
meaning that owning, consuming, buying and selling is restricted to the public authorities. Δ9-THC itself 
can also be prescribed under these restrictions by medical doctors for certain indications such as 
cachexia and chronic pain.  
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Cannabis in its various dosage forms is the most sold, consumed and seized illegal drug in the 
European Union. Cannabis plant material and hashish resin still represent the major amount of 
consumed cannabinoids in Europe. Nevertheless, the amount of synthetic cannabinoids is 
increasing.275 They are sold as “harmless” but effective alternatives to the restricted plant materials 
and resins of cannabis, as so-called ‘legal highs’. Normally, they are labeled as ‘not for human 
consumption’ to circumvent medicinal and nutritional specifications. They are normally found to be 
mixed with plant material and also declared as such. These synthetic cannabinoids in plant material 
appeared in Europe in 2006 under the trademark ‘Spice’ or ‘K2’. They are normally sold in colorful 
small plastic bags with an eye on the front. Many different types and tastes exist. In the early days of 
‘Spice’ the true ingredients were not known, and the herbal plant material was declared to be the main 
component. Two groups later on identified nearly simultaneously synthetic cannabinoids in these 
“legal highs”.276,277 The two major identified compounds were JWH-018 and CP47,497 (see Figure 108), 
and derivatives of the latter. CP47,497 and derivatives are very similar to the well-known CP55,940. 
Both of these compound groups have been known for long times in medicinal chemistry as potent 
cannabinoid receptor agonists. Compounds with the compound identifier JWH have been developed 
by John W. Huffman as cannabinoid receptor ligands in the mid 90s,278 and the CP compound identifier 
refers to Carl Pfizer and to the pharmaceutical company Pfizer, which developed cannabinoid receptor 
ligands in the late 80s and early 90s as antinociceptive drugs.279 
 
Figure 108: Δ9-THC and the two synthetic cannabinoids CP55,940 and JWH-018 with their affinity to 
the CB receptors. 30,278 
 
These synthetic cannabinoids are more potent than the partial agonist Δ9-THC, which can be 
referred to as a typical dirty drug – a compound that not selectively interacts with one target, but 
shows effects on various other targets. These synthetic cannabinoids are mostly highly potent 
cannabinoid receptor ligands, and their effects and also side-effects are more severe than those of 
Δ9-THC itself. CP55,940 shows antinociceptive, antiemetic, anticonvulsive and anti-inflammatory 
effects via the CB receptors, and has been proposed for many indications, including Parkinson’s disease 
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and cancer therapy-induced emesis, but never marketed as such.280,281,282 CP55,940 nevertheless is the 
standard cannabinoid ligand that has been used in research for decades.  
JWH-018, which has been developed to study the structure-activity relationships of the 
aminoalkylindoles and was only one compound out of many synthesized ones mainly to understand 
CB2 receptor selectivity has had its inglorious revival as an abused drug in ‘spice’ blends. Upon 
discovery, it was restricted by law to the Narcotic Drug Act (BtMG in Germany), especially as these 
compounds are more potent and therefore can cause more severe side effects than Δ9-THC. The most 
common side effects reported in context with JWH-018 have been an increased risk to induce 
psychosis283 and direct toxic effects on the heart: tachycardia and arrhythmias.284,285 More recently 
identified compounds such as 5-F-PB-22 (375) have been reported in context with lethal 
consumptions.286 A climax was the reported “zombie-outbreack” in Brooklyn, Manhattan, USA, when 
around 30 unresponsive or slowly responsive persons staggered through their neighborhood. Later on, 
the synthetic compound AMB-FUBINACA (323) was identified to have caused these effects.287 
 
Figure 109: Chemical structure of AMB-FUBINACA (323) and 5F-PB-22 (375) 
 
The severity and frequency of side-effects caused by synthetic cannabinoids is increasing and 
brought them intto the focus of the health care systems. One of the few studies on the hospitalization 
caused by synthetic cannabinoid intake was conducted in Anchorage, Alaska, from July 2015 to March 
2016. They identified over 1000 ambulance transports in that time and a regular hospitalization with 
severe side-effects. Around 40% of the patients were homeless.288 The increasing endangerment 
potential and the criminal intention of the sellers has accelerated the compounds restriction by law.  
In 2009, only JWH-018 and CP47,497 and derivatives were restricted, but from that time on more 
and more synthetic cannabinoids have been appeared on the illicit drug market. The total number of 
restricted compounds has increased each year (compare Figure 110).  
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Figure 110: Newly restricted synthetic cannabinoids in the BtMG (Narcotic Drug Act in Germany) 
per year 
 
Restriction by law can be circumvented by modifying the structure of the compounds. Due to the 
nature of the Narcotic Drug Act only clearly defined chemical compounds with an evidence to be 
abused can be restricted. There are many known cannabinoid compounds in the scientific literature, 
completely reported with synthesis and bioactivity data. Moreover, the already restricted synthetic 
compounds could also be altered in their chemical structure with the purpose of preserving bioactivity 
and circumventing the restriction by law.289 Forensic researchers have to analyze the new compounds 
and investigate their chemical structure, compare these to known compounds, collect case studies 
until enough evidence exists to restrict them. As consumption of illegal compounds and of ‘legal highs’ 
is often associated with criminal behavior, clear facts are necessary to judge these cases correctly.  
The EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) defines a scaffold 
common to all of the synthetic cannabinoids. Their main constitution remains quite preserved, only 
the residues are exchanged. As most of these compounds have adventurous names on the illicit drug 
market, most often to enhance the sales, the EMCDDA also agreed on a common labeling system to 
describe each emerging compound uniquely.  
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Figure 111: Scaffold of the synthetic cannabinoids as defined by the EMCDDA290 
 
To circumvent restriction the residues that can be found in the ‘tail’ part and the ‘ring’ part of this 
scaffold are varied most commonly. Also, the substitutions have been combined in almost every 
possible way. There are three different types of ‘linkers’: amides, esters or carbonyl residues. These 
structure-activity relationships had already been established by Huffman et al.291 and also by 
researchers from Abbott.292 The main purpose of changing the chemical structure of the compounds 
is to circumvent restriction but maintaining bioactivity. Therefore typical bioisoteric groups are 
introduced into the main scaffolds. In 6.2, we will describe the different groups and how the affinity to 
the cannabinoid receptors is altered.  
In November 2016, a new law was put into force in Germany that restricts compound classes based 
on their structure-activity relationships. Two groups of compounds were described in the 
enforcement, the synthetic cannabinoids and the cathinones (amphetamine-like compounds). 
However, clandestine chemists already launched compounds, which are not restricted by the New 
Psychotic Drugs Act.  
In the present study we investigated a series of compounds − collected by the Insotute of Forensic 
Toxicology and Medicine, University of Bonn, based on the analysis of forensic samples − in radioligand 
binding assays for their interaction with both CB receptor subtypes, CB1 and CB2. Subsequently, the 
compounds were investigated for their functional properties in cAMP accumulation assays. Moreover, 
the potential of potent CB receptor agonists to cross the blood-brain barrier was estimated in silico. 
The compounds were additionally investigated for their ability to interact with the CB-like orphan 
receptors GPR18 and GPR55. The analysis of structure-activity relationships of the investigated 
compounds will help in predicting properties of novel derivatives.  
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6.2. Affinity to the cannabinoid receptors 
 
In this study we investigated the CB receptor binding affinities and functional properties of different 
classes of compounds structurally related to known CB receptor agonists. These compounds had been 
identified in “spice” preparations suspected to be commercialized for drug abuse (unpublished data).  
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Table 44: Affinities of spice constituents to the cannabinoid receptors. 
 
Compd. 
No. 
Compd. 
Name 
   Ki ± SEM (nM) 
R1 R2 X human CB1 Human CB2 
3 CP55,940 for structure see figure 1 1.28 ± 0.44 1.42 ±0.75 
4 THC for structure see figure 1 3.87 ± 0.91 71.6 ± 2.4 
5 JWH-018 for structure see figure 1 1.51 ± 0.67 2.24 ± 1.20 
3-Amidoindoles and –indazoles (A) 
324 NNEI 
 
 
CH 
1.82 ± 0.35 
(Ki =1.25  
Blaazer et al.293) 
21.9 ± 5.5 
(Ki =100 
Blaazer et al.293) 
325 5F-NNEI 
 
 
CH 3.69 ± 1.97 13.4 ± 1.6 
326 5Cl-NNEI 
 
 
CH 10.2 ± 2.2 32.8 ± 10.8 
327 FDU-NNEI 
 
 
CH 7.42 ± 2.51 64.0 ± 15.0 
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328 
5F-NNEI-2-naphthyl-
isomer 
 
 
CH 235 ± 15 226 ± 24b 
329 MN-18 
 
 
N 3.86 ± 0.90 3.47 ± 0.89 
330 5F-MN-18 
 
 
N 1.65 ± 0.26 2.50 ± 0.86 
331 THJ 
 
 
N 103 ± 25 12.7 ± 4.1 
332 5F-THJ 
 
 
N 22.6 ± 7.5 2.75 ± 0.99 
333 SDB-006 
 
 
CH 
53.0 ± 1.1 
(EC50 = 134 
Banister et al.294) 
188 ± 38 
(EC50 = 19  
Banister et al.294) 
334 5F-SDB-006 
 
 
CH 
71.9 ± 13.5 
(EC50 = 50 
Banister et al. 294) 
430 ± 73 
(EC50 =123 
Banister et al. 294) 
335 SDB-006-N-phenyl-
analog 
 
 
CH 163 ± 17 275 ± 25 
336 APICA 
 
 
 
 
 
 
CH 
6.52 ± 3.73 
(EC50 = 128 
Banister et al. 294) 
1.22 ± 0.14  
(EC50 = 29 
Banister et al. 294) 
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337 
STS-135 
(5F-APICA) 
 
 
CH 
 
2.51 ± 0.35  
(EC50 = 51 
Banister et al. 294) 
 
0.794 ± 0.071  
(EC50 = 13 
Banister et al. 294) 
338 
5F-APINACA 
(5F-AKB48) 
 
 
N 1.94 ± 0.55 0.266 ± 0.041 
339 FUB-AKB-48 
 
 
N 1.06 ± 0.29 0.174 ± 0.018 
340 MMB-018 
 
 
 
CH 15.1 ± 5.9 14.0 ± 0.8 
341 AMB 
 
 
N 0.866 ± 0.057 0.973 ± 0.104 
342 MMB-2201 
 
 
CH 15.2 ± 5.0 19.8 ± 4.2 
343 5F-AMB 
 
 
 
N 
1.13 ± 0.48 
(EC50 = 1.9 
Banister et al.295) 
1.38 ± 0.22 
(EC50 = 10 
Banister et al.295) 
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344 FUB-AMB 
 
 
N 
0.387 ± 0.135 
(EC50 = 2.0 
Banister et al.295) 
0.536 ± 0.115 
(EC50 = 18 
Banister et al.295) 
345 MDMB-CHMICA 
 
 
CH 
0.410 ± 0.141 
(EC50 = 10 
Banister et al.295) 
0.354 ± 0.050 
(EC50 = 71 
Banister et al.295) 
346 MA-CHMINACA 
 
 
N 
0.339 ± 0.073 
(EC50 = 5.1 
Banister et al.295) 
0.301 ± 0.092 
(EC50 = 29 
Banister et al.295) 
347 5-F-ADB 
 
 
N 
23.3 ± 10.2 
(EC50 = 0.59 
Banister et al.295) 
5.99 ± 2.47 
(EC50 = 7.5 
Banister et al.295) 
348 MDMB-FUBINACA 
 
 
N 
0.0985 ± 0.0291 
(EC50 = 3.9 
Banister et al.295) 
0.130 ± 0.010 
(EC50 = 55 
Banister et al.295) 
349 MDMB-CHMINACA 
 
 
 
N 
0.135 ± 0.028 
(EC50 = 10 
Banister et al.295) 
0.222 ± 0.034 
(EC50 = 128 
Banister et al.295) 
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350 5F-ABPICA 
 
 
CH 
35.0 ± 7.7 
(EC50 = 12 
Banister et al.295) 
89.0 ± 33.2 
(EC50 = 12 
Banister et al.295) 
351 5F-AB-PINACA 
 
 
N 
4.96 ± 1.37 
(EC50 = 0.48 
Banister et al.296) 
3.77 ± 0.25 
(EC50 = 2.6 
Banister et al.296) 
352 5-Cl-AB-PINACA 
 
 
N 4.06 ± 1.95 12.0 ± 1.7  
353 AB-FUBINACA (3-F-
benzyl-isomer) 
 
 
N 
12.6 ± 0.7 
(EC50 = 51.1 
Buchler et al.297) 
52.2 ± 10.2 
354 
AB-FUBINACA (2-F-
benzyl-isomer) 
 
 
N 
6.91 ± 3.42 
(EC50 = 4.69 
Buchler et al.297) 
25.0 ± 6.1 
355 AB-CHMINACA 
 
 
 
N 
1.72 ± 0.14 
(EC50 = 0.78 
Wiley et al.298) 
1.91 ± 0.20 
(EC50 = 0.45 
Wiley et al.298) 
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356 
5-F-ADB-PINACA-
isomer 2 
 
 
N 3.10 ± 1.53 4.28 ± 2.86 
357 5F-ADBICA 
 
 
CH 
2.72 ± 0.35 
(EC50 = 0.77 
Banister et al.296) 
1.83 ± 0.11 
(EC50 = 1.2 
Banister et al.296) 
358 5F-ADB-PINACA 
 
 
N 
1.43 ± 0.69 
(EC50 = 0.24 
Banister et al.296) 
0.694 ± 0.078 
(EC50 = 2.1 
Banister et al.296) 
359 ADB-FUBINACA 
 
 
N 
0.360 ± 0.002 
(EC50 = 1.2 
Banister et al.296) 
0.339 ± 0.059 
(EC50 = 3.5 
Banister et al.296) 
360 ADB-CHMICA 
 
 
CH 1.24 ± 0.360 0.628 ± 0.231 
361 MAB-CHMINACA 
 
 
N 
0.333 ± 0.059 
(EC50 = 0.289 
Buchler et al.297) 
0.331 ± 0.048 
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362 PX-2 
 
 
CH 127 ± 43 17.4 ± 1.4 
363 PX-1 
 
 
CH 485 ± 117 164 ± 17 
364 APP-FUBINACA 
 
 
N 
56.3 ± 19.8 
(EC50 = 47.6 
Buchler et al.297) 
58.1 ± 17.3 
365 APP-CHMINACA 
 
 
N 
9.81 ± 4.56 
(EC50 = 708 
Buchler et al.297) 
4.39 ± 0.59 
366 Cumyl-PICA 
 
 
CH 
3.27 ± 0.32 
(EC50 = 0.66 
Bowden et al.299) 
24.0 ± 8.8 
(EC50 = 13 
Bowden et al.299) 
367 5F-Cumyl-PICA 
 
 
CH 
1.37 ± 0.26 
(EC50 = <0.1 
Bowden et al.299) 
29.1 ± 2.4 
(EC50 = 0.37 
Bowden et al.299) 
368 Cumyl-THPINACA 
 
 
N 
1.23 ± 0.20 
(EC50 = 0.1 
Bowden et al.299) 
1.38 ± 0.86 
(EC50 = 0.59 
Bowden et al.299) 
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3-Oxycarbonylindoles and –indazoles (B) 
369 NM-2201 
 
 
CH 0.332 ± 0.107 0.732 ± 0.174 
370 FDU-PB-22 
 
 
CH 1.19 ± 0.39 2.43 ± 0.92 
371 3-CAF 
 
 
CH ~10,000 (48%) 423 ± 106c 
372 SDB-005 
 
 
N 
3.59 ± 0.89 
(EC50 = 116 
Banister et al.294) 
2.61 ± 1.07 
(EC50 = 140 
Banister et al.294) 
373 5F-SDB-005 
 
 
N 
 
2.58 ± 1.09  
(EC50 = 148 
Banister et al.294) 
3.41 ± 1.34  
(EC50 = 136 
Banister et al.294) 
374 PB-22 
 
 
CH 
 
 
0.318 ± 0.071  
(EC50 = 5.1 
Banister et al.294) 
0.433 ± 0.106 
(EC50 = 2.8 
Banister et al.294) 
375 5F-PB-22 
 
 
 
CH 
 
0.468 ± 0.069  
(EC50 = 148 
Banister et al.294) 
0.633 ± 0.058 
(EC50 = 136 
Banister et al.294) 
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376 FUB-PB-22 
 
 
CH 0.386 ± 0.117 0.478 ± 0.124 
377 BB-22 
 
 
CH 0.217 ± 0.056 0.338 ± 0.045 
378 MO-CHMINACA 
 
 
 
N 10.4 ± 7.4 1.11 ± 0.14 
3-Carboxyindoles and -indazoles (C) 
379 FUB-JWH-018 
 
 
CH 3.27 ± 1.76 1.34 ± 0.48 
380 THJ018 
 
 
N 5.84 ± 1.32 4.57 ± 0.28 
381 THJ2201 
 
 
N 1.34 ± 0.54 1.32 ± 0.39 
382 MAM-2201 
 
 
CH 1.58 ± 0.76 0.582 ± 0.123 
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383 EAM-2201 
 
 
CH 0.380 ± 0.111 0.371 ± 0.052 
384 MAM-2201-4-
fluorpentyl-isomer 
 
 
CH 3.23 ± 1.56 0.808 ± 0.057 
385 F-2201 
 
 
CH 0.852 ± 0.192 1.89 ± 0.57 
386 Cl-2201 
 
 
CH 0.772 ± 0.101 1.18 ± 0.19 
387 RCS-4 
 
 
CH 
26.6 ± 6.6 
(EC50 = 145 
Banister et al.300) 
2.86 ± 0.39 
(EC50 = 145 
Banister et al.300) 
388 RCS-8 
 
 
CH 81.3 ± 15.8 14.6 ± 6.1 
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389 AB001 
 
 
CH 
33.0 ± 7.42 
(EC50 = 35 
Banister et al.301) 
1.72 ± 0.15 
(EC50 = 45 
Banister et al.301) 
390 5F-AB001 
 
 
CH 12.3 ± 3.0 1.47 ± 1.03 
391 UR-144 
 
 
CH 
55.9 ± 6.5 
(Ki = 150  
Frost et al.302) 
1.49 ± 0.25 
(Ki = 1.8  
Frost et al.302) 
392 XLR-11 
 
 
CH 
29.4 ± 11.0 
(EC50 = 98 
Banister et al.294) 
0.608 ± 0.151 
(EC50 = 83 
Banister et al.294) 
393 
XLR-11-2-fluorpentyl-
isomer 
 
 
CH 59.5 ± 16.9 1.83 ± 0.47 
394 FAB-144 
 
 
N 17.5 ± 1.1 0.450 ± 0.111 
395 XLR-12 
 
 
CH 
43.7 ± 5.9 
(Ki = 15  
Frost et al.302) 
0.831 ± 0.331 
(Ki = 0.09 
Frost et al.302) 
396 FUB-144 
 
 
 
CH 14.0 ± 2.7 0.846 ± 0.209 
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397 AB005 
 
 
CH 
59.4 ± 13.1 
(Ki = 5.5 
Frost et al.302) 
1.04 ± 0.11 
(Ki = 0.48 
Frost et al.302) 
398 AB005-azepane-
isomer 
 
 
CH >10,000 (13%) 212 ± 55 
399 A-796,260 
 
 
CH 
738 ± 142 
(Ki = 845 
Frost et al.292) 
8.02 ± 0.77 
(Ki = 4.4 
Frost et al.292) 
400 A-834,735 
 
 
 
CH 
25.0 ± 6.8 
(Ki = 12 
Frost et al.292) 
0.566 ± 0.153 
(Ki = 0.21 
Frost et al.292) 
2-Methyl-3-carboxyindoles (D) 
401 M-144 
 
 
 
CH 19.4 ± 7.8 4.59 ± 1.48 
7-Methoxy-3-amidoindole (E) 
402 MN-25 
 
 
 
 
 
 
CH 
780 ± 66 
(Ki = 245 
Wroblenski et 
al.303) 
2.77 ± 1.59 
(Ki = 11 
Wroblenski et al. 303) 
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3-Carboxy-carbazol (F) 
403 EG-018 
 
 
- 7.17 ± 1.27 2.27 ± 0.383 
404 EG-2201 
 
 
 
- 22.4 ± 12.8 4.36 ± 2.91 
AM2201-benzimidazol (G) 
405 FUBIMINA 
- - - 
502 ± 181 
(Ki = 296 
Wiley et al.299) 
99.0 ± 28.4 
(Ki = 23.5 
Wiley et al.299) 
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All compounds were investigated in radioligand binding experiments at CHO cell membrane 
preparations stably expressing the human CB1 or CB2 receptor using [3H]CP55,940 as a radioligand. Ki 
values are presented in Table 44. CB1 or CB2 selectivity of compounds was calculated based on the Ki 
values, and can be found in Table 45. All of the investigated compounds share a common core 
structure): (aza)indole. The only exceptions are EG-018 (403), EG-2201 (404) and FUBIMINA (405). 
Three different types of linkers between the (aza)indole ring system and a bulky, lipohilic residue are 
observed: an amide, an ester or a shorter carboxy linker. The most potent compounds for the CB1 
receptor were found among the ester-linked subgroup (BB22 (377), PB-22 (374) and 5F-PB-22 (375), 
NM2201 (369)) with Ki values ranging from 0.217 to 0.468 nM. The only exception is the carboxy-linked 
compound EAM-2201 (383), with a similarly low Ki value of 0.380 nM and the amido-linked MDMB-
FUBINACA (348) with a Ki value of 0.0985 nM for CB1 and a Ki value of 0.130 nM for CB2. 
In all three subgroups compounds with typical bioisosteric exchanges are found. Three features of 
the molecule are varied: the N1-substituent, which was originally a pentyl moiety in the lead 
compounds of the JWH group 291; in the current compounds it is fluorinated or exchanged for a para-
fluorobenzyl residue. The effect of fluorination on binding affinity was moderate: in the nine examples 
included in our study binding affinity for the CB1 receptor was slightly enhanced for fluorinated 
compounds (compare MN-18 (329) and 5F-MN-18 (330); THJ (331) and 5F-THJ (332); APICA (336) and 
STS-135 (337); SDB-005 (372) and 5F-SDB005 (373); THJ018 (380) and THJ2201 (381) and AB001 (389) 
and 5F-AB001 (390)) or slightly decreased (compare NNEI (324) and 5F-NNEI (325); SDB-006 (333) and 
5F-SDB-006 (334); PB-22 (374) and 5F-PB-22 (375)). Banister et al. investigated the effects of 
fluorinated compounds and found that although the EC50 value of the investigated compounds were 
lower in vitro, this was not translated to higher in vivo potencies, leading to the assumption that 
pharmacokinetic effects play a role.294 In their study they investigated, amongst others, the pairs UR-
144 (391) and XLR-11 (392), PB-22 (374) and 5F-PB-22 (375), and also APICA (336) and STS-135 (337). 
They performed membrane potential measurements using a FLIPR assay kit (Molecular Devices) and 
determined slightly higher EC50 values for the compounds compared to the radioligand binding data 
obtained in the present study. XLR-11 (392), a derivative with a 2-fluoropentyl side chain, is the only 
compound in this series with a fluorine introduced at position 2 of the pentyl side chain. In comparison 
to the non-fluorinated analogue UR-144 (391) the affinity at the CB1 receptor was almost the same, 
but it was not as potent as XLR-11, the 5-fluoinated derivative. MAM-2201 (384), a 4-fluoropentyl-
substituted isomer, showed also slightly higher Ki values than the 5-fluoropentyl derivative MAM-2201 
(382). In this series only one compound contains of a 5-chloro-substitution: 5Cl-NNEI (326), which 
displayed 10-fold lower affinity for the CB1 receptor than the unsubstituted derivative NNEI (324). 
Another bioisosteric replacement of the 5-fluoropentyl side chain is a para-fluorobenzyl residue. This 
variation is observed in four compounds of the present series (compare: 5F-AKB48 (338) and FUB-
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AKB48 (339); NM2201 (342) and FDU-PB-22 (370); 5F-PB-22 (375) and FUB-PB-22 (376); XLR-11 (392) 
and FUB-144 (396)). The affinity for both CB receptors was almost identical in three of the four pairs, 
only FDU-PB-22 (370) was not quite as potent as NM2201 (369). Thus, a para-fluorobenzyl residue 
appears to be an optimal bioisosteric exchange for obtaining compounds with a similarly high affinity 
as the 5-fluoropentyl-substituted parent compound. 
Other side chains have been introduced at the indole nitrogen atom. Huffmann et al. who 
established alkylindoles as cannabinoid receptor ligands already performed a comprehensive 
structure-activity relationship study introducing different side chains. They showed that a five-carbon-
side chain is preferred.291 Thus, pentyl side chains and their bioisosteric analogs confer high potency 
and activity at the CB1 receptor. Whenever the size is decreased, affinity for the CB1 receptor is largely 
reduced. As this structural feature is crucial for high CB1 affinity, it had previously been modified to 
design CB2-selective compounds.292 
Another frequently observed variation is the replacement of the indole core by an indazole ring 
system. In the group of compounds with an amide linker (A) it could be observed that the affinity for 
the CB1 receptor was quite similar for indoles and indazoles, while the affinity for the CB2 receptor was 
slightly increased in indazole derivatives (compare NNEI (324) and MN-18 (329); 5F-NNEI (325) and 5F-
MN-18 (330); STS-135 (337) and 5F-APINACA (338)). In the group of compounds with an ester linkage 
(B) the indole derivative NM-2201 (369) showed lower Ki values at CB1 and CB2 receptors than the 
corresponding indazole derivative 5F-SDB-005 (373). In group C compounds containing a keto-group 
as a linker, XLR-11 (392) and its indazole analogue FAB-144 (394) displayed almost identical binding 
affinities. Thus, a variation of the heterocyclic core from indole to indazole is widely tolerated. 
One other common feature of this group of compounds is the bulky lipophilic residue in position R1. 
Huffman et al. introduced mainly naphthyl residues in that position.304 A variation of this structural 
element represents the introduction of a quinolone found in some compounds such as THJ (331) and 
PB-22 (374).305 In group A compounds with an amide linker the introduction of a quinolone led to 14- 
and 27-fold higher Ki values at CB1 receptors, respectively (compare MN-18 (329) with THJ (331), and 
5F-MN-18 (330) with 5F-THJ (332)), while the affinity for CB2 receptors remained unaltered in the low 
nanomolar range. In the ester-linked compounds (B) the quinolone-substituted analogue of NM2201 
(369), 5F-PB-22 (375), showed comparable affinities for both receptors. FUB-PB-22 (376) is a quinolone 
derivative with somewhat higher affinity at CB1 and CB2 receptors compared to its analogue FDU-PB-
22 (370). The most potent compound in this series of cannabinoid ligands, BB-22 (377) − someomes 
referred to as QUCHIC − is also a quinolone derivaove, which was first described in illicit drug material 
in 2013 in Japan.305 This compound has a cyclohexylmethyl residue in position R2, which imitates the 
length of a pentyl chain that was previously described to be important for CB potency,291 and which 
was beneficial for CB1 receptor affinity also in a series of magnolol derivatives.133  
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Compounds MAM-2201 (382) and EAM-2201 (383) display substitution of the naphthyl residue, 
containing a methyl (MAM-2201 (382)) or an ethyl (EAM-2201 (383) group in position 4 of the naphthyl 
ring. EAM-2201 (383) was highly potent at the CB1 receptor with a Ki value of 0.380 nM without 
preference for any of the CB receptor subtypes. MAM-2201 (382), which had been described to cause 
severe toxicity in the cerebellum of rats 306, was found to be four times less potent at the CB1 receptor. 
Further, F-2201 (385) and Cl-2201 (386), which are the respective fluoro- and chloro-derivatives, both 
display comparable subnanomolar potencies at CB1 and very low nanomolar potencies at CB2.  
The only compound which is not linked in the 1-position of the naphthyl residue but in the 2-
position, 5F-NNEI-2-naphthyl-isomer (328), was a much weaker CB1 receptor ligand and showed only 
partial inhibition of radioligand binding at the CB2 receptor. NNEI (324), which was first described by 
Blaazer et al. 2011, showed a pKi value of 8.9 in their binding experiments at the CB1 receptor,293 which 
we have now confirmed. The authors also synthesized a non-fluorinated derivative of compound 328 
(5F-NNEI-2-naphthyl-isomer) which displayed a lower pKi value of 7.2 for the CB1 receptor. The same 
relation could be shown in the present study (compare 5F-NNEI (325) and 5F-NNEI-2-naphthyl-isomer 
(328)): if the naphthyl residue is linked in meta-position to the amide the affinity was decreased by 
100-fold. 
Huffman et al. investigated effects of substituting the naphthyl ring by smaller aromatic residues, 
which reduced affinity to the CB1 receptor.291 This could also be observed for the benzyl-substituted 
compounds SDB-006 (333) and 5F-SDB-006 (334) investigated in the present study. They showed much 
lower affinity for both CB receptors as compared to the napththyl-substituted compounds with Ki 
values in the high nanomolar range. The phenyl-substituted derivative SDB-006-N-phenylanalog (335) 
displayed even higher Ki values. In group C compounds RCS-4 (387) and RCS-8 (388) also feature a 
phenyl or a benzyl residue. Wiley et al. described that the substitution in the ortho-position is crucial 
for high affinity, which is realized in both compounds.307 RCS-8 (388), first described in 2012 in the 
United States,308 is benzyl-substituted in position 1 and has a cyclohexylethyl residue in position 2; it 
shows weaker affinity for both CB receptors than RCS-4 (387). RCS-4 (387) and isomers were 
investigated by Banister et al. who found that RCS-4 (387) displayed EC50 values of 145 nM for CB1 and 
46 nM for CB2, respectively.300 In the present study RCS-4 (387) with Ki values of 26.6 nM for CB1 and 
2.86 nM for CB2 displayed higher binding affinities. 
The aromatic residue R1 may be replaced by a more bulky lipophilic group, namely an adamantyl or 
a tetramethylcyclopropyl residue. Comparing the naphthyl derivatives NNEI (324) and 5F-NNEI (325) 
with the adamantyl derivatives APICA (336) and STS-135 (337) it can be observed that CB2 affinity was 
increased. Also the tetramethylcyclopropyl derivatives of group C displayed, independently of the side 
chain variations, a CB2 preference. Compounds UR-144 (391), A-796,260 (399), A-834,735 (400) and 
XLR-12 (395) were first described by Frost et al. in the search for selective CB2 agonists.292 We could 
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confirm the reported Ki values, only XLR-12 (395) displayed a 10-fold higher Ki value in our hands as 
compared to the literature data. From this group of compounds some derivatives emerged on the illicit 
drug market, mainly in Sweden.309,310 FAB-144 (394), the indazole and 5-fluoropentyl analogue of UR-
144 (391), showed slightly increased affinity for both CB receptors, and FUB-144 (394), the para-
fluorobenzyl derivative displayed similar affinity. Also, compound M-144 (401) which is substituted in 
position 2 of the indole ring system with a methyl group, displayed a similar profile. AB-005 (397), a 
chimeric compound with the CB2 selectivity-increasing tetramethylcyclopropyl residue for R1 and N-
methyl-2-piperidinylmethyl substitution as R2 which retains CB1 affinity, was first introduced by Frost 
et al. in 2010.292 A derivative with an azepane ring (398) appeared on the illicit drug market but as we 
found it displayed no affinity for the CB1 receptor at concentrations up to 10 µM. If it should exert any 
psychotropic effect, that would not be mediated via this receptor. At CB2 receptors a moderate affinity 
was observed for 398. A structurally related but more potent compound is MN-25 (402), which was 
introduced by Wrobelenski et al. that also has been reported to be abused in previous years.303 
We further investigated compounds, which showed substitutions with amino acids as t-leucinate 
and t-valinate. These type of compounds was described in a patent of Pfizer, who developed this 
compound class as pain therapeutic and studied their structure-activity relationship extensively.297 
However, they always introduced an aryl or heteroaryl residue in R2 and coupled the amino acid in R1 
with an amine.297 The here presented compounds show a pentyl or 5-fluoropentyl side chain. MMB-
018 (340), the indole derivative with a valine methyl ester, was active in the low nanomolar range with 
a Ki value of 15.1 µM at CB1. The corresponding indazole AMB (341) showed a subnanomolar affinity 
to the both CB receptors. The 5-fluoropentyl derivatives MMB-2201 and 5F-AMB (343) were 
comparably active. The p-fluorobenzyl residue and the bioisosteric cyclohexylmethyl residue showed 
for both, indoles and indazoles, affinities in the subnanomolar range (FUB-AMB (344), MDMB-CHMICA 
(345) and MA-CHMINACA (346)). Banister et al. had already investigated these compounds and also 
5F-AMB (343) in a FLIPR membrane potential assay system from Molecular Devices. Their potencies 
were in the nanomolar range (EC50 values ranging from 1.9 nM to 71 nM). Our radioligand binding 
assay showed a higher potency here.  
Three t-valine methyl ester compounds were investigated: 5F-ADB (347), MDMB-FUBINACA (348) 
and MDMB-CHMINACA (349), which also have been substituted with 5-fluoropentyl, p-fluorobenzyl 
and cyclohexylmethyl residues. MDMB-FUBINACA (348) was the most potent compound of this set 
with a Ki value of 0.0985 nM for the CB1 receptor and a Ki value of 0.130 nM for the CB2 receptor. 
Banister et al. reported here an EC50 value of 3.9 nM for CB1 and of 55 nM for CB2.296 
Furthermore, the compounds with a valine amide in R1 were studied. The valinamide showed to be 
less potent then the valine methylester (compare 5F-ABPICA (350) with MMB-2201 (342); AB-
CHMINACA (355) and MA-CHMINACA (346) or comparably potent (5F-AB-PINACA (351) and 5F-AMB). 
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5F-ABPICA (350), which is the 5-F-pentyl indole, showed affinities of 35.0 nM and 89.0 nM for CB1 and 
CB2, the corresponding indazole 5F-ABPINACA (351) displayed affinities in the low nanomolar range. 
We further investigated the 5-Cl-pentyl derivative, 5-Cl-ABPINACA (352), which showed comparable 
Ki values of 4.06 nM for CB1 and 12.0 nM for CB2. The m-fluorobenzyl and o-fluorobenzyl derivatives 
showed similar affinities at CB1, as also reported by Buchler et al in radioligand binding assays.297 AB-
CHMINACA (355) also showed comparable potencies as reported by Wiley et al in radioligand binding 
assays.298 
5-F-ADB-PINACA Isomer 2 (356) contains another structural isomer of isoleucineamide with a 
differently substituted side chain. However, this did not alter the binding affinity as compared to 5F-
AB-PINACA (351), the corresponding valinamide. Furthermore, t-valineamides have been investigated. 
The 5-fluoropentyl substituted indole 5F-ADBICA (357) showed low nanomolar affinities with a Ki of 
2.72 nM for CB1 and 1.83 nM for CB2. This corroborates the data from Banister et al., who reported 
similar potencies in a FLIPR membrane potential assay.296 We found the corresponding indazole to be 
slightly more potent at the CB2 receptor with a Ki value of 0.694 nM. Here, Banister et al. found a higher 
potency concerning CB1 with an EC50 value of 0.24 nM, whereas we obtained a Ki value of 1.43 nM. The 
p-fluorobenzyl-substituted indazole ADB-FUBINACA (359) showed even lower Ki values of 0.360 nM 
for CB1 and 0.339 nM for CB2. The indole ADB-CHMICA (360) was substituted in R1 with 
cyclohexylmethyl and showed a Ki value of 1.24 for CB1 and 0.628 nM for CB2. The corresponding 
indazole MAB-CHMINACA (346), which was introduced by Buchler et al., was even more potent with 
a Ki value of 0.333 nM for CB1 and 0.331 nM for CB2, which fits well with data reported by Buchler et 
al. in radioligand binding assay.297 
PX-1 (363) and PX-2 (362) are the two enantiomers of the phenylalaninamide derivatives. PX-1 
(363) is the R-enantiomer, while PX-1 (363) is the S-enantiomer. PX-2 (362) showed a Ki value for CB1 
of 127 µM and was less potent than a comparable valinamide derivative as 5F-ADBICA (357). The Ki 
value for CB2 (17.4 nM) was in the lower than the Ki value of 1.83 nM for 5F-ADBICA (357). The S-
enantiomer PX-1 (363) however displayed a Ki value of 485 nM for CB1, which means a 4-fold decrease 
in affinity compared to the R-enantiomer. The Ki value of CB2 (164 nM) was 10-fold higher. This shows 
that the phenylalanineamides behave differently depending on the configuration at the α-carbon 
atom. However, we do not have any other example to investigate this effect further. The two other 
phenylalanineamides APP-FUBINACA (364) and APP-CHMINACA (365) were introduced by Buchler et 
al. 297 They contain both an indazole and vary in position R1. The p-fluorobenzyl derivative APP-
FUBINACA (364) showed potencies for both CB receptors of around 50 nM and the corresponding 
cyclohexylmethyl derivative APP-CHMINACA (365) was more potent displaying a Ki value of 9.81 nM.  
Instead of an amino acid, R1 can also be substituted with a cumyl-residue. This type of compounds 
was first described by Bowden et al. and was often found in illicit drug material in 2016. We could show 
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for all three derivatives affinities in the low nanomolar range for CB1. Bowden et al. reported 
subnanomolar EC50 values in their homogeneous time resolved fluorescence (HTRF) based cAMP assay. 
Cumyl-PICA (366) and 5-F-Cumyl-PICA (367) displayed potencies of around 25 nM for CB2 in our hands.  
In this series of compound, we only had one compound with a 3-Oxycarbonyl linker: MO-
CHMINACA (378), which is an indazole with a cyclohexylmethyl residue in R1 and a t-valine methylester 
for R2. It displayed a Ki value of 10.4 nM at CB1 and 1.11 nM at CB2. The only other cyclohexylmethyl 
compound we investigated was BB-22 (377), however this is substituted with a quinolone at R2 and 
contains an indole core. It showed a Ki value of 0.217 nM. However, we cannot conclude from this that 
valinamidemethlesters are less potent.  
We further investigated three structural dissimilar compounds, which contain a carbazol core. This 
carbazol is substituted in position 3 with residues we observed in the former compounds. EG-018 (403) 
and EG-2201 (404) show a carboxy linker and a naphthoyl residue. EG-018 (403) displayed low 
nanomolar potencies with a Ki value of 7.17 nM for CB1. We can compare EG-018 (403) to JWH-018, 
which showed similar potencies. EG-2201 (404) was less potent at CB1 with a Ki value of 22.4 nM, but 
similar potency at CB2. The here observed switch from indoles and indazoles to carbazols can be 
interpreted as reaction to the NpSG and similar regulations in other countries that restricted the whole 
class of indoles and indazoles based on the known structure-activity relationships.  
We further investigated the only benzimidazol FUBIMINA (405), which was also described by Wiley 
et al. We obtained a Ki value of 502 nM for the CB1 receptor, which is perfectly in the same range as 
the reported Ki value of 296 nM from Wiley et al. in radioligand binding assays.298 
 
Table 45: Selectivity index of selected compounds 
No. Compd 
CB1 selectivity 
Ki CB2/KiCB1 
CB2 selectivity 
Ki CB1/KiCB2 
3 CP55,940 1.1  
4 THC 18.5  
324 
NNEI 
12.0  
325 5F-NNEI 3.6  
326 5Cl-NNEI 3.2  
327 FDU-NNEI 8.6  
328 5F-NNEI-2-
naphthyl-isomer 
1.0 1.0 
329 MN-18 0.9 1.1 
330 5F-MN-18 1.5  
331 THJ  8.1 
332 5F-THJ  8.2 
333 SDB-006 3.5  
334 5F-SDB-006 6.0  
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335 SDB-006-N-phenyl-
analog 
1.7  
336 APICA  5.3 
337 STS-135 
(5F-APICA) 
 3.2 
338 5F-APINACA 
(5F-AKB48) 
 7.3 
339 FUB-AKB-48  6.1 
340 MMB-018 1.1  
341 AMB 1.1  
342 MMB-2201 1.3  
343 5F-AMB 1.2  
344 FUB-AMB 1.4  
345 MDMB-CHMICA 1.2  
346 MA-CHMINACA  1.1 
347 5F-ADB  3.9 
348 MDMB-FUBINACA 1.3  
349 MDMB-CHMINACA  1.2 
350 5F-ABPICA 2.5  
351 5F-AB-PINACA  1.3 
352 5-Cl-AB-PINACA 3.0  
353 AB-FUBINACA 
(3-F-benzyl-isomer) 
4.1  
354 AB-FUBINACA 
(2-F-benzyl-isomer) 
3.6  
355 AB-CHMINACA 1.1  
356 5-F-ADB-PINACA-
isomer 2 
1.4  
357 5F-ADBICA  1.5 
358 5F-ADB-PINACA  2.1 
359 ADB-FUBINACA  1.1 
360 ADB-CHMICA  2.0 
361 MAB-CHMINACA 1.0 1.0 
362 PX-2  7.3 
363 PX-1  3.0 
364 APP-FUBINACA 1.0 1.0 
365 APP-CHMINACA  2.2 
366 Cumyl-PICA 7.3  
367 5F-Cumyl-PICA 21.2  
368 Cumyl-THPINACA  1.1 
369 NM-2201 2.2  
370 FDU-PB-22 2.0  
371 3-CAF  23.6 
372 SDB-005  1.4 
373 5F-SDB-005 1.3  
374 PB-22 1.4  
375 5F-PB-22 1.4  
376 FUB-PB-22 1.2  
377 BB-22 1.6  
378 MO-CHMINACA 10.0  
379 FUB-JWH-018  2.44 
380 THJ018  1.3 
381 THJ2201 1.0 1.0 
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382 MAM-2201  2.7 
383 EAM-2201 1.0 1.0 
384 MAM-2201-4-
fluorpentyl-isomer 
 4.0 
385 F-2201 2.2  
386 Cl-2201 1.5  
387 RCS-4  9.3 
388 RCS-8  5.6 
389 AB001  19.2 
390 5F-AB001  8.4 
391 UR-144  37.5 
392 XLR-11  48.4 
393 XLR-11-2-
fluorpentyl-isomer 
 32.5 
394 FAB-144  38.9 
395 XLR-12  52.6 
396 FUB-144  16.5 
397 AB005  57.1 
398 AB005-azepane-
isomer 
 47.2 
399 A-796,260  92.0 
400 A-834,735  44.2 
401 M-144  4.2 
402 MN-25  282 
403 EG-018  3.2 
404 EG-2201 5.1  
405 FUBIMINA 5.1  
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Figure 112: Summary on the investigated structure-activity relationships 
 
In summary, almost all investigated compounds showed high affinity for CB receptors. Some 
compounds displayed Ki values in the subnanomolar range and thus are many times more potent than 
the psychoactive drug Δ9-THC. Of special interest to public might be the here observed scaffold 
hopping. Carbazol derivatives circumvent restriction by law up to now and display a completely new 
lead structure for CB receptor ligands.  
 
6.3. Functional properties of investigated compounds  
 
To investigate the functional properties of the compounds cAMP accumulation assays were 
performed. Both CB receptors are Gi-coupled receptors, whose activation results in decreased cAMP 
levels in the cell. For comparison the full agonist CP55,940 and the partial agonist Δ9-THC were 
investigated and results were normalized to maximal receptor activation by the full agonist CP55,940 
(see Figure 2). Compounds were tested at a concentration where maximal binding was observed, 
either at 1 µM for the more potent compounds (Ki below 10 nM) or at 10 µM for the less potent 
compounds (Ki higher than 10 nM).  
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Figure 113: Functional properties of investigated compounds determined in cAMP accumulation 
assays, in the presence of forskolin (10 µM). Compounds were applied at 10 µM concentration in 
case their Ki value was > 10 nM and at 1 µM concentration when their Ki  value was < 10 nM. All 
results were normalized to maximal receptor activation by the full agonist CP55,940 (1 µM); (A) 
compounds 324 to 339; (B) compounds 340 to 368 
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Figure 114: Functional properties of investigated compounds determined in cAMP accumulation 
assays, in the presence of forskolin (10 µM). Compounds were applied at 10 µM concentration in 
case their Ki value was > 10 nM and at 1 µM concentration when their Ki  value was < 10 nM. All 
results were normalized to maximal receptor activation by the full agonist CP55,940 (1 µM); (A) 
compounds 369 to 378; (B) compounds 379 to 390; (C) compounds 391 to 405 
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In the utilized recombinant cell lines, Δ9-THC behaved as a partial agonist, at both CB1 and CB2 
receptors, with 60% - 70% activation compared to the full CB1/CB2 agonist CP55,940. Almost all 
compounds showed a high degree of activation of both receptor subtypes. Exceptions were 3-CAF 
(371), FUBIMINA (405) and AB-005 azepane isomer (398), which did not activate the CB receptors at 
all. As 3-CAF (371) and AB-005 azepane isomer (398) showed affinity for the CB2 receptor they may be 
characterized as moderately potent, CB2-selective antagonists. The only agonistic compounds with 
lower efficacy than THC were NNEI-2-naphthyl isomer (328), MN-18 (329), XLR-12 (395) and AB005 
(397). Most of the compounds had similar efficacies at both receptor subtypes, only 5F-APINACA (351) 
activated CB1 receptor more efficaciously than CB2.  
For the CB2-selective derivative XLR-12 (395) full concentration response curves were recorded and 
EC50 values were determined (Figure 115). It showed a 30 times lower EC50 value of 0.391 nM at the 
CB2 receptor than at the CB1 receptor, thus the compound’s preference could also be observed in 
functional assays. 
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Figure 115: Concentration-dependent inhibition of radioligand binding (left side) and cAMP 
accumulation (right side); (A) by XLR-12 (395); (B) by MDMB-FUBINACA (348) 
 
 
Ki values measured in radioligand binding in many cases correlated quite well with reported and 
the EC50 values deterimined in cAMP accumulation assays. CB2-selectivity of compound XLR-12 (395) 
could be confirmed, but in our hands it was lower (only 30-fold) than previously reported (167-fold302). 
It should be emphasized that EC50 values depend on receptor expression levels while radioligand 
binding data are independent of receptor density or G protein expression. They directly reflect the 
affinity of compounds for the binding site on the receptors. 
Moreover, we determined the EC50 values of MDMB-FUBINACA (348) by measuring full 
concentration-inhibition curves, because it had shown very low Ki values in radioligand binding assays 
(see Figure 115). With an EC50 value of 0.0641 nM for CB1 and 0.756 at CB2 MDMB-FUBINACA (348) 
confirmed its high potency.  
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Compounds that activate the CB1 receptor to a comparable extent as Δ9-THC and that can cross the 
blood-brain barrier will likely cause similar psychotropic effects as Δ9-THC. Some compounds showed 
even higher efficacy than the full agonist CP55,940, including the very potent compounds EAM-2201 
(383), NM-2201 (369) and BB-22 (377). Their toxicity may be much higher than that of Δ9-THC due to 
their high potency and full efficacy. PB-22 (374), a CB1/CB2 partial agonist with similar efficacy as 
Δ9-THC but with higher, subnanomolar affinity, had previously been reported to even cause lethal 
intoxications.286,311 
 
6.4. Prediction of in-silico drug properties 
As a precondition to achieve psychoactive effects brain penetration of the compounds is required. 
This property can be determined in animal studies. Alternatively, an in silico prediction based on 
established data sets can be used to gain an idea whether a set of compounds is able to cross the 
blood-brain barrier. For the investigated compounds (compound 324-339, 369-377, 380-402) this was 
accomplished using the QSAR software Stardrop 5.4 (Optibrium). In Figure 116, affinities of the 
investigated compounds were compared to their lipophility, which is one of the major determinants 
for crossing biomembranes. As can be observed all compounds share a rather high logP value between 
3 and 7. All highly potent compounds exceeded a log P of 4.5. The standard CB agonists displayed 
similarly high logP values of 6.50 (Δ9-THC), and 5.36 (CP55,940), respectively. The compounds’ potency 
is not directly correlated with their lipophilicity (see Figure 116). Based on calculations to estimate 
lipophilicity (logP), topographical polar surface area (tPSA) and other parameters a prediction whether 
compounds are able to cross the blood-brain barrier (log BBB) is made by the program. The compounds 
could thus be divided into two groups, blood-brain barrier-penentrant and non-penetrant compounds. 
THJ (331) and 5F-THJ (332), both of which are 3-(8-quinolonyl)amido-indazoles, were predicted not to 
cross the blood-brain barrier. Based on in silico predictions it is, however, likely that the majority of 
the investigated compounds has the ability to cross the blood brain barrier.  
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Figure 116: (A) Affinities of investigated compounds at the CB1 receptor plotted against logP 
values. (B) Affinities of investigated compounds at the CB2 receptor plotted against logP values. 
(A) 
(B) 
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Figure 117: Blood-brain barrier category. Two groups of compounds were defined according to 
their predicted blood-brain barrier penetration. Stardrop 5.5 (Optibrium) defines scores based on 
established QSAR models. The prediction of the BBB category returns a binary prediction of 
penetration of the blood-brain barrier (+ : accuracy and specifity is 91%; - : accuracy and specificity is 
83%) 
 
6.5. Effects on the orphan GPR18 and GPR55 
 
The orphan GPCRs GPR18 and GPR55 have been shown to be targeted by a range of cannabinoid 
receptor ligands.106,245,132 Therefore we investigated whether the investigated spice constituents also 
interact with those cannabinoid-related receptors (Table 2). None of the compounds was able to 
activate GPR18 or to inhibit GPR18 activation up to a concentration of 10 µM. At GPR55 some 
compounds were found to be moderate antagonists, namely, APICA (336) and STS-135 (337) with IC50 
values of 3-4 µM, as well as several compounds from group C. EAM-2201 (383) was the most potent 
GPR55 antagonists of this series with an IC50 value 1.86 µM. Interestingly, none of the ester compounds 
(B) showed any inhibitory effect, and most of the active compounds were tetramethylcyclopropyl-
substituted derivatives containing the CB2-preferring structure. UR-144 (391), XLR-11-2-
fluorpentylisomer (393) and XLR-12 (395), which feature a lipophilic aliphatic or fluoropentyl side chain, 
were more potent than A-769,260 (399) or A834,735 (400) with a morpholino or pyran substituent. A 
typical functional behavior of cannabinoids at GPR55 can also be observed here: Although all of the 
identified GPR55 ligands were agonists at the CB receptors, they showed inhibitory effects at GPR55. 
The same had been demonstrated for the CB-agonist CP55,940 as well as other CB receptor agonists. 
66; 132 On the other hand, CB1 receptor antagonists, such as rimonabant, are agonists of GPR55.54,103,66,103 
Both receptors, CB1 and GPR55, were reported to be co-localized in the brain, and receptor 
heteromerization has been postulated.114; 112,114 
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Figure 118: Inhibitory potency of selected compounds at the two orphan receptors GPR18 and 
GPR55. 
Table 46: Results for spice constituents in β-arrestin recruitment assays at GPR55 and GPR18.  
No. Compd. Human GPR55 Human GPR18 
  EC50 (µM) 
(% 
activation) 
IC50 (µM) 
(% 
inhibition) 
EC50 (µM) 
(% 
activation) 
IC50 (µM) 
(% inhibition) 
4 THC - 14.2129 4.61132 - 
3 CP55,940 - 1.61245 - 5.99245 
 3-Amido-indole and –indazoles (A) 
324 NNEI >10 (26%) >10 (30%) >10 (42%) >10 (-15%) 
325 5F-NNEI >10 (25%) >10 (-8%) >10 (-3%) >10 (-17%) 
326 5Cl-NNEI >10 (28%) >10 (5%) >10 (1%) >10 (-13%) 
328 
5F-NNEI-2-
naphthyl-isomer 
>10 (19%) >10 (20%) >10 (9%) >10 (5%) 
329 MN-18 >10 (27%) >10 (35%) >10 (2%) >10 (37%) 
330 5F-MN-18 >10 (38%) >10 (-5%) >10 (-26%) >10 (23%) 
331 THJ >10 (11%) >10 (50%) >10 (4%) >10 (30%) 
332 5F-THJ >10 (28%) >10 (10%) >10 (-17%) >10 (44%) 
333 SDB-006 >10 (-5%) >10 (36%) >10 (-9%) >10 (22%) 
334 5F-SDB-006 >10 (-3%) >10 (11%) >10 (13%) >10 (-24%) 
335 
SDB-006-N-phenyl-
analog 
>10 (20%) >10 (1%) >10 (9%) >10 (-13%) 
336 APICA >10 (11%) 4.77 ± 1.69 >10 (8%) >10 (44%) 
337 
STS-135 
(5F-APICA) 
>10 (1%) 3.41 ± 0.47 >10 (-2%) >10 (30%) 
339 FUB-AKB-48 >10 (-11%)  (83%) >10 (-27%) (69%) 
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3-Oxycarbonylindoles and -indazoles (B) 
369 NM-2201 >10 (17%) >10 (23%) >10 (-8%) >10 (32%) 
370 FDU-PB-22 >10 (11%) >10 (30%) >10 (30%) >10 (-4%) 
371 3-CAF >10 (26%) >10 (41%) >10 (4%) >10 (10%) 
372 SDB-005 >10 (8%) >10 (23%) >10 (15%) >10 (24%) 
373 5F-SDB-005 >10 (21%) >10 (47%) >10 (21%) >10 (24%) 
374 PB-22 >10 (15%) >10 (-12%) >10 (-18%) >10 (26%) 
375 5F-PB-22 >10 (5%) >10 (-10%) >10 (-5%) >10 (-5%) 
376 FUB-PB-22 >10 (5%) >10 (24%) >10 (15%) >10 (8%) 
377 BB-22 >10 (9%) >10 (34%) >10 (2%) >10 (18%) 
3-Carboxylindoles and -indazoles (C) 
380 THJ018 >10 (6%) 8.20 ± 2.11 >10 (33%) >10 (-5%) 
381 THJ2201 >10 (-1%) >10 (47%) >10 (18%) >10 (21%) 
383 EAM-2201 >10 (-24%) 1.86 ± 0.16 >10 (14%) >10 (4%) 
384 
MAM-2201-4-
fluorpentyl-isomer 
>10 (-41%) 3.07 ± 1.48 n.d n.d 
389 AB001 >10 (-14%) ~10 (56%) >10 (-12%) ~10 (62%) 
390 5F-AB001 >10 (19%) ~10 (48%) >10 (-6%) ~10 (18%) 
391 UR-144 >10 (-5%) 6.70 ± 1.65 >10 (17%) >10 (14%) 
393 
XLR-11-2-
fluorpentyl-isomer 
>10 (-8%) 5.69 ± 1.95 >10 (24%) >10 (29%) 
394 FAB-144 >10 (5%) ~10 (77%) >10 (2%) ~10 (57%) 
395 XLR-12 >10 (-5%) 4.56 ± 1.97 >10 (27%) >10 (13%) 
396 FUB-144 >10 (-3%) ~10 (62%) >10 (-12%) ~10 (74%) 
397 AB005 >10 (16%) >10 (39%) >10 (-38%) >10 (-2%) 
398 
AB005-azepane-
isomer 
>10 (21%) >10 
(18%) 
>10 (11%) >10 (-6%) 
399 A-796,260 >10 (-1%) 14.3 ± 2.5a >10 (20%) >10 (-10%) 
400 A-834,735 >10 (8%) 6.88 ± 1.51a >10 (6%) >10 (6%) 
2-Methyl-3-carboxyindole (D) 
401 M-144 >10 (-5%) ~10 (86%) >10 (-7%) ~10 (67%) 
7-Methoxy-3-amidoindole (E) 
402 MN-25 >10 (-8%) >10 (47%) >10 (-12%) >10 (30%) 
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6.6. Conclusion 
 
In conclusion we determined the binding affinity of a large number of synthetic compounds 
suspected to be constituents of spice herbal blends. Our results confirm that the majority of the 
investigated compounds behave as highly potent CB receptor ligands with affinities in the low 
nanomolar to subnanomolar concentration range. Furthermore we could show that they behave as 
agonists with high efficacy. In an in-silico approach all except for two derivatives from a selected set 
were predicted to cross the blood-brain barrier, and therefore are likely to produce psychoactive 
effects. The main structural variations of the compounds represent typical bioisosteric exchanges 
altering the structure of the compounds in order to circumvent restriction by law, but to retain the 
intended psychoactive effects. Knowledge of classical medicinal chemistry provides in these cases 
powerful strategies to bypass controlled substances. In our study we provide a comprehensive analysis 
of the structure-activity relationships of spice constituents including 41 compounds of previously 
unknown potency and efficacy. The obtained data were compared to those of established CB receptor 
ligands. In the future this may help to predict pharmacological behavior of novel compounds that 
appear on the illicit drug market. 
The compounds were further investigated at the CB receptor-related orphan GPCRs GPR18 and 
GPR55. While no interaction with GPR18 was detected, some derivatives behaved as weak antagonists 
of GPR55. Since knowledge about these newly discovered orphan receptors is still very limited our 
results contribute to a better understanding of their ligands’ structural requirements. Moreover, we 
have identified novel GPR55 antagonists that could be used as starting points for future optimization. 
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7. SUMMARY  
7.1. Cannabinoid and cannabinoid-like receptors 
 
The family of G protein-coupled receptors (GPCRs) represents one of the largest membrane-bound 
protein families, which are targeted by approximately 30% of all approved drugs. However, out of the 
ca. 800 human GPCRs more than 100 receptors remain orphan, i.e. their endogenous agonists have 
not been identified or confirmed yet. Orphan GPCRs likely represent future drug targets. Reliable and 
well-characterized tool compounds are required to study the receptors’ functions and their effects.  
In this study, we developed tool compounds for the orphan receptors GPR18 and GPR55. These 
belong to the δ-branch of the class A subfamily of GPCRs, to which nucleotide- and lipid-activated 
receptors belong among others. GPR18 and GPR55 interact with cannabinoids, although they are 
relatively unrelated to the classical cannabinoid receptors CB1 and CB2. GPR18 can be activated by Δ9-
tetrahydrocannabinol (Δ9-THC). N-arachidonoylglycine (NAGly) has been proposed as an endogenous 
ligand of GPR18, which is, however, controversially discussed in the literature. GPR18 is predominantly 
expressed in cells of the immune system and plays a role in inflammation and pain. GPR55 is more 
widely expressed, activated by lysophosphatidylinositol (LPI), and has been proposed as a potential 
drug target in inflammation, metabolic dysfunctions and neuronal diseases.  
 
7.2. Development of GPR18 and GPR55 antagonists based on an 
imidazothiazinone scaffold 
 
Rempel et al. developed PSB-CB-5 (17), a benzylidene-imidazothiazinone derivative, as the first 
potent GPR18 antagonist with an IC50 value of 0.279 µM determined in β-arrestin recruitment assays. 
However, this compound only showed partial inhibition of the Δ9-THC-induced GPR18 activation and 
may therefore be described as an allosteric antagonist with respect to the agonist Δ9-THC. In this study, 
we varied the substitution pattern of the benzylidene residue either by introducing large lipophilic 
substituents to target GPR18 or by small lipophilic substituents to target GPR55. Furthermore, we 
varied the heterocycle and the position of the substituents at the benzylidene residue. Structure-
activity relationships are summarized in Figure 119. 
 
Compounds with a p-chlorobenzyloxyalkyoxy residue in the meta-position of the benzlidene 
residue with different alkyl chain length were investigated. They proved to fully inhibit the effect of 
Δ9-THC, with compound 79 being the most potent derivative with an IC50 value of 0.650 µM. Some of 
the p-chlorobenzyloxyalkyoxy-substituted derivatives showed ancillary inhibition of GPR55. For 
GPR55, the structure-activity relationships could be extended. Small halogen- and methyl-substituents 
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at the benzylidene residue resulted in increased inhibitory potency. The best GPR55 antagonist of the 
present series was 63 with an IC50 value of 2.93 µM. The developed antagonists displayed high 
selectivity as shown in Figure 120. 
 
Figure 119: Structure-activity relationships of imidazothiazinones as GPR18 and GPR55 
antagonists. 
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Figure 120: Chemical structures and pharmacological data of the most potent imidazothiazinone 
derivatives at human GPR18 and human GPR55. 
 
7.3. Development of potent and selective GPR18 agonists 
 
In order to develop potent and selective agonists for GPR18, we screened a xanthine sublibrary of 
the Pharma-Zentrum Bonn compound library. We discovered compound 182 (Figure 121), originally 
synthesized in the group of Prof. Dr. Katarzyna Kieć-Kononowicz, Jagiellonian University, Cracow, 
Poland, as a potent GPR18 agonist with an EC50 value of 0.556 µM. Compound 182 displays peptide-
like features and consists of an 8-indolylethylaminoxanthine core structure. The compound showed 
high selectivity for GPR18 versus GPR55, CB1 and CB2 receptors.  
The identified scaffold was further optimized in cooperation with the research group of Prof. Kieć-
Kononowicz. Firstly, the third heterocycle was varied and later on completely omitted. Further 
variations were made at the N1 and N7 of the xanthine core structure. However, no substitutions 
except for methyl were tolerated at the N1-position. At the N7-position different substituents with 
varying chain-length were introduced. The most potent compound was a p-chloro-substituted 
derivative, compound 162 (Figure 120). The indole residue turned out to be crucial for GPR18 
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activation. A whole library of compounds with different residues instead of the indole were tested and 
none of them was active at GPR18. Structure-activity relationships are summarized in Figure 122. 
 
Figure 121: Most potent GPR18 agonist of indolylethylaminoxanthine series; efficacy was 
compared to the maximum response of Δ9-THC. 
 
 
Figure 122: Structure-activity relationships of the indolylethylaminoxanthines at GPR18. 
The compounds were tested for their selectivity versus the closely related GPR55 in the same assay 
system and showed no activating or inhibiting activity. They were further investigated at CB1 and CB2 
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receptors in radioligand binding studies. Some compounds showed affinity for the CB2 receptor. The 
most selective compound was 161, which showed no affinity to the CB receptors up to 10 µM, but a 
high potency at GPR18 with an EC50 value of 0.0454 µM. The most potent CB2 receptor ligand within 
this class of compounds was 168 with a Ki value of 0.344 µM. Compound 162 also showed nanomolar 
affinity for the CB2 receptor (Ki = 0.481 µM).  
We further investigated the potencies of the newly discovered agonists at the mouse GPR18. This 
murine orthologue shares a high degree of sequence similarity with the human GPR18. We expressed 
it in the same assay system and tested the agonists at the mouse receptor. Similar potencies were 
observed: the EC50 values of the agonists were slightly, but insignificantly higher at the mouse as 
compared to the human GPR18, while the structure-activity relationship were identical. The lipid-like 
compound N-arachidonoylglycine neither interacted with the mouse nor with the human GPR18 in our 
experiments.  
Concentration-dependent inhibition of Δ9-THC versus compound 182-induced β-arrestin 
recruitment by the antagonist PSB-CB-5 (17) indicated different binding sites for both receptors. The 
antagonist was 40-fold weaker versus compound 182 than versus Δ9-THC. Thus, PSB-CB-5 (17) appears 
to occupy the same binding site as Δ9-THC, which is plausible since both are lipid-like compounds, while 
Δ9-THC and the new indole antagonists probably have different binding sites on GPR18. 
In order to get more insight into the binding sites of GPR18, we performed a molecular modeling 
study. To this end, we used the Rosetta protein design modeling suite in the laboratory of Prof. Dr. 
Jens Meiler at Vanderbilt University, Nashville, TN, USA. Twenty GPCR crystal structures were provided 
as templates together with the human GPR18 sequence resulting in an ensemble of models, which 
were selected by energy scores, clustering and reasonable visual appearance. By subsequent 
optimization the extracellular loops of the receptor models were individually adapted to the proposed 
secondary structure prediction (Figure 123). GPR18 shows the unusual DVILY instead of the conserved 
NPxxY motif found in most other GPCR. The effects of this sequence variation are unknown. The β-
strand prediction for the extracellular loop 2 could not be captured in the loop refinement study, 
although it seemed likely by secondary structure prediction.  
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Figure 123: Homology modeling and docking of GPR18. 
 
An ensemble of well-scoring models from different clusters with reasonable appearance were 
selected for ligand docking. The potent agonist 162 was selected as a ligand. The docking was 
conducted over six rounds, where ligand mobility was decreased in each step. A final ensemble of 
models was selected based on energy scoring and clustering. Out of each cluster the best models were 
evaluated concerning the ligand pose and the interaction profile with the amino acids of the receptor. 
Four different poses deemed reasonable and eleven suggestions for mutagenesis studies were made 
based on the models (Figure 124). 
 
Figure 124: Procedure and results from the docking of compound 162 into the GPR18 homology 
models. 
 
Experiments are in the progress to confirm or discard the proposed agonist-receptor interactions. 
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7.4. Chromen-4-ones as GPR55 agonists 
 
In another subproject, we investigated and optimized a series of chromen-4-one derivative as 
GPR55 ligands (Figure 126). Based on chromen-4ones that had been identified as weak GPR55 
antagonists we performed a number of structural modifications to increase their potency and to 
modulate their functionality. By aliphatic meta-substitution of the 8-benzamido residue, compounds 
with partial agonistic activity were obtained as compared to the full agonist lysophosphatidylinositol 
(LPI). Interestingly, the agonistic properties were lost when the compounds were substituted with an 
aromatic residue (for example, compound 283, Figure 126). By subsequent optimization, we developed 
compound 299, which showed an EC50 value of 0.196 µM and a high efficacy of 86%. The optimized 
compounds proved to be selective versus the phylogenetically most closely related GPR35 and GPR18. 
Compound 299 was 75-fold selective for GPR55 versus the cannabinoid receptors and 8-fold selective 
versus GPR17. Structure-activity relationships are summarized in Figure 125. 
 
Figure 125: Structure-activity relationships for chromen-4-ones as GPR55 agonists. 
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Figure 126: The most potent compounds of the chromen-4-one series. 
 
7.5.  Pharmacological evaluation of synthetic cannabinoids derived from “spice” 
 
In a further subproject we pharmacologically investigated constituents of “Spice”. The abuse of 
synthetic cannabinoids in incenses called ‘spice’ has increased in the last years. Highly potent synthetic 
CB1 agonists that had been published in the scientific literature, were sprayed onto herbal materials 
which are sold as legal highs. These synthetic compounds are psychoactive and cause severe side 
effects up to lethal intoxications. As soon as the structure of a compound, its potential abuse and its 
effects on CB1 receptors are known, these compounds will be restricted by law. The illicit sellers often 
circumvent restrictions by preparing compounds with slightly changed structure.  
In cooperation with the Institute of Forensic Medicine, University of Bonn, we investigated a large 
set of compounds that had been reported to be distributed in herbal blends (“spice”). We determined 
their ability to bind to the CB receptors and also investigated the interaction of selected compounds 
with GPR18 and GPR55.  
Our results confirmed that the majority of the investigated compounds behaved as highly potent 
CB receptor agonists with affinities in the low nanomolar to subnanomolar concentration range 
combined with high efficacy (see Figure 127). The main structural variations of the compounds 
represent typical bioisosteric exchanges altering the structure of the compounds in order to 
circumvent restriction by law, but retaining the intended psychoactive effects. Knowledge of medicinal 
chemistry provides powerful strategies to bypass controlled substances. In our study, we have 
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provided a comprehensive analysis of the structure-activity relationships of spice constituents 
including 41 compounds of previously unknown potency and efficacy. The obtained data were 
compared to those of established CB receptor ligands. In the future, this may help to predict 
pharmacological behavior of novel compounds that appear on the illicit drug market. 
The compounds were further investigated at the CB receptor-related orphan GPCRs GPR18 and 
GPR55. While no interaction with GPR18 was detected, some derivatives behaved as weak antagonists 
of GPR55. Since knowledge about these newly discovered orphan receptors is still very limited our 
results contribute to a better understanding of their ligands’ structural requirements. Moreover we 
have identified novel GPR55 antagonists that could be used as starting points for future optimization. 
 
Figure 127: Chemical structure of the most potent CB receptor ligand MDMB-FUBINACA (348) 
and EAM-2201 (383), the most potent GPR55 antagonist. 
 
7.6. Conclusion 
 
The discovered structure-activity relationships of several classes of compounds at cannabinoid and 
cannabinoid-like orphan GPCRs, namely GPR18 and GPR55, the new optimized and characterized tool 
compounds, and performed molecular modeling studies will be highly useful since they will allow 
studies towards validation of GPR18 and GPR55 as drug targets. Extensive studies on spice constituents 
will help to limit their illegal use.  
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8. EXPERIMENTAL METHODS 
8.1.  Cell culture  
8.1.1. Cell culture 
 
Cells were cultured in their respective medium in incubators, maintaining 37° and 5% or 10% CO2. 
They were passaged under a laminar air flow when reaching a confluence of 80-90% up to 35 passages. 
To remove cells from cell culture flask, initial medium was removed and cells were rinsed with 10 ml 
PBS buffer. After removing this buffer, cells were treated with 3 ml trypsin/EDTA solution (for 175 cm2 
tissue culture flasks, 1.5 ml for 75 cm2 and 1 ml for 25 cm²) for up to five minutes at 37° degrees. When 
cells were detached, the reaction was stopped by adding their respective medium up to 10 ml. Cells 
were resuspended by pipetting and then split into prepared cell culture flask.  
 
8.1.2. Thawing and freezing of cells 
 
Cells were thawed from kryo-stocks (-80°/-150°/nitrogen stored) by warming them, until the 
medium could be removed from the kryo-stocks directly into cell culture medium.  
To produce kryo stocks, cells were removed as described in 8.1.1. Detached cells were transferred 
into prepared falcon tubes. They were centrifuged for 5 minutes at 1200 rpm to spin down cell 
material. Subsequently, the supernatant was removed and cells were resuspended in FCS containing 
10% DMSO (microbiological grade) and transferred into prepared kryo stocks. Initially, they were 
stored in freezing devices in a -80° freezer to ensure moderate freezing rates. On the next day, they 
were transferred to long time storage (-80° freezer, -150° freezer or nitrogen tank).  
 
8.1.3. Membrane preparations 
 
For membrane preparations, cell suspensions were split into petri dishes (75 cm2) in a total volume 
of 20 ml cell culture medium and grown, until the density reached >80%. The medium was removed 
and the petri dish rinsed with 10 ml PBS buffer. The PBS buffer was discarded and petri dishes were 
frozen at -20° degrees. Upon thawing, 1 ml dissociation buffer (5 mM Tris, 2 mM NaEDTA, pH 7.4) was 
transferred on every dish. Cells were removed and collected, and always kept on ice. The total amount 
of cell suspension was homogenized with an Ultra-Turrax at maximum speed. After this, the 
suspension was further treated with a potter at maximum speed. This suspension was transferred into 
centrifuge tubes and centrifuged for 10 min and 1000g at 4° in a Beckman centrifuge (Beckman-
Coulter, Brea, CA, USA). The supernatant was collected, the pellet discarded. The supernatant was 
further centrifuged with 48,300g for 1h at 4°. The supernatant was discarded and the pellet was 
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resuspended in radioligand binding assay wash buffer (50 mM Tris, pH 7.4) in an amount that 
corresponded to 0.1 ml per initial dish. All pellets were collected and homogenized, transferred into 
Eppendorf tubes and stored in a -80° freezer.  
 
8.1.4. Protein determination in membrane preparations using the Lowry assay 
 
For determining the protein amount, a stock solution of BSA (1 mg/ml in 50 mM Tris, pH 7.4) was 
used for calibration. The solution was diluted in 50 mM Tris, pH 7.4 to the following concentrations: 
50, 100, 200, 300, 400 and 500 µg/ml. The test solution was diluted 1:10, 1:20 and 1:50. As a control 
50 mM Tris buffer, pH 7.4 was used. 200 µl of the test solutions or the calibration dilutions were initially 
disposed in reaction tubes in duplicates. A fresh solution of copper sulfate was prepared by mixing 50 
parts of a 2% Na2CO3 solution in 0.1 N NaOH and 1 part of a CuSO4*5 H2O 0.5%, sodium tartrate 1% in 
aqua bidest. 1000 µl of this solution was transferred to each reaction tube, mixed by vortexing and 
incubated for 20 min at room temperature. 100 µl of the Folin’s Ciocalteau Phenol Reagent Working 
Solution (1:5 solution of Folin’s Reagent in aqua bidest.) were transferred to each reaction tube, mixed 
by vortexing and incubated for 30 min at room temperature. The content of each reagent tube was 
transferred to cuvettes, suitable for determination of absorption at 550 nm. The absorption of the 
control was put to zero in a photometer from Beckman, Brea, CA, USA (pre-warmed for 30 min). 
Subsequently, all following dilutions were measured and the absorptions determined. From the 
calibration with BSA, a linear equation was obtained for calculating the amount of protein in the 
membrane preparartions.312 
 
8.2. Pharmacological assays 
8.2.1. Preparation of cAMP binding protein  
 
cAMP binding protein (proteinkinase A) was extracted from bovine adrenals, as described by 
Nordstedt et al.313 The adrenals were transferred to 4° cold buffer (100 mM Tris*HCl, 250 mM NaCl, 
10 mM NaEDTA, 0.25 M sucrose and 0.1% mercaptoethanol, pH 7.4) or stored frozen in -80° until the 
cAMP binding protein was prepared. Adrenals were cleared of visual fat and other tissue with a knife 
or a scalpel and kept on ice or in ice-cold buffer. Then, the adrenal cortex was divided from the adrenal 
mark as complete as possible. Hence, the slices were cut into small pieces, covered with buffer and 
crushed with an Ultra-Turrax in varying speeds. The mixture was transferred to a potter and processed 
at varying speeds. The suspension was filtered over mull with a water-jet vacuum pump to separate 
tissue pieces and fat from the flow-through. The whole amount of liquid was divided in centrifuge 
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tubes and spinned for 1 h at 30.000g and 4°. The pellet was discarded and the supernatant was 
aliquoted in 2 ml tubes and stored at -20° (ready-to be used stocks), or at -80° (long-time storage).  
 
8.2.2. cAMP assay 
 
Inhibition of adenylate cyclase activity was determined in Chinese Hamster Ovary (CHO) cells stably 
expressing the CB1 or the CB2 receptor subtype, respectively, using a competition binding assay for 
cAMP, adapted from the procedure described by Nordstedt et al.313 Cells were seeded into a 24-well 
plate at a density of 200 000 cells/well 24 h before performing the assay. After the incubation, the cells 
were washed with Hank’s buffered saline solution (HBSS) consisting of NaCl (13 mM), HEPES (20 mM), 
glucose (5.5 mM), KCl (5.4 mM), NaHCO3 (4.2 mM), CaCl2 × 2 H2O (1.25 mM), MgSO4 (0.8 mM), MgCl2 
(1 mM), KH2PO4 (0.44 mM), and Na2HPO4 (0.34 mM) dissolved in deionized, autoclaved water. After 
addition of 190 μL of HBSS per well, cells were incubated for 2 h at 37°C. After this period of time, 20 
µl of the phosphodiesterase inhibitor Ro-20-1724 (4-(3-butoxy-4-methoxybenzyl)-2-imodazolidinone), 
final concentration 40 μM, dissolved in HBSS, was added and the suspension incubated for 10 min. 15 
µl of test compound was diluted in HBSS containing 10% dimethylsulfoxide (DMSO) to the desired 
concentration and added to the suspension. After 5 min of incubation 15 µl forskolin (final 
concentration: 10 μM), prepared in HBSS containing 10% DMSO, were added to each well. Antagonists 
were added at the desired concentration 20 min before adding the agonist. The final DMSO 
concentration was 1.9%. The suspension was incubated for 10 min after the addition of Ro-20-1724, 
again for 5 min after the addition of test compound, and for another 15 min after adding forskolin. 
cAMP accumulation was stopped by removing the supernatant from the cell suspension and 
subsequently lyzing the cells with 500 μL of hot lysis buffer (100 °C; 4 mM EDTA, 0.01% Triton X-100). 
Aliquots of 50 μL of cell suspension were transferred to 2.5 mL tubes, 30 μL of [3H]cAMP (3 nM) and 
40 μL of cAMP-binding protein (50 µg per well) were added, followed by 1 h of incubation on ice. The 
cAMP binding protein was obtained from bovine adrenal cortex as described above. Bound and free 
radioligand were separated by rapid filtration through GF/B glass fiber filters using a Brandel 48-
channel cell harvester (Brandel, Gaithersburg, MD). Radioactivity on the filters was determined in a 
liquid scintillation counter (TRICARB 2900TR, Packard/Perkin-Elmer) after 6 h of preincubation with 3 
mL of scintillation cocktail (LumaSafeplus, Perkin-Elmer). Data were obtained from three independent 
experiments, performed in duplicates. 
 
8.2.3. Radioligand binding studies at cannabinoid receptors 
 
Competition binding assays were performed using the CB agonist radioligand [3H](−)-cis-3-[2-
hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)¬cyclohexanol ([3H]CP55,940, final 
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concentration 0.1 nM). As a source for human CB1 and CB2 receptors membrane preparations of 
Chinese hamster ovary (CHO) cells stably expressing the respective receptor subtype were used (30 μg 
of protein/well for CB1 and 8 µg of protein/well for CB2-receptor preparations) as described above. 
Stock solutions of the test compound were prepared in DMSO. The final DMSO concentration in the 
assay was 2.5%. After addition of 15 μL of the test compound in DMSO, 60 μL of [3H]CP55,940 solution 
in assay buffer, and 60 μL of membrane preparation to 465 μL of assay buffer (50 mM TRIS, 3 mM 
MgCl2, 0.1% BSA, pH 7.4), the suspension was incubated for 2h at room temperature. Total binding 
was determined by adding DMSO without test compound. Nonspecific binding was determined in the 
presence of 10 μM of unlabeled CP55,940. Incubation was terminated by rapid filtration through GF/C 
glass fiber filters presoaked for 0.5 h with 0.3% aq. polyethyleneimine solution, using a Brandel 96-
channel cell harvester (Brandel, Gaithersburg, MD). Filters were washed three times with ice-cold 
washing buffer (50 mM TRIS, 0.1% BSA, pH 7.4) and then dried for 1.5 h at 50 °C. Radioactivity on the 
filters was determined in a liquid scintillation counter (Topcount NXT, Packard/Perkin-Elmer) after 10 
h of preincubation with 50 µl of scintillation cocktail (Multiscint 25, Perkin-Elmer). Data were obtained 
in three independent experiments, performed in duplicates. Data were analyzed using GraphPad Prism 
Version 4.02 (San Diego, CA, USA). For the calculation of Ki values the Cheng-Prusoff equation314 and a 
KD value of 2.4 nM ([3H]CP55,940 at CB1) and 0.7 nM ([3H]CP55,940 at CB2) were used.315 
 
8.2.4. β-Arrestin recruitment assay (PathHunter®) 
 
In white 96-well-plates, 20.000 cells per well, stably expressing GPR18 or GPR55 and prolink1, were 
seeded in 90 µl medium (Opti-Mem, 2% FCS, 100 U/ml Penicillin, 100 µg/ml Streptomycin, 800 µg/ml 
Geneticin and 300 µg Hygromycin) and incubated for 24h at 37°C and 5-10% CO2. Antagonist and 
agonists (stocks in 10 mM DMSO were diluted in PBS containing 0.1% BSA, until the final concentration 
of DSMO is 1% and the final concentration of screens was 10 µM). Antagonists were added to the wells 
in an amount of 5 µl, incubated 60 min at 37°, than agonist was added in an amount of 5 µl and 
incubated for 90 min. The final assay volume was 100 µl. 50 µl detection reagent per well (for GPR18 
by mixing 220 µl of Galacton-StaR® (2 mM), with 1000 µl the luminescence enhancer Emerald-II™ and 
a lysis buffer consisting of 5 mM K2HPO4, 5 mM KH2PO4, 150 mM NaCl, 10 mM MgAc2 and 2% Chaps, 
pH7,4; and for GPR55 by mixing the chemiluminescent substrate Galacton-StarR® (2 mM), with the 
luminescence enhancer Emerald-II™ and a lysis buffer (10 mM TRIS, 1 mM EDTA, 100 mM NaCl, 5 mM 
MgCl2, 1 % Triton-X; pH 8) in a ratio of 1:5:19) were added and incubated for 60 min at room 
temperature. After that luminescence signals were counted in a TopCount NXT, Packard, Perkin-Elmer, 
in one second per well. For the human GPR18, Δ9-THC as agonist was used in concentration of 10 µM, 
and later on the agonist 162 in a concentration of 0.1 µM. As maximum response of the respective 
agonist Δ9-THC was used at 30 µM and compound 162 at 1 µM. For the human GPR55, LPI was used as 
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agonist in a concentration of 1 µM, as maximal response at 10 µM. For the mouse GPR18, compound 
162 was used at 0.3 µM and 3 µM to obtain the maximal response.  
 
8.2.5. Radioligand binding studies at GABAA receptor channels 
 
Test compounds were diluted in DMSO to obtain a final test concentration of 10 µM in the assay. 
For unspecific binding diazepam was used in a concentration 10 µM, for determining total binding 
DMSO was added. As the assay did not tolerate a DMSO concentration higher than 1%, 10 µl of the 
DMSO dilutions were transferred onto 790 µl of assay buffer (50 mM Tris, pH 7.4). As radioligand 
[3H]diazepam in a concentration of 2 nM and rat cortex preparations with a protein amount of 100 µg 
per well were added to the assay buffer each in 100 µl of assay buffer. After 1h of incubation (shaking 
on ice), the assay was filtered through a 48-well harvester (Brandel, Gaithersburg, MD, USA) using 
GF/B-filters and washed three times with 4°C cold Tris 50 mM buffer, pH 7.4. Filters were then 
transferred to scintillation vials, soaked in 2 ml scintillation cocktail (LumaSafePlus, Perkin-Elmer, 
Waltham, MA, USA) and counted after 6h in a luminescence counter (TRICARB 2900 TR, Canberra 
Packard, Perkin-Elmer) for 1 min.316 
For the calculation of Ki values the Cheng –Prusoff equation314 and a Kd of 4 nM for diazepam were 
used.  
 
8.2.6. Data Analysis 
 
All data were processed with Microsoft Excel (2007, 2010 and 2013) and further analyzed using 
Prism 4.02 or Prism 5.01 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com.  
 
8.3. Molecular biology 
8.3.1. Production of competent bacteria 
 
Untransformed Top10 E. coli bacteria were cultivated in 4 ml of LB-medium (without antibiotics) at 
37° and 220 rpm overnight. They were transferred into 40 ml LB-medium on the next day and 
incubated for 40 min. Optical density was controlled, until it reached 0.5. The bacterial suspension was 
then centrifuged for 20 min at 1700g and 4°C. The supernatant was removed and the cells resuspended 
in 20 ml of an ice-cold 0.1 mM CaCl2 solution. They were incubated for 30 min on ice. After that, they 
were centrifuged again for 20 min at 1700g and 4°. The supernatant was removed again and the cells 
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resuspended in 2 ml of ice-cold 0.1 mM CaCl2 solution. 0.5 ml glycerol was added and the suspension 
was aliquoted (100 µl each) and stored at -80°C.  
 
8.3.2. Transformation of competent bacteria 
 
The competent bacteria were removed from the -80°C freezer and stored on ice for 30 min. 10 ng 
of the plasmid of interest were gently mixed into the suspension with a tip and everything was 
incubated for further 30 min on ice. After that, the bacterial suspension underwent a heat shock (either 
in a thermomixer plate or in a water bath at 37°C for 2 min). Subsequently, they were stored on ice for 
further 2 min. Then, 200 µl of LB-medium was added and the culture was incubated at 37°C and 220 
rpm for one hour. After that, the suspension was added to an agar-plate containing the corresponding 
antibiotic for selection and was spread with a Drigalski-spatula. After air drying, the agar plate was 
stored in an incubator at 37°C upside down overnight.  
 
8.3.3. Single colony picking and growth 
 
From the agar plate, one colony was picked with a pipette tip and transferred to 4 ml of the 
corresponding liquid bacterial culture medium (LB-medium with selection antibiotics). The tubes were 
incubated over night (or 18 h) in a 37° incubator in shaking mode (220 rpm). For DNA mini-preparations 
3 ml of the medium were used, for larger scales, the bacterial colony were transferred into a 150 ml 
LB-medium containing heat-sterilized Erlenmeyer flask and shaken overnight.  
 
8.3.4. Glycerin cultures for long time storage 
 
For long time storage, the bacterial culture of interest in their overnight culture medium was gently 
mixed with glycerin (5:1) and immediately deep-frozen at -20°C and for long-time storage at -80°C.  
 
8.3.5.  Purification of plasmid-DNA (Mini-prep, Midi-prep) 
 
The ZR plasmid Miniprep™ - Classic kit (Zymo Research Corporation, Irvine, CA, USA) was used for 
plasmid purification according to the instructions of the supplier. In the last step, the DNA was eluted 
with 30 µl purified water.  
The PureLink® HiPure Plasmid Filter Midiprep Kit (Invivogen, ThermoScientific, Waltham, MA, USA) was 
used to obtain larger amounts of DNA according to the instructions of the supplier. Only the last 
centrifugation step was prolonged to 30 min.  
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8.3.6. Gel electrophoresis of DNA 
 
To verify DNA length and purity, the plasmid DNA was assessed via gel electrophoresis on an 
agarose gel (1%; 0,25 mg agarose were dissolved in 25 ml TAE buffer (Tris-acetat-EDTA-buffer) by 
carefully heating in a microwave, then 1.75 µl Gel-Red™ were added). For cooling, the gel was 
transferred on a gel trail, where a comb was put in the liquid gel. The samples were prepared by mixing 
2 µl 6x loading dye, the volume of DNA necessary for detection, normally, 1-3 µl. Then purified water 
was added to a total volume of 12 µl. The gel was posed in the electrophoresis chamber, covered with 
TAE-buffer and loaded with 10 µl of the samples, along with a DNA marker (λ-marker). After applying 
a voltage of 105 V, the gel was run for 30 -60 minutes.  
 
8.3.7. DNA purification out of a gel 
 
With the Zymoclean™ Gel DNA Recovery Kit (Zymo Research Corporation, Irvine, CA, USA), the DNA 
was purified according to the instructions of the supplier.  
 
8.3.8. Sequencing  
 
The sequencing of plasmid DNA and PCR products was carried out by the biotech company GATC. 
Therefore, up to 1000 ng of the DNA in Aqua bidest. and if necessary primer suitable for sequencing 
were sent to GATC. The data analysis was done with Chromas Lite 2.01. 
 
8.3.9. Restriction digest of plasmid DNA 
 
Restriction was performed with 0.5 µl of each of the corresponding restriction enzymes (for the 
prolink1 and pBlueskripthGPR18 digest HindIII and NheI) with 1 µl reaction buffer (CutSmart®), the 
purified plasmid DNA (not less than 50 ng) and filled with sterile H2O up to a total volume of 10 µl. The 
mixture was incubated for one hour at 37° in a heat block. In controls, samples are prepared lacking 
one of the restriction enzyme and also one lacking the plasmid DNA.  
 
8.3.10. Ligation  
 
For the ligation, at least 50 ng (but possibly more) cut plasmid DNA from step 8.3.9 and at least 150 
ng of the insert DNA piece (this ratio can be adapted depending on performance and molecular weight) 
were put together with 1 µl of ligation buffer, 0.5 µl of T4-ligase and filled up with sterile H2O up to 10 
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µl. As control, the ligation was performed lacking the insert and further lacking the enzyme and the 
insert.  
 
8.3.11. Transfection of mammalian cells with Lipofectamine® 
 
The parent cell line was grown in a minimum of three 25 cm2 tissue culture flasks, till the cells 
reached a density of 80%. On the day of transfection, 4 hours prior to the transfection procedure, the 
medium was removed and the cells were incubated in their normal medium and 10% FCS, without any 
antibiotics. The transfection was carried out with Lipofectamine® according to the instructions of the 
supplier. 10 µl Lipofectamine® were gently mixed in 620 µl F12 Nutri-Mix (without anything) for 5 min. 
The volume containing 10 µg of the plasmid DNA was filled-up to 625 µl total volume with F-12 Nutri-
Mix (without anything). Both solutions were gently mixed and incubated for 20 min. After this time, 
the solution was transferred to the respective tissue culture flask. As controls, in a second tissue 
culture flask the procedure above was performed without adding DNA. As further control, one flask 
was not treated at all. On the next day, the medium was removed and exchanged for the medium of 
the untransfected cells. One day later, the medium was exchanged once more to the selection 
medium. The third control was not exchanged, as it was necessary for controlling transfected versus 
untransfected cells in the pharmacological assay. Whenever the cells reached confluence, they were 
transferred to a 75 cm2 flask. After some days of incubation with selection medium the untransfected 
cells (second control) were dead. When the transfected cells were confluent, kryo-stocks were made 
and pharmacological assays could be performed with untransfected cells as control.  
This procedure was used to produce the CHO prolink1 mGPR18 cell line. Here, the parent cell line 
was already stably expressing a β-arrestin construct (selection on 0.3 mg/ml hygromycin B) and was 
further transfected with a pCMV-prolink1 mGPR18 vector (selection on 0.8 mg/ml G418).  
 
8.3.12. Monoclone selection 
 
For monoclone selection, the polyclonal mixture was removed from the tissue culture flask and 
cells were counted and further passaged, so that in 100 µl one cell could be expected. The suspension 
was transferred to a flat bottom adherent cell suitable 96-well plate (100 µl each) and incubated for 
some days. Cell growth was controlled regularly. When growth was detected, every well was controlled 
and only those were passaged to a 25 cm2 flask, where exclusively one colony could be detected. Clones 
were cultured until they filled a 75 cm2 tissue culture flask and then seeded according to the protocol 
of the assay. Maximum response to a standard agonist was measured and compared. The clones with 
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the highest differences in baseline to maximum response and a suitable background were chosen and 
retested. After the retest, one clone was chosen to be used for further assays.  
 
8.3.13.  Determining DNA concentration 
 
The DNA concentration was either estimated by comparing the results from the gel electrophoresis 
samples to the λ-ladder, which shows characteristic bands of defined DNA amounts, or it was 
determined using 1 µl of the DNA solution with a nano-drop instrument (Colibri, Titertek-Berthold, 
Pfortzheim, Germany). 
 
8.3.14. Used DNA sequence 
 
For the cloning of the mouse GPR18, a pBluescript-mGPR18 sequence was ordered, containing 
restriction sites for NheI and HindIII and no stop-codon, with the following sequence:  
>mGPR18 
ggtaccgctagcaccATGGCCACCCTGAGCAATCACAACCAGCTTGATCTTTCTAATGGCTCACACCC
AGAGGAATACAAAATCGCAGCCCTAGTCTTCTACAGCTGCATCTTCCTGATTGGGCTGTTTGTTAATG
TCACTGCGTTGTGGGTTTTCAGCTGTACGACCAAGAAAAGAACCACAGTGACCATCTACATGATGAAC
GTTGCACTACTGGACCTCGTATTTATACTCAGTCTGCCCTTTCGGATGTTTTACTATGCAAAAGGCGA
GTGGCCATTTGGAGAGTACTTCTGCCACATTCTTGGGGCCCTGGTGGTGTTTTACCCAAGCCTCGCTC
TGTGGCTTCTTGCTTTCATTAGTGCTGACAGATACATGGCCATCGTACAGCCAAAATATGCCAAGGAG
CTGAAGAACACCGGCAAGGCCGTGCTTGCGTGTGGGGGGGTCTGGGTAATGACCCTGACCACCACTGT
CCCCCTGCTACTGCTCTACGAAGACCCAGACAAGGCCTCCTCCCCGGCCACCTGCCTGAAGATCTCCG
ACATCACCCACTTAAAAGCTGTCAACGTGCTCAACTTCACGCGACTCATATTTTTCTTCCTGATCCCT
TTGTTCATCATGATCGGGTGCTACGTGGTCATCATTCACAGTCTCCTCCGAGGGCAGACGTCTAAGCT
GAAGCCCAAGGTCAAGGAGAAGTCCATACGGATCATCATGACCCTCCTGCTGCAGGTGCTCGTCTGCT
TCGTGCCCTTCCACATCTGCTTTGCCGTCCTGATGCTACAAGGACAGGAGAACAGCTATAGCCCCTGG
GGAGCCTTCACCACCTTCCTCATGAACCTCAGCACCTGTCTCGATGTAGTCCTCTACTACATCGTTTC
CAAACAGTTCCAGGCTCGAGTCATCAGCGTCATGCTGTACCGCAATTACCTTCGCAGTGTTCGCAGAA
AAAGTGTCCGATCGGGCAGTTTACGGTCACTTAGCAACATGAACAGTGAGATGCTTtcaagcttaTGA
gaattc 
 
8.4. LC/MS analyses 
 
The purities of specific products were determined by ESI-mass spectra obtained on an LC/MS 
instrument (Applied Biosystems API 2000 LCMS/MS, HPLC Agilent 1100) using the following procedure: 
the compounds were diluted to 10 mM or 1 mM in DMSO. Then, 5-10 μL of the sample were injected 
into a HPLC column (Macherey-Nagel Nucleodur 3 μ C18, 50 mm × 2.00 mm). Elution was performed 
with a gradient of water/acetonitrile (containing 2 mM ammonium acetate) from 90:10 to 0:100 for 
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20 min at a flow rate of 300 μL/min, starting the gradient after 10 min. UV absorption was detected 
from 200 to 950 nm using a diode array detector.257  
8.5. Chemicals, materials, devices and software 
 
 
Table 47: Materials. 
Materials  
Safe Seal® microtubes 1.5 and 5 ml Eppendorf AG, Hamburg, Germany 
Tips, nonsterile  Sarstedt, Nümbrecht, Germany 
Ri-tips® Ritter GmbH Medical, Schwabmünchen, 
Germany 
Disposable pipettes 1, 5, 10 and 25 ml Sarstedt, Nümbrecht, Germany 
Megablocks VWR International, Darmstadt, Germany 
Falcons 15 ml and 50 ml Corning Science Tanaulipas, Mexiko 
GF/B filters Whatman GE Healthcare, Little Chalfont, UK 
GF/C filters  Perkin-Elmer, Waltham, MA, USA 
Tissue culture flasks (25 cm2, 75 cm2 and 175 
cm2) 
Sarstedt, Nümbrecht, Germany 
NUNClon™ Delta Surface Thermo Fisher Scientific, Rosenkilde, Denmark 
TipOne filter tips sterile 10, 100 and 1000 μl STARLAB, Hamburg, Germany 
Reservoirs, nonsterile 50 ml VWR International, Darmstadt, Germany 
Rotilabo® microtest plates, V profile, 96 Well Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Reservoirs, sterile 50 ml VWR International, Darmstadt, Germany 
Sterile, disposable pipettes 1, 5, 10 and 25 ml Sarstedt, Nümbrecht, Germany 
Scinti-Vials, 3.5 ml, 10 ml VWR International, Darmstadt, Germany; 
Perkin-Elmer, Waltham, MA, USA 
Biozym® steril aerosol pipette tips Labcon, Petatunia, CA, USA 
Cuvettes for UV-Vis photometry Ratiolab, Dreieich, Germany 
Kryo vials Sarstedt, Nümbrecht, Germany 
Disposable petri-dishes (25 cm2) and sterile 
disposable petri-dishes  
Sarstedt, Nümbrecht, Germany 
Bacterial tubes, 4 ml Sarstedt, Nümbrecht, Germany 
 
 
Table 48: Chemicals. 
Chemicals  
Agarose TE Biozym Scientific GmbH, Hessisch-Oldendorf, 
Germany 
Tris Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
Glucose Sigma Aldrich Corp., St. Louis, MO, USA 
Sodium EDTA (ethylenediaminetetraacetic acid) Sigma Aldrich Corp., St. Louis, MO, USA 
NaCl Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
MgCl2 Alfa Aesar, Ward Hill, MA, USA 
Triton X-100 Sigma Aldrich Corp., St. Louis, MO, USA 
Cut-Smart New England Biolabs, Ipswich, MA, USA 
λ-DNA/EcoRI/Hind III New England Biolabs, Ipswich, MA, USA 
K2HPO4 Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
KH2PO4 Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
Magnesiumacetata (MgAc2) Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
Chaps  
Tropix® Emerald II Applied Biosystems, Thermo Fisher Scientific 
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Galacton StaR® Applied Biosystems, Thermo Fisher Scientific 
Lipofectamie™ Thermo Fisher Scientific, Waltham, MA, USA 
NaOH Fluka, Sigma Aldrich Corp., St. Louis, MO, USA 
Na-Tartrat Riedel-de-Haen, Seelze, Germany 
LB-medium Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
LB-agar Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
HEPES Sigma Aldrich Corp., St. Louis, MO, USA 
Na-Ampicillin Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
Glycerol Sigma Aldrich Corp., St. Louis, MO, USA,  
methyleneparabene Acros Organics, Thermo Fisher Scientific, 
Waltham, MA, USA 
Kanamycinsulfat Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
DMSO, micobiological grade Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
Polyethyleneimine 50% Fluka, Sigma Aldrich Corp., St. Louis, MO, USA 
BSA (bovine serum albumin) Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
FCS (fetal calf serum) Sigma Aldrich Corp., St. Louis, MO, USA 
Trypsin PANBiotech GmbH, Aidenbach, Germany 
NheI-HF, restriction enzyme New England Biolabs, Ipswich, MA, USA 
HindIII-HF, restriction enzyme New England Biolabs, Ipswich, MA, USA 
Hygromycin  InvivoGen, San Diego, CA, USA 
PenStrep (Penicillin-streptomycin 10 000 I.E./ml, 
10 mg/ml) 
Gibco®, Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA 
Ultraglutamin / L-Glutamin  Gibco®, Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA 
G418 (Geneticin) 100 mg/ml 
and Paneticin G418 100 mg/ml 
Invitrogen, Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA and PANBiotech 
GmbH, Aidenbach, Germany 
F-12 (Nutri-Mix) Gibco®, Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA 
DMEM/F-12 Gibco®, Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA 
DMEM (Dulbecco’s Modified Eagle Medium) Gibco®, Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA 
Opti-MEM Gibco®, Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA 
CaCl2 Sigma Aldrich Corp., St. Louis, MO, USA 
DMSO AppliChem GmbH, Darmstadt, Germany 
Hydrochloric Acid 37% Carl Roth GmbH & Co. KG, Karlsruhe, Gemany 
LumaSafe™ Perkin-Elmer, Waltham, MA, USA 
MicroScint 25™ Perkin-Elmer, Waltham, MA, USA 
mercaptoethanol AppliChem, Damstadt, Germany 
Ethanol, pure Sigma Aldrich Corp., St. Louis, MO, USA 
 
Table 49: Devices and instruments. 
Devices  
Eppendorf pipette Research plus  Eppendorf AG, Hamburg, Germany 
Biometra® Thermocycler Biometra GmbH, Göttingen, Germany 
Hettich centrifuge for tubes Hettich, Tuttlingen, Germany 
UV/Vis spectrometer Beckman, Brea, CA, USA 
Hettich centrifuge for falcons Hettich, Tuttlingen, Germany 
Beckman centrifuge Avanti J-20 I Beckman, Brea, CA, USA 
Tricarb 2900TR, luminescence Counter Perkin-Elmer, Waltham, MA, USA 
Topcount NXT  Perkin-Elmer, Waltham, MA, USA 
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Brandel Harvester 96 Brandel, Gaithersberg, MD, USA 
Brandel Harvester 48 Brandel, Gaithersberg, MD, USA 
UltraTurrax IKA®-Werke GmbH & Co. KG, Staufen, Germany 
Potter Büchi, Flawil, Switzerland 
Shaker Thermostat Elmi, Riga, Latvia. 
Vortexer  IKA®-Werke GmbH & Co. KG, Staufen, Germany 
Accu-Jet® pipetting controller Brand, Wertheim, Germany 
Analytical balance 440-47N (max. 2000 g) Kern & Sohn GmbH, Balingen-Frommern, 
Germany 
Analytical balance CP225D Sartorius, Göttingen, Germany 
Axiovert 25 microscope Carl Zeiss AG, Oberkochen, Germany 
Neubauer Counting chamber 10 mm2/ 
0.0025 mm2 
Paul Marienfeld GmbH & Co. KG, Lauda 
Königshofen, Germany 
Eppendorf Multipette® plus  Eppendorf AG, Hamburg, Germany 
NUNC® BIOFLOW workbench Nunc GmbH & Co. KG, Langenselbold, Germany 
NUNC® Safe flow 1.2 workbench  Nunc GmbH & Co. KG, Langenselbold, Germany 
Ultrasonic bath Bandelin Sonorex Bandelin, Berlin, Germany 
Systec 3850 ELV autoclave  Systec, Wettenberg, Germany 
pH-Meter Mettler-Toledo, Columbus, OH, USA 
Rotofix 32 centrifuge  Hettich, Tuttlingen, Germany 
 
Compounds were stored at 4° in 10 mM solution in DMSO. In exception, they were stored at -20° 
due to a lack of stability, or solutions were made in 1 mM due to a lack of solubility in DMSO. 
Compounds were diluted in DMSO. For cell assays, the last solution step was performed in the 
according assay buffer.  
Table 50: Compounds 
Compounds  
LPI Sigma Aldrich Corp., St. Louis, MO, USA 
Δ9-THC (as Dronabinol) Bionorica, Neumarkt in der Oberpflaz, Germany 
Ro-20-1724 Sigma Aldrich Corp., St. Louis, MO, USA 
Forskolin Enzo Biochem Inc., Farmingsdale, NY, USA 
CP55,940 Sigma Aldrich Corp., St. Louis, MO, USA 
[3H]CP55,940 ARC American radiolabeled chemicals. St. Louis, 
MO, USA 
[3H]cAMP Perkin-Elemer, Waltham, MA, USA 
[3H]Diazepame Perkin-Elemer, Waltham, MA, USA 
CB-compounds Synthesized by the group of Professor 
Katarzyna Kiec-Kononowicz 
MZ and KD compounds Synthesized by the group of Professor 
Katarzyna Kiec-Kononowicz 
O-1918 Tocris Bioscience, Bristol, UK 
abn-CBD Tocris Bioscience, Bristol, UK 
O-1602 Tocris Bioscience, Bristol, UK 
Cannabidiol (CBD) Tocris Bioscience, Bristol, UK 
Xanthine sublibrary  PharmaZentrum Bonn, Prof. Christa E. Müller, 
Bonn, Germany 
THV-compounds Synthezised by The Hung Vu, lab of Prof. Christa 
E. Müller, Bonn, Germany 
AF compounds Synthezised by Alexander Fuchs, lab of Prof. 
Christa E. Müller, Bonn, Germany 
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Stemphol, epipyrone, 4-butyl-3,5-dihydroxy-
benzoic acid, coriolide 
Supplied by the group of Prof. Gabriele König, 
Bonn, Germany 
RmF compounds Supplied by Dr. Mahmoud Elsebai, Oulu, Finland 
SZ compounds Synthesized by the group of Prof. Stefan Bräse, 
Karlsruhe, Germany 
 
 
8.6. Computational methods 
 
Two main procedures were employed in this computational approach. With comparative modeling 
using the Rosetta protein design software suite, mainly its applications RosettaCM, homology models 
were built. In the second step small molecule docking was performed using RosettaLigand. The 
evaluation of all computational work was done by using the BioChemicalLibrary (BCL). Note that every 
command documented here was constructed for the environment it was used in and refers to the used 
data paths. In other systems with differently organized file paths the command has to be changed 
accordingly. Further, in the depicted options files some options have been commented out by a “#” -  
but as this options have been used in some other steps, they are also written down here. 
 
8.6.1. Alignment 
 
The alignment to suitable protein sequences was done based on the PDB search of BLAST from 
NCBI. Main criteria were sequence homology, e-value, resolution of crystal structures and 
conformation of the crystal structure. 20 structures were used as templates for the comparative 
modeling approach. A preliminary alignment was done with ClustalOmega, EMBL-EBI.317; 318 The 
alignment was transferred to Excel, where it was manually adapted for each hybridization step and 
according to the sequence part that was build.  
 
8.6.2. Threading 
 
In this step, the aligned sequences wee used to give every amino acid the coordinates of the aligned 
template amino acid. To use the basic alignment for this procedure, it had to be transferred into a so-
called grishin-alignment. An example can be found below: 
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## hGPR18 3VW7.pdb 
# 
scores from program: 0 
0 ------------PDEYKIAALVFYSCIFIIGLFVNITALWVFSCTT---KKRTTVTIYMMNVALVDLIF-
IMTLPFRMFYYAK-D--EWPFGEYFCQILGALTVFYPSIALWLLAFISADRYMAIVQPKY---
AKELKNTCKAVLACVGVWIMTLTTTTPLLLLYK-------------------------------
IYLKAVNVLNLTRLTFFFLIPLFIMIGCYLVIIHNLLHGR---
TSKLKPKVKEKSIRIIITLLVQVLVCFMPFHICFAFLML---GTGENS-----------
YNPWGAFTTFLMNLSTCLDVILYYIVSKQFQARVISVMLY---- 
0 -------------------------------------------------------------------------
---------------------------------------------------------------------------
---------------------------------------------------------------------------
---------------------------------------------PTNVLLIAHYS---FLSHTS------
TTEAAYFAYLLCV-CV--------------------------------- 
 
All template pdb-files were downloaded from the RCSB PDB protein data bank (www.rcsb.org).319 
Further, the pdb-templates had to be transformed into so-called cleaned-up pdb-files by removing all 
unnecessary information, e.g. ligands, crystallization relicts in the structure, water etc. This can be 
accomplished by using the following command:  
~/rosetta/rosetta_2015.12.57698/tools/protein_tools/scripts/clean_pdb.py 
*.pdb 
The grishin-alignments and the cleaned templates were transformed into threaded templates by 
the following command: 
~/rosetta/rosetta_2015.12.57698/main/source/bin/partial_thread.default.linu
xgccrelease -in:file:fasta hGPR18_3.fasta -in:file:alignment 
"$a"_L1.grishin -in:file:template_pdb "$a".pdb -database 
~/rosetta/rosetta_2015.12.57698/main/database/ 
 
8.6.3. Fragment generation 
 
For fragment insertion, 3mers and 9mers had to be created (these are fragments with 3 or 9 amino 
acids). For fragment generation the Rosetta fragmentpicker was used.320 In an initial step of the 
fragmentpicker secondary-structure predictions were made, based on which the fragments were 
extracted from the RCSB PDB. For secondary structure prediction the fragmentpicker uses jufo_2 and 
psipred: The jufo_2 application as a built-in in rosetta and the BCL with a smooth prediction profile217 
and the open-source secondary structure prediction tool psipred distributed from University College 
London (UCL)218. 
The secondary structure predictions were created in the first step with the following command: 
~/scripts/rosetta_tools/fragmentpicker_runss hGPR18.fasta 
Fragments are further created with the command below: 
~/rosetta/rosetta_2015.12.57698/main/source/bin/fragment_picker.linuxgccrel
ease –database ~/rosetta/rosetta_2015.12.57698/main/database 
@fragment_picker_quota.options 
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For processing the request, the fragmentpicker further needs some information concerning scoring 
options, library paths, etc. They were written down in the fragment_picker_quota.options. 
#input databases 
-in:file:vall 
~/rosetta/rosetta_2015.31.58019/tools/fragment_tools/vall.jul19.2011.gz 
  
#query-related input files ##generated in the previous step 
-in:file:checkpoint hGPR18_3.checkpoint 
-in:file:fasta hGPR18_3.fasta 
-frags:ss_pred hGPR18_3.psipred_ss2 psipred hGPR18_3.jufo9d_ss jufo 
  
#the name root for the output fragment files 
-out:file:frag_prefix hGPR18_frags 
  
#show score components for each selected fragment 
-frags:describe_fragments hGPR18_frags.fsc 
  
#weights 
-frags:scoring:config ./fragment_picker_quota.wghts 
  
#we need 9-mers and 3-mers ##could be 5-mers or whatever you need 
-frags:frag_sizes 9 5 3 
  
#select 500 fragments from 2500 candidates. we need more candidates than 
fragments to fill quota pools 
-frags:n_candidates 2500 
-frags:n_frags 500 
  
#quota.def file defines the shares between different quota pools. the total 
should be 1.0 
-frags:picking:quota_config_file ./fragment_picker_quota.cfg 
 
fragment_picker_quota.cfg: 
#pool_id pool_namefraction 
1 psipred 0.6 
2 jufo 0.4 
 
fragment_picker_quota.wghts: 
#score name priority weight min_allowed extras 
SecondarySimilarity 350 0.5 - psipred 
SecondarySimilarity 250 0.5 - jufo 
RamaScore 150 1.0 - psipred 
RamaScore 150 1.0 - jufo 
ProfileScoreL1 200 1.0 - 
 
 
8.6.4. Creating models  
 
In the so-called hybridize step, the models were built from sequence, fragment insertion and 
threaded templates. The required format of this application in Rosetta was a so-called .xml file, where 
rosetta task operations were defined. Further, the already created files are needed, and additionally, 
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a span file, that defines the transmembrane domains. These domains are predicted using the online 
tool octopus (http://octopus.cbr.su.se).213  
<dock_design> 
    <TASKOPERATIONS> 
    </TASKOPERATIONS> 
    <SCOREFXNS> 
        <stage1 weights="stage1_membrane.wts" symmetric=0> 
            <Reweight scoretype=atom_pair_constraint weight=1/> 
        </stage1> 
        <stage2 weights="stage2_membrane.wts" symmetric=0> 
            <Reweight scoretype=atom_pair_constraint weight=0.5/> 
        </stage2> 
        <fullatom weights="stage3_rlx_membrane.wts" symmetric=0> 
            <Reweight scoretype=atom_pair_constraint weight=0.5/> 
        </fullatom> 
    </SCOREFXNS> 
    <FILTERS> 
    </FILTERS> 
    <MOVERS> 
        <Hybridize name=hybridize stage1_scorefxn=stage1 
stage2_scorefxn=stage2 fa_scorefxn=fullatom batch=1 
stage1_increase_cycles=1.0 stage2_increase_cycles=1.0 
linmin_only=1  add_hetatm=0 disulf_file="hGPR18.disulfide" realign_domains=0> 
            <Fragments 3mers="hGPR18_frags.500.3mers" 
9mers="hGPR18_frags.500.9mers"/> 
            Template pdb="3ODU_thread.pdb.pdb" cst_file="AUTO" 
weight=   0.000 /> 
 <Template pdb="01_10_relax_16_ECL3_S_0028_0001_0018.pdb" cst_file="AUTO" 
weight=   1.000 /> 
</Hybridize> 
    </MOVERS> 
    <APPLY_TO_POSE> 
    </APPLY_TO_POSE> 
    <PROTOCOLS> 
        <Add mover=hybridize/> 
    </PROTOCOLS> 
</dock_design> 
 
Options-file: 
# i/o 
-in:file:fasta hGPR18_full.fasta 
-in:file:psipred_ss2 hGPR18_full.psipred_ss2 
-constraints:cst_fa_file angle.cst 
#-constraints:cst_fa_weight 10 
-in:file:extra_res_fa LG.params #Ligand file  
-in:file:extra_res_cen LG.cen.params #Ligand centroid file 
-score:extra_improper_file LG.tors #Ligand torsion angles file 
-parser:protocol hybridize1.xml 
#-nstruct 10 # for testruns 
#-nstruct 2000 # for production run 
  
# membrane options 
-in:file:spanfile hGPR18.span 
-membrane:no_interpolate_Mpair 
-membrane:Menv_penalties 
-rg_reweight .1 
  
# relax options 
-relax:minimize_bond_angles 
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-relax:minimize_bond_lengths 
-relax:jump_move true 
-default_max_cycles 200 
-relax:min_type lbfgs_armijo_nonmonotone 
-relax:jump_move true 
-score:weights stage3_rlx.wts 
-score:weights stage3_rlx_membrane.wts 
-use_bicubic_interpolation 
-hybridize:stage1_probability 1.0 
-sog_upper_bound 15 
-in:fix_disulf hGPR18.disulfide 
# loop options 
  
# reduce memory footprint 
-chemical:exclude_patches LowerDNA  UpperDNA Cterm_amidation SpecialRotamer 
VirtualBB ShoveBB VirtualDNAPhosphate VirtualNTerm CTermConnect sc_orbitals 
pro_hydroxylated_case1 pro_hydroxylated_case2 ser_phosphorylated 
thr_phosphorylated  tyr_phosphorylated tyr_sulfated lys_dimethylated 
lys_monomethylated  lys_trimethylated lys_acetylated glu_carboxylated 
cys_acetylated tyr_diiodinated N_acetylated C_methylamidated 
MethylatedProteinCterm 
  
# run multiple processors to produce output for one file 
-multiple_processes_writing_to_one_directory 
 
Further, Rosetta needs some options (called “weights”), due to the fact that the here performed 
modelling concerns a membrane embedded protein rather than a soluble protein.  
stage1_membrane.wts: 
# stage1 weights for hybridization: membrane score weights added 
Menv 2.019 
Mpair 1.0 
Mcbeta 2.5 
cenpack 1.0 
hs_pair 1.0 
ss_pair 1.0 
rsigma  1.0 
sheet   1.0 
vdw     3.0 
rg      .1 
rama    0.15 
linear_chainbreak    2.0 
atom_pair_constraint 1.0 
Menv_non_helix 2.019 
Menv_termini 2.019 
Menv_tm_proj 2.019 
Mlipo 1.0 
 
stage2_membrane.wts: 
STRAND_STRAND_WEIGHTS 0 6 
# stage2 weights for hybridization: membrane scoring weights added 
hbond_sr_bb 1.17 
hbond_lr_bb 1.17 
rama        0.15 
omega       0.2 
rg          0.1 
vdw         3.0 
Menv 2.019 
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Mpair 1.0 
Mcbeta 2.5 
cenpack_smooth  1.0 
cart_bonded     0.05 
atom_pair_constraint 0.5 
Mlipo 1.0 
rsigma 1.0 
sheet 1.0 
ss_pair 1.0 
hs_pair 1.0 
Menv_non_helix 2.019 
Menv_termini 2.019 
Menv_tm_proj 2.019 
 
stage3_rlx_membrane.wts: 
# stage3 fullatom weights for hybridization: adopted with membrane scores. 
METHOD_WEIGHTS ref  0.16 1.7 -0.67 -0.81 0.63 -0.17 0.56 0.24 -0.65 -0.1 -
0.34 -0.89 0.02 -0.97 -0.98 -0.37 -0.27 0.29 0.91 0.51 
fa_atr  0.8 
fa_rep  0.44 
fa_sol  0.00 
fa_intra_rep 0.004 
fa_pair 0.49 
fa_plane 0 
fa_dun  0.56 
ref     1 
hbond_lr_bb 1.17 
hbond_sr_bb 1.17 
hbond_bb_sc 2.34 
hbond_sc 2.2 
p_aa_pp     0.32 
dslf_ss_dst 0.5 
dslf_cs_ang 2 
dslf_ss_dih 5 
dslf_ca_dih 5 
pro_close   1.0 
rama    0.2 
omega   0.5 
atom_pair_constraint    0.5 
coordinate_constraint   0.0 
cart_bonded     0.5 
fa_mbenv 0.3 
fa_mbsolv 0.35 
Menv_smooth 0.5 
 
The command to run hybridize is the following: 
~/rosetta/rosetta_2015.12.57698/main/source/bin/rosetta_scripts.default.lin
uxgccrelease @hybridize.options -out:prefix loop_01_ -out:file:scorefile 
cmloops_1_3.sc -nstruct 1 -database 
~/rosetta/rosetta_2015.12.57698/main/database/ 
In total between 4000 and 8800 models were created in each hybridize step.  
Another option can be introduced, when a restraint in the model was known before. This was called 
constrain in Rosetta. An example, where this option was taken, was the loop modeling in chapter 
3.5.4.2. There, the orientation of a certain amino acid side chain was defined by angles and ranges in 
the following way: 
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### trp-proline orientation 
# 
Dihedral CG 70 CB 70 CA 70 O 70 SCALARWEIGHTEDFUNC 10 CIRCULARHARMONIC 1.13 0.35 
Dihedral NE1 70 CD1 70 CG 70 CB 70 SCALARWEIGHTEDFUNC 10 CIRCULARHARMONIC 3.14 0.35 
Dihedral O 70 C 70 N 71 CD 71 SCALARWEIGHTEDFUNC 10 CIRCULARHARMONIC 3.14 0.35 
AtomPair NE1 70 O 73 SCALARWEIGHTEDFUNC 10 BOUNDED 2.5 4.0 0.5 NOE 
AtomPair O 70 N 73 SCALARWEIGHTEDFUNC 10 BOUNDED 2.5 4.0 0.5 NOE 
AtomPair CH2 70 CD2 72 SCALARWEIGHTEDFUNC 10 FLAT_HARMONIC 8 2 4 
AtomPair CZ2 70 CD2 80 SCALARWEIGHTEDFUNC 10 FLAT_HARMONIC 8 2 4 
 
This constraint was also used in relax, which still defines the noted orientation. 
 
8.6.5. Energy optimization  
 
The primarily built structures were further optimized in their overall conformational structure by 
running through a so-called relax, a refinement of the full-atom model. This was achieved by the relax 
application, which runs with the command: 
~/rosetta/rosetta_2015.31.58019/main/source/bin/relax.default.linuxgccrelea
se @relax.options -l $PDB -nstruct 1 -out:prefix relax_ -database 
~/rosetta/rosetta_2015.31.58019/main/database/ 
In the options for the relax protocol, the extent to which side chains and backbone are moved can 
be defined – and have to be defined - according to the problem to solve. For example, different options 
were needed, when a small molecule was present in the models.  
#-in:fix_disulf hGPR18.disulfide #read disulfide connectivity information 
-in:file:spanfile hGPR18.span #read predicted transmembrane regions 
-in:file:extra_res_fa LG.params 
-in:file:extra_res_cen LG.cen.params 
-score:extra_improper_file LG.tors 
  
-membrane:no_interpolate_Mpair # membrane scoring specification 
-membrane:Menv_penalties # turn on membrane penalty scores 
  
-score:weights membrane_highres_Menv_smooth.wts 
  
-relax:dualspace #use dualspace relax protocol 
-relax:minimize_bond_angles #dualspace relax protocol setting 
-set_weights cart_bonded .5 pro_close 0 #score proline ring closure using 
energy term for all bond lengths (pro_close uses virtual atom NV for 
proline ring scores) 
-default_max_cycles 200 
#-flip_HNQ 
#-no_optH false 
#-relax:constrain_relax_to_start_coords 
#relax:coord_constrain_sidechains 
#-relax:ramp_constraints false 
-constraints:cst_fa_file angle.cst 
-constraints:cst_fa_weight 10 
  
 -out:file:fullatom 
-out:pdb 
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8.6.6. Model selection I - Scoring and Clustering 
 
To evaluate the models and select models that were suitable to be further processed two 
procedures were chosen: scoring by the energy scores rosetta creates with every model, and 
clustering, which means to sample those models that resemble the biggest groups that were created. 
The visualization of this similarity was achieved by comparing the models by their RMSD (root mean 
square deviation of the alpha carbon atom). The BCL was used to generate the necessary calculations.  
By the following command RMSD calculations against the best scoring model were done: 
bcl.exe protein:Compare -quality RMSD -specify_residues residues.ls -
reference_pdb relax_80_ECL3_S_0021_0001.pdb -pdb_list ../evaluate_models.txt 
-prefix ECL1_RMSD_ -atoms All -aaclass AAComplete -convert_to_natural_aa_type 
-scheduler PThread 12 
A plot of the RMSD versus the score was done with Gnuplot, 5.0.  
For the Clustering, one model was compared to each other model based on their RMSD. A linker 
defined groups of models that were more similar to another. Results can afterwards be processed so 
that all best scoring models of the biggest clusters can be collected.  
bcl.exe PDBCompare -quality RMSD -atoms CA -specify_residues residues.ls -
pdb_list models.pdb.ls -prefix ECL2_cluster_ -aaclass AACaCb -
convert_to_natural_aa_type -scheduler PThread 12 
bcl.exe Cluster -distance_input_file "ECL2_cluster_RMSD.txt" -input_format 
TableLowerTriangle -output_format Rows Centers -output_file cluster_ECL2_ -
linkage Average -remove_internally_similar_nodes 0.05 -scheduler PThread 12 
grep "Leaf : 1 : " *.Centers. | sort -nk10 | tail     
 
8.6.7. Docking of small molecules  
 
The first step of ligand docking is to create an ensemble of possible rotamers of the small molecule 
of interest. This was achived by using the bcl application bcl::conf – the ConformerGenerator.219 
Therefore, the ligand had to be processed to a sdf file and the following command was executed: 
bcl.exe molecule:ConformerGenerator -ensemble_filenames THC.sdf -add_h -
sample_all_rotamers -generate_3D -conformers_single_file Conformer.sdf 
The ligand has to be positioned in the receptor models of the chosen models for the docking step. 
In PyMOL the receptor model was loaded, the ligand positioned and everything was saved together as 
pdb file. Rosetta itself cannot deal with typical small molecule information files as “sdf” because it is 
only comparable to pdb file format. Therefore, a so-called params file had to be made, that gives 
Rosetta coordinates and ligand information in a pdb file friendly format.  
~/rosetta/mini/mini_trunk/src/python/apps/public/molfile_to_params.py 
conformers0.sdf 
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The docking protocol needs an options file that defined some basic parameters: 
-database ~/rosetta/rosetta_2015.31.58019/main/database/ 
-in 
  -file 
      -extra_res_fa MZ1415.params 
-packing 
 -ex1 
 -ex1aro 
 -ex2 
-parser 
 -protocol dock_MZ1415.xml 
  
-out 
 -file 
  -fullatom 
 -pdb 
  
-score 
 
All other information for the program were again defined in an xml file: 
<ROSETTASCRIPTS> 
    <SCOREFXNS> 
        <ligand_soft_rep weights=ligand_soft_rep> 
            <Reweight scoretype=fa_elec weight=0.42/> 
            <Reweight scoretype=hbond_bb_sc weight=1.3/> 
            <Reweight scoretype=hbond_sc weight=1.3/> 
            <Reweight scoretype=rama weight=0.2/> 
        </ligand_soft_rep> 
        <hard_rep weights=ligand> 
            <Reweight scoretype=fa_intra_rep weight=0.004/> 
            <Reweight scoretype=fa_elec weight=0.42/> 
            <Reweight scoretype=hbond_bb_sc weight=1.3/> 
            <Reweight scoretype=hbond_sc weight=1.3/> 
            <Reweight scoretype=rama weight=0.2/> 
        </hard_rep> 
    </SCOREFXNS> 
    <LIGAND_AREAS> 
            <docking_sidechain_X chain=X cutoff=6.0 add_nbr_radius=true 
all_atom_mode=true minimize_ligand=10/> 
                <final_sidechain_X chain=X cutoff=6.0 add_nbr_radius=true 
all_atom_mode=true/> 
                 <final_backbone_X chain=X cutoff=7.0 add_nbr_radius=false 
all_atom_mode=true Calpha_restraints=0.3/> 
    </LIGAND_AREAS> 
  
    <INTERFACE_BUILDERS> 
        <side_chain_for_docking ligand_areas=docking_sidechain_X/> 
        <side_chain_for_final ligand_areas=final_sidechain_X/> 
        <backbone ligand_areas=final_backbone_X extension_window=3/> 
    </INTERFACE_BUILDERS> 
    <MOVEMAP_BUILDERS> 
        <docking sc_interface=side_chain_for_docking minimize_water=true/> 
        <final sc_interface=side_chain_for_final bb_interface=backbone 
minimize_water=true/> 
    </MOVEMAP_BUILDERS> 
    <MOVERS> 
        StartFrom name=start_from_X chain=X > 
            Coordinates x=-38.5825 y=69.8486 z=39.1026/> 
        /StartFrom> 
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        <CompoundTranslate name=compound_translate randomize_order=false 
allow_overlap=false> 
            <Translate chain=X distribution=uniform angstroms=4.0 cycles=50/> 
        </CompoundTranslate> 
        <Rotate name=rotate_X chain=X distribution=uniform degrees=360 
cycles=500/> 
        <SlideTogether name=slide_together chains=X/> 
        <HighResDocker name=high_res_docker cycles=6 repack_every_Nth=3 
scorefxn=ligand_soft_rep movemap_builder=docking/> 
        <FinalMinimizer name=final scorefxn=hard_rep movemap_builder=final/> 
        <InterfaceScoreCalculator name=add_scores chains=X 
scorefxn=hard_rep/> 
        <ParsedProtocol name=low_res_dock> 
            Add mover_name=start_from_X/> 
            <Add mover_name=compound_translate/> 
            <Add mover_name=rotate_X/> 
            <Add mover_name=slide_together/> 
        </ParsedProtocol> 
        <ParsedProtocol name=high_res_dock> 
            <Add mover_name=high_res_docker/> 
            <Add mover_name=final/> 
        </ParsedProtocol> 
    </MOVERS> 
    <PROTOCOLS> 
        <Add mover_name=low_res_dock/> 
        <Add mover_name=high_res_dock/> 
        <Add mover_name=add_scores/> 
    </PROTOCOLS> 
</ROSETTASCRIPTS> 
 
Usually, up to 10.000 models were constructed. Everything can be executed by typing the following 
command (example): 
~/rosetta/rosetta_2015.31.58019/main/source/bin/rosetta_scripts.default.lin
uxgccrelease @dock_Mz1415_in_hGPR18.options -out:prefix test_02_ -nstruct 3 
-database ~/rosetta/rosetta_2015.31.58019/main/database/ -s 
templates/10_ECL2_1_S_0005_0001.pdb 
 
8.6.8. Model selection II – scoring and clustering 
 
The docking results had to be evaluated and suitable results had to be taken forward. The suitability 
of the models was judged based on their scoring (in this case either ddg or interface_energy can be 
taken as parameters). These parameters describe the energy that was gained by binding the ligand in 
the corresponding way, so lower, negative values were better than higher values. To compare this 
energy term, normally depicted in RosettaEnergyUnits (REU), all models had to be aligned and the 
position of the ligand in comparison had to be determined.  
The alignment of all models was done with the program ProFit (Martin, A.C.R. and Porter, C.T., 
http://www.bioinf.org.uk/software/profit/), which uses the McLachlan algorithm (McLachlan, 1982)321 
as depited below, whereby all aligned structures were written down in align.script.  
profit -h -f align.script 
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Further, the position of the ligand had to be described. This was achieved by calculating the ligand-
RMSD. Therefore, the ligand had to be separated out of the models, and all had to be compared to one 
ligand position. This was accomplished by the BCL with the following command (example): 
bcl.exe molecule:Compare all_ligand.sdf model.pdb_ligand.sdf -method 
RealSpaceRMSD -output ligand_reference_rmsd 
 
Again, the ligand position was also clustered to know which positions had been proposed more 
often than others and how they look like. Therefore, the ligand_RMSD had to be calculated with 
respect to each other model. An example command can be found below: 
bcl.exe molecule:Compare cluster_ligands.sdf -method RealSpaceRMSD -output 
ligand_rmsd -bcl_table_format 
bcl.exe Cluster -distance_input_file ECL1_ligand_rmsd -input_format 
TableLowerTriangle -output_format Rows Centers -output_file Cluster_ECL1 -
linkage Average -remove_internally_similar_nodes 4 
grep "Leaf : 1 : " *.Centers. | sort -nk10 | tail 
 
Out of 10000 models between 100 and 500 models were collected to further be processed in 
another round of docking. For each following round of docking, the dimension of the ligand movement 
was narrowed down in the xml protocol by adapting the torsion angle and the rotation of the ligand in 
the enzyme pocket. After each docking round, the models were processed as described above, sorted 
and chosen for further docking rounds. When the interface_score cannot be further decreased, the 
docking cannot improve further. Out of the last round of focused docking a final selection of models 
had to be chosen by scoring and clustering.  
 
8.6.9. Amino acid interaction  
 
As a last step of the docking procedure, crucial amino acid interactions had to be determined to 
predict possible mutagenesis candidates. An application of rosetta that is called energy-breakdown 
was used for this purpose. It calculates which residue participates in the allover Rosetta energy score 
with which impact on the atom level. An example command is depicted below: 
~/rosetta/rosetta_2016.08.58479/main/source/bin/residue_energy_breakdown.de
fault.linuxgccrelease -in:file:s model.pdb -in:file:extra_res_fa 
MZ1415.params -database ~/rosetta/rosetta_2016.08.58479/main/database/ 
Out of the resulting table, only the interactions with the ligand were extracted and transferred to 
Excel, where they were calculated in percentages and for up to ten bestscoring models out of one 
cluster. This was done for every cluster of interest.  
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8.6.10.  Visualization tools 
 
Models (as pdb format text-files) and chemical structures (sdf) were visualized in PyMol (The 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC) or with the UCSF Chimera package. 
Chimera was developed by the Resource for Biocomputing, Visualization, and Informatics at the 
University of California, San Francisco (supported by NIGMS P41-GM103311).322 
 
8.7.  In-silico prediction of drug properties 
 
Properties of compounds were predicted with the program Stardrop 5.5 (Optibrium) using the 
ADME QSAR (Quantitative Structure-Activity Relationship) tool predicting the Lipinski rule of five, oral 
CNS scoring profile and intravenous CNS scoring profile with standard conditions.  
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9. LIST OF ABBREVIATIONS 
 
2-AG  2-arachidonoylglycerol 
2-AG-PI  2-arachidonoylphoyphatidylinositol 
5-HT  5-Hydroxy-tryptamine, serotonine 
AA-5-HT  Arachidonoylserotonine 
Abn-CBD  abnormal cannabidiol 
AEA   anandamide, arachidonoylethanolamine 
BCL   BioChemical Library 
BSA   bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
CASP  Critical Assessment of Techniques for Protein Structure Prediction 
CBD   cannabidiol 
CB receptor  cannabinoid receptor 
CHO  cells  chinease hamster ovary cells 
CNS   central nervous system 
Compd.  compound 
CTX   cholera toxin 
CysLT1 receptor cysteinyl leukotriene receptor 
DAG   diacylglycerol 
DAGL  diacylglycerol lipase 
DMEM  Dulbecco’s Modified Eagle’s Medium  
DMSO  dimethylsulfoxide 
EC50   halfmaximal activatory concentration 
ECL   extracellular loop 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme linked immunosorbent assay 
ENT   equilibrative nucleoside transporter 
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction 
ERK   extracellular singal-regulated kinase 
ESI   electronspray ionization 
FAAH  fatty acid amide hydrolase 
FCS   fetal calf serum 
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FRET  Förster-resonance energy transfer 
GABA  γ-aminobutyric acid 
GlYT1 receptor glycine transporter 1  
GlYT2a receptor glycine transporter 2a  
GPCR  G protein-coupled receptor 
GDP   guanosine diphosphate 
GIRK  G protein-coupled inwardly-rectifying potassium channels 
GRK   G protein-coupled receptor kinase 
GSK   GlaxoSmithKline 
GTP   guanosine triphosphate 
GTPγS  guanosine 5'-O-[γ-thio]triphosphate 
HBSS  Hank’s Balanced Salt Solution 
HEK293  human embryonic kidney cell line  
HEPES  (4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC  high performance liquid chromatography 
HUVEC  human umbilical vein endothelial cells 
IC50   half-maximal inhibitory concentration  
ICL   intracellular loop 
IP3   inositoltriphosphate 
IUPHAR  International Union of Basic and Clinical Pharmacology 
LB medium  Lysogeny broth medium 
LogP  partition coefficient 
LPI   lysophosphatidylinositol 
LPS   lipopolysaccharide 
MAGL  monoacylglycerol lipase 
MAPkinase  mitogen activated protein kinase 
NAGly  N-arachidonoylglycine 
NAPE  N-acyl phosphatidylethanolamine 
NAPE-PDL  N-acyl phosphatidylethanolamine-specific phospholipase D 
NCBI  National Center for Biotechnology Information 
NFAT  nuclear factor of activated T-cells 
NFκB  nuclear factor kappa-light-chain-enhancer of activated B-cells 
NIH   National Insitute of Health 
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NMDA-receptor N-methyl-D-aspartate receptor, a glutamate receptor 
NMR  nuclear magnetic resonance spectroscopy 
NOS   nitric oxide synthase 
PAR1  protease-activated receptor 1  
PCR   polymerase chain reaction 
PDB   protein data bank 
PPARγ receptor peroxisome proliferator-activated receptor gamma 
PTX   pertussis toxin 
PZB   Pharma-Zentrum Bonn 
QSAR  Quantitative structure-activity relationships 
REU   Rosetta Energy Units 
RLU   relative luminescence units 
RMSD  root mean square deviation 
SAR   structure-activity relationships 
SRE   serum response element 
TAE buffer  Tris-acetate-EDTA buffer 
Δ9-THC  Δ9-tetrahydrocannabinol 
TM   transmembrane 
tPSA  total polar surface area 
Tris   tris(hydroxymethyl)-aminomethan 
TRPA  transient receptor potential cation channels  
TRPV  transient receptor potential cation channels subfamily V (“Vanilloid”) 
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